65. Annual Report 2010 20 februari 2016 — PDF bestand Page 1

Comments

Transcription

65. Annual Report 2010 20 februari 2016 — PDF bestand Page 1
VUmc Cancer Center Amsterdam /
VUmc Institute for Cancer & Immunology
CCA/V-ICI
Annual Report 2010
Address
VUmc Cancer Center Amsterdam / VUmc Institute for Cancer & Immunology (CCA/V-ICI)
VU University Medical Center
CCA 3.36
De Boelelaan 1117
1081 HV Amsterdam
The Netherlands
phone:
e-mail:
website :
(31)20 4443113
[email protected]
www.vumc.nl/afdelingen/CCA-V-ICI
1
2
List of contents
List of contents
1.
Preface
5
2.
Description of CCA/V-ICI
7
3.
Structure of CCA/V-ICI
9
4.
SWOT analysis
11
5.
International collaboration
13
6.
Input CCA/V-ICI
17
7.
Output CCA/V-ICI
19
8.
The research programs of CCA/V-ICI
21
9.
Scientific Research Committee
37
10.
Training and education
47
Appendices
53
3
4
1. Preface
1. Preface
It is a great pleasure to present the 2010 annual report of CCA/V-ICI. The institute is really
flourishing with an even rising production in scientific output, both quantitatively and qualitatively.
In 2010, some important steps were made: the foci in patient care of VUmc: "zwaartepunten", were
further defined. For CCA/V-ICI cancer and immunology in patient care go side by side with the
researchprograms and further integration of care and research are very rapidly progressing.
I wish you much pleasure in reading this report!
Peter Huijgens,
director
5
6
2. Description of CCA/V-ICI
2. Description of CCA/V-ICI
CCA/V-ICI is one of the five research institutes of the VU University Medical Center. CCA/V-ICI was
created to integrate all research efforts in oncology and immunology in such a way that they
strengthen themselves to reach well-defined, interconnected goals. Furthermore, CCA/V-ICI aims to
create new facilities for fundamental and clinical research, both in terms of laboratory facilities,
and technical equipment, and will stimulate cooperation.
CCA/V-ICI is positioned horizontally in the structure of the VUMC, thus interfacing with the different
divisions of clinical and pre-clinical departments. The CCA/V-ICI organization is built around the top
researchers in oncology and immunology in the VUMC. They are the members of the executive
board, advising the management board that heads the institute. A detailed description of the
organization of CCA/V-ICI, together with the organization scheme is given in appendix 1.
About 75% of all VUmc medical departments are involved in research focussed on oncology and/or
immunology. Research is conducted within five well defined research themes. Furthermore, five
tumour types and two immunological disorders have been selected to form the focus for ongoing
research efforts during virtually every stage of the disease. These include colorectal cancer, lung
cancer, head and neck cancer, haematological cancers, neuro-oncology, rheumatoid disease,
coeliakie, contact dermatitis and inflammatory bowel disease. In these patient groups,
comprehensive clinical and research programmes will be established in which clinical care and
research are fully integrated. These range from early detection and diagnosis to treatment and
palliative care. Furthermore, CCA/V-ICI has excellent research expertise on HPV-related tumors,
esophagus cancer, prostate cancer, retinoblastomas,breast cancer, psoriasis, insulin allergy and
autoimmune hepatitis.
To ensure that all the clinicians and researchers within CCA/V-ICI remain highly qualified, a lifelong
learning programme has been set up, starting with undergraduate (bio)medical students and
continuing through Master’s and PhD level to postgraduate/specialist training and beyond.
Mission
The mission of CCA/V-ICI is to coordinate, stimulate and facilitate:
- top level fundamental, translational and patient related research in immunology and cancer,
within the framework of a defined number of research themes
- top level multidisciplinary patient care
- creation of excellent facilities for research and patient care
- training of (young) investigators to ensure excellent fundamental and clinical researchers
- optimal training of health care workers
- fundraising
To this end the tasks of CCA/V-ICI are:
- Development of long-term policy
- Attuning the institutional policy and the policies of the participating (heads of) departments
- Facilitation and coordination of oncology and immunology research
- Quality control and stimulation of research by stimulating cross interfaces between
departments, research groups and clusters
- Training, supervision and assessment of graduate students in research
- Organization of courses, national and international seminars, entrance examinations,
publications, conferences and all that is necessary in this frame work
- Facilitation of multidisciplinary patient care and early diagnosis
- Facilitation of providing information to patients and their relatives
- Facilitation of the development of cure/care pathways for oncological and immunological
patients groups
- Facilitation of research facilities
- Quality control and stimulation of support systems for clinical research
- Training of health care workers; a.o. in the medical curriculum, and post-academic education
- Coordination of the funding of programs
7
2. Description of CCA/V-ICI
CCA/V-ICI future plans
CCA/V-ICI aims to take and hold a leading position in fundamental and patient related research in
cancer and immunology and to improve curative and palliative patient care and to be an attractive
partner for external partners.
In particular CCA/V-ICI will focus on:
• Virus-induced oncogenesis and the role of cancer genes in frequently occurring sporadic and
inherited tumors
• Development of cell based immunotherapy against cancer and new immunosuppressive methods
in immunological diseases
• Classification of diseases and disease monitoring by molecular imaging, genomics and
proteomics
• Introduction and evaluation of new therapeutic modalities, combining immunotherapeutical
approaches, DNA technology and improving existing therapy methods
• Translational research: what benefit will the aforementioned focus points bring for the
patients.
• Generation of improved knowledge about quality of life of childhood and adult patients with
oncological and immune-mediated diseases and their families and conduction of high quality
innovative translational research into developments and readily available new supportive care
strategies.
8
3. Structure of CCA/V-ICI
3.
Structure of CCA/V-ICI
The research projects in CCA/V-ICI are grouped in programs headed by three to five program
leaders who are responsible for the organization, the coordination and the quality of the program.
The program leaders constitute the Executive Board of CCA/V-ICI that reports to the Management
Board of CCA/V-ICI.
Program 1: Oncogenesis
Program 1 covers both basic and translational research and is divided into two subthemes:
1. Viral oncogenesis, progression and early diagnostics
2. Genetic predisposition and cancer genes
Program 2: Immunopathogenesis
The CCA/V-ICI program 2 covers both fundamental and pre-clinical research in which immunological
processes underlying homeostasis control, in relation with inflammatory diseases and cancer form
major topics of research. Program 2 is subdivided into three research lines:
1. Homeostasis control and Inflammation
2. Host-pathogen interaction
3. Tumor immunology and pre-clinical immune therapy
Program 3: Disease profiling
The CCA/V-ICI program 3 covers fundamental and translational research to identify new
determinants for diagnosis, prognosis and tailored treatment for immunological and oncological
diseases. Program 3 is subdivided in three disease oriented research lines:
1. Solid tumors
2. Hematological malignancies
3. Chronic inflammatory diseases
Program 4: Innovative therapy
The CCA/V-ICI program 4 encompasses translational research within the field of oncological and
immune-mediated, non-oncological diseases. The program has been organized along four research
lines:
1. Chemotherapy
2. Immunotherapy
3. Radiotherapy and surgery
4. Gene therapy
Program 5: Quality of life
The CCA/V-ICI program 5 encompasses research within the field of quality of life of childhood and
adult patients with oncological and immune-mediated, non-oncological diseases. The program
“Quality of life” addresses four main topics:
1. Patient and proxy reported outcome
2. Allied health services and lifestyle
3. Psycho-oncology
4. Palliative Care
9
10
4. SWOT analysis
4.
SWOT analysis
Strengths:
• Strong clinical and fundamental research units in one institute with excellent translational
research lines
• Excellent facilities
• Excellent teaching program, including strong masterprograms
• Flat organization, theme meetings and general meetings
• Coordinated project applications
• Outpatient facility
• Strong departments represented in all crucial committees
• A number of exceptional strong clinical departments nationwide and worldwide (Pathology,
Otolaryngology/Head-Neck Surgery, Hematology, Medical Oncology)
Weakness:
• Dispersion in “therapy program”
• Limited equipment budget
• Strong dependence of translational research on patient mix
Opportunities:
• Development of more bench to bedside research lines
• Integration of immunological and cancer research to develop new immunotherapeutical
approaches
• New imaging facility
• Cooperation with other research institutes in Amsterdam and the western part of the
Netherlands
Threats:
• Financial situation of university medical centers in the Netherlands
• Increasing focusing of VUMC towards patient care because of financial reasons
11
12
5. International collaboration
5.
International collaboration
Investigator
Prominent associates
Ang CW
•
K.A. Krogfelt, Statens Serum Institut, Copenhagen, Denmark
Appelmelk BJ
•
J. Nigou, Centre National de la Recherche Scientifique, Département,
Mécanismes Moléculaires des Infections Mycobacteriennes, Institut de
Pharmacologie et de Biologie Structurale, and Institut de Pharmacologie et de
Biologie Structurale, Université deToulouse, Université Paul Sabatier (Toulouse
III), Toulouse, France
G. Besra, School of Biosciences, University of Birmingham, Edgbaston , United
Kingdom
D. Umetsu, Harvard Medical School, Boston, USA
•
•
Beelen RHJ
•
•
J. Loreiro/M. Lopez Cabrera, Insituto de Biologica, Moleculas Eladio Vinuela,
Madrid, Spain
M. Bohm/C. Aufricht, Medizinische Universitaet, Pediatric and Adolescent
Medicine, Vienna, Austria
P. Fabbrini, Instito Renal Medicine, Milan, Italy
Bitter W
•
Richard Losick, Harvard University, Cambridge, USA
Boers M
•
•
•
•
•
•
•
•
Prof P. Tugwell, Prof G. Wells, University of Ottawa, Ca
Prof D. Felson, University of Boston, USA
Prof P. Brooks, University of Brisbane, Australia
Prof V. Strand, University of Stanford, USA
Prof. J. Kirwan, University of Bristol, UK
Prof, W. Maksymovich, University of Edmonton, Canada
Prof. J. Blazenby, University of Bristol, UK
Dr. R. Christensen, University of Copenhagen, Denmark
Braakhuis BJM
•
Dr P. Golusinsky, Poznan University of Medical Sciences, Poznan, Poland
Brakenhoff RH
•
•
•
Prof A Ferlito, Dept Surgical Sciences, University of Udine, Italy
Prof F McCormick, Director Cancer Centre UCSF, USA
Dr N Korokhov, Vector Logics Inc, Birmignham AL, USA
Castelijns JA
•
P. Galluzzi, A.Cerasi, Department of Neurosciences, Azienda Ospedaliera
Universitaria Senese, Interdepartmental Center of Nuclear Magnetic Resonance,
University of Siena, Siena, Italy.
Gizewski ER, Forsting M, Department of Diagnostic and Interventional
Neuroradiology, University Hospital, Essen, Germany.
Brisse HJ, Department of Radiology, Institute Curie, Paris, France
Maeder P, Pediatric Hematology Oncology Unit and Radiology Department Service
de radiodiagnostic et de radiologie interventionnelle CHUV Centre Hospitalier
Universitaire Vaudois University Hospital CHUV, Lausanne, Switzerland
•
•
•
•
Cloos J
•
A.D. Schimmer, Princess Margaret Hospital, Ontario Cancer Institute, Toronto,
Canada
de Gruijl TD
•
Dr C.H. June, Abramson Family Cancer Research Institute, University of
Pennsylvania, Philadelphia, Philadelphia, USA
Dr D.T. Curiel, Division of human gene therapy, University of Alabama at
Birmingham, Birmingham Alabama, USA
•
de Winter JP
•
•
Krystyna H. Chrzanowska, Department of Medical Genetics, The Children’s
Memorial Health Institute, Warsaw, Poland
Weidong Wang, National Institute on Aging, Baltimore, USA
Dorsman JC
•
Antoine M. Snijders, Cancer Research Institute, Comprehensive Cancer, University
of California, San Francisco, CA, USA
Gibbs S
•
Sens-it-iv consortium (30 international partners – multiple publications), Multiple
in Europe (www.sensitiv.eu), Europe
Giovannetti E
•
•
•
Prof.
Prof.
Prof.
Italy
Prof.
Italy
•
F. De Braud, European Institute of Oncology, Milano, Italy
U. Boggi, University of Pisa, Italy
Daniela Campani, Associate Professor of Pathology, University of Pisa, Pisa,
Federico Cappuzzo, head dept. Oncology, Livorno Civil Hospital, Carrara,
13
5. International collaboration
Investigator
Prominent associates
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Heideman DAM
•
•
•
•
Prof. Armando Santoro, head dept. Oncology and Hematology, Humanitas
Hospital, Milan, Italy
Prof. A. Falcone, Dept. Oncology, University of Pisa, Pisa, Italy
Prof. R. Rosell, Dept. Oncology, Barcelona, Spain
Dr. F. Crea, Scuola di Studi Superiori S.Anna, Pisa, Italy
Dr. M. Cantore, Dept. Oncology, Civic Hospital Carrara, Carrara, Italy
Dr. Marco del Chiaro, Karolinska Institute, Stockholm, Sweden
Dr. Leticia G Leon, Instituto Universitario de Bio-Organica Antonio Gonzalez
(IUBO-AG), C/Astrofísico Francisco Sanchez Universidad de La Laguna, La Laguna,
Spain
R. Danesi, University of Pisa, Pisa, Italy
Prof. Giuseppe Giaccone, Chief Medicine Oncology Branch, National Cancer
Institute, Bethesda, USA.
Dr. P.A. Zucali & Prof. Dr. A Santoro, Humanitas Hospital, Milan, Italy
Prof Filippo Minutolo, Associate Professor of Medicinal Chemistry, University of
Pisa, Pisa, Italy
Dr. Carmelo Tibaldi, University of Livorno, Livorno, Italy
Dr. N Funel, University of Pisa, Pisa, Italy
Prof. Dr. Y. Assaraf, Technion-Israel, Institute of Technology University, Haifa,
Israel
Dr. S. Franceschi, International Agency Research on Cancer (IARC), Lyon, France
Dr. G. Clifford, International Agency Research on Cancer (IARC), Lyon, France
Dr. R. Thomas and colleagues, Max Planck Institute for Neurological Research,
Klaus-Joachim-Zülch Laboratories of the Max Planck Society and the Medical
Faculty of the University of Cologne, Cologne, Germany
European Early Lung cancer (EUELC) Consortium: John K. Field, Roy Castle Lung
Cancer Research Programme, Cancer Research Centre, University of Liverpool,
Liverpool, United Kingdom; Christian Brambilla, Institut Albert Bonniot, Université
Joseph Fourier, INSERM U823; Grenoble, France
Jansen G
•
Prof dr. Y.G. Assaraf, The Technion-Israel Institute of Technology, Haifa, Israel
Jiménez C, Schaaij-Visser TB, Pham
TV, Piersma SR, Wurdinger T,
Peerdeman SM, Saydam O, and
Stemmer-Rachamimov AO
•
O. Senol, Harvard Medical School, Boston, USA
Kirtschig G
•
•
Prof. Dr. H Williams, Nottingham University, Nottingham, UK
EADV task force “Skin disease in pregnancy”, EADV, last meeting at the EADV
event in Gotheburg, Sweden
Mebius R
• Ronen Alon, the Weizmann Institute of Science, Rehovot, Israel
• Steven Pals, AMC, dept Pathology, Amsterdam
• A.J. Habenicht, Institute for Vascular Medicine, Friedrich Schiller University of
Jena, Germany
Meijer GA
• Prof. E. Schröck, Institut für Klinische Genetik, Medizinische Fakultät Carl Gustav
Carus der TU Dresden, Dresden, Germany
• Prof. J.G. Herman and Prof. S. Bayling, The Sidney Kimmel Comprehensive Cancer
Center at Johns Hopkins, Baltimore, Maryland, USA
• Prof. F Pontén, Department of Genetics and Pathology, Rudbeck Laboratory,
Uppsala University, Uppsala, Sweden
• Prof. P. Quirke and H. Grabsch, PhD, Academic Unit of Pathology, University of
Leeds, United Kingdom
• Prof. D. Sidransky,The Johns Hopkins School of Medicine, Baltimore, Maryland,
United States of America
• Prof. W. van Criekinge, OncoMethylome Sciences S.A, Liege, Belgium
• R.T. Cormier, University of Minnesota Medical School, Duluth, MN, USA
• Prof. G.Giaccone, Center for Cancer Research, National Cancer Institute,
Bethesda, MD, USA
• K.H. Buetow PhD, Center for Biomedical Informatics and Information Technology
National Cancer Institute, Bethesda, MD, USA
Mooi WJ
•
•
•
•
•
•
•
14
Prof. R.L. Barnhill, Université Paris VII, France
Prof. M. Cook, Nuffield Health Guildhford Hospital, England
Prof. L. Cerroni, University of Graz, Austria
Prof. D.E. Elder, University of Pennsylvania, USA
Prof. H. Kerl, University of Graz, Austria
Prof. P.E. LeBoit, University of San Francisco, USA
Prof M. Mihm, Harvard University, USA
5. International collaboration
Investigator
Peters GJ
Prominent associates
•
•
•
Prof. R. Scolyer, University of Sydney, Australia
Prof. L. Cerroni, University of Sydney, Australia
Prof. L. Cerroni, University of Graz, Austria
•
•
•
•
•
•
•
•
•
Dr. R.A. Schwendener, University of Zürich, Zürich, Switserland
Prof. Dr. H Schott, University of Tubingen, Tubingen, Germany
prof. Dr. J Balzarini, Rega Instituut, KU Leuven, Leuven, Belgium
Prof. Dr. O Fodstadt, Radium Hospital, Oslo, Norway
Prof. Dr. S. Eriksson, Uppsala University, Uppsala, Sweden
Dr. M. Sandvold, Clavis Pharma ASA, Oslo, Norway
C. Calhau, University of Porto, Porto, Portugal
I. Fichtner, Max-Delbrück-Center for Molecular Medicine, Berlin-Buch, Germany.
Dr. J.M. Padron, Instituto Canario de Investigación del Cáncer (ICIC), Tenerife,
Spain
Dr. M Fukushima, Taiho Pharmacenticals, Tokushima, Japan
Prof.dr. H. Schott, University of Tubingen, Germany
Dr. C.M. Galmarini, PharmaMar, Madrid, Spain
Prof. Alfredo Falcone, Head Department of Oncology, University of Pisa, Pisa,
Italy
Prof. Ugo Boggi, Full Professor of Surgery, University of Pisa, Pisa, Italy
Prof. Daniela Campani, Associate Professor of Pathology, University of Pisa, Pisa,
Italy
Prof. Federico Cappuzzo, Head Department of Oncology, Livorno Civil Hospital,
Livorno, Italy
Dr. Maurizio Cantore, Head Department of Oncology, Carrara Civic Hospital,
Carrara, Italy
Prof. Filippo De Braud, Head Unit Oncology and New Drugs, European Institute of
Oncology, Milan, Italy
Dr. Marco Del Chiaro, Karolinska Institute, Stockholm, Sweden
Dr. Leticia G Leon, Instituto Universitario de Bio-Organica Antonio Gonzalez
(IUBO-AG), C/Astrofísico Francisco Sanchez Universidad de La Laguna, La Laguna,
Spain
R. Danesi, University of Pisa, Pisa, Italy
Prof. Giuseppe Giaccone, Chief Medicine Oncology Branch, National Cancer
Institute, Bethesda, USA.
Dr. P.A. Zucali & Prof. Dr. A Santoro, Humanitas Hospital, Milan, Italy
Prof Filippo Minutolo, Associate Professor of Medicinal Chemistry, University of
Pisa, Pisa, Italy
Dr. Carmelo Tibaldi, University of Livorno, Livorno, Italy
Dr. N Funel, University of Pisa, Pisa, Italy
Prof. Dr. Y. Assaraf, Technion-Israel, Institute of Technology University, Haifa,
Israel
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Rustemeyer T
•
Sens-it-iv consortium (30 international partners – 1 publication), Multiple in
Europe (www.sensitiv.eu), Europe
Savelkoul PHM
•
Nuno Pais, Roche Molecular Systems, Plesangton, USA
Senan S
•
•
•
•
•
•
•
•
•
D. Palma, London Regional Cancer Program, Ontario, Canada
Kong (Spring) FM, University of Michigan Medical School; Ann Arbor, Michigan
W.D. D’Souza, University of Maryland School of Medicine, Baltimore, USA
C. le Péchoux, Institut Gustave Roussy, Paris, France
J.P. van Meerbeeck, University of Ghent, Ghent, Belgium
G. Scagliotti, University of Turin, San Luigi Hospital, Turin, Italy
U Nestle, Freiburg University Medical Center, Freiburg, Germany
C. Faivre-Finn, The Christie, Manchester, United Kingdom
S. Ishikura, National Cancer Center Hospital East, Kashiwa, Japan
Slotman BJ
•
D. Palma, London Regional Cancer Program, Ontario, Canada
Sminia P
•
Fedrigo C.A. Catholic University Rio Grande do Sul, Porte Alegro, Rio Grande do
Sul, Brazil
van Beusechem VW
•
•
Prof. F. McCormick, UCSF Cancer Center, San Francisco, California, USA
Dr. Z.B. Zhu, Gene Therapy Center, UAB, Birmingham, Alabama, USA
van de Loosdrecht AA
•
•
•
•
Dr. S.M. van Ham, Sanquin Research at CLB, Amsterdam
Dr. T. van den Berg, Sanquin Research at CLB, Amsterdam
Prof. Dr S. Ostrand-Rosenberg; Baltimore, USA
Dr. M. Loken and D. Wells. HematoLogics Inc. Seattle USA
15
5. International collaboration
Investigator
Prominent associates
•
•
•
van den Elsen PJ
•
•
•
European LeukemiaNet MDS working package 8 (implemanatation of
flowcytometry in MDS)
Dr. J. Janssen, Prof.dr. T. de Witte. UMCN, Nijmegen
Dr. M. Raaijmakers, ErasmusMC, Rotterdam
K Kobayashi, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA,
USA
M Villalba, Institut de Génétique Moléculaire de Montpellier, Unité Mixte de
Recherche 5535, Centre National de Recherche Scientifique, Montpellier, France
J. McClusky, Department of Microbiology & Immunology, The University of
Melbourne, Parkville, Victoria 3010, Australia
van der Horst-Bruinsma IE
•
ASAS- Society: internationaal samenwerkingsverband van reumatologen mbt
spondylitis ankylopoetica
van der Sar AM
•
Dr. S. Bird, University of Aberdeen, Aberdeen, UK
van der Waal I
•
•
•
Meleti M, Unit of Oral Pathology and Medicine, Section of Odontostomatology,
Department of ENT/Dental/Ophthalmological and Cervico-Facial Sciences,
University of Parma, Italy
R.A. Mendes, Department of Oral Surgery, Faculty of Dental Medicine, University
of Porto, Porto, Portugal
J.F.C. Carvalho, Department of Oral Surgery, Faculty of Dental Medicine,
University of Porto, Porto, Portugal
R.A. Mendes, Instituto Superior de Ciências da Saúde, Norte, Porto, Portugal.
G. Warfvinge, Department of Pathology, Malmö, Sweden
van Die I
•
•
R. Geyer, Giessen University, Germany
R.D. Cummings, Emory University Medical School, Atlanta, USA
van Dongen GAMS
•
Kiefer GE, Jurek P, Macrocyclics Inc, Dallas, Texas, USA
van Egmond M
•
•
Prof.dr. P. Kubes, University of Calgary, Calgary, Canada
Prof.dr. J. Ivanyi, Kings College, London, UK
van Furth AM
•
Prof . dr. J. Schoeman, Tijgerberg Hospital, Cape Town, South-Africa
van Furth AM and van der Kuip M
•
Prof. D. Kirschner, Department of Microbiology and Immunology, Uiversity of
Michigan, Ann Arbor, Michigan, USA
van Kooyk Y
•
Collaboration with the group of Dr. Eduardo Arranz (Mucosal Immunology Lab,
Dept. of Paediatrics & Immunology-IBGM, University of Valladolid, Valladolid,
Spain) on immunomodulation of gliadin-specific immune responses through C-type
lectin receptor targeting. Resulted in the visit of a PhD student (Enrique
Montalvillo) for two months (October-November, 2010)
Verweij CL
•
•
•
•
Prof. dr. P.h. De Jager, Harvard University, Boston, USA
Prof. Dr. D.A. Hafler, Yale University, Rochester, USA
Prof. dr. M. Holers/ Dr. K. Dean, University of Colorado, Denver, USA
Prof. dr. M. Comabella/Prof. dr. X. Montalban, , University of Vall d’Hebron, ,
Barcelona, Spain
Wurdinger T
•
Dr. Bakhos Tannous, Massachusetts General Hospital/Harvard Medical School,
Boston/USA
Ylstra B
•
•
Prof. dr. Nick Gilbert, Univeristy of Edinburgh, Edinburgh, UK
Prof. dr. Patricia Maciel, University Minho, Portugal
Zweegman S
•
M.Huizing, Medical Genetics Branch, National Human Genome Research Institute,
National Institutes of Health, Bethesda, MD, USA
•
•
16
6. Input CCA/V-ICI
6.
Input CCA/V-ICI
a. Acquisition per type of funding in euros
Funding
2010
2009
2008
2007
Direct funding
8.109.439
6.927.240
6.605.989
6.665.874
Research funding
2.116.673
1.744.730
1.651.343
1.278.026
Contracts
5.596.577
4.830.820
4.865.624
3.177.712
15.822689
13.502.790
13.122.956
11.121.613
Funding
2010
2009
2008
2007
Direct funding
51,3%
51,3%
50,3%
59,9%
Research funding
13,3%
12,9%
12,6%
11,5%
Contracts
35,4%
35,8%
37,1%
28,6%
Total
100%
100,0%
100,0%
100,0%
Total
As percentage:
b. Fte per type of funding
For a full list of all scientific input, see appendix 2.
Total fte (including PhD students)
WP1
Fte
WP2
fte
WP3
fte
WP4
fte
Total
fte
1. Oncogenesis
13,97
5,13
22,62
3,17
44,89
2. Immunopathogenesis
21,61
24,55
16,33
3,67
66,16
3. Disease profiling
15,78
5,50
14,85
5,50
41,63
4. Innovative therapy
23,89
2,89
27,84
13,40
68,02
2,2
1,51
3,24
2,42
9,37
Total 2010
77,45
39,58
84,88
28,16
230,07
Total staff 2009
70,63
37,32
80,53
24,22
212,70
Total staff 2008
68,31
34,90
65,21
19,58
188,00
Total staff 2007
75,24
28,60
55,78
18,91
178,53
Program
5. Quality of life
17
6. Input CCA/V-ICI
Total fte PhD students
Program
WP1
Fte
WP2
fte
WP3
fte
WP4
fte
Total
fte
1. Oncogenesis
3,42
2,10
11,30
1,50
18,32
2. Immunopathogenesis
7,85
7,71
6,80
2,25
24,61
3. Disease profiling
6,38
2,30
9,15
3,90
21,73
4. Innovative therapy
4,40
1,81
18,10
7,61
31,92
5. Quality of life
0,95
0,61
2,24
1,42
5,22
Total 2010
23,00
14,53
47,59
16,68
101,80
Total 2009
20,24
14,40
44,41
15,79
94,84
Total 2008
10,69
23,87
16,16
29,25
79,97
Total 2007
13,55
21,45
16,79
29,25
81,04
Total fte (including PhD students)
30
25
20
program 1
program 2
15
program 3
program 4
program 5
10
5
0
WP1
WP2
WP3
WP4
c. Number of all newly started PhD projects in 2010
In 2010, 19 new PhD projects were started. For a full list of all newly started projects and PhD
students, see appendix 3.
18
7. Output CCA/V-ICI
7.
Output CCA/V-ICI
a. Scientific output
A full list of the scientific output can be found in appendix 4.
Program
WpR
WpNR
WP
VP
PP
OCT
DI
49
5
-
-
-
-
6
128
9
2
1
5
1
14
83
5
1
5
-
-
5
332
24
6
15
1
4
20
33
4
-
-
-
-
2
Total 2010
625*
47
9
21
6
5
47
Total 2009
522
59
31
15
1
2
43
Total 2008
502
32
27
12
-
-
32
Total 2007
473
34
33
16
-
-
26
1. Oncogenesis
2. Immunopathogenesis
3. Disease profiling
4. Therapy
5. Quality of life
WpR:
WpNR:
WP:
VP:
PP:
OCT:
DI:
Scientific papers refereed (former WI, WN + LE)
Scientific papers non refereed (former WI*)
Scientific publications (book, book chapters, proceedings) (former WB, WBC, RA)
Professional publications
Popular publications
Patents
Dissertations
*Due to an intense search on the internet, the amount of scientific papers are significantly higher
than the years before.
b. Scientific quality
Evaluation of peer-reviewed publications (Science Citation Index (SCI) journals)
Program
5
4
3
2
1
A
B
C
D
1. Oncogenesis
17
19
8
3
2
49
193
3,9
73,5
2. Immunopathogenesis
46
47
26
4
5
128
509
4,0
72,7
3. Disease profiling
39
21
12
6
5
83
332
4,0
72,3
134
98
50
28
22
332
1290
3,9
69,9
6
14
11
2
-
33
123
3,7
60,6
Total 2010
242
199
107
43
34
625
2447
3,9
70,6
Total 2009
201
166
94
44
17
522
2056
3,9
70,3
Total 2008
145
157
68
58
19
447
1692
3,8
67,6
Total 2007
153
108
100
37
22
420
1592
3,8
62,1
4. Therapy
5. Quality of life
Relation between scores and journal
5: SCI journal belonging to > 90th percentile (5 points)
4: SCI journal belonging to 75th – 90th percentile (4 points)
3: SCI journal belonging to 50th - 75th percentile (3 points)
2: SCI journal belonging to 25th – 50th percentile (2 points)
1: SCI journal from lowest quarter, publications in peer-reviewed journals without an Impact Factor (1 point)
19
7. Output CCA/V-ICI
A:
B:
C:
D:
WI total
Total points
Average points
Percentage of WI SCI journals in upper quartile (4 + 5)
c. Indicators of esteem
An overview of editorships, memberships, invited lectures, awards, grants obtained, organisation of
congresses and news are outlined in appendix 5.
d. Societal impact
An overview of the Societal Impact of CCA/V-ICI is shown in appendix 6.
e. Input/Output correlation
Program
Total fte
Total WpR
Average
WpR/fte
2010
Average
WpR/fte
2009
Average
WpR/fte
2008
Average
WpR/fte
2007
1. Oncogenesis
44,89
49
1,1
1,0
1,3
1,6
2. Immunopathogenesis
66,16
128
1,9
2,7
2,2
2,3
3. Disease profiling
41,63
83
2,0
2,6
4,1
2,3
4. Innovative therapy
68,02
332
4,9
2,6
2,2
2,7
9,37
33
3,5
6,4
-
-
230,07
625
2,7
2,5
2,5
2,4
5. Quality of life
Total
20
8. The research programs of CCA/V-ICI
8.
The research programs of CCA/V-ICI
A long-term policy is developed for the programs, covering their focus, the need for
personnel and materials, their budgets and their development. These long-term plans
constitute the basis of the long-term policy of CCA/V-ICI.
Research projects are evaluated on their (intrinsic) qualities and on their potential to
strengthen the program as a whole. The program leaders present such projects in the EB for
advice upon which the Management Board decides to allow or not to allow the project into
CCA/V-ICI. A list of all ongoing projects per program is shown in appendix 7.
a. Description
Program 1: Oncogenesis
Program leaders:
- Prof. R.H. Brakenhoff, PhD (Otolaryngology/Head-Neck Surgery)
- Prof. H. Joenje, PhD (Clinical Genetics)
- Prof. P.J.F. Snijders, PhD (Pathology)
Program 1 covers both basic and translational research and is divided into three subthemes:
1. Viral oncogenesis
2. Cancer genomics
3. Genetic predisposition
A major common objective of the research brought together in this program is to identify
and characterize viral and non-viral cancer genes as well as genes responsible for inherited
cancer predisposition. Their roles in oncogenic pathways are evaluated in models and
clinical material. In addition, molecular markers are sought that may be utilized for a)
screening for cancer and precancerous lesions, b) risk assessment of precancerous lesions,
and c) cancer prevention. To this end an integrated bench to bedside approach is followed
encompassing: 1) marker identification and clinical validation, 2) test development,
validation and up-scaling by robotics, 3) risk group identification, 4) cost-effectiveness
modelling, and 5) public acceptance studies. Screening studies are running for oral
precancer, colorectal cancer and cervical cancer, in various risk groups, and often in the
context of population-based screening trials.
1. Viral oncogenesis
This subtheme focuses on the role of human papillomaviruses (HPVs) and Epstein Barr
virus (EBV) in the development of human cancers, such as anogenital cancers, head and
neck cancers, and lymphomas. Virus-induced oncogenic progression is investigated
using both in vitro models and clinically well-defined patient material, and the genes
involved in this process are identified and characterized. Viral and host markers are
already being tested in screening and clinical trials for their capability to assess the
risk of premalignant disease with an increased sensitivity and specificity compared to
currently existing methods, and newly identified markers will be investigated likewise.
2. Cancer genomics
Aimed at testing progression models for several human cancers, such as head and neck,
lung, gastrointestinal, cervical and ovarian cancers, this subtheme uses wellcharacterized cohorts of patients and state-of-the art high-throughput methods for
genetic, epigenetic, transcriptome and proteome analyses. Candidate cancer genes are
identified, placed in their respective cancer pathways, and tested for their oncogenic
capacity with the aid of in vitro models. Promising progression markers are evaluated
in clinical studies.
3. Genetic predisposition
In this subtheme understanding the molecular mechanisms of genome destabilization,
as related to the occurrence of cancer, both familial and sporadic is studied. Attention
is currently focusing on Fanconi anemia (FA), for which the pathway is being unravelled
(13 FA genes known to date) and mouse models are being developed. It is recognized
21
8. The research programs of CCA/V-ICI
that a subset of sporadic cancers may possess a cellular FA phenotype, which might be
exploited through targeted therapeutic intervention. The possibility to sensitize
(resistant) tumor cells by inhibition of the FA/BRCA pathway will also be explored.
Recently the genetic predisposition to breast/ovarian and colorectal cancer has come
into focus and will be developed during the years to come.
A strong aspect of the research brought together in this program is that patient-oriented
research is complemented by unique model systems allowing to dissect the carcinogenic
process in the laboratory. These model systems include: HPV-transformed cultured
keratinocytes mimicking cervical carcinogenesis (Pathology), conditionally immortalized
oral keratinocytes allowing unraveling of the carcinogenic cascade mimicking head and
neck carcinogenesis (ORL/HNS), and transgenic animals to study the role of genomic
instability in the origin of cancer (Clinical Genetics).
Research highlights Program 1 within period 2004-2009
1. Establishment that implementation of HPV testing in regular cervical screening leads to
earlier detection of cervical (pre)cancerous lesions, permitting extension of the
screening interval.
2. Demonstration that offering self-sampling of cervico-vaginal specimens for HPV testing to
non-attendees of regular cervical screening is an effective instrument to increase the
coverage of the screening program.
3. Collection of evidence that high-grade cervical premalignant lesions can be subdivided
into potentially early and advanced lesions on the basis of their chromosomal profiles
and that HPV positive women with clinically relevant cervical lesions can be recognised
by hypermethylation of certain tumor suppressor genes.
4. Development of a novel test algorithm for archival formalin fixed paraffin-embedded
specimens to assess HPV involvement and establishment of the role of HPV in penile
and head and neck cancer, the latter both in sporadic patient groups as in genetically
predisposed Fanconi anemia patients.
5. Development of a non-invasive high-througput molecular screening test for oral
precancer.
6. Classification of head and neck cancers into in least three prognostically relevant
groups: those with transcriptionally active HPV, those with many genetic changes, and
those without apparent changes and a normal DNA index.
7. Generation of a unique in vitro model for head and neck cancer using conditionally
immortalized oral keratinocytes that will pay off the coming years.
8. Identification of five novel Fanconi anemia genes: FANCB (responsible for an X-linked
form of FA), BRIP1/FANCJ (encoding a BRCA1-interacting helicase), FANCM/Hef
(encoding a DNA gyrase), PALB2/FANCN (a stabilizer of BRCA2), and FANCI (encoding a
binding partner of FANCD2).
9. Identification of ESCO2 as the gene defective in Roberts syndrome, a neighboring
syndrome characterized by a specific type of chromosomal instability. The latter two
discoveries have yielded valuable pieces to the puzzle of the FA/BRCA pathway of
genomic maintenance.
10. Identification of biomarkers for stool based and serum based colorectal cancer
screening
The activities of program 1 can further be inferred from the extra impuls by a large Center
for Translational Molecular Medicine grant with the acronym DECODE to the research line
on early detection of colorectal cancer, coordinated by VUmc (prof GA Meijer). A main
focus of this 18.5 million euro program will be large scale validation of molecular markers
for early detection of colorectal cancer.
In addition, within this program large, unique biobanks have been established. These
include 200,000 cervical scrape samples from regular screening and triage cohorts, 15,000
brush samples of the oral cavity of various controls groups, Fanconi anemia patients,
leukoplakia patients and treated oral cancer patients. We also have collected clinical
information as well as tumor biopsies, mucosa biopsies, serum and plasma of over 350 head
and neck and 200 lung cancer patients. In addition, 1,000 AFB-guided bronchial biopties of
patients at risk of lung cancer, 600 sputum samples of lung cancer and COPD patients as
22
8. The research programs of CCA/V-ICI
well as 750 faeces samples of colorectal cancer cases and controls have been collected and
stored.
The total number of genetic subtypes in Fanconi anemia has now grown to 13. However, a
unique collection of cell lines and materials from Fanconi anemia families has been
accumulated containing a sizable number of unclassifiable cell lines that still wait for their
gene defects to be identified. This includes patients with ‘overlapping’ syndromes such as
Seckel syndrome.
Perspectives
Within the next five years several research aims are defined. These include the
establishment of a novel, cost-effective algorithm for primary HPV testing in cervical
screening with additional biomarkers added for optimal triage of HPV positive women. We
will also have developed (epi)genetic screening assays for colorectal and oral cancer and
precancer detection, and gained insight in the cost–effectiveness of population-based
screening programs in the various risk groups. In addition, we expect that the function of
several existing candidate-cancer genes in head and neck, gastrointestinal, lung and
cervical cancer will have been elucidated and their impact on human cancer will have been
evaluated. We further expect to have detailed progression models worked out for head and
neck cancer, cervical cancer as well as gastrointestinal cancers, and to have identified
novel candidate-cancer genes that play a role in the development of these tumors using a
combined approach of functional genetic screens, validation of putative targets by genetic
analysis of tumor DNA and testing in models. Novel genes involved in the FA pathway and
other chromosome fragility syndromes will have been mapped and/or identified. Mouse
models for genome destabilization syndromes will have been generated and the role of FA
genes in sporadic human cancers ascertained. Finally, we will have established whether loss
of the FA pathway makes cells hypersensitive to inhibition of other biochemical pathways in
so called synthetic lethality screens. This information may be applicable to develop new
non-genotoxic therapies for sporadic cancers with the FA phenotype. In addition, targeted
interference with the FA/BRCA pathway will be explored as a means to sensitize (resistant)
tumor cells for chemotherapy.
Together, it will be clear that the knowledge of the molecular alterations leading to
cancer, as to be gained from this CCA/V-ICI program, will be of vital importance for the
development of new measures to successfully prevent and/or treat cancer in the human
population.
Summary of the research aims for the coming 5 years:
1. Elucidation of specific genomic stabilisation mechanisms and the role of deficiencies in
these mechanisms in the occurrence of cancer, both familial and sporadic. Interference
with recognized targets will be explored as a means to sensitize tumor cells. This
approach includes in vitro model systems as well as animal models.
2. Determination of the role of specific cancer genes in the origin of sporadic tumors.
3. Establishing the exact role of oncogenic viruses in the origin of cancer, in particular
HPV and EBV. This includes the identification of viral cancer genes and additional
genetic and epigenetic alterations essential for the tumors they induce. The roles of
these genetic alterations in oncogenesis will be assessed, both in in vitro models and in
the cancer patient.
4. Unraveling the carcinogenic process in squamous cell carcinoma of the upper
aerodigestive tract and colorectal cancer, both in in vitro models, and in the cancer
patient. This includes the recognition of the cancer genes and miRNAs that are most
relevant in these tumors, and can be exploited for development of treatment
strategies.
5. Detection of new markers to monitor progressive precursor lesions of the cervix, head
and neck, colon, lung and ovarium that may develop into carcinoma.
6. Development and improvement of high-throughput molecular diagnostic methods for
secondary prevention of cervical (i.e. scrapings), head and neck (i.e. scrapings),
colorectal (i.e. faeces), and lung (i.e. sputum) cancer.
23
8. The research programs of CCA/V-ICI
Collaboration
This program is build around the three major departments that participate: Pathology,
Otolaryngology/Head-Neck Surgery, and Clinical Genetics. The collaboration not only
involves common research interests, but also extends to the organization of the annual
master course Oncogenesis. The program leaders meet at least monthly, to make optimal
use of opportunities for collaboration, and this has led to a number of important papers.
The recent development of an institution for early diagnosis and prevention of cancer
(Cancer Center Amsterdam, in collaboration with V-ICI) has added new perspectives on a
fruitful collaboration within and amongst the various programs. Especially the
establishment of a Familial Cancer Clinic with a separate Laboratory for Clinical
Oncogenetics, will stimulate further collaboration within the program. Collaboration has
been established with many outstanding groups, including those of the Netherlands Cancer
Institute (Prof. R. Bernards, Prof. D. Peeper, Dr. R. Agami, Prof. S. Horenblas, Prof. A.
Berns and Prof. H. Te Riele) and the Hubrecht laboratory is expected to pay off in the years
to come. Both Profs. Peeper and Te Riele have been appointed to VUmc, and are active
participants within CCA/V-ICI. There are also intensive contacts with HPV, EBV and Fanconi
anemia support groups all over the worlds.
Means
Modern technology such as proteomics technology, microarray platforms and functional
genetic screens are needed to identify new biomarkers and candidate-cancer genes that
may be exploited as reliable risk-predictors for the progression of premalignant lesions,
especially in cervix, colon, the head & neck region, and the lung. In addition, biostatistical
support is warranted, as well as investment in high-throughput robotics. Mouse models are
accessible through Prof Te Riele.
Key publications
1. Gok M, Heideman DAM, van Kemenade FJ, Berkhof J, Rozendaal L, Spruyt JWM, Voorhorst F, Belien JAM,
Babovic M, Snijders PJF, Meijer CJLM. HPV testing on self collected cervicovaginal lavage specimens as
screening method for women who do not attend cervical screening: cohort study. Brit Med J 2010; 340:
art.nr. c1040
2. Veldhuijzen MJ, Snijders PJF, Reiss P, Meijer CJLM, van de Wijgert JH. Factors affecting transmission of
mucosal human papillomavirus; 2010, pp 862-874.. Lancet Infect Dis 2010; 10(12): 862-874
3. van der Lelij P, Chrzanowska KH, Godthelp BC, Rooimans MA, Ostra AB, Stumm M, Zdzienicka MZ, Joenje H,
de Winter JP. Warsaw Breakage Syndrome, a Cohesinopathy Associated with Mutations in the XPD Helicase
Family Member DDX11/ChIR1. Am J Hum Genet 2010; 86: 262-266
4. van Harn T, Foijer F, van Vugt M, Banerjee R, Yang FT, Oostra AB, Joenje H, te Riele H. Loss of Rb proteins
causes genomic instability in the absence of mitogenic signaling. Genes Dev 2010; 24: 1377-1388
5. Van Zeeburg HJT, Huizenga A, Van den Doel PB, Zhu Z, McCormick F, Brakenhoff RH, Van Beusechem VW.
Comparison of oncolytic adenoviruses for selective eradication of oral cancer and precancerous lesions. Gene
Therapy 17: 1517-1524, 2010
Program 2: Immunopathogenesis
Program leaders:
- Prof. R.H.J. Beelen, PhD (Molecular Cell Biology and Immunology)
- E. Hooijberg, PhD (Pathology)
- Prof. Y. van Kooyk, PhD (Molecular Cell Biology and Immunology)
- Prof. R. Mebius, PhD (Molecular Cell Biology and Immunology)
The CCA/V-ICI program 2 covers both fundamental and pre-clinical research in which
immunological processes underlying homeostasis control, in relation with inflammatory
diseases and cancer form major topics of research. Program 2 is subdivided into three
research lines:
1. Homeostasis control and Inflammation
2. Host-pathogen interaction
3. Tumor immunology and pre-clinical immune therapy
Program 2 studies the immune system both during its natural homeostatic control as well as
its response towards micro-organisms and tumors. We have identified the following key
24
8. The research programs of CCA/V-ICI
elements of which regard as the major themes within the next five years and we like to
focus and strengthen our program into that direction.
1. Homeostasis control and Inflammation.
Main topics are: understanding the homeostatic control of the immune system and its
dysregulation in inflammatory conditions. The ontogeny of lymph node structures and
the central role of stroma cells in dictating the micro-environment during lymph node
development, as well as in established lymphoid organs for the induction of regulatory
T cells and the induction of homing receptors on T cells. Study of immune cell subsets
and post-translational modifications, in particular glycosylation are major components
of study in cellular communication of immune cells, such as DC neutrophil interaction,
migration of DC. In relation to the induction of inflammatory processes (bacterial,
tumor related, colitis related, arthritis related, or neurology related, wound related, or
allergic contact dermatitis related) we study dendritic cell and macrophage activation,
receptor function and their heterogeneity, as well as interaction with matrix and
endothelial cells, as well as human skin tissue models. We aim to define at the
molecular level anti-inflammatory and protective actions of neutrophils, macrophages
and dendritic cells that interfere with their function. Also genetic and epigenetic
processes that play a critical role in the regulation of the immune response in health
and disease with a specific focus on antigen presentation, T cell activation and
differentiation is studied.
2. Host-pathogen interaction.
Main topic is to understand immune modulatory processes of pathogens and to make a
link with immune modulation in cancer. Central theme is the immune modulation of
antigen presenting cells (APC), such as dendritic cells (DC) and Langerhans cells.
Research will focus on how pathogens interact with different DC subsets such as
myeloid DC and Langerhans cells, and how these interactions modulate DC signaling
pathways resulting in immune activation or immune escape. Key innate signalling routes
are investigated in DC upon pathogen contact. Identification of molecular mechanisms
governing these processes will help developing novel strategies to combat not only
infectious diseases but also immunological diseases and can help developing better
cancer therapies. As pathogens we will study viruses (HIV-EBV, HSV, measles, HPV),
bacteria’s (Mycobacterium), and helminths (schistosomes). Research on mycobacterial
virulence, helminths and various viruses focuses, on understanding the immuno
suppression they establish. Mycobacterial protein secretion, virulence and factors
involved in granuloma formation are studied using a zebrafish infection model.
3. Tumor immunology and pre-clinical immune therapy.
Central aim is to understand micro-environmental induced modulation of the immune
system (function of APC) by tumors through modifications of molecular and
posttranslational signatures of stromal cells and or tumor antigens. Also epigenetic
processes that account for silencing of antigen presentation functions of tumor cells
will be studied. For pre-clinical immune therapy, our main line of research for the next
years will remain the in vivo modulation of DC phenotype and function for tumor
immunotherapeutic purposes, through adenovirus-mediated genetic targeting and or
liposomal technology of skin resident APC. By in-vivo modulation of DC by local cytokine
administration, or the use of small molecule inhibitors, tumor-induced
immunosuppressive conditions are enhanced in vivo in order to optimize DC and antitumor T cell activation. Aim is to develop widely applicable “off-the-shelf”
therapeutics to boost anti-tumor immunity in adjuvant settings, combined with other
treatment modalities. As separate strategies we are evaluating the potency of adoptive
transfer of tumor reacting T cells, as anti-tumor therapy.
The major goals of Program 2 are to progressively acquire knowledge of the normal control
mechanisms of the immune system and subsequently of the subversion and modifications in
pathological situations that can be accomplished by tumor development and invading
pathogens or inflammatory processes such as colitis or rheumatoid arthritis. These insights
should enable the identification of immunological parameters crucial for disease
development and severity. The main objective is to lay the grounds for translational
research programs into therapy of chronic inflammatory diseases, infections and cancer.
This program combines the study of infectious diseases as well as cancers, as common
25
8. The research programs of CCA/V-ICI
denominators in the immune system that may be altered or suppressed. Importantly,
several cancers are due to viral infections such as EBV and HPV, linking pathogens to cancer
development. The program aims to molecularly define how pathogens as well as developing
tumors mitigate the immune system for their own benefit. We aim to develop strategies to
overcome immune suppression and design vaccination to strengthen immune responses to
eliminate tumor development and infectious diseases. Strong focus within the 3 research
lines is on the study of antigen presenting cells such as dendritic cells (DC) and
macrophages (MF), i.e. how they are suppressed by the tumor microenvironment
(e.g.stromal cells, chemokines, secretion of inhibitory factors, genetic factors) and
pathogens, to silence their immune stimulating immune responses, and induce regulatory T
cells. Tumor antigens, such as CEA, MUC1 and virally derived antigens, as well as posttranslational modifications of tumors and pathogens form major focus elements employing
proteomics and glycomics. To come towards pre-clinical immune strategies in-vitro and invivo targeting of tumor antigens to DC and MF is fully explored as well as adoptive transfer
of tumor-specific T cells. Both innate and adaptive components of the immune system in
relation with their microenvironment such as stromal cells, that may steer immune
responses during infectious diseases as well as tumor development, are therefore studied.
Perspectives
For the next five years we aim to identify immunological parameters on molecular and
cellular basis that have immune suppressive activity due to modifications in pathological
situations, such as chronic inflammation, tumor development and invading pathogens.
These immune regulatory parameters may lie in the field of inflammatory or tumor microenvironment, altered glycosylation, altered DC/MF function, understanding the induction of
regulatory T cells preceding and during tumor development and infectious diseases. We
envisage that a good combination with basic research that forms the basis of understanding
escape mechanisms for immune activation will help to create innovative pre-clinical
strategies to come to a better treatment of chronic inflammation, cancer and infectious
diseases.
The following keys were identified in program 2:
1. Strong DC and stromal cell biology and preclinical knowledge and experimental setting
2. Strong expertise in glycobiology and related tools for research
3. Excellent setting for performing human immunology based research
4. Certified laboratory available for developing immune diagnostic and monitoring
strategies (Medical Immunology)
5. Unique human skin model systems for pathogen infection, DC targeting and skin
inflammation and wound healing
6. Presence of unique murine tumor-models, tolerance induction models, as well as
models of auto-immunity leading to chronic inflammation
7. Strong expertise in lymph node development
8. Well developed adoptive transfer technology and tetramer technology
9. Unique setting of various pathogen related research and technology
10. Very strong expertise for developing pre-clinical DC related therapies
Summary of the research aims for the coming 5 years:
1. Within the next five years we envisage setting out strategic ways to target DC in-vivo
with tumor antigens (receptor-targeting, adeno-viral targeting, altered-glycantargeting) with a special focus on improving treatment of colon carcinoma, breast
cancer, melanoma and virally induced malignancies. Focus will lie in targeting DC invivo in such a way that both tumor specific CTL and T-helper cells are induced. For
adoptive transfer purposes, we aim at generating and redirecting high avidity cytotoxic
and helper T cells against virally induced malignancies such as ano-genital cancers,
head and neck cancers and lymphomas, as well as against non-virally induced
malignancies.
2. In the field of infection/inflammation due to invading pathogens we will especially
focus on the role of stroma cells in regulating the defence mechanisms by innate cells
and how this influx may be suppressed.
26
8. The research programs of CCA/V-ICI
3. In the field of inflammation, we will focus on mechanisms of allergic contact dermatis
and skin wound healing in order to develop novel preventative as well as diagnostic
strategies in order to prevent and treat skin related inflammation.
4. Detailed determination of molecular and genetic regulators that play a key role in
tumor suppression and pathogen evasion. Knowledge on these regulatory pathways may
be further developed and incorporated into clinical applications, in particular into
combination with current treatments for cancer, inflammatory and infectious diseases
Collaboration
In VUMC:
Projectleaders with projects in program 2 are based at the departments of Molecular Cell
Biology and Immunology (MCBI), Medical Microbiology and Infection (MMI), Dermatology
(Derma), Hematology (HEMA), Medical Oncology (Onco) and Pathology (PA) and are
therefore hosted at various locations at the VUmc/CCA. Because of this lack of natural
encounter for all CCA/V-ICI program 2 participants monthly seminars are organised in which
projectleaders as well as scientist present their current research and future directions to
stimulate collaboration. This will make projectleaders and their members more aware of
the importance of conducting research within one of the CCA/V-ICI programs, and facilitate
collaborations to further define and strengthen the different sub-themes within our
program. The leaders of program 2 will regularly invite all projectleaders to attend to
discus CCA/V-ICI related matters and ongoing research and project calls. We aim at
achieving synergy by combining know-how and technical skills. This might lead to better
projects that can be financed externally by for instance KWF, NWO, the EU or other
sources.
Outside VUMC:
We have set up monthly immunology seminars in which we invite top-researchers within the
field of immunology and tumor immunology to give a seminar, and to visit senior scientists
within program 2 to discuss their work. This will give the scientists within program 2 an
opportunity to present their work to leaders in the field which may improve their quality as
well as their international exposure. We aim at promoting the PhD students to actively
participate in the (after-) seminar discussions, in order to improve their skills in questioning
and answering. Furthermore, for the PhD students a masterclass with the invited speakers
will allow them to learn more about the research area that the seminar speaker is an
expert on. We think this will be an excellent opportunity and learning process for the junior
and senior scientists.
Key publications
1. van de Pavert SA, Mebius RE. New insights into the development of lymphoid tissues. Nat Rev Immunol 2010;
10: 664-U24
2. Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, van Eijndhoven MAJ, Hopmans ES, Lindenberg JL, de Gruijl
TD, Wurdinger T, Middeldorp JM. Functional delivery of viral miRNAs via exosomes. P Natl Acad Sci USA 2010;
107: 6328-6333
3. Backer R, Schwandt T, Greuter M, Oosting M, Jungerkes F, Tuting T, Boon L, O'Toole T, Kraal G, Limmer A,
den Haan JMM. Effective collaboration between marginal metallophilic macrophages and CD8(+) dendritic
cells in the generation of cytotoxic T cells. P Natl Acad Sci USA 2010; 107: 216-221
4. Christerson L, de Vries HJC, de Barbeyrac B, Gaydos CA, Henrich B, Hoffmann S, Schachter J, Thorvaldsen J,
Vall-Mayans M, Klint M, Herrmann B, Morre SA. Typing of Lymphogranuloma Venereum Chlamydia trachomatis
Strains. Emerg Infect Dis 2010; 16: 1777-1779
5. Budding AE, Grasman ME, Lin F, Bogaards JA, Soeltan-Kaersenhout DJ, Vandenbroucke-Grauls CMJE, Van
Bodegraven AA, Savelkoul PHM. IS-pro: high-throughput molecular fingerprinting of the intestinal microbiota.
Faseb J 2010; 24: 4556-4564
Program 3: Disease profiling
Program leaders:
- Prof. G.A.M.S. van Dongen, PhD (Otolaryngology/Head and Neck Surgery + Nuclear
Medicine & PET research)
- Prof. O.S. Hoekstra, MD, PhD (Nuclear Medicine & PET research)
- C.R. Jimenez, PhD (OncoProteomics Laboratory, Medical Oncology)
- Prof. C.L. Verweij, PhD (Pathology)
27
8. The research programs of CCA/V-ICI
The CCA/V-ICI program 3 covers fundamental and translational research to identify new
determinants for diagnosis, prognosis and tailored treatment for immunological and
oncological diseases. Program 3 is subdivided in three disease oriented research lines:
1. Solid tumors
2. Hematological malignancies
3. Chronic inflammatory diseases
The emerging and rapidly growing fields of molecular imaging and genomics provide new
opportunities to unravel the unique biology of a specific disease in a specific patient.
Integrating imaging and global molecular information with clinical data will allow for a
model that may yield tremendously valuable indicators for the individual patient to
personalize diagnosis and predictions. This program is a key connection in the line: target
discovery - ligand development - molecular imaging – molecular diagnostics- molecular
targeted therapy
Solid tumors, hematological malignancies and chromic inflammatory diseases
- In all 3 research lines, modern state-of-art CT and MRI-machines enable imaging of
anatomical details with high precision. In addition, imaging techniques like SPECT, PET,
PET-CT and MRI provide, non-invasively, unique molecular and biological in vivo
information at the tissue level (“molecular imaging”). For this purpose novel reporter
probes will be developed and evaluated in (pre)clinical studies making use of the
unique facilities (cyclotrons, GMP facilities, animal and clinical PET- and MRI-machines)
and expertise available at the campus.
- Genomics and proteomics have emerged as global tools to measure genetic variation
and gene expression at several levels ie., from a gene‘s primary structure to its protein
products and their role in the biology of the organism. The VUmc Microarray-facility
offers high resolution oligonucleotide arrays and CGH arrays for human and mouse
studies. These arrays are increasingly being applied in studies to improve criteria for
disease classification, such as for colorectal, lung and head and neck cancer, lymphoma
and other malignancies, and in chronic inflammatory diseases such as rheumatoid
arthritis.
- The OncoProteomics Laboratory provides expertise in biomarker discovery in body fluids
and tissue (sub-cellular) samples along with state-of-the art facilities for liquid
chromatography and tandem mass spectrometry on two complementary platforms (one
for global discovery and one for targeted analyses). In-depth discovery analyses
typically yield datasets of > 1000 identified proteins per sample along with quantitative
information on relative abundancy, while the targeted analyses allow for multiplexed
semi-high-throughput, antibody-free quantitative analyses of tenth of biomarker
candidates in larger cohorts. In addition, a high throughput method has been developed
for automated biofluid peptide profiling for pattern-based approaches where a
combination of mass spectral peak intensities constitutes a classifier. The
glycoimmunology group at the Dept. of MCBI provides expertise in glycan profiling
(glycomics) using mass spectrometry.
- It is the promise of high-throughput analyses that patterns of transcripts, proteins,
post-translational modifications and/or metabolites can be used to define “molecular
signatures” of different forms of the disease, as well as different stages in the clinical
progression. The patterns that are generated with this integral approach, termed
systems biology, provide insight into the processes that take place in a cell.
Research highlights Program 3 within period 2006-2010
1. Identification of peripheral blood biomarkers to predict responsiveness to TNF-blockade
in rheumatoid arthritis
2. Identification of peripheral blood biomarkers to predict responsiveness to IFN-beta
therapy in multiple sclerosis
3. Gene signatures implicated with a 4-fold increased risk to develop arthritis in
autoantibody positive arthralgia patients
4. Identification DNA copy number profiles associated with response to drug therapy in
advanced colorectal cancer
28
8. The research programs of CCA/V-ICI
5. Development of immuno-PET with long-lived positron emitters 124I and 89Zr for
navigation of antibody development and clinical applications: European distribution of
technology.
6. Development of TKI-PET (PET with Tyrosine Kinase Inhibitors radiolabed with 11C or
18F) for navigation of TKI development and clinical applications.
7. Development of PET and optical tracers for SN and tumor detection.
8. Development of nanobody technology for targeting critical growth factors and their
receptors: perspectives for imaging and therapy
9. Identification of novel protein biomarkers for non-invasive early detection of colorectal
cancer
10. Serum peptide mass spectral signature with prognostic value in NSCLC
11. Protein signature for identification of homology repair deficient breast tumors with
prognostic value
12. Implementation and standardization of PET: clinical practice and trials
13. Monitoring response using FDG, H2O PET scanning and DCE-MRI during treatment with
EGFR and VEGF inhibitors in NSCLC
Perspectives
Within the next five years we foresee the discovery of targets for, and development and
(pre)clinical evaluation of several new SPECT and PET tracers for diagnosis, staging,
treatment planning and response evaluation as well as the exploitation of PET, PET-CT,MRI
and PET-MRI imaging in the development of novel therapeutics. The innovative technologies
described above should contribute to further individualization of treatment, e.g. by more
accurate staging, prognostication and therapy response monitoring. In recent years, we and
others have introduced and validated the sentinel node biopsy (a combined procedure of
imaging, taking biopsies and morphological evaluation) which proved to be an important
improvement within TNM staging. The multidisciplinary infrastructure developed for breast
cancer and melanoma has now been extended to head and neck cancer, gastrointestinal
and gynecological tumors, using the local expertise in ultrasound guided aspiration cytology
and laparoscopic surgery.
The novel molecular imaging techniques have promise to step beyond the classical TNMparadigm. To this end, we aim to optimize the use of genomics and proteomics technology
to reach a molecular signature of disease subtypes e.g. in colon, head and neck and lung
cancer, lymphoma, and other malignancies, and in chronic inflammatory disease such as
rheumatoid arthritis. In addition, we aim to translate protein candidate biomarkers into
non-invasive routine antibody-based assays. The available expertise will allow for
integrated application and assessment of imaging, sampling and profiling. Promising
applications will be evaluated with respect to their clinical relevance and (cost)
effectiveness. Efforts will be put on forming a link between molecular profiling and
molecular imaging. Molecular profiling by genomics and proteomics will contribute to
identification of relevant disease markers and targets. These markers will yield new
molecular tests and the targets can be exploited in the development of disease specific
contrast agents (e.g. using monoclonal antibodies, peptides or small molecules) for imaging
as well as for therapy. Combined molecular profiling – molecular imaging approaches will be
applied in several tumor types, e.g. colorectal, head and neck, lung, lymphoma and other
malignancies, and in chronic inflammatory disease.
Imaging will contribute to increased insight in tumor biology and pathophysiology, e.g. by
pharmacokinetic and dynamic PET analysis. Also molecular interactions can be confirmed
and elucidated, which might be of particular value in the development of new cutting-edge
therapeutic agents like monoclonal antibodies, peptides and small molecules that target
the root courses of the disease. Emerging imaging innovations that are candidates for largescale clinical application will be further evaluated with respect to their (cost) effectiveness
in clinical practice, as is presently done with several PET applications.
Summary of the research aims for the coming 5 years:
Information on disease biology must be enhanced to facilitate the development of disease
specific diagnostic and therapeutic approaches. Opportunities can be found (but are not
restricted) in the following areas:
1. Development of methods to reproducibly measure DNA (e.g. maCGH,and deep
sequencing) and expression profiles (e.g. expression arrays and proteomics) in
29
8. The research programs of CCA/V-ICI
2.
3.
4.
5.
6.
7.
8.
9.
pathological and healthy tissue, or surrogate tissues like blood, urine and faeces. This
approach aims to identify disease signatures, markers and targets. These markers and
targets will be exploited for the development of molecular tests and tracers for
imaging. Alternatively the cell type can be identified.
For the aforementioned aim, SOPs have to be developed for banking of tissues, blood,
saliva, and feces.
Characterization of molecular signatures of tumors (precurser lesions, established
tumors, metastases) or immunological diseases, which are of value for selection of the
proper therapeutic intervention.
Definition and integration of molecular profiles at various stages of development and
progression, to provide a comprehensive view of the pathways involved in pathogenesis.
Definition of tumor/pathogen and host interaction.
Validation of the predictive value of various biomarkers using either tissues (see
above), body fluids or images of well defined patient groups who had well-defined
therapy with accurate follow-up.
Development of novel in vivo imaging tools enabling non-invasive biological and
molecular disease characterization for individual patients. For example for early
response monitoring or for prediction of poor response upon therapy (e.g. hypoxia and
angiogenesis in case of cancer therapy) or for evaluation of the specificity of targeted
drugs. Disease-specific contrast agents and software tools for quantification will be
developed.
Initiation of clinical studies with molecular targeting agents to validate molecular
targets, by taking tissue samples and or imaging, and to predict the efficacy of a given
therapy.
Initiation of clinical studies with targeted mass spectrometry and antibody-based
methods to assess the biomarker potential in body fluids of disease-related proteins and
to establish values for sensitivity and specificity.
Collaboration
In and outside VUmc:
Projectleaders with projects in program 3 are based at several departments in the VUMC:
Pathology, Otolaryngology/Head & Neck Surgery, Nuclear Medicine & PET Research,
Molecular Cell Biology, Rheumatology, Hematology, Medical Oncology, Pulmonology,
Gastroenterology, Radiology, Gynecology. Bilateral collaborations with leading national and
international research groups have been established in the fields of genomics, proteomics,
and molecular imaging. In these fields VUmc also participates in many strategic consortia
(STW, TIPharma, CTMM, EU and NCI programs). In addition, many collaborations and
preferred partnerships exist with leading innovative industries in the fields of molecular
diagnosis, molecular imaging, and molecular targeted therapy.
Means
Research within CCA/V-ICI program 3 requires availability of various technology platforms,
i.e. presence of state-of-the-art facilities and know-how. The following technology
platforms are available, or planned to be available and in active operation within the
coming year:
1. Microarray-facility that includes massive parallel sequencing
2. OncoProteomics Laboratory
3. Functional genomics unit
4. (molecular)Imaging facilities
5. Tissue microarray facility
6. Human monoclonal antibody phage display facility
7. Bio-informatics support
The technology platforms are organized as user-groups. For each facility a business plan has
been made and currently a business plan is being made for a VUmc Genome Center. For
optimal use of capacity, an inventory is made of projects planned for each facility. Program
3 of CCA/V-ICI takes care for optimal use of these facilities, and if required the particular
user-group will be contacted. In addition, projects making use of the facilities will be
reviewed at a regular basis.
30
8. The research programs of CCA/V-ICI
Key publications
1. Albrethsen J, Knol JC, Piersma SR, Pham TV, de Wit M, Mongera S, Carvalho B, Verheul HMW, Fijneman RJA,
Meijer GA, Jimenez CR. Subnuclear Proteomics in Colorectal Cancer: Identification of proteins enriched in the
nuclear matrix fraction and regulation in adenoma to carcinoma progression. Mol Cell Proteomics 2010; 9:
988-1005
2. Martin-Trujillo A, van Rietschoten JGI, Timmer TCG, Rodriguez FM, Huizinga TWJ, Tak PP, Marsal S, Ibrahim
SM, Dijkmans BAC, Kraan TCTM, Verweij CL. Loss of imprinting of IGF2 characterises high IGF2 mRNAexpressing type of fibroblast-like synoviocytes in rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1239-1242
3. Diosdado B, Buffart TE, Watkins R, Carvalho B, Ylstra B, Tijssen M, Bolijn AS, Lewis F, Maude K, Verbeke C,
Nagtegaal ID, Grabsch H, Mulder CJJ, Quirke P, Howdle P, Meijer GA. High-Resolution Array Comparative
Genomic Hybridization in Sporadic and Celiac Disease-Related Small Bowel Adenocarcinomas. Clin Cancer Res
2010; 16: 1391-1401
4. Brosens RPM, Haan JC, Carvalho B, Rustenburg F, Grabsch H, Quirke P, Engel AF, Cuesta MA, Maughan N,
Flens M, Meijer GA, Ylstra B. Candidate driver genes in focal chromosomal aberrations of stage II colon
cancer. J Pathol 2010; 221: 411-424
5. Frings V, de Langen AJ, Smit EF, van Velden FHP, Hoekstra OS, van Tinteren H, Boellaard R. Repeatability of
Metabolically Active Volume Measurements with F-18-FDG and F-18-FLT PET in Non-Small Cell Lung Cancer. J
Nucl Med 2010; 51: 1870-1877
Program 4: Innovative therapy
Program leaders:
- Prof. B.A.C. Dijkmans, MD, PhD (Rheumatology)
- Prof. G.J. Ossenkoppele, MD, PhD (Hematology)
- Prof. G.J. Peters, PhD (Medical Oncology)
- Prof. S. Senan, MB, BS, PhD (Radiotherapy)
- Prof. H.M.W. Verheul, MD, PhD (Oncology)
The CCA/V-ICI program 4 encompasses translational research within the field of oncological
and immune-mediated, non-oncological diseases and focuses on the following two research
lines:
1. Targeted therapy, including radiotherapy, surgery and systemic therapy
2. Immunotherapy
The major aim of the program is to explore potential synergies when innovative and
targeted therapies are combined with classical radiotherapy and chemotherapy for both
oncological and immunological diseases. This includes pre-clinical evaluation and clinical
application of the new generation of the so-called molecular targeted therapies against
novel cellular targets, anti-angiogenesis agents and the pharmacological optimalization of
conventional cytotoxic and antirheumatic drugs. Identifying novel targets and in-house drug
discovery for which (pharmaco)genomics and proteomics, as well as investigating
mechanisms of drug resistance are a key focus. Imaging and disease profiling will be
performed in close collaboration with CCA/V-ICI program 3. Preclinical and early studies in
radiotherapy currently focus on combining radiotherapy with radiosensitizing molecular
targeted therapies, with the aim of developing experimental arms for future clinical trials.
Another active area of research is the optimisation of 4-dimensional image-guided
approaches that aim to improve local control and reduce normal tissue toxicity.
The program encompasses the work many Clinical Departments involved in clinical cancer
research. It remains a fact that a significant number of them do not actively focus on
clinical translational research, but are instead major referral centers for distinct
immunological and oncological diseases. In the case of the latter, the clinical activities of
such Departments have led to recognition as national referral centers for some disease
types, stimulated patient accrual to novel clinical trials, access to new drugs, facilitated
strong contacts with pharmaceutical companies, and resulted in key clinical publications. It
is expected that the contributions of such clinically-orientated departments will continue to
add to high-quality output of program 4
The research line Immunotherapy investigates new immunotherapeutic approaches for the
treatment of rheumatoid arthritis and other immunological disorders as well as oncological
disorders. For example a major focus of immuno-therapy of malignant disorders is
evaluating the role of vaccination in the adjuvant and primary settings. Improved survival
31
8. The research programs of CCA/V-ICI
rates are now achievable for a number of common malignancies by using combined
modalities. Collaboration with program 2 has been initiated and will be broadened in next
years.
Perspectives
In the next five years, specific patient-tailored therapies will be developed in a range of
oncological and immunological diseases. These therapies will be directed to defined
cellular- and tumor environment targets and characterization of genetic polymorphisms in
order to prevent toxicity and increase anti-tumor or anti-inflammatory activity. The new
techniques will be used in concert with image-guided controlled radiotherapy and surgery
to further refine the concept of personalized tailored therapy. The existing expertise of
both the VUMC micro-array facility and the VUMC OncoProteomics Laboratory will form a
solid extension to faciclitate these aims. Furthermore, effective dendritic vaccines will be
developed and evaluated in clinical studies of various malignancies. By exploiting the
existing expertise within the V-ICI in immune effector-targeted approaches in cancer
therapies, novel immune-therapies willl also be explored in treating auto-immune disorders
Research aims for the coming 5 years:
1. Increase translational research with a focus on the early clinical application of relevant
discoveries. The process of clinical evaluation can range from early studies of feasibility
and toxicity to the validation of efficacy of new techniques, drugs or vaccines.
2. Focus on targeted therapy in all its forms, including pharmaceuticals, radiation,
immunotherapy and surgery, directed towards the deregulated cell (arising from either
malignant or immunological dysfunction) so as to improve efficacy and minimise
collateral damage to normal tissues.
3. In the clinical departments that are more heavily involved in clinical cancer research in
Phase I,II and III trials, every effort will be made to ensure that such trials are better
integrated into existing lines of translational and immunological research.
4. Exploit the existing expertise in both immunology, oncology and imaging in order to
develop novel therapeutic approaches.
Collaboration
In VUMC
A large number of departments are involved in program 4. Translational researchers in
program 4 are now working in close contact with more fundamental/pre-clinical
researchers from program 1-3 in order to allow the transition of bench-to-bedside research.
Information about the research meetings of all the departments in program 4 are now
disseminated on the V-ICI website to stimulate cooperation among the different
departments. It is anticipated that this will increase the merging of oncological and
immunological research.
Outside VUMC
Researchers in program 4 have partnerships with industry and with other academic centers
in and outside the Netherlands. This will be further exploited in the coming years.
Key publications
1. Mir SE, Hamer PCD, Krawczyk PM, Balaj L, Claes A, Niers JM, Van Tilborg AAG, Zwinderman AH, Geerts D,
Kaspers GJL, Vandertop WP, Cloos J, Tannous BA, Wesseling P, Aten JA, Noske DP, Van Noorden CJF,
Wurdinger T. In Silico Analysis of Kinase Expression Identifies WEE1 as a Gatekeeper against Mitotic
Catastrophe in Glioblastoma. Cancer Cell 2010; 18: 244-257
2. Palma DA, Visser O, Lagerwaard FJ, Belderbos J, Slotman BJ, Senan S. Impact of Introducing Stereotactic
Lung Radiotherapy for Elderly Patients With Stage I Non-Small-Cell Lung Cancer: A Population-Based TimeTrend Analysis. J Clin Oncol 2010; 28: 5153-5159
3. Paulis YWJ, Soetekouw PMMB, Verheul HMW, Tjan-Heijnen VCG, Griffioen AW. Signalling pathways in
vasculogenic mimicry. BBA-Rev Cancer 2010; 1806: 18-28
4. Westers TM, Alhan C, Chamuleau MED, van der Vorst MJDL, Eeltink C, Ossenkoppele GJ, van de Loosdrecht
AA. Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in
predicting response to growth factor treatment. Blood 2010; 115: 1779-1784
5. Klarenbeek NB, Kerstens PJSM, Huizinga TWJ, Dijkmans BAC, Allaart CF. Recent advances in the management
of rheumatoid arthritis. Brit Med J 2010; 341: art.nr. c6942
32
8. The research programs of CCA/V-ICI
Program 5: Quality of Life
Program leaders:
- Prof. J. Dekker, PhD (Dept Rehabilitation / Dept Psychiatry)
- Prof. G.J.L. Kaspers, MD, PhD (Dept Pediatrics / Oncology-Hematology)
- Prof. I.M. Verdonck-de Leeuw, PhD (Dept Otolaryngology–Head & Neck Surgery / VU
Dept Clinical Psychology)
- Drs. O. Visser, MD (Dept Hematology)
The CCA/V-ICI program 5 encompasses research within the field of quality of life of
childhood and adult patients with oncological and immune-mediated, non-oncological
diseases. The program “Quality of life” addresses four main topics:
1.
2.
3.
4.
Patient and proxy reported outcome
Allied health services and lifestyle
Psycho-oncology
Palliative Care
In addition to traditional outcome measures like disease control and overall survival,
quality of life has grown to become a standard outcome parameter in clinical studies. The
general purpose of health-related quality of life assessment is to evaluate both the shortand long-term well-being of individuals or groups of patients/survivors and their proxies (in
case of pediatric patients). It is known that self-reported health is related to mortality and
morbidity and that it can be used to screen for high-risk groups. Quality of life evaluation
can also be used to improve clinical management of patients by obtaining real-time
feedback from individuals on quality of life issues. In addition, data from individual patient
and proxy quality of life assessments can facilitate improved communication between
patients and their clinicians. In general, tools to assess quality of life are questionnaires
also called patient/proxy reported outcomes. Patients with oncological and immunemediated diseases and their families have to deal with adverse side-effects of disease and
treatment which may be both physical and psychological. These adverse side-effects may
affect quality of life substantially both in the short and the long run. Supportive care is the
prevention and management of these adverse effects from diagnosis through anticancer
treatment to post-treatment and palliative care in both patients and their relatives.
Information technology has the potential to improve the efficiency of supportive care (ehealth).
1. The research line Patient and Proxy Reported Outcome comprises methodological and
implementation aspects of patient and proxy reported outcomes (PRO’s) and the use of
PRO’s to assess the impact of the disease and treatment and their short- and long term
adverse side-effects on quality of life. This research line also addresses the prognostic
value of quality of life for overall survival in relation to a broad perspective of possible
confounders or mediators such as sociodemography, general health status
(comorbidity), lifestyle, coping style, comorbid depression and anxiety, biomarkers,
and tumour and treatment related aspects. PRO’s refer to questionnaires completed by
patients and/or their proxies or interviewer-administered questionnaires.
Questionnaires may be generic or condition-specific: developed specifically to assess
outcome of patients with a specific condition like cancer. International collaboration
within the European Organisation for Research and Treatment of Cancer (EORTC) is
ongoing regarding further development of patient reported outcome including
computerized adaptive testing (CAT). In our hospital, a touch screen computer system
(OncoQuest) was developed including the general EORTC-QLQ-C30 and the various
EORTC tumour specific modules, and the Hospital Anxiety and Depression Scale (HADS)
and appears to be feasible for scientific and clinical documentation of quality of life. A
similar system is being developed for childhood cancer patients and (adult) survivors
including quality of life questionnaires as recommended by the Dutch DCOG-LATER
Guidelines (Dutch Childhood Oncology Group-Late Effects following childhood cancer).
OncoQuest will be adapted for patients treated for retinoblastoma and their proxies
(RetinoQuest) and for patients with multiple sclerosis (MSQuest).
33
8. The research programs of CCA/V-ICI
2. The research line Allied Health Services and Lifestyle focuses on improving symptoms
and function such as physical condition, pain, nausea, constipation, sexual functioning
and fertility, speech and swallowing, oral function, cognitive function, and return to
work, and also on lifestyle issues as smoking, alcohol use, and nutrition and weight.
Some of these symptoms and functions also apply for children but in the pediatric
population focus is also directed at improving neuro-cognitive and social-emotional
development, school performance, return-to school, family functioning, both shortly
and long after treatment has been completed. Medical and technical innovations such
as microvascular reconstruction surgery, organ preservation strategies as
chemoradiation and new radiation delivery techniques as IMRT, as well as new
rehabilitation strategies and allied health services may lead to improved outcome but
evidence is scarce. Currently, several cost-effectiveness studies are ongoing. Also,
research is focusing on improving disease management by implementing structured
monitoring of quality of life as a tool for supportive care navigators to set up
individualized care plans.
3. The research line Psycho-Oncology encompasses the psychological aspects for both
patients and their proxies of living with oncological and immune-mediated diseases.
Patients often have to deal with side-effects of initial treatment, and the considerable
threat to self-image, confidence, and identity may be difficult to cope with and can be
a cause of psychosocial problems also for patient-proxies. Specific stressors as fear of
death, interruption of life plans, and changes in quality of life often lead to comorbid
anxiety and depression. This may occur during or shortly after treatment but also years
after completion in therapy in the so-called long-term survivors, particularly in those
who experience long-term adverse sided effects. Current research is focussing on
efficacy of psychosocial care. There is close cooperation with the departments of
Medical Psychology, Clinical Psychology, and Psychiatry. Within the scope of a stepped
care approach, a tool is under development regarding several self-help programmes
targeting insomnia, fatigue, anxiety, and depression in cancer patients. Randomised
trials have started investigating cost-effectiveness of (on-line) self-help programs and
face to face interventions, and stepped care strategies to improve disease management
and patient empowerment.
4. The research line Palliative Care includes projects on palliative care and end of life
studies. Approximately half of all adult cancer patients are treated without curative
intent. Incurable ill patients often experience feelings of sadness, depression,
hopelessness and spiritual distress, such as an evaluation of one’s past and problems
with finding a new meaning in life. It is estimated that in 30%-50% of patients in the
palliative phase, comorbid symptoms of depression are present. In the daily practice of
psychosocial care there is an urgent need for evidence-based psychosocial intervention
methods enhancing the quality of life and dying and relieving the emotional distress in
patients. A randomised controlled trial is ongoing investigating the effectiveness of
narrative therapy (a structured life review protocol) on decreasing depressive
symptoms and enhancing quality of life of patients in the palliative phase of the
disease. The research projects of CCA/V-ICI are tuned into the VUmc Expertise Center
for Palliative Care.
Perspectives
In the Netherlands, government policy statements and the recent guidelines “Cancer
Rehabilitation” and “Screening for the need for psychosocial care” reflect broad scientific
and social support for a structured, integrated approach to supportive care. Supportive care
providers may improve the operational and organizational means to deliver care in a
structured, comprehensive, and cost-effective manner. Care can be organized according to
stepped care principles in which several evidence-based interventions are offered in a
structured way while a care navigator carefully monitors the recovery of the patients. IT
applications based on persuasive or motivational designs can be used as helpful tools and
have the potential to improve the efficiency of care. At present, interventions are often
practice-based and scientific evidence is lacking regarding cost-effectiveness. In the next
five years, various specific patient-tailored interventions and care strategies will be
developed in a range of oncological and immunological diseases and cost-effectiveness
studies will be carried out. Besides improving and innovating care programmes, more
34
8. The research programs of CCA/V-ICI
insight will be obtained about quality of life by conducting large-scale prospective cohort
studies.
These ambitions require funding of specific issues as IT analists and consultancy, data
storage and management, and care navigators to implement innovative supportive care
solutions into clinical practice. Investing in the research lines of CCA / V-ICI programme 5
“Quality of life” has the potential to utilise market opportunities and to make concepts,
knowledge, and supportive care innovations available to society.
Research aims for the coming 5 years
The common research aims of the four research lines in programme 5 are to generate
improved knowledge about quality of life of childhood and adult patients with oncological
and immune-mediated diseases and their families and to conduct high quality innovative
translational research into developments and readily available new supportive care
strategies.
Highlights of our priorities in the coming 5 years are as follows:
1. Further implementation and evaluation of IT applications for structured assessment of
quality of life for clinical and research purposes.
2. Development and cost-effectiveness of a web-based knowledge and decision support
system to improve disease management.
3. Development and cost-effectiveness of innovative care programmes and e-health to
improve quality of life.
4. Collaboration in clinical trials regarding quality of life outcomes.
5. Large-scale prospective cohort studies to generate improved knowledge about quality
of life of patients.
Collaboration
In VUmc
The existing expertise of the VUmc Cancer Center Amsterdam CCA/V-ICI Research Institute,
the VU University Institute for Health and Care Research (EMGO+), the mental health
institute GGZ InGeest, and the VUmc Expertise Center for Palliative Care will form a solid
basis to facilitate the aims of programme 5. Quality of life researchers in program 5 are
working in close contact with medical staff and allied health services to enable rapid
implementation of research results into clinical practice and with biomedical researchers
from programmes 1-4 in order to allow large-scaled cohort studies. Also, the large-scale
patient cohort studies will be tuned into running longitudinal cohort studies at EMGO+.
Seminars will be organised at least twice a year in which senior scientists within the field of
quality of life will be challenged to discuss their work. Furthermore, we aim at 6-12
meetings per year in which PhD students actively participate in discussions under
supervision of at least one senior researcher. Information about the research of all the
departments cooperating in program 5 has been collected and this will be made public on
the V-ICI website to stimulate cooperation among the researchers working at the different
departments.
Outside VUmc
Researchers in program 5 collaborate with researchers in other university and oncological
expertise centers in and outside the Netherlands. There are also collaborations with the
Integral Cancer Center Amsterdam, the Ingeborg Douwes Center for psychosocial care in
Amsterdam, Trimbos Institute on Mental Health, Stivoro, NDDO Institute on Prevention and
Early Diagnostics (NIPED), and the Alpe d’HuZes Foundation. Also, members of the various
patient societies are involved in our research projects. This will be further exploited in the
coming years.
Key publications
1. Oskam IM, Verdonck-de Leeuw IM, Aaronson NK, Kuik DJ, de Bree R, Doornaert P, Langendijk JA, Leemans CR.
Quality of life as predictor of survival: A prospective study on patients treated with combined surgery and
radiotherapy for advanced oral and oropharyngeal cancer. Radiother Oncol 2010; 97: 258-262
2. Sizoo EM, Braam L, Postma TJ, Pasman HRW, Heimans JJ, Klein M, Reijneveld JC, Taphoorn MJB. Symptoms
and problems in the end-of-life phase of high-grade glioma patients. Neuro-Oncology 2010; 12: 1162-1166
3. van der Meij BS, Langius JAE, Smit EF, Spreeuwenberg MD, von Blomberg BME, Aarden L, Heijboer AC, Paul
MA, van Leeuwen PAM. Oral nutritional supplements containing (n-3) polyunsaturated fatty acids affect the
35
8. The research programs of CCA/V-ICI
4.
5.
36
nutritional status of patients with stage III non-small cell lung cancer during multimodality treatment. J Nutr
2010; 140: 1774-1780
Dommering CJ, van den Heuvel MR, Moll AC, Imhof SM, Meijers-Heijboer EJ, Henneman L. Reproductive
decision-making: a qualitative study among couples at increased risk of having a child with retinoblastoma.
Clin Genet 2010; 78: 334-341
de Vries MC, Wit JM, Engberts DP, Kaspers GJL, van Leeuwen E. Pediatric Oncologists' Attitudes Towards
Involving Adolescents in Decision-Making Concerning Research Participation. Pediatr Blood Cancer 2010; 55:
123-128
9. Scientific Research Committee
9.
Scientific Research Committee
Clinical protocols that need approval of the medical ethical committee (METC) of the VUmc are first
evaluated by the scientific research committee (CWO), see appendix 1 for the participating
members.
In 2010 a total of 95 clinical protocols were evaluated, with specific attention to the quality and
feasibility of the proposed protocol, and all of them were approved.
In addition, the CWO evaluated a total of 71 research projects/grant proposals in 2010. These
included the following grant applications: NWO (VENI: 6, Mozaïek: 2, middelgroot: 3), ZonMw
(AGIKO: 1, translationeel: 1), KWF: 6, CCA: 28, other: 17, and 7 research project proposals . All
were approved by the CWO. New research projects were firstly checked by the executive board for
embedding in one of the five CCA/V-ICI research programs.
Animal related protocols that need approval of the animal ethical committee (DEC) of the VUmc
were evaluated first by the CWO-DEC committee, see chapter 2 for the participating members. In
2010, a total of 56 animal-related protocols were evaluated and approved.
An overview of the approved protocols and projects is given in the next paragraphs.
CWO: Clinical protocols
Principal investigator
Title
S. Zweegman
A phase II, multi-center, non-randomized, open-label study of TKI258 in patients
with relapsed or refractory multiple myeloma, who are with or without t(4;14)
translocation
J.J. van der Vliet
Invloed van aminobisfosfonaten en statinen op circulerende Vγ9Vδ2-T cellen
J.M. Zijlstra
OMB 110928 / HOVON 98 NHL: Ofatumumab versus Rituximab Salvage
Chemoimmunotherapy followed by ASCT in Relapsed of Refractory DLBCL
V. de Haas
Comparative effect and safety of recombinant asparaginase in infants (<1 year) with
previously untreated acute lymphoblastic leukaemia, a phase II clinical trial
S. Peerdeman
A randomized, controlled study to evaluate the safety and effectiveness of EVICEL*
as an adjunct to sutured dural repair
E.G. Haarman
Confirmed wheezing in infancy as basis for molecular fingerprinting in the prediction
of asthma.
J. Dekker
Risk factors for impairments of quality of life after colorectal cancer: a feasibility
study
E.F. Smit
A prospective double-blind randomized phase III study of 300 mg versus 150 mg
erlotinib in current smokers with locally advanced of metastatic NSCLC in secondline setting after failure of chemotherapy
E.F. Smit
Determination of the predictive value of early FDG-PET-CT scans for the prognosis of
patients with stage III non-small-cell lung cancer receiving concurrent chemoradiation
J. van der Laken
PET-CT of biodistribution of rituximab in relation to therapeutic outcome and
histological response of lymphoid tissue in rheumatoid arthritis patients
E.F. Smit
Phase 1b open-label clinical trial of continuous once daily oral treatment using BIBW
2992 plus cetuximab (Erbitux®) in patients with non-small cell lung cancer with
progression following prior ertlotinib (Tarceva®) of gefintinib (Iressa®)
G.J. Ossenkoppele
HOVON 102 AML/SAKK 30/09: Randomized study with a run-in feasibility phase to
assess the added value of Clofarabine in combination with standard remissioninduction chemotherapy in patients aged 18-65 years with previously untreated
acute myeloid leukemia (AML) or myelodysplasia (MDS) (RAEB with IPSS ≥ 1.5)
A.A. van der Loosdrecht
Dentric cell Vaccination in patients with Acute Myeloid Leukemia
A.J.M. van den Eertwegh
Adjuvant immunotherapy with anti-CTLA-4 monoclonal antibody (ipilimumab) versus
placebo after complete resection of high-risk Stage III melanoma: A randomized,
double-blind Phase III trial of the EORTC Melanoma Group.
C.M.J. van Nieuwkerk
High-dose versus standard-dose weight-based ribavirin in combination with
peginterferon alfa-2a for patients infected with hepatitis C virus genotype 1 or 4.
M.J. Wondergem
Zevalin (90Yttrium-ibritumomab tiuxetan)-BEAM and atulogous stem cell
37
9. Scientific Research Committee
Principal investigator
Title
transplantation or single dose 90Yttrium ibritumomab tiuxetan as consolidation of
induction chemotherapy in patients with transformed non-Hodgkin’s lymphoma
(Phase II, clinical trial).
S. Meijer
Ultrasound-guided breast-sparing surgery to improve cosmetic outcomes and quality
of life.
M. Dijkstra
High risk human papilloma virus detection in semen.
J. Buter
Randomized phase II study of Bevacizumab versus Bevacizumab plus Lomustine in
patients with recurrent Glioblastoma: the BELOB trial.
G.J. Ossenkoppele
Pro no. CAMN107EIC01 – A phase IIIb, multicentre, open-label study of nilotinib in
adult patients with newly diagnosed Philadelphia chromosome and/or BCR-ABL
positive CML in chronic phase.
M. Labots
Targeted therapy selection based on tumor tissue kinase activity profiles for patients
with advanced solit malignancies, an exploratory study.
J.J.W.M. Janssen
HOVON 106 double UCBT: a phase II study to assess engraftment and engraftment
kinetics after double cord blood transplantation with a reduced-intensity
conditioning regimen in patients eligible for allogeneic stem cell transplantation
lacking a matched urelated donor.
H.M.W. Verheul
A randomized, souble-blind, placebo-controlled phase III study of regorafeib plus BSC
versus placebo plus BSC in patients with metastatic colorectal cancer (CRC) who
have progressed after standard therapy.
A.J.M. van den Eertwegh
BRIM3: A Randomized, Open-label, Controlled, Multicenter, Phase III Study in
Previously Untreated Patients with Unresectable Stage IIIC of Stage IV Melanoma.
T.M. van der Sluis
Intraprostatic Androgen level Assessment: Clinical Implications and Potential for
Optimising Medical Treatment of Benign Prostatic Hyperplasia and Prostate Cancer
V. de Haas
Bortezomib (Velcade®): A feasibility and phase II study in childhood relapsed acute
lymphoblastic leukemia, study ITCC021
J.M. Zijlstra
A Phase III randomized, double blind, placebo controlled multi-center study of
panobinostat for maintenance of response in patients with Hodgkin’s lymphoma who
are at risk for relapse after high dose chemotherapy and autologous stem cell
transplant.
W.R. Gerritsen
CA184-095 – Randomized, Double-Blind, Phase 3 Trial to Compare the Efficacy of
Ipilimumab vs Placebo in Asymptomatic of Minimally Symptomatic Patients with
Metastatic Chemotherapy Naive Castration Resistant Prostate Cancer
W.H.M. Verbeek
Clinical Staging and Survival in Refractory Celiac Disease: Validation and Refinement
of a New Staging Model using a Multinational Cohort
W.R. Gerritsen
A multinational phase 3, randomized, double blind, placebo controlled efficacy and
safety study or oral MDV3100 in patients with progressive castration-resistant
prostate cancer previously treated with Docetaxel based chemotherapy.
J.M. Zijlstra
HD 16: Treatment optimization trial in the first-line treatment of early stage
Hodgkin lymohoma; treatment stratification by means of FDG-PET
J.J.W.M. Janssen
HOVON 96 GVHD: Prevention and treatment of severe GVHD after allogeneic
hematopoietic stem cell transplantation, applied as consolidation immunotherapy in
patients with hematological malignancies; a prospective randomized phase III trial.
E.F. Smit
Open label study of bevacizumab maintenance therapy (Avastin) with or without
pemetrexed after a first line treatment chemotherapy with bevacizumab-cisplatinpemetrexed in patients with advanced, metastatic or recurrent non-squamous cell
lung cancer (NSCLC)
G.J.L. Kaspers
Glucocorticoid induced HPA axis suppression in childhood acute lymphoblastc
leukemia and lymphoma
E. Boven
Effectiveness of physical exercise during chemotherapy to improve physical fitness
and reduce fatigue: a randomized trial
J. Swart
Inzet en effectiviteit TNF-alfa blokkerende geneesmiddelen bij Juveniele
Idiopatische Artritis
O.S. Hoekstra
Induction of hypoxia following radiofrequency ablation of liver tumors
H. Swank / D. van der Peet
Laparoscopic peritoneal lavage or resection for generalised peritonitis for perforated
diverticulitis: a nationwide mulitcenter randomised trial [NTR 2037]
M.E.D. Chamuleau
Protocol: GAO4753g- An Open Label, Multicenter, Randomized, Phase III Study of the
Efficacy and Safety of Bendamustine compared with Bendamustine + RO5072759
(GA101) in Patients with Rituximab-Refractory Indolent non-Hodgkin’s Lymphoma
38
9. Scientific Research Committee
Principal investigator
Title
(NHL)
G.J. Ossenkoppele
HOVON 103 AML (Lenalidomide): A randomized phase II multicenter study with a
safety run-in to assess the tolerability and efficacy of the addition of oral
lenalidomide to standard induction therapy in AML and RAEB ≥ 66 years and very
poor risk AML ≥ 18 years
T.M. van der Sluis
Castration levels of testosterone in men who receive LHRH agonist therapy for
prostate cancer measured by conventional radio-immuno assay and tandem mass
spectrometry
G.J. L. Kaspers
ICC APL Study 01. International consortium Childhood Acute Promyelocytic Leukemia
Study 01
J. Frantzen
Randomized phase III trial comparing immediate versus deferred nephrectomy in
patients with synchronous metatstatic renal cell carcinoma
W. Menke- van der Houven van
Oordt
Treatment of optimization of cetuximab in patients with metastatic colorectal
cancer based on tumour uptake of 89Zr-labeled cetuximab assessed by PET
J.J. van der Vliet
Chemoradiation combined with panitumumab followed by surgery for patients with
operable esophageal cancer
W.R. Gerritsen
A phase 3 study to evaluate the efficacy and safety of Docetaxel and Prednisone
with or without Lenalidomide in subjects with castrate-resistant Prostate Cancer
J.M. Zijlstra
HOVON 105 PCNSL / ALLG NHL 24: Rituximab in Primary Central nervous System
Lymphoma. A randomized HOVON / ALLG intergroup study
V. de Haas
A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose
Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children with Newly
Diagnosed Standard Risk Medulloblastom: A Phase III Double Randomized Trial
W.A. Kors
Whole-body MR imaging for staging malignant lymphomas in children (dos.
NL16860.041.07)
S. Zweegman
Carfilzomib in combination with Thalidomide and Dexamethasone for remission
induction and consolidation op Multiple Myeloma at first presentation (Protocol no:
IST-CAR-503)
E.M. de Boer
A double blind, comparative, superiority, multi center investigation evaluating the
efficacy of an absorbent foam dressing containing silver (Mepilex AG) versus the
same dressing without dressing used on subjects with venous leg ulcers or mixed
ulcers – PUMA 416
V. de Haas
Is early revaccination after ALL therapy feasible? (EVA Study )
V. de Haas
Caphosol, a therapeutic option in case of cancer therapy induced mucositis in
children?
C.C.L.M. Boons
Adherence and patients’ experiences with oral anticancer agents
S. Grewal
The role of surgery-induced inflammatory mediators in macrophage activation
A.A. van Bodegraven
A randomized, double-blind, placebo-controlled study to evaluate the safety,
tolerability , and efficacy of AMG 827 in subjects with moderate to severe Crohn’s
disease
M. Wondergem
A phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial
to Study the Safety, Tolerability, Efficacy and Immunogenicity of V212 in Recipients
of Autologous Hematopoietic Cell Transplants (HCTs)
R. de Bree
The clinical value of combined FDG-PET/CT imaging in response evaluation after
radiochemotherapy in patients with potentially operable locally advanced patients
cell carcinoma
R. de Bree
Standardized early detection of primary and recurrent nasopharyngeal carcinoma
(NPC) using (anti-)EBV based tumor markers the Netherlands UI-Jakarta, UGMYogyakarta and Airlangga-Surabaya
R. de Bree
Multicenter studie naar de waarde van ‘whole body’ MRI bij screening op
afstandsmetastasen bij hoofd-halskankerpatiënten
K.P.M. van Galen
Pharmacokinetics of the addition of an acidic beverage to posaconazole coadministered with a proton pump inhibitor in GVHD patients
P. Lips
Jodium 131 remnant ablation in defferentiated thyroid cancer
J. van der Laken
A phase 0 single microdose study to evaluate the pharmacokinetics/-dynamics and
specific targeting properties of 124-I-F8IL10 in patients with active rheumatoid
arthritis
39
9. Scientific Research Committee
Principal investigator
Title
G.J. Ossenkoppele
HOVON 103 AML/SAKK 30/10 Tosedostat: A randomized phase II multicenter study
with a safety run-in to assess the toletability and efficacy of the addition of oral
tosedostat to standard induction therapy in AML and RAEB ≥66 years and very poor
risk AML ≥18 years
S. Zweegman
A phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, ParallelGroup Study to Compare the Efficacy and Safety of Pomalidomide in Subjects with
Myeloproliferative Neoplasm-Associated Myelofibrosis and Red Blood CellTransfusion-Dependence
G.J. Ossenkoppele
A Pivotal phase 2 trial of ponatinib (AP24534) in patients with Refractory Chronic
Myeloid leukemia and ph+ Acute Lymphoblastic Leukemia
R. de Bree
Electrochemotherapy in head and neck cancer patients
E. Boven
Nature and mechanism of cognitive deficits following chemotherapy: an (f)MRI study
A.J.M. van den Eertwegh
Ónderzoek naar de aanwezigheid en functionaliteit van immuncellen in het bloed
van onbehandelde gezonde mannen en prostaatkankerpatiënten die behandeld zijn
met GM-CSF-getransduceerde allogene vaccins en anti-CTLA-4 antistoffen
I.E. van der Horst-Bruinsma
NA 22823B: A Ph II/III seamless, multi-center, randomized, double-blind, placebo
controlled study of the reduction in signs and symptoms and inhibition of structural
damage during treatment with tocilizumab versus placebo in patients with
ankylosing spondylitis who have failed non-steroidal anti-inflammatory drugs and are
naïve to TNF antagonist therapy
I.E. van der Horst-Bruinsma
WA 22908B: A randomized, double-blind, parallel-group placebo-controlled study of
the safety and reduction of signs and symptoms during treatment with tocilizumab
(TCZ) versus placebo in patients with ankylosing spondylitis who have had an
inadequate response to previous TNF antagonist therapy
V. de Haas
Development of chronic disease in newly diagnosed Idiopathic Thrombocytompenic
Purpura of Childhood. A randomized controlled study on the influence of treatment
with intravenous gammaglobulin on the course of the disease (korte titel: De TIKI
studie: therapie met of zonder IVIG voor kinderen met acute ITP)
S.H.S Hashemi
A randomized trial comparing longstanding indwelling pleural catheters with
pleurodesis as a frontline treatment for malignant pleural effusion
R.J.F. Felt
A 12-week, randomised, double-blind, placebo-controlled trail to evaluate the
efficacy, quality of life, safety and tolerability of prucalopride in male subjects with
chronic constipation
E. Boven
Randomized double-blind trial of Bepanthen cream versus Cetomacrogel cream in
the prevention of papulopustular eruption in patients receiving epidermal growth
factor receptor inhibitors (EGFRI) BeCet
I.M. Verdonck – de Leeuw
Preventive Swallowing Exercises to prevent persistent swallowing dysfunction after
curative (chemo)-radiation in head and neck cancer
I.M. Verdonck – de Leeuw
Preventive Swallowing Exercises to prevent persistent swallowing dysfunction after
curative (chemo)-radiation in head and neck cancer ( kleine wijziging t.o.v. eerder
protecoll)
O. Visser
Risk factors for alloimmunization after erythrocyte transfusion: a transfusion case
control study.
A.A. van de Loosdrecht
Role of flow cytometry in the assessment of restoration of hematopoiesis during
standard exjade® treatment in patients with low-intermediate-I risk
myelodysplastisc syndromes
R.J.B.J Gemke
Dutch version of the Adolescent Sleep Habits Questionnaire; assessment of a Dutch
norm-reference and evaluation of reliability and validity
P.E. Postmus
De prevalentie van het Birt-Hogg-Dubé syndroom bij spontane pneumothorax
patiënten
A.J.M. van den Eertwegh
The TEAM trial (tasigna efficacy in advanced melanoma): A randomized, phase III,
open label, multi-center, two arm study to compare the efficacy of Tasigna® versus
decarbazine (DTIC) in the treatment of patients with metastatic and/or inoperable
melanoma harbouring a c-Kit mutation
V. de Haas
SIOP LGG 2004: Cooperative multicenter study for children and adolescents with low
grade glioma
A.A. van Bodegraven
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Comparing REMICADE (infliximab) and placebo in het Prevention of recurrence in
Crohn’s disease patients undergoing surgical resection who are at an increased risk
of recurrence (PREVENT-study)
40
9. Scientific Research Committee
Principal investigator
Title
A.A. van Bodegraven
A phase II, randomized, double-blind, placebo-controlled study to evaluate the
clinical efficacy, safety and immunogenicity of Neovacs’ TNF-alpha Kinoid in adults
subjects with Crohn’s disease
E.F. Smit
A Randomised phase III trial of Gemcitabine / Carboplatin with or without BSI-201 (a
PARP 1 Inhibitor) in patients with previously untreated advanced squamous cell lung
cancer
E.F. Smit
A phase II, multi-center, open-label study of AUY922 administered IV on a once
weekly schedule in patients with advanced non-small-cell lung cancer that have
progressed after at least two line of prior chemotherapy (CAUY922A2206)
E.F. Smit
LUME-Lung 3: A phase I/II study of continuous oral treatment with BIBF 1120 added
to standard gemcitabine/cisplatin therapy in first line NSCLC patients with squamous
cell histology
A.A. van de Loosdrecht
A multicenter, randomized, double blind, placebo controlled clinical trail of
deferasirox in patients with myelodysplastic syndromes (low/int-1 risk) and
transfusional iron overload (TELESTO)” (‘ICL670A2302’)
J.A. Castelijns
Comparison of ADC-values in head and neck region of normal volunteers regarding
different DW-MR-scanners acquired at different time points
A.J.M van den Eertwegh
Releasing the brakes on CD8+ T cells in the melanoma sentinel lymph node by preoperative local administration of low-dose anti CTLA-4 (tremelimumab)
R.H.M. Verheijen
A Fase IIIb, open, multi-centre gynaecological extension study for the follow-up of a
subset of HPV-015 study subjects (protocol HPV-062 EXT:015)
E.F. Smit
A randomized phase II study of paclitaxel-carboplatin-bevacizumab with or without
nitroglycerin patches in patients with stage IV non-squamous-non-small cell lung
cancer: NVALT12
J.J. van der Vliet
Phase 1-2 study of everolimus and low dose oral cyclophoshamide in patients with
metaststic renal cell cancer
E.F. Smit
Chloroquine as anti-autophagy drug in small cell lung cancer (SCLC) patients: A
phase I trial to be followed by a phase II trial
CWO: Research projects / grant proposals
Grant
Principal investigator
Title
KWF
P. Sminia
Targeting resistance to radio-chemotherapy by inhibition of the PI3KinaseAkt signalling pathway
Reumaresearch
C.L. Verweij
Cross-talk between TNF and IFN in rheumatoid arthritis
Top-Go
J.P. de Winter
The role of DDX11, ESCO1 and ESCO2 in sister chromatid cohesion, DNA
damage response and carcinogenesis
ERC
R.H. Brakenhoff
Selection of drugable gene targets for squamous cancer therapy by
functional genetic screens
ZonMW Transl
N.H. Hendrikse
Imaging of [11C]erlotinib pharmacokinetics in non small cell lung cancer
patients; an in vivo study with positron emission tomography
Instituutspromovendus
B. Carvalho
Identification of novel oncogenes/oncomirs located at 13q involved in the
progression of colorectal adenoma to carcinoma
KWF
M. van Egmond
Identify inflammatory mediators responsible for induction of liver
metastases development after surgery
Instituutspromovendus
E. Bloemena
The possible diagnostic role of mucin expression in tissue and sliva in
patients with a salivary gland tumor
KWF
J.P. de Winter/ J.C.
Dorsman
Novel players in the Fanconi anemia pathway
KWF
C.J.A. Haasbeek
Stereotactic radiotherapy of oligometastic disease
Instituuspromovendus
S. Gibbs
The development of immuno-competent human skil and oral mucosa
equivalents and their use in determining factors involved in T cell skewing
and imprinting
Promovendus
S. Gibbs
Use of Skin Tissue Engineering to Study Keloid Formation
Instituutspromovendus
Q. Waisfisz
Towards targeted treatment of (familial) breast cancer
41
9. Scientific Research Committee
Grant
Principal investigator
Title
VONK
H. Blufpand
Renal (dys)function in pediatric oncology
BioRange II
R.X. Menezes /
N. Chaturvedi
Statistical integration of multiple-source high-throughput genomics and
phenotypic data
HLW bv Helmond
C. Mulder / M. Seinen
Improving Thiopurine and Methotrexaat therapies in inflammatory bowel
diseases
ZonMW
R. Beelen
Innovative Cryo-Electronmicroscopy on living cells
Promovendus
J. Berkhof
Modelling HPV infection dynamics
VONK
M.H.A. Jansen
Pontine gliomas
AGIKO
A. Vis /
T. van der Sluis
Measuring Intraprostatic Androgen Concentrations Using Lc-Ms/Ms: From
Bench To Bedside
ZonMW Doelmatigheid
L. van Tuyl
Pay less and achieve more with monitoring and intensive combination
therapy in early rheumatoid arthritis
ZonMW Doelmatigheid
R. de Bree
Response evaluation after chemoradiation for advanced oropharyngeal
cance (REACTION study)
ZonMW Doelmatigheid
M. van Egmond
‘Perioperative selective decontamination of the digestive tract (SDD) in
elective colorectal cancer patients (SELECT trial)’
Instituutspromovendus
B. Appelmelk
Live Mycobacterium bovis BCG bacteria as a platform for the induction of
enhanced tumor antigen-specific immunity.
ERC starting grant
L. Smit
The specific eradication of AML leukemic stem cells. Speradileuk
Industry
E. Boven
Phase II randomized trial of combination therapy of paclitaxel and
bevacizumab versus paclitaxel, capecitabine and bevacizumab as first-line
treatment for locally recurrent or metastatic breast cancer patients with
HER2/neu negative tumor.
Industry
S. Zweegman/
J. Regelink
Bone disease in multiple myeloma
Kika
J. Cloos
The role of impaired FPGS splicing in methotrexate response in childhood
acute lymphoblastic leukemia.
Maag-Lever-Darm
Stichting
S.A.G.M. Cillessen /
Marijn Radersma
Is c-Abl a potential target for therapy in Enteropathy Associated T-cell
Lymphomas?
KWF
M. van Egmond
Surgical removal of primary colorectal cancer: a double-edged sword?
CCA
Victor van Beusechem
Monitoring of cancer progression and therapy response by analysis of viral
microRNAs
CCA
Nicole van Grieken
(vi-miRNAs) in circulating exosomes.
CCA
Sandra van Vliet
Identification of predictive markers in esophageal carcinoma in patients
receiving neoadjuvant chemoradiotherapy
CCA
Thom Würdinger
Exploring the sweet spot in colon cancer mutations
CCA
Gerd Bouma
Blood platelets: a potential RNA source for companion diagnostics of
cancer
CCA
Dries Budding
The role of tight junctions in the development of gastrointestinal
neoplasia
CCA
Tanja de Gruijl
Non-invasive screening for colonic carcinoma by profiling of the intestinal
microbiota
CCA
Joke den Haan
Locoregional immunopotentiation and vaccination with anti-CD40 in early
and advanced stage melanoma.
CCA
Ab Geldof
Development of anti-melanoma immunotherapy by targeting to Siglec-1:
Translation into the human setting
CCA
Elisa Giovannetti
Choline-PET scanning for chemotherapy response monitoring in prostate
cancer
CCA
Astrid Greijer
Novel predictive parameters for pemetrexed-based therapy of lung cancer
and mesothelioma
CCA
Astrid Greijer
Cytolytic virus activation (CLVA) therapy for EBV-driven gastric carcinoma
CCA
John Jacobs
Targeted therapy and PET-imaging of virus reactivation as new approach
for EBV driven cancers
CCA
Annette Moll
Systemic immunomodulation local Interleukine 2 (IL-2) treatment in
42
9. Scientific Research Committee
Grant
Principal investigator
Title
recurrent bladder carcinoma after complete and incomplete surgery.
CCA
Gemma Kenter
Diagnosis of vital tumor tissue by OCT and MRI in retinoblastoma patients
CCA
Jacqueline Langius
The role of the immune status of tumour draining lymph nodes in cervical
cancer.
CCA
Saskia Mostert
Predictive factors for severe weight loss in head and neck cancer patients
during radiotherapy and the consequences on quality of life and survival.
CCA
Daniel Peeper
Compliance with childhood cancer treatment in the low-income country
Kenya
CCA
Michiel Pegtel
Development of diagnostic and therapeutic tools from a metastatic breast
cancer signalling network
CCA
Frits Peters
Development of autologous RNAi nanoparticles for cancer treatment
CCA
Thang Pham
Principal Investigator : Michiel Pegtel
CCA
Alex Poot
Regulation of subcellular localization of BCRP (ABCG2) and MRP1 (ABCC1)
by AKT-signalling: implications for EGFR-targeted therapies.
CCA
Saskia Santegoets
Database construction to enable integrative analysis of proteomics
experiments for cancer specific markers and pathways
CCA
Suresh Senan
The development of radiolabeled tyrosine kinase inhibitors for PET
imaging: a predictive tool for cancer therapy.
CCA
Linda Smit
Tumor antigen-specific autoantibody responses before, during and after
cancer immunotherapy: identification of candidate biomarkers for patient
selection and (early) clinical response prediction.
CCA
Victor Thijssen
Designing information for patient participation in treatment decisions for
stage I non-small cell lung cancer
CCA
Wendy Unger
Target identification specific for leukemic stem cells of Acute Myeloid
Leukemia.
CCA
S. Wilting
Cancer development modelling by integrated multilevel molecular
characterisation of a longitudinal model system for HPV-induced
carcinogenesis
Van Walree Fonds
E.J.M. Stoop
Keystone symposium on Tubercolosis, Vancouver, Canada;
posterpresentatie abstract: ‘Zebrafish embryo screen for identification of
mycobacterial genes involved in granuloma formation’
Van Walree Fonds
E.M. Weerdenburg
Keystone symposium on Tubercolosis, Vancouver, Canada;
posterpresentatie abstract: ‘Less is more: ESX-5 deficient mycobacteria
are hypervirulent in zebrafish’
KWF
M. van Bokhorst-de
van der Schueren
Is cancer cachexia preventable or delayable? (tbv KWF Voeding en Kanker,
zie ook PV10/60)
VENI
P. Papadopoulos
Transcriptional control during maturation of dendritic vells
VENI
L.H.D. van Tuyl
The patient perspective on remission in chronic diseases.
VENI
M. Irandoust
Protein tyrosine phosphatises as novel treatment targets in acute myeloid
leukemia
VENI
C. Vermeulen
Determinants of oncolytic adenovirus therapy in human tumor cells:
elucidating the mechanism of telomere maintenance
VENI
J.M. Ilarregui
Cross-talk between MGL and galectin-1 in the regulation of tolerogenic
responses in autoimmune inflammation
VENI
I.V. Bijnsdorp
Identifying high risk prostate cancer
KWF
J.J. van der Vliet
Specific tumor-targeting of iNKT cells and Vy9Vδ2 T cells using nanobody
technology
Vumc/MCA
J.A.J. Rood
Information needs of patients with heamatological malignancies
Mozaiek
S. Grewal
Colorectal cancer surgery: a Trojan horse for liver metastases?
Mozaiek
E. Boven/S.W. Lam
Towards a tumor-specific protein fingerprint for early detection of breast
cancer
43
9. Scientific Research Committee
9.3. CWO-DEC: Animal related protocols
Principal investigator
Title
W. Unger
Development of EAE in human DC-SIGN transgenic mice
W. Unger
Development of EAE in MGL deficient mice
R. Roozendaal
Regulatie van antigeen specifieke T-cellen door lymfeklier stroma
J. Koning
Recrutering van mesenchymale stamcellen naar lymfeklieren uit omliggend
vetweefsel na immuunactivatie
L. Smit
Vast stellen van het effect van CLL-1 antilichaam (CR2357), CLL-1
antilichaam-drug-conjugaat (CR2357-ADC) en bispecifieke CLL-1xCD3 BiTE
antilichaam op de leukemie initiërende capaciteit van CLL-1 positieve
stamcellen in AML
G. van Dongen
Targeted optical imaging of subcutaneous tumors with anti-EGFR nanobodies
coupled to near-infrared fluorophores
J. den Haan
Practicum FACS and CFSE Proliferatie Assay (april 2010)
J. den Haan
Vergelijking effectiviteit van antilichaam-antigeen complexen in de activatie
van cytotoxische T cellen.
J. den Haan
Deletie van specifieke macrofaag en dendritische cel types door middel van
cytochroom C-antilichaam complexen
T. Lagerweij
Selectie van geschikte primaire cellijnen voor 3 vormen van
kinderhersentumoren (hoog-gradig glioom, medulloblastoom en
ependymoom).
D.A. Heuveling
Tumor targeting performance of the 89Zr-labeled anti-CD44 antibody
RO5429083
I. Ouwehand
De inductie van anti-tumor responsen via C-type lectine targeting
G. van Dongen
Hersenopname van liposomale systemen die de “blood brain barrier” (BBB)
kunnen passeren
R. Molenaar
Effect van vitamine A op DC en T cel migratie
M. van Hout
Het beschermend effect van IgA en/of FcαRI tegen Salmonella enterica
infectie
N. Gul
Effecten van LPS op het ontstaan van trauma geïnduceerde lever metastases
Nathalie Koning
Ontwikkeling van EAE in MGL-deficiënte muizen
Marieke Beijer
Effect van vitamine A op de ontwikkeling en homeostase van dendritische
cellen in de milt
Marjolein van Egmond
Mechanisme van tumor celdood inductie na incubatie met bispecifieke
antistoffen gericht tegen FcαRI op neutrofielen
B. Mahdavian Delavary
Kan het veranderen van macrofaag fenotype de genezing van diepe brandwonden
verbeteren?
E.D.Keuning
Oefenprotocol voor Delayed-Type Hypersensitivity (DTH) Response bij
muizen.
G. van Dongen
Inert coupling of near-infrared fluorophore IRDye800CW to monoclonal
antibodies for clinical photoimmunodetection
N. Gül
Effecten van LPS en operatie op het ontstaan van lever metastases
A. Stavenuiter
Potentieel gunstige effecten van de selectieve Vitamine D analogen op
peritoneale veranderingen in een preklinisch dier model voor peritoneale
dialyse
J. Glim
Verschil in herstel tussen mucosale en cutane wonden
G. van Dongen
Dosis-respons-, biodistributie- en combinatie therapie studies met anti-HGF
nanobodies
D.A. Heuveling
Evalueren van de waarde van tumor- en schildwachtklierdetectie met behulp
van optische detectie in een lymfogeen metastase model in het konijn
T. Lagerweij
Toediening van geneesmiddelen via convection enhanced delivery in de
hersenstam
R. Fijneman
Identification and validation of colon tumor biomarkers for early detection of
colorectal cancer (CRC)
44
9. Scientific Research Committee
Principal investigator
Title
N. Koning
Development of EAE in human DC-SIGN transgenic mice
K. Gotink/H. Verheul
Resistentie tegen anti-angiogene tyrosine kinase remmers
M. van der Pas
Darm perfusiestudie
E. Stoop
Virulentie en vaccin potentie van Mycobacterium marinum mutanten in
volwassen zebravissen
R. Fijneman
Molecular imaging of colon tumors for early detection of colorectal cancer
(CRC)
I. Bijnsdorp
Het vergelijken van de eiwit expressie in de verschillende stadia van
prostaatkanker in het Dunning model
L. Smit
De invloed van microRNA expressie op tumor initiërende capaciteit,
chemotherapie resistentie en tumorigeniteit van acute myeloide leukemie
(AML)
B. Braakhuis
Identificatie van stamcellen in hoofd-halskanker
E. Weerdenburg
Opgroeien van zebravis embryo’s geïnfecteerd met ESX-5 deficiënte
Mycobacterium marinum
M. Bögels
Effecten van darm chirurgie op de aanhechting van levermetastasen
I. Hiemstra
Invloed van Toll-like receptor signalering op de aanwezigheid van DC subsets in de
darm
H. Veninga
Het effect van antigen targeting naar verschillende types dendritische cellen en
macrofagen op CD4 T cel en B cel responsen
M. van Hout
Het effect van FcαRI gemedieerde neutrofiel activatie op macrofaag functie
M. Bögels
Geeft een IgG3 antilichaam variant met verhoogde halfwaardetijd een betere
antilichaamtherapie tegen ontwikkeling van carcinoma levermetastases in muizen
B. Braakhuis
Behandeling van hoofd-halskanker door selectieve targeting van Wee1 kinase
G. van Dongen
Therapeutic efficacy of the human-like camelid-derived anti-IL6 antibody “ARGX109ARGX-109” in xenograft bearing nude mice
J. den Haan
Opname van verschillende serotypes Neisseria meningitidis bacteriën door
macrofagen in de milt
T. Lagerweij
Toediening van IFN-beta producerend virus via ‘convection enhanced delivery’
voor de behandeling van hersenstamtumoren.
T. van der Sluis
Serumconcentratie van testosteron ten gevolge van prostaatkanker en stabiliteit
van androgenen in prostaatkanker na loskoppelen van de circulatie
S. van Rijn
In vivo en ex vivo detectie of epitope getagged Gaussia luciferase uit bloed
M. van Egmond
De rol van van immunoglobulin A (IgA) en de IgA Fc receptor (Fc RI) in allergische
luchtweg ontstekingen
M. Ulrich
Effect van foetale cellen gezaaid in collageen scaffolds op de littekenvorming
(varkensmodel, vervolg)
M. Ulrich
Vergelijking tussen lokale en systemische toediening van een ACE-remmer bij de
genezing van halfdiepe brandwonden bij de rat
T. Lagerweij
Therapeutische toepassingen voor de behandeling van hersentumoren
G. van Dongen
Preclinical optical molecular imaging with a near-infrared fluorescent anti-EGFR
nanobody
V. van Beusechem
Evaluatie van een nieuw conditioneel replicerend adenovirus dat een shRNA
gericht tegen synoviolin tot expressie brengt in een humaan subcutaan longtumor
model in de naakte muis
J. Posthuma de Boer
Evaluatie van therapeutisch effect van Doxorubicine in combinatie met kinase
knockdown in een subcutaan model voor humaan osteosarcoom
45
46
10. Training and education
10. Training and education
Training and education
Performing high quality research and patient care is an important goal of CCA/V-ICI. To this end, it
is essential to train and to pass on knowledge to students, (young) researchers, technicians as well
as to clinicians and care professionals. This educational path includes lectures, workshops, tutorials,
practical training and clinical demonstrations.
To ensure highly qualified professionals in the future, it is essential to provide a well defined
educational program starting already at medical and biomedical undergraduate students. CCA/V-ICI
is involved in a high number of theoretical and practical courses during the bachelor as well as
master phase. Furthermore, a high number of training positions are available at our laboratories.
For medical students CCA/V-ICI organizes both an Oncology and an Immunology graduation profile.
Furthermore, for the top medical students CCA/V-ICI is providing a Honours Program in Oncology
and Immunology. In the General Master Biomedical Sciences CCA/V-ICI organizes the differentiation
Immunology. For biomedical students a specific TOP-Master Oncology is available, which is aimed at
the training of students for a research function in an oncological research institute.
PhD students attend various theoretical and practical courses, most of them organized by the
graduate schools in which CCA/V-ICI participate, such as the Oncology Graduate School Amsterdam
(Oncologie onderzoeksschool Amsterdam -OOA) and Amsterdam Leiden Institute for Immunology
(ALIFI). Monthly CCA/V-ICI lectures are organized in which the program/project leaders of the 5
research programs of CCA/V-ICI are actively involved. These lectures are aimed at achieving more
integration of the research performed in the 5 different research programs and for education
purposes for researchers in CCA/V-ICI.
Postgraduate Education for (care) professionals is organized by the individual departments involved
in CCA/V-ICI. In the future these and new activities will be organized together within CCA/V-ICI.
1. Training and education
To ensure highly qualified clinicians and researchers within CCA/V-ICI, it is essential to train and
pass on knowledge in a long-life learning program. Therefore, training and education is a major
focus of CCA/V-ICI. Aim is to stimulate and facilitate education in the field of oncology and
immunology at various levels, starting already with undergraduate (bio)medical students, through
Master-students, PhD-students, postgraduate (specialist) training and beyond to education of (care)
professionals.
This educational path includes lectures, workshops, tutorials, practical training and clinical
demonstrations.
Committee for Education & Training
This committee supervises and advices about all training and education activities within CCA/V-ICI.
The graduate training is organized within the Oncology Graduate School Amsterdam (OOA) and the
Leiden Amsterdam Institute for Immunology (ALIFI).
Committee for Education & Training:
- Prof. dr. C.R Leemans (chair)
- Prof. dr. R.H.J. Beelen
- Prof. dr. G.A. Meijer
- Dr. M.M. van Duist
- Dr. E.M. Ruhé-Hoogervorst (secretary)
Perspective
At present, CCA/V-ICI is already highly involved in Training and Education at various levels,
including:
- Compulsory semester courses during Bachelor and Master phase of (bio)medicine study.
- 6 week optional course ‘Immunology and infection’ and ‘Oncology’ during Bachelor phase of
Medicine study
- Scientific traineeship during Master phase of (bio)medicine study
- TopMaster Oncology Programme for biomedicine students (about 30/year)
47
10. Training and education
- Differentiation Immunology in the Master Programme Biomedical Sciences (about 30/year)
- Honoursprogramme
- Oncology graduate school Amsterdam
- Amsterdam-Leiden institute for Immunology
- Development of a post-graduate centre
- Organization Keynote lectures, workshops and Symposia
To guarantee high quality training programs, in which numerous CCA/V-ICI members are involved,
the main perspective of our educational program is to survey and coordinate these, and initiate new
training activities (within the scope of development of a graduate school).
Collaboration
CCA/V-ICI stimulates international collaborations and exchanges with top-leading scientist all over
the world.
For the PhD students in the oncology field CCA/V-ICI participates in the Oncology Graduate School
Amsterdam (OOA). OOA is a joint graduate school of the Netherlands Cancer Institute (Nederlands
Kanker Instituut - NKI) and the medical faculties VUmc and AM) of the VU and the UvA, respectively.
These organizations strive for excellence in research and education in oncology, the realization of
which is promoted by their participation in OOA.
The mission of the OOA is to offer education in oncology research in the widest sense at an
excellent level, and ensure proper supervision to graduate students in the Amsterdam region. OOA’s
graduate students are scientist-in-training who receive additional theoretical and practical
education on various subjects related to cancer research. In addition, collaboration is stimulated
between the research groups of the 3 institutes as well as (inter)nationally. In this way, the PhD
students have the opportunity to conduct high level research and attend courses that are organized
by a faculty of outstanding researchers with evident scientific output in international literature and
excellent track records.
For the education of PhD students specifically in the immunology field, there is a collaboration with
the University of Leiden, Sanquin Amsterdam and the Amsterdam Medical Center. AmsterdamLeiden Institute for Immunology (ALIFI) provides special courses for PhD students. A specific
program for PhD students has been set up providing a training programme according to the criteria
of the “Stichting voor opleiding tot Medisch-Biologisch Wetenschappelijk Onderzoeker” (SMBWO).
For graduate and postgraduate training cooperation with the VUmc Education Institute (Instituut
voor Onderwijs en Opleiding) exists.
In addition, regular keynote lectures, symposia and workshops with renowned international speakers
are organized.
2. Graduate profile for medical students
Medical students graduate in one of the ten elective profiles/ specialization programmes. This
includes a theoretical course of 6 weeks (3rd bachelor year) and a research internship of minimal 18
weeks (during the master phase). CCA/V-ICI coordinates the profiles ‘Oncology’ and ‘Immunology
and Infection’. About 20% of students chose for one of those profiles.
Oncology course
In 2010 a 6-week course on Oncology was given, 53 students participated: 50 medical students and 3
Master Oncology students. The course consisted of lectures, literature discussions, practical work
and laboratory/clinical visits. These weeks were organized around four specific themes: 1.
hematological malignancies, 2. colorectal cancer, 3. head and neck cancer, 4. breast cancer and 5.
lung cancer. During the course students worked in small groups on a specific research question,
guided by a senior researcher. A research proposal was written which was presented and discussed
at the final day of the course.
Immunology course
In 2010 a six-week course on Immunology and infection was given in which 20 medical students
participated. The course consisted of lectures, practical work and laboratory and clinical visits. The
weeks were organized around three specific themes: 1. rheumatoid diseases, 2. tuberculosis and 3.
celiac diseases and inflammatory bowel diseases. During the course students worked in small groups
48
10. Training and education
on a scientific review, guided by a senior researcher. This review was presented and discussed at
the final day of the course.
Honours Programme
The Honours Programme (HP) has started in 2000 (called Masterclass). This program is focused on
the top 10% medical students. These students start in their 2nd bachelor year, with a research
training program. The selected students first follow introduction courses in 4 of the 10 different
research profiles. CCA/V-ICI coordinates the profiles ‘Oncology’ and ‘Immunology and Infection’.
Afterwards they choose their specialization profile and write a research proposal on that subject.
This research project is carried out for 1-2 years next to their regular medicine study. The goal is to
write a scientific paper as first author at the end of this training programme. In 2010, 4 of the 13
selected students started their HP research program at CCA/V-ICI. In addition, 6 students were
already enrolled and 5 students finished their HP research program in 2010.
3. Masters for biomedical students
Master Oncology
The Master’s Programme in Oncology (a VU topmaster’s programme) aims to train students with a
bachelor degree in Biomedical Sciences or other relevant Life Sciences in the field of cancer
research and therapy. Approximately 30 students with different background start each year.
The program consists of compulsory and optional courses, two practical training periods and a
literature surveys. Courses (co)-organized by CCA/V-ICI researchers in 2010 were: “Oncogenesis”,
“Tumour biology and clinical behaviour”, “Immunity” and “Innovative tumour therapy”. Master
Oncology students followed in addition, specific optional courses organized by CCA/V-ICI or OOA
such as: “In the footsteps of Antoni van Leeuwenhoek”, “Epigenetics”, “Radiation Oncology”,
“Gene Regulation Networks”, “Anatomy of the mouse” and the “Oncology” course organized by
CCA/V-ICI for 3rd year medical students.
After completion of the master’s programme, most graduates in oncology continue their careers as
PhD student (75%); either at our research institute or other national or international research
institutions. 16% of the graduates continued with a medical training and 9% went for various other
job positions (e.g. research technician, Clinical Research Associate).
Master differentiation Immunology
Since 2003, biomedical students can follow a general Master offered by the Faculty of Earth and Life
Sciences (FALW). In this master a differentiation Immunology is offered, coordinated by Prof. Y. van
Kooyk, PhD. About 30-40 students enter each year. De course ‘Advanced Molecular Immunology and
Cell Biology’ organized by dr. M. van Egmond is obligatory for all students. Furthermore, optional
courses are organized, like “Clinical Immunology” (prof. dr. Y. van Kooyk), “Molecular Infection
Biology” (W. Bitter) and “Glycoimmunology” (I.M. van Die).
4. PhD student program
CCA/V-ICI is involved in the graduate schools Oncology Graduate School Amsterdam (OOA) and
Amsterdam Leiden Institute for Immunology (ALIFI). PhD students can follow various theoretical and
practical courses in addition to their research training such as general courses on biostatistics and
epidemiology, on laboratory animal technology, writing and presenting in scientific English which
are organized by the VUmc. In addition, several specialized courses on oncology or Immunology
were organized in 2010 by the graduate schools. PhD students are encouraged to participate in
laboratory meetings to actively discuss their findings and those of others, which are organized at
their own department but also at other departments in the same institute or at the collaborating
institutes: the Netherlands Cancer Institute (NKI), Academic Medical Center (AMC) and Leiden
University Medical Center (LUMC). In this way PhD students are actively prepared to present their
results to a critical audience and are able to present their data at (inter)national meetings.
International collaborations and active participation of young researchers is strongly encouraged. To
this end, PhD students are able to visit international meetings and are urged to actively participate.
Furthermore, several of our PhD students perform part of their research project in the research
institute of a collaborating group abroad.
49
10. Training and education
CCA/V-ICI organizes monthly CCA/V-ICI evening lectures in which experienced researchers and PhD
students present their ongoing research, this allows the PhD students to meet other researchers
working at different departments and stimulates cooperation.
Oncology Graduate School Amsterdam (OOA)
PhD students in CCA/V-ICI with an oncology profile are trained within the framework of the OOA, a
joint venture of the VUmc (CCA/V-ICI), NKI and AMC. The OOA strives for excellence in their
research and teaching in basic and clinical oncology and provides every year a high standard training
program. PhD students follow two OOA courses a year and participate twice in the annual graduate
student retreat.
In 2010, 7 courses and 2 Meet-the-Expert session were organized.
- Techniques in Cancer Genomics
- The Microscopic, Macroscopic and Pathologic Anatomy of the Mouse
- Radiation Oncologie
- Gene Regulation Networks
- Epigenetics and non-coding RNA
- Basic medical statistics for clinical and experimental research
- In the footsteps of Anomi van Leeuwenhoek Basic Microscopy
- Novel cancer vaccine strategies: putting it into practice: B.A. Fox (meet-the expert session)
- How to Write High Impact Papers and What to Do When One Gets Rejected?: J.C. Coyne (meet
the expert)
The yearly three-day OOA retreat at Texel allowed PhD students to meet other students working at
the participating institutes or at different divisions within the same institute both at scientific and
social level. See for more information about OOA: www.ooa-graduateschool.org
Amsterdam Leiden Institute for Immunology (ALIFI)
ALIFI is a joint venture of the VUMC (CCA/V-ICI), AMC, NKI, Sanquin, and LUMC. PhD students with
an immunology profile are trained within this framework.
The highly recommended advanced course in Immunology was held at the VUMC and Sanquin. The
course aimed to further extend the knowledge on recent developments in immunology and to
contribute to insight in scientific questions and approaches in immunological research. PhD students
could participate in meet-the-expert sessions, and on several courses and meetings, organized
mostly by the Dutch Society for Immunology (NVVI). In the Immunology Seminar Series, organised by
the MCBI department, (inter)national researchers are regularly invited to present their exiting
findings, PhD students are encouraged to actively participate.
5. CCA/V-ICI evening lectures
The CCA/V-ICI evening lectures were organized by the CCA/V-ICI evening lecture committee. These
evenings are meant to provide information about the ongoing projects and future perspectives in
the five CCA/V-ICI programs and moreover to increase cooperation between the different research
programs and departments. The speakers consisted of a mix of experienced researchers and PhD
students and both laboratory oriented researchers and clinicians.
January 19, 2010
Highlights program 1 (Oncogenesis) and program 3 (Disease profiling)
Host: Otto Hoekstra
Meike de Wit: Identification of prion protein as a cell surface candidate biomarker for colorectal adenoma-to-carcinoma
progression
Otto Hoekstra: Development of prognostically relevant PET tracers for colorectal liver metastases: a pragmatic
approach
February 16, 2010
Highlights program 2 (Immunopathogenesis) and program 4 (Innovative therapy)
Host: Tanja de Gruijl
Jeroen Geurtsen: Cyanovirin: a novel way to prevent Mycobacterium tuberculosis infections?
Fons van den Eertwegh: Vaccination strategies in prostate cancer
March 16, 2010
Highlights program 1 (Oncogenesis) and program 4 (Innovative therapy)
Host: Gert Ossenkoppele
50
10. Training and education
-
David Palma: The ABCs of Stage I NSCLC: Population-based studies from Amsterdam and British Columbia
Petra van der Lelij: Warsaw breakage syndrome: a novel cohesinopathy associated with mutations in the DNA helicase
DDX11
April 20, 2010
Highlights program 2 (Immunopathogenesis) and program 3 (Disease profiling)
Host: Guus van Dongen
Johannes de Boer: Optical Coherence Tomography in clinical medicine
Gijs Wuite: See me, Feel me: New tools for optical manipulation and visualization of biomolecules
May 18, 2010
Highlights program 1 (Oncogenesis) and program 2 (Immunopathogenesis)
Host: E. Hooijberg
Beatriz Carvalho: 20q amplicon driven colorectal cancer progression: who is at the driver seat?
Michiel Pegtel: Functional transfer of viral miRNAs via exosomes
June 15, 2010
Highlights program 3 (Disease Profiling) and program 4 (Therapy)
Host: F. Peters
Nafees Rivzi: PET to predict biodistribution in radio-immunotherapy: the case of Zevalin
Niels Franke: Bortezomib resistance in hematological malignancies
September 21, 2010
Highlights program 3 (Disease Profiling) and program 4 (Therapy)
Host: F. Peters
Nafees Rivzi: PET to predict biodistribution in radio-immunotherapy: the case of Zevalin
Niels Franke: Bortezomib resistance in hematological malignancies
October 19, 2010
Highlights program 5 (Quality of life) and program 1 (Oncogenesis)
Host: Ruud Brakenhoff
Irma Verdonck: Living with cancer: building a winning team by managing knowledge
Marlon van der Plas: Prognostic significance of TP53 mutations in head and neck cancer
November 16, 2010
Highlights program 2 (Immunopathogenesis) and program 3 (Disease Profiling)
Host: Connie Jimenez
Marjolein van Egmond : IgA and its receptor FcalphaRI in chronic inflammation
Marc Warmoes: Proteomics of murine BRCA1 deficient breast tumors identifies DNA repair proteins with prognostic value
in human breast cancer
December 14, 2010
Highlights program 4 (Innovative therapy) and program 5 (Quality of life)
Host: Irma Verdonck
Bregje Philipsen : Regulation of euthanasia in the Netherlands: empirical evidence against the slippery slope
Canan Alhan: The application of flow cytometry for the evaluation of azacitidine treatment in intermediate-2 and high
risk myelodysplastic syndrome patients
51
52
List of contents
Appendices
1.
Organization of CCA/V-ICI
55
2.
Scientific input
59
3.
Newly started PhD projects
71
4.
Scientific output
73
5.
Indicators of esteem
103
6.
Societal impact
145
7.
Ongoing projects
149
53
54
Appendix 1: Organization of CCA/V-ICI
Appendix 1: Organization of CCA/V-ICI
Structure of CCA / V-ICI
Stichting CCA VUmc
Board VUmc
Supportive Staff
1. Oncogenesis
Program Group CCA
Executive
Board
Management Board
CCA / V-ICI
2. Immunopathogenesis
Internal Advisory
Board
3. Disease profiling
External Advisory
Board
4. Therapy
Scientific Research
Committee
5. Quality of life
Committee for
Education
& Training
Management Board
Management Board (MB) members:
- P.C. Huijgens, director of CCA/V-ICI
- G. Kraal, deputy director of CCA/V-ICI
- W.R. Gerritsen, program director CCA
- H.M.W.Verheul, member
- C.R. Leemans, chairman of internal advisory board
- G.C.P.M. Hoskens, manager finances division I
Supportive staff
- Y.M. Duiker (board assistant)
- M.A.J. Koelink (secretary)
- G.K. Kuipers, PhD (senior board assistant)
- E.M. Ruhé-Hoogervorst, PhD (senior board assistant)
Executive Board
The Executive Board (EB) of CCA/V-ICI consists of the program leaders. The EB meets every 2
months together with the MB, chaired by one of the MB directors. The EB advises the MB about:
- research projects
- long-term policy with respect to personnel and materials
- first money stream graduate students
- allocation of equipment for research of > € 12.000
- patient care projects
- clinical and translational research
- education
- fundraising for cancer research, care and education
55
Appendix 1: Organization of CCA/V-ICI
-
early diagnostics
all matters concerning CCA/V-ICI whether on request or not.
The complete EB convenes regularly to discuss the long term policy of CCA/V-ICI.
Executive Board members:
Program 1: Oncogenesis:
- R.H. Brakenhoff
- H. Joenje
- P.J.F. Snijders
Program 2: Immunopathogenesis:
- R.H.J. Beelen
- E. Hooijberg
- Y. van Kooyk
- R. Mebius
Program 3: Disease profiling:
- G.A.M.S. van Dongen
- O.S. Hoekstra
- C. Jimenez
- C.L. Verweij
Program 4: Therapy:
- B.A.C. Dijkmans
- G.J. Ossenkoppele
- G.J. Peters
- S. Senan
- H.M.W. Verheul
Program 5: Quality of Life
- J. Dekker
- G.J.L. Kaspers
- I.M. Verdonck
- O. Visser
Internal Advisory Board
The members of the internal advisory board consist of 5 to 10 heads of departments involved in
cancer and immunology within the VUMC. The chairman is member of the MB. The board meets 4
times a year.
Internal Advisory Board members:
- C.R. Leemans (Chair)
- M.A. Blankenstein
- H.J. Bonjer
- C.J.H. Buren
- B.A.C. Dijkmans
- C.D. Dijkstra
- J.J. Heimans
- K.K. Kenter
- G.A. Meijer
- H. Meijers
- C.J.J. Mulder
- B.J. Slotman
- E.F. Smit
- H.M.W. Verheul
Scientific Research Committee (CWO)
The CWO is divided into a section that advises merely animal related protocols and a section that
advises patient related protocols and other project proposals.
56
Appendix 1: Organization of CCA/V-ICI
The CWO advises about the research policy and about the feasibility of new research projects upon
request of the MB. The CWO advises the MB specifically about the quality and the feasibility of all
research proposals that need permission of the ethical committees for patient related or animal
related research before they can be realized.
Research proposals made on behalf of (inter)nationally recognized joint ventures (EORTC, HOVON,
SIOP, SKION) and multi-center studies in which the VUMC is not the main judging committee, are
judged only marginally on local feasibility.
The CWO also advises on other research proposals for which judgment by the CWO is desired. The
CWO gives asked and unasked advice to the MB about the quality of research within CCA/V-ICI. The
CWO section for patient related protocols meets twice a month, the CWO section for animal related
protocols meets once a month.
The VUMC Management Regulations stipulate that the CCA/V-ICI CWO section for patients related
protocols is composed of 5 to 9 members. In view of the institute’s size and in order to have
sufficient expertise in the different research fields, the CWO has been extended to a maximum of
15 members.
Scientific Research Committee (CWO) members - Section for patient related protocols:
- A.A. van der Loosdrecht (chair)
- A.A. van Bodegraven
- B.J.M. Braakhuis
- A.J.M. van den Eertwegh
- M. van Egmond
- T.D. de Gruijl
- N.H. Hendrikse
- M. Klein (advisor)
- G.K. Kuipers (secretary)
- F.B.J.M. Thunnissen
- A.E. Voskuyl
- Q. Waisfisz
Scientific Research Committee (CWO) members - Section for animal related protocols:
- R. Scheper (chair)
- B.J. Appelmelk
- V. van Beusechem
- G. Kraal
- G.K. Kuipers (secretary)
Committee for Education & Training
This committee supervises and advices about all training and education activities within CCA/V-ICI.
The graduate training is organized within the Oncology Graduate School Amsterdam (OOA) and the
Leiden Amsterdam Institute for Immunology (ALIFI).
More in detail, by means of subgroups, this committee organizes and advises about training in the
framework of the:
- oncology profile
- immunology profile
- masters education in oncology
- masters education in immunology
- graduate students education
- postgraduate education
- SMBWO (Foundation for the Training of Biomedical Scientists)
- NVVI (Dutch Society for Immunology)
- all other types of education within CCA/V-ICI.
57
Appendix 1: Organization of CCA/V-ICI
Each of these subgroups is composed of the main teachers within the education involved. The
committee gives asked and unasked advice about the quality and quality maintenance of education
within CCA/V-ICI. The committee meets at least six times a year.
Members of the Committee for Education & Training:
- C.R Leemans (chair)
- R.H.J. Beelen
- M.M. van Duist
- G.A. Meijer
- E.M. Ruhé-Hoogervorst (secretary)
Subgroups:
Oncology profile committee members:
- B.J.M. Braakhuis
- E. Boven
- A.A. van de Loosdrecht
- N.C.T. van Grieken
- E.M. Ruhé-Hoogervorst (profile coordinator)
Immunology and Infection committee members:
- B.J. Appelmelk
- I.E.M. Bultink
- I. van Hoogstraten
- M. Schreurs
- M.B.E. von Blomberg
- G.K. Kuipers (profile coordinator)
Directorate OOA (Oncology Graduate School Amsterdam)
- G.A. Meijer, chairman (VUmc)
- J.P. Medema (AMC)
- E.M. Ruhé-Hoogervorst, secretary (VUmc)
- T. Sixma (NKI)
ALIFI PhD committee (Amsterdam Leiden Institute For Immunology)
- R.A.W. van Lier (AMC)
- R.E. Mebius (VUmc-CCA/V-ICI)
- H. Schuitemaker (Sanquin)
Funding by Stichting VUmc CCA
The Stichting VUmc CCA supports VUmc and CCA/V-ICI in their cancer research and care for patients
with cancer.
Program group CCA
The program group CCA
- functions as liaison between CCA/V-ICI and the foundations supporting CCA/V-ICI, i.e. ‘Stichting
VUmc CCA’ and VUmc foundations as to their ambitions and goals;
- advices the Board VUmc as to the allocation of finances raised by the foundations supporting
CCA/V-ICI and as to fundraising and long term strategy of VUmc towards the foundations;
contributes to effective governance and responsibility over the finances involved in fundraising and
support of the ‘Stichting VUmc CCA’.
Members of the program group CCA:
- W.R. Gerritsen, program director CCA (chairman)
- G.C.P.M. Hoskens, manager finances divisie I
- C.J.H. Buren, director finances
- Open chair for dean/member Board VUmc
58
Appendix 2: Scientific input
Appendix 2. Scientific input
Program 1: Oncogenesis
Department
WP
fte
Joenje H
Clinical Genetics
1
1,00
Meijers-Heijboer HE
Clinical Genetics
1
0,10
Bloemena E
Oral and Maxillofacial Surgery and Pathology
1
0,20
van der Waal I
Oral and Maxillofacial Surgery and Pathology
1
0,15
Brakenhoff RH
Otolaryngology/Head and Neck Surgery
1
0,85
Leemans CR
Otolaryngology/Head and Neck Surgery
1
0,06
Meijer CJLM
Pathology
1
0,10
Middeldorp JM
Pathology
1
0,50
Mooi WJ
Pathology
1
0,10
Snijders PJF
Pathology
1
0,20
Oudejans CBM
Clinical Chemistry
1
0,05
Berkhof J
Clinical Epidemiology and Biostatistics
1
1,00
van de Wiel MA
Clinical Epidemiology and Biostatistics
2
0,50
de Winter JP
Clinical Genetics
1
1,00
van Egmond M
Molecular Celbiology and Immunology
1
0,90
Full professor
Associated professor
Braakhuis BJM
Otolaryngology/Head and Neck Surgery
1
0,85
Steenbergen RDM
Pathology
1
0,10
Kuik DJ
Clinical Epidemiology and Biostatistics
1
0,16
Dorsman JC
Clinical Genetics
1
1,00
Gille JJP
Clinical Genetics
1
0,10
Menko FH
Clinical Genetics
1
0,10
Waisfisz Q
Clinical Genetics
1
0,80
Bleeker MCG
Pathology
1
0,20
Rozendaal L
Pathology
1
0,10
Thunnissen FBJM
Pathology
1
0,20
Assistant professor
van Baars R
Pathology
3
1,00
van Hattum AH
Pathology
1
0,10
van Kemenade F
Pathology
1
0,10
Pathology
3
1,00
Other tenured staff
Cillessen SAGM
Gok M
Pathology
1
0,10
Heideman DAM
Pathology
1
0,50
Hesselink AT
Pathology
3
1,00
Hubers J
Pathology
3
1,00
Kocken M
Pathology
4
0,92
Louwers JA
Pathology
4
0,25
Pegtel M
Pathology
2
1,00
van Boerdonk R
Pathology
3
0,75
van der Meide W
Pathology
3
0,92
Zaal A
Pathology
3
0,25
Krekel NMA
Surgery
3
0,40
Total tenured staff
19,61
Non tenured staff
Agarwal S
Clinical Genetics
2
Pham TV
Medical Oncology
3
1,00
1,00
van Beynum JR
Medical Oncology
3
1,00
59
Appendix 2: Scientific input
Department
WP
fte
Vermeulen C
Medical Oncology
3
1,00
Nagel R
Otolaryngology/Head and Neck Surgery
2
1,00
Wilting SM
Pathology
3
1,00
Giannakopoulos GF
Surgery
3
1,00
Adank M
Clinical Genetics
1
0,60
Bakker JL
Clinical Genetics
1
0,08
Corbin M
Clinical Genetics
2
0,60
Dommering CJ
Clinical Genetics
1
0,10
Haitjema A
Clinical Genetics
3
0,75
Massink M
Clinical Genetics
2
0,75
PhD students
Mol BM
Clinical Genetics
3
0,75
Stoepker C
Clinical Genetics
1
0,75
van der Lelij P
Clinical Genetics
1
0,44
de Leeuw DC
Hematology
3
0,36
Heusschen R
Medical Oncology
3
0,75
Nowee ME
Obstetrics and Gynaecology
-
0,00
Dekker H
Oral and Maxillofacial Surgery and Pathology
3
0,05
Dekker H
Oral and Maxillofacial Surgery and Pathology
1
0,05
Matse JH
Oral and Maxillofacial Surgery and Pathology
1
0,40
Graveland APJ
Otolaryngology/Head and Neck Surgery
1
0,10
Martens-de Kemp SR
Otolaryngology/Head and Neck Surgery
1
0,75
Rietbergen MM
Otolaryngology/Head and Neck Surgery
2
0,75
van der Plas M
Otolaryngology/Head and Neck Surgery
3
0,75
Bierkens M
Pathology
1
0,75
de Strooper LMA
Pathology
3
0,75
Dijkstra M
Pathology
3
0,75
Henken FE
Pathology
3
0,75
Mollers M
Pathology
3
0,75
Reinen E
Pathology
3
0,75
Rijkaart D
Pathology
4
0,75
Scherpenisse M
Pathology
3
0,75
Schütze DM
Pathology
3
0,75
Snellenberg S
Pathology
3
0,75
Uijterwaal MH
Pathology
3
0,75
van der Marel J
Pathology
4
0,75
Verhoef VMJ
Pathology
3
0,75
Verweij FJ
Pathology
3
0,75
Total non tenured staff
26,28
Total research staff
45,89
Program 2: Immunopathogenesis
Department
WP
fte
Full professor
Mulder CJJ
Gastroenterology
1
0,07
Bitter W
Medical Microbiology and Infection Control
1
0,50
Savelkoul PHM
Medical Microbiology and Infection Control
1
0,15
Vandenbroucke-Grauls CMJE
Medical Microbiology and Infection Control
1
0,13
Beelen RHJ
Molecular Celbiology and Immunology
1
0,50
Dijkstra CD
Molecular Celbiology and Immunology
1
0,05
Kraal G
Molecular Celbiology and Immunology
1
0,60
60
Appendix 2: Scientific input
Department
WP
fte
Mebius RE
Molecular Celbiology and Immunology
1
0,80
van Kooyk Y
Molecular Celbiology and Immunology
1
0,60
Scheper RJ
Pathology
1
0,30
van den Elsen PJ
Pathology
1
0,10
Verweij CL
Pathology
1
0,10
Dijkmans BAC
Reumatology
1
0,07
Gibbs S
Dermatology
1
0,80
Stoof TJ
Dermatology
1
0,10
Appelmelk BJ
Medical Microbiology and Infection Control
1
0,70
Bitter W
Medical Microbiology and Infection Control
1
0,17
van Die IM
Molecular Celbiology and Immunology
1
0,60
von Blomberg BME
Pathology
1
0,10
de Boer EM
Dermatology
1
0,10
Gibbs S
Dermatology
2
0,20
Kirtschig G
Dermatology
1
0,05
Rustemeyer T
Dermatology
1
0,30
van Montfrans C
Dermatology
1
0,20
Bersma RJF
Gastroenterology
1
0,20
Felt-Bersma RJF
Gastroenterology
1
0,20
van Bodegraven AA
Gastroenterology
1
0,20
van Nieuwkerk CMJ
Gastroenterology
1
0,20
van den Eertwegh AJM
Medical Oncology
1
0,25
Ang W
Medical Microbiology and Infection Control
1
0,05
van der Sar AM
Medical Microbiology and Infection Control
1
0,55
den Haan JMM
Molecular Celbiology and Immunology
2
0,60
Roozendaal R
Molecular Celbiology and Immunology
2
0,54
Douma CE
Nefrology
3
0,20
Farhat K
Nefrology
1
0,20
Nurmohamed SA
Nefrology
1
0,15
Rüger JW
Nefrology
1
0,20
Associated professor
Assistant professor
Hooijberg E
Pathology
3
0,50
Morré SA
Pathology
1
0,10
Schreurs MWJ
Pathology
1
0,07
Molecular Celbiology and Immunology
2
1,00
Other tenured staff
Menckeberg C
van Es T
Molecular Celbiology and Immunology
4
0,42
van Vliet SJ
Molecular Celbiology and Immunology
2
1,00
Crusius JBA
Pathology
1
0,10
Greijer AE
Pathology
2
0,83
Gross S
Pathology
3
1,00
Ouburg S
Pathology
3
1,00
Scheffer GL
Pathology
3
0,50
Scholten KBJ
Pathology
3
0,50
van Hoogstraten IMW
Pathology
1
0,00
van den Tol MP
Surgery
1
0,20
Total tenured staff
18,05
Non tenured staff
Reijnders CMA
Dermatology
2
1,00
Reinders J
Dermatology
2
1,00
Abdallah AM
Medical Microbiology and Infection Control
3
0,75
Bestebroer J
Medical Microbiology and Infection Control
3
0,75
61
Appendix 2: Scientific input
Department
WP
fte
Geurtsen J
Medical Microbiology and Infection Control
2
0,75
Houben E
Medical Microbiology and Infection Control
2
0,75
Llamas MA
Medical Microbiology and Infection Control
2
0,75
Ambrosini M
Molecular Celbiology and Immunology
3
1,00
Bakema JE
Molecular Celbiology and Immunology
2
1,00
Garcia-Vallejo JJ
Molecular Celbiology and Immunology
2
1,00
Ilarregui JM
Molecular Celbiology and Immunology
3
1,00
Koning N
Molecular Celbiology and Immunology
4
1,00
Kuijk LM
Molecular Celbiology and Immunology
3
1,00
Molenaar R
Molecular Celbiology and Immunology
2
1,00
Papadopoulos P
Molecular Celbiology and Immunology
2
1,00
Saeland E
Molecular Celbiology and Immunology
3
0,83
Tefsen B
Molecular Celbiology and Immunology
2
1,00
Unger WWJ
Molecular Celbiology and Immunology
2
1,00
van Beelen AJ
Molecular Celbiology and Immunology
1
0,42
van de Pavert SA
Molecular Celbiology and Immunology
2
1,00
Veninga H
Molecular Celbiology and Immunology
3
1,00
Vos JB
Molecular Celbiology and Immunology
2
1,00
Vroling AB
Molecular Celbiology and Immunology
2
0,42
Broers CJM
Paediatrics
1
0,10
van der Kuip M
Paediatrics
1
0,20
Gelderman KA
Pathology
1
0,00
0,75
PhD students
dos Santos G
Dermatology
2
Kosten IJ
Dermatology
1
0,75
Limandjaja GC
Dermatology
2
0,75
Ouwehand K
Dermatology
1
0,06
Pentinga SE
Dermatology
3
0,75
van den Broek L
Dermatology
3
0,75
Lam TJ
Gastroenterology
4
0,75
Tack GJ
Gastroenterology
4
0,08
Ates LS
Medical Microbiology and Infection Control
1
0,75
Daleke M
Medical Microbiology and Infection Control
3
0,70
Driessen NN
Medical Microbiology and Infection Control
1
0,50
Stoop EJM
Medical Microbiology and Infection Control
3
0,35
Stoop EJM
Medical Microbiology and Infection Control
2
0,40
van de Weerd R
Medical Microbiology and Infection Control
2
0,75
Weerdenburg EM
Medical Microbiology and Infection Control
1
0,75
Lindenberg JJ
Medical Oncology
2
0,44
Beijer MR
Molecular Celbiology and Immunology
1
0,75
Bloem K
Molecular Celbiology and Immunology
4
0,75
Bogels M
Molecular Celbiology and Immunology
1
0,75
da Silva Aresta Belo van Wijk AI
Molecular Celbiology and Immunology
4
0,75
de Jong MAWP
Molecular Celbiology and Immunology
2
0,25
Fehres CM
Molecular Celbiology and Immunology
3
0,75
Galama SM
Molecular Celbiology and Immunology
2
0,75
Goverse G
Molecular Celbiology and Immunology
2
0,75
Gul N
Molecular Celbiology and Immunology
1
0,75
Hiemstra IH
Molecular Celbiology and Immunology
1
0,75
Klaver EJ
Molecular Celbiology and Immunology
1
0,75
Koning JJ
Molecular Celbiology and Immunology
2
0,62
Ouwehand I
Molecular Celbiology and Immunology
1
0,75
Perdicchio M
Molecular Celbiology and Immunology
2
0,75
62
Appendix 2: Scientific input
Department
WP
fte
Schilte MN
Molecular Celbiology and Immunology
3
0,50
Stavenuiter AWD
Molecular Celbiology and Immunology
3
0,75
van der Steen L
Molecular Celbiology and Immunology
2
0,75
van Hout MWM
Molecular Celbiology and Immunology
2
0,75
Bloemers BL
Paediatrics
1
0,14
Sanders M
Paediatrics
1
0,20
van Dungen F
Paediatrics
1
0,20
de Jong T
Pathology
3
0,75
Hoebe EK
Pathology
3
0,75
Turksma A
Pathology
3
0,75
Total non tenured staff
45,41
Total research staff
63,46
Program 3: Disease profiling
Department
WP
fte
Clinical Chemistry
1
0,05
Full professor
Blankenstein MA
Mulder CJJ
Gastroenterology
1
0,07
Huijgens PC
Hematology
1
0,10
Kluytmans J
Medical Microbiology and Infection Control
1
0,10
Savelkoul PHM
Medical Microbiology and Infection Control
1
0,15
Vandenbroucke-Grauls CMJE
Medical Microbiology and Infection Control
1
0,12
Dijkstra CD
Molecular Celbiology and Immunology
1
0,05
Heimans JJ
Neurology
1
0,06
Taphoorn MJB
Neurology
1
0,00
Comans EFI
Nuclear Medicine and PET Research
1
0,20
Hoekstra OS
Nuclear Medicine and PET Research
1
0,30
Lammertsma AA
Nuclear Medicine and PET Research
1
0,15
van Dongen GAMS
Nuclear Medicine and PET Research
1
0,10
de Bree R
Otolaryngology/Head and Neck Surgery
1
0,10
Leemans CR
Otolaryngology/Head and Neck Surgery
1
0,06
van Dongen GAMS
Otolaryngology/Head and Neck Surgery
1
0,70
Meijer CJLM
Pathology
1
0,10
Meijer GA
Pathology
1
0,20
Snijders PJF
Pathology
1
0,20
Verweij CL
Pathology
1
0,10
Postmus PE
Pulmonology
1
0,20
Smit EF
Pulmonology
1
0,20
Castelijns JA
Radiology
1
0,20
Dijkmans BAC
Reumatology
1
0,07
Lems WF
Reumatology
1
0,10
Meijer S
Surgery
1
0,20
Associated professor
van de Wiel MA
Clinical Epidemiology and Biostatistics
2
0,50
Boellaard R
Nuclear Medicine and PET Research
1
0,15
Herscheid JDM
Nuclear Medicine and PET Research
1
0,20
Molthoff CFM
Nuclear Medicine and PET Research
1
0,30
Windhorst AD
Nuclear Medicine and PET Research
1
0,15
Ylstra B
Pathology
1
0,40
van der Horst-Bruinsma IE
Reumatology
1
0,40
Assistant professor
63
Appendix 2: Scientific input
Department
WP
fte
Kuik DJ
Clinical Epidemiology and Biostatistics
1
0,17
Xavier de Menezes R
Clinical Epidemiology and Biostatistics
1
1,00
Zijlstra JM
Hematology
1
0,30
al Naiemi N
Medical Microbiology and Infection Control
3
0,02
van der Pouw-Kraan CTM
Molecular Celbiology and Immunology
1
0,90
Klein M
Neurology
1
0,20
Postma TJ
Neurology
1
0,10
Reijneveld JC
Neurology
1
0,10
Hendrikse NH
Nuclear Medicine and PET Research
1
0,30
Lubberink M
Nuclear Medicine and PET Research
1
0,20
Oprea D
Nuclear Medicine and PET Research
4
0,40
Raijmakers PG
Nuclear Medicine and PET Research
1
0,10
van Schie A
Nuclear Medicine and PET Research
3
0,10
Visser GWM
Nuclear Medicine and PET Research
1
0,10
Beliën JAM
Pathology
1
0,20
Diosdado Calvo MB
Pathology
1
0,10
Morré SA
Pathology
1
0,10
van Grieken NCT
Pathology
1
0,20
Bahce I
Pulmonology
1
0,20
Becker A
Pulmonology
1
0,20
Daniels JMA
Pulmonology
1
0,20
Hashemi SMS
Pulmonology
1
0,20
Sutedja TG
Pulmonology
1
0,20
van Schaardenburg D
Reumatology
1
0,05
Voskuyl AE
Reumatology
1
0,10
Reuland EA
Medical Microbiology and Infection Control
3
0,75
Jimenez CR
Medical Oncology
3
0,50
Adema AD
Pathology
3
0,83
Carvalho B
Pathology
3
1,00
Crusius JBA
Pathology
1
0,10
de Ridder A
Pathology
2
1,00
Fijneman RJA
Pathology
3
1,00
Other tenured staff
Parlayan
Pathology
3
1,00
Sie DLS
Pathology
1
0,40
Smeets SJ
Pathology
1
0,10
Bultink IEM
Reumatology
1
0,10
van der Laken CJ
Reumatology
4
0,20
te Velde EA
Surgery
1
0,20
Total tenured staff
18,90
Non tenured staff
van Velden FHP
Nuclear Medicine and PET Research
3
Poot AJ
Otolaryngology/Head and Neck Surgery
2
1,00
1,00
van Denderen A
Otolaryngology/Head and Neck Surgery
2
0,20
Vugts D
Otolaryngology/Head and Neck Surgery
4
1,00
Bosch LJW
Pathology
1
1,00
Díaz-López R
Pathology
2
1,00
Taghipour Bazargani Y
Clinical Epidemiology and Biostatistics
3
0,75
Wubulikasimu A
Clinical Epidemiology and Biostatistics
2
0,38
Wubulikasimu A
Clinical Epidemiology and Biostatistics
1
0,38
de Baaij LR
Gastroenterology
3
0,25
Tack GJ
Gastroenterology
4
0,08
PhD students
64
Appendix 2: Scientific input
van de Water JMW
Department
WP
fte
Gastroenterology
1
0,75
van Turenhout ST
Gastroenterology
3
0,75
Budding A
Medical Microbiology and Infection Control
1
0,10
Rood IGH
Medical Microbiology and Infection Control
1
0,75
Soeltan-Kaersenhout D
Medical Microbiology and Infection Control
3
0,10
van Cleef BAGL
Medical Microbiology and Infection Control
3
0,75
Bosma I
Neurology
4
0,00
de Groot M
Neurology
4
0,28
Douw L
Neurology
3
0,40
Froklage F
Neurology
2
0,36
Sizoo E
Neurology
3
0,25
van Dellen E
Neurology
3
0,25
van Nieuwenhuizen D
Neurology
1
0,00
Cheebsumon P
Nuclear Medicine and PET Research
3
0,75
Makris N
Nuclear Medicine and PET Research
4
0,75
Rizvi SN
Nuclear Medicine and PET Research
4
0,40
van der Veldt AAM
Nuclear Medicine and PET Research
3
0,75
Börjesson PKE
Otolaryngology/Head and Neck Surgery
4
0,00
Flach GB
Otolaryngology/Head and Neck Surgery
2
0,42
Flach GB
Otolaryngology/Head and Neck Surgery
1
0,20
Heuveling D
Otolaryngology/Head and Neck Surgery
4
0,75
van der Putten L
Otolaryngology/Head and Neck Surgery
1
0,10
Vosjan MJWD
Otolaryngology/Head and Neck Surgery
2
0,36
Blits M
Pathology
3
0,75
Bosch LJW
Pathology
4
0,50
de Groen FLM
Pathology
1
0,75
de Wit M
Pathology
4
0,75
Goos JACM
Pathology
2
0,75
Groen FLM
Pathology
1
0,75
Haan JC
Pathology
3
0,75
Krijgsman O
Pathology
1
0,75
Timmer LM
Pathology
3
0,75
van Thuijl HF
Pathology
3
0,75
Voorham QJM
Pathology
3
0,75
Vosslamber S
Pathology
3
0,75
de Langen AJ
Pulmonology
3
0,10
Lind J
Pulmonology
4
0,75
Phernambucq E
Pulmonology
3
0,25
Schook R
Pulmonology
1
0,10
Siebring-van Olst E
Pulmonology
1
0,90
de Graaf P
Radiology
1
0,10
Ljumanovic R
Radiology
3
0,20
Rodjan F
Radiology
3
0,75
de Cuba E
Surgery
1
0,75
van der Pas MHGM
Surgery
2
0,75
Total non tenured staff
29,65
Total research staff
48,55
65
Appendix 2: Scientific input
Program 4: Innovative therapy
Department
WP
Fte
Zuurmond WWA
Anesthesiology
1
0,20
Boers M
Clinical Epidemiology and Biostatistics
1
0,30
Mulder CJJ
Gastroenterology
1
0,06
Huijgens PC
Hematology
1
0,10
Ossenkoppele GJ
Hematology
1
0,30
Boven E
Medical Oncology
1
0,50
Gerritsen WR
Medical Oncology
1
0,30
Griffioen AW
Medical Oncology
1
0,80
Peters GJ
Medical Oncology
1
Verheul H
Medical Oncology
Heimans JJ
Neurology
Taphoorn MJB
Neurology
1
0,00
Vandertop WP
Neurosurgery
1
0,20
van der Waal I
Oral and Maxillofacial Surgery and Pathology
1
0,15
de Bree R
Otolaryngology/Head and Neck Surgery
1
0,10
Festen JM
Otolaryngology/Head and Neck Surgery
1
0,05
Leemans CR
Otolaryngology/Head and Neck Surgery
1
0,06
Kaspers GJL
Paediatrics
1
0,20
van Furth AM
Paediatrics
1
0,30
Bloemena E
Pathology
1
0,10
Scheper RJ
Pathology
1
0,30
Senan S
Radiation Oncology
1
0,20
Slotman BJ
Radiation Oncology
1
0,20
Dijkmans BAC
Reumatology
1
0,06
Full professor
0,80
0,00
1
0,07
Lems WF
Reumatology
1
0,10
Cuesta MA
Surgery
1
0,05
van Moorselaar RJA
Urology
1
0,10
Associate professor
Perez RSGM
Anesthesiology
1
0,10
Schuurhuis GJ
Hematology
1
0,75
van Agtmael MA
Internal Medicine
1
0,20
de Gruijl TD
Medical Oncology
1
1,00
van Beusechem VW
Medical Oncology
2
1,00
Wurdinger T
Neurosurgery
1
0,10
von Mensdorff-Pouilly S
Obstetrics and Gynaecology
1
0,50
Assistant professor
Coupe VMH
Clinical Epidemiology and Biostatistics
1
0,89
Kuik DJ
Clinical Epidemiology and Biostatistics
1
0,17
Chamuleau MED
Hematology
1
0,30
Dräger AM
Hematology
1
0,20
Janssen JJWM
Hematology
1
0,30
Thielen N
Hematology
4
0,40
van de Loosdrecht AA
Hematology
1
0,30
Visser O
Hematology
1
0,30
Zweegman S
Hematology
1
0,30
Broxterman HJ
Medical Oncology
1
1,00
Buter J
Medical Oncology
1
1,00
den Broeder E
Medical Oncology
5
0,80
66
Appendix 2: Scientific input
Department
WP
Fte
van den Eertwegh AJM
Medical Oncology
1
0,25
van der Vliet JJ
Medical Oncology
1
0,26
Klein M
Medical Psychology
1
0,40
Klein M
Neurology
1
0,20
Postma TJ
Neurology
1
0,10
Reijneveld JC
Neurology
1
0,10
Noske DP
Neurosurgery
1
0,30
Geldof AA
Nuclear Medicine and PET Research
1
0,30
Moll AC
Opthalmonology
1
0,05
Erenstein-Kraay SJ
Otolaryngology/Head and Neck Surgery
1
0,02
van Weert S
Otolaryngology/Head and Neck Surgery
1
0,02
Cloos J
Paediatrics
1
0,75
Dahele MR
Radiation Oncology
1
0,05
Doornaert P
Radiation Oncology
1
0,05
Lafleur MVM
Radiation Oncology
1
0,05
Sminia P
Radiation Oncology
1
0,40
van Schaardenburg D
Reumatology
1
0,05
Voskuyl AE
Reumatology
1
0,10
Geldof AA
Urology
1
0,30
Vis A
Urology
1
Total tenured staff
0,10
28,96
Other tenured staff
Bongers ML
Clinical Epidemiology and Biostatistics
3
1,00
Chaturvedi N
Clinical Epidemiology and Biostatistics
3
0,65
Demirel E
Clinical Epidemiology and Biostatistics
3
0,50
van Oostveen JW
Hematology
1
0,05
Dong W
Medical Oncology
4
1,00
Jimenez CR
Medical Oncology
3
0,50
Meulenberg JJ
Medical Oncology
4
0,50
Langius JAE
Nutricion and dietics
1
1,00
Chiarino Tabacco S
Obstetrics and Gynaecology
1
0,50
Abbink F
Paediatrics
1
0,10
Scheffer GL
Pathology
3
0,50
Haasbeek CJ
Radiation Oncology
1
0,05
Lagerwaard FJ
Radiation Oncology
1
0,05
Thijssen VLJL
Radiation Oncology
3
0,60
van Sörnsen de Koste JR
Radiation Oncology
1
0,20
Bultink IEM
Reumatology
1
0,10
Jansen G
Reumatology
1
1,00
ter Wee MM
Reumatology
4
1,00
van Dam DA
Surgery
3
0,60
van der Sluis TM
Urology
1
0,00
Non tenured staff
Bontkes HJ
Hematology
4
0,69
Irandoust M
Hematology
3
0,13
Noordhuis P
Hematology
4
0,60
Smit L
Hematology
1
0,75
Hangalapura BN
Medical Oncology
3
0,25
Honeywell R
Medical Oncology
1
1,00
Oosterhoff D
Medical Oncology
2
0,08
67
Appendix 2: Scientific input
Piersma S
Department
WP
Fte
Medical Oncology
3
0,25
Schaaij-Visser BM
Medical Oncology
3
1,00
van de Ven R
Medical Oncology
3
0,33
Hulleman E
Neurosurgery
3
0,80
van der Stoop PM
Neurosurgery
3
0,80
Tijink BM
Otolaryngology/Head and Neck Surgery
1
0,10
van Dulmen-den Broeder E
Paediatrics
4
0,80
van Tuyl L
Reumatology
3
0,66
Bijnsdorp IV
Urology
3
1,00
Jacobs JJL
Urology
3
1,00
Lemos ACFA
Urology
3
0,17
Radersma M
Gastroenterology
3
0,75
Tack GJ
Gastroenterology
4
0,09
PhD student
van Asseldonk DP
Gastroenterology
1
0,25
van Gerven NMF
Gastroenterology
3
0,75
Alhan C
Hematology
4
0,75
de Leeuw DC
Hematology
3
0,37
Issa DE
Hematology
4
0,40
Niewerth D
Hematology
3
0,75
Regelink JC
Hematology
4
0,40
Ruben JM
Hematology
3
0,75
Terwijn M
Hematology
3
0,69
van den Ancker W
Hematology
1
0,75
van Luijn M
Hematology
3
0,50
Wondergem MJ
Hematology
1
0,30
Azijli K
Medical Oncology
2
0,75
Bijnsdorp IV
Medical Oncology
3
0,19
de Bruin R
Medical Oncology
3
0,75
Giovannetti E
Medical Oncology
3
0,50
Gotink KJ
Medical Oncology
3
0,75
Hodzic J
Medical Oncology
3
0,75
Kuipers L
Medical Oncology
3
0,75
Labots M
Medical Oncology
3
0,37
Lam SW
Medical Oncology
4
0,75
Neerincx M
Medical Oncology
4
0,75
Schulkens I
Medical Oncology
3
0,75
van der Mijn JC
Medical Oncology
4
0,75
Vroling L
Medical Oncology
3
0,75
Walraven M
Medical Oncology
3
0,75
Warmoes M
Medical Oncology
3
0,75
Bosma I
Neurology
4
0,00
de Groot M
Neurology
4
0,28
Douw L
Neurology
3
0,40
Froklage F
Neurology
2
0,37
Sizoo E
Neurology
3
0,25
van Dellen E
Neurology
3
0,25
van Nieuwenhuizen D
Neurology
1
0,00
Badr C
Neurosurgery
1
0,25
Caretti V
Neurosurgery
3
0,75
68
Appendix 2: Scientific input
Department
WP
Fte
Hiddingh L
Neurosurgery
1
0,40
Idema S
Neurosurgery
1
0,20
Smits M
Neurosurgery
3
0,75
van Rijn S
Neurosurgery
3
0,75
Posthuma de Boer J
Orthopaedics
4
0,75
Cohen R
Otolaryngology/Head and Neck Surgery
2
0,75
Vosjan MJWD
Otolaryngology/Head and Neck Surgery
2
0,37
Bachas C
Paediatrics
3
0,75
Blufpand HN
Paediatrics
4
0,75
Franke N
Paediatrics
3
1,00
Jansen MHA
Paediatrics
4
1,00
Kors WA
Paediatrics
1
0,20
Mir SE
Paediatrics
2
0,31
van Vuurden DG
Paediatrics
1
0,60
Visser D
Paediatrics
1
0,10
Wilhelm AJ
Pharmacy
1
0,20
Ong CL
Radiation Oncology
3
0,60
Phernambucq E
Radiation Oncology
1
0,40
den Uyl D
Reumatology
3
0,75
Gent YYJ
Reumatology
3
0,75
Raterman HG
Reumatology
4
0,75
van der Weijden MAC
Reumatology
4
0,56
Verbrugge CSE
Reumatology
1
0,75
Weijers K
Reumatology
3
0,75
Total non tenured staff
44,71
Total research staff
73,67
Program 5: Quality of life
Department
WP
fte
Full professor
Heimans JJ
Neurology
1
0,07
Taphoorn MJB
Neurology
1
0,00
Leemans CR
Otolaryngology/Head and Neck Surgery
1
0,07
Verdonck-de Leeuw IM
Otolaryngology/Head and Neck Surgery
1
0,60
Kaspers GJL
Paediatrics
1
0,20
Veerman AJP
Paediatrics
1
0,40
Dekker J
Rehabilitation Medicine
1
0,10
Medical Psychology
1
0,00
van Dijk EM
Medical Psychology
3
0,20
Reijneveld JC
Neurology
1
0,10
Rinkel RNPM
Otolaryngology/Head and Neck Surgery
1
0,05
Uden-Kraan
Otolaryngology/Head and Neck Surgery
2
0,90
Veening MA
Paediatrics
1
0,10
Associated professor
Huisman J
Assistant professor
Other tenured staff
Total tenured staff
2,79
Non tenured staff
69
Appendix 2: Scientific input
Department
WP
fte
Mostert SM
Paediatrics
5
1,00
van der Berg MH
Paediatrics
3
0,80
Neurology
3
0,25
PhD students
Sizoo E
van Nieuwenhuizen D
Neurology
1
0,00
Brueckers-Schipper RG
Otolaryngology/Head and Neck Surgery
1
0,05
Cnossen IC
Otolaryngology/Head and Neck Surgery
4
0,67
de Bruijn M
Otolaryngology/Head and Neck Surgery
3
0,60
Krebber AMH
Otolaryngology/Head and Neck Surgery
3
0,14
Krebber AMH
Otolaryngology/Head and Neck Surgery
2
0,61
Oskam IM
Otolaryngology/Head and Neck Surgery
1
0,05
van Gogh CDL
Otolaryngology/Head and Neck Surgery
1
0,10
Braam KI
Paediatrics
3
0,75
Gordijn MS
Paediatrics
4
0,75
Overbeek A
Paediatrics
3
0,75
van Litsenburg R
Paediatrics
1
0,75
Total non tenured staff
7,27
Total research staff
10,06
70
Appendix 3: Newly started PhD projects
Appendix 3: Newly started PhD projects
PhD student
Project leader
Department
Project
Program
Bakker J
Waisfisz Q
Clinical Genetics
Towards targeted treatment of (familial) breast
cancer
1
Blufpand HN
Bökenkamp A
Paediatrics
Carboplatin study: assessment and optimization of
carboplatin exposure in pediatric oncology using
different markers of kidney function
4
Boink M
Gibbs S
Dermatology
Novel saliva-derived peptides for state-of-the-art
clinical wound-healing applications
2
de Cuba E
Bonjer HJ
Surgery
Peritoneal metastases from colorectal carcinoma;
Diagnostic markers to identify patients that will
benefit from radical surgical resection
3
de Groen FLM
Meijer GA
Pathology
Identification of novel oncogenes/oncomirs
located at 13q involved in the progression of
colorectal adenoma to carcinoma
1
de Jong TD
Verweij CL
Pathology
TNF and IFN cross-regulation in rheumatoid
arthritis
2
de Strooper LMA
Meijer CJLM
Pathology
Stratifying high-risk HPV positive women for risk
of CIN 3 and cervical carcinoma by methylation
analysis
1
Dekker H
Bloemena E
Pathology
Peri-implantitis, implant loss and radioosteomyelitis in head and necktumor patients
4
Fehres CM
van Kooyk Y
Molecular
Celbiology and
Immunology
Development of a skin APC targeting glyco-vaccin
for potentiation of anti-melanoma immunity
2
Gent YYJ
van der Laken CJ
Reumatology
Development of imaging markers, using PET(-CT),
for early detection of RA and therapy monitoring
3
Goverse G
Mebius RE
Molecular
Celbiology and
Immunology
Retinoic acid mediates macrophage differentiation
towards a separate lineage
2
Jimenez CR
Steenbergen RDM
Medical
Oncology
Cervix cancer proteomics. Unraveling protein
expression changes during HPV-induced
transformation using a label-free proteomics
approach
1
Kosten I.J.
Starink T
Dermatology
The development of immuno-competent human
skin and oral mucosa equivalents and their use in
determining factors involved in T cell skewing and
imprinting
2
Krekel NMA
Van den Tol MP
Surgery
Ultrasound-guided breast-sparing surgery to
improve cosmetic outcomes and quality of life A
prospective multicentre randomised controlled
clinical trial comparing ultrasound-guided surgery
to traditional palpation-guided surgery (COBALT
trial)
4
Lam SW
Boven E
Medical
Oncology
A multicenter, randomized phase II trial of
paclitaxel plus bevacizumab versus paclitaxel,
bevacizumab plus capecitabine in HER2-negative
locally recurrent or metastastic breast cancer
4
Radersma M
Cillessen SAGM
Gastroenterology
Is c-Abl a potentail target for therapy in
Enteropathy Associated T-cell Lymphomas?
4
van de Weerd R
Geurtsen JJG
Medical
Microbiology and
Infection Control
Mysteries beyond the mycomembrane:biogenesis
of the mycobacterial capsule and its role in the
host-pathogen interaction
2
van Thuijl H
Heimans JJ
Pathology
Chromosomal aberrations associated with
progression characteristics of low-grade glioma
1
71
Appendix 3: Newly started PhD projects
patients
Weijers K
72
Van der Laken CJ
Reumatology
Imaging and targeting of macrophage folate
receptor-beta in rheumatoid arthritis
4
Appendix 4: Scientific output
Appendix 4: Scientific output
Abbreviations:
(Cat.A): Dissertations prepared and defended at VUmc
(Cat.B): Dissertations prepared elsewhere and defended at VUmc
(Cat.C): Dissertations prepared at VUmc and defended elsewhere
(Cat.D): Dissertations prepared and defended elsewhere
(x /y):
After publications, x: quartile score (1-5), y: Impact Factor of journal
-:
Publications in non peer-reviewed journals without an Impact Factor
1:
Quartile score: SCI journal from lowest quarter, publications in peer-reviewed journals without an Impact Factor
2:
Quartile score: SCI journal from the second quarter (>25th and < 50th percentile)
3:
Quartile score: SCI journal from the third quarter (>50th and < 75th percentile)
4:
Quartile score: SCI journal belonging to the highest quarter 75th-90th percentile
5:
Quartile score: SCI journal belonging to > 90th percentile
Program 1: Oncogenesis
Scientific papers refereed
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
Adank MA, Segers H, van Mil SE, van Helsdingen YM, Ameziane N, van den Ouweland AMW, Wagner A, MeijersHeijboer EJ, Kool M, de Kraker J, Waisfisz Q, van den Heuvel-Eibrink M. Fanconi Anemia Gene Mutations Are Not
Involved in Sporadic Wilms Tumor. Pediatr Blood Cancer 2010; 55: 742-744 (3 / 2.134)
Antoniou AC, Beesley J, McGuffog L, Sinilnikova OM, Healey S, Neuhausen SL, Ding YC, Rebbeck TR, Weitzel JN, Lynch
HT, Isaacs C, Ganz PA, Tomlinson G, Olopade OI, Couch FJ, Wang XS, Lindor NM, Pankratz VS, Radice P, … MeijersHeijboer EJ, et al. Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2
Mutation Carriers: Implications for Risk Prediction. Cancer Res 2010; 70: 9742-9754 (5 / 7.543)
Antoniou AC, Wang XS, Fredericksen ZS, McGuffog L, Tarrell R, Sinilnikova OM, Healey S, Morrison J, Kartsonaki C,
Lesnick T, Ghoussaini M, Barrowdale D, Peock S, Cook M, Oliver C, Frost D, Eccles D, Evans DG, … Meijers-Heijboer H,
et al. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone
receptor-negative breast cancer in the general population. Nature Genet 2010; 42: 885-+ (5 / 32.284)
Arbyn M, Simoens C, Van Damme P, Scharpantgen A, Meijer CJLM, Beutels P. Introduction of Human Papillomavirus
Vaccination in Belgium, Luxembourg and the Netherlands. Gynecol Obstet Inves 2010; 70: 224-232 (2 / 1.045)
Berkhof J, Coupe VMH, Bogaards JA, van Kemenade FJ, Helmerhorst TJ, Snijders PJF, Meijer CJLM. The health and
economic effects of HPV DNA screening in the Netherlands. Int J Cancer 2010; 127: 2147-2158 (4 / 4.722)
Bogaards JA, Xiridou M, Coupe VMH, Meijer CJLM, Wallinga J, Berkhof J. Model-Based Estimation of Viral
Transmissibility and Infection-Induced Resistance From the Age-Dependent Prevalence of Infection for 14 High-Risk
Types of Human Papillomavirus. Am J Epidemiol 2010; 171: 817-825 (5 / 5.589)
Bossers K, Ylstra B, Brakenhoff RH, Smeets SJ, Verhaagen J, van de Wiel MA. Intensity-based analysis of dual-color
gene expression data as an alternative to ratio-based analysis to enhance reproducibility. BMC Genomics 2010; 11:
art.nr. 112 (4 / 3.759)
Braakhuis BJM, Bloemena E, Leemans CR, Brakenhoff RH. Molecular analysis of surgical margins in head and neck
cancer: More than a marginal issue. Oral Oncol 2010; 46: 485-491 (5 / 3.123)
Blokhuis MM, Pietersen GE, Goldberg PA, Algar U, Van der Merwe L, Mbatani N, Vorster AA, Ramesar RS. Lynch
syndrome: the influence of environmental factors on extracolonic cancer risk in hMLH1 c.C1528T mutation carriers
and their mutation-negative sisters. Familial Cancer 2010; 9: 357-363 (2 / 2.189)
Holstege H, van Beers E, Velds A, Liu XL, Joosse SA, Klarenbeek S, Schut E, Kerkhoven R, Klijn CN, Wessels LFA,
Nederlof PM, Jonkers J. Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated
breast cancers. BMC Cancer 2010; 10: 455 (3 / 2.736)
Seeber LMS, Zweemer RP, Marchionni L, Massuger LFAG, Smit VTHB, van Baal WM, Verheijen RHM, van Diest PJ.
Methylation profiles of endometrioid and serous endometrial cancers. Endocrine-Related Cancer 2010; 17: 663-673 (4
/ 4.282)
Wilson JB, Blom E, Cunningham R, Xiao YX, Kupfer GM, Jones NJ. Several tetratricopeptide repeat (TPR) motifs of
FANCG are required for assembly of the BRCA2/D1-D2-G-X3 complex, FANCD2 monoubiquitylation and phleomycin
resistance. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis 2010; 689: 12-20 (4 / 3.556)
Martinelli S, De Luca A, Stellacci E, Rossi C, Checquolo S, Lepri F, Caputo V, Silvano M, Buscherini F, Consoli F,
Ferrara G, Digilio MC, Cavaliere ML, van Hagen JM, Zampino G, van der Burgt I, Ferrero GB, Mazzanti L, Screpanti I,
Yntema HG, Nillesen WM,. Heterozygous Germline Mutations in the CBL Tumor-Suppressor Gene Cause a Noonan
Syndrome-like Phenotype. Am J Hum Genet 2010; 87: 250-257 (5 / 12.303)
van der Klift HM, Tops CMJ, Bik EC, Boogaard MW, Borgstein AM, Hansson KBM, Ausems MGEM, Garcia EG, Green A,
Hes FJ, Izatt L, van Hest LP, Alonso AM, Vriends AHJT, Wagner A, van Zelst-Stams WAG, Vasen HFA, Morreau H,
Devilee P, Wijnen JT. Quantification of Sequence Exchange Events between PMS2 and PMS2CL Provides a Basis for
Improved Mutation Scanning of Lynch Syndrome Patients. HUM MUTAT 2010; 31: 578-587 (4 / 6.887)
Coupe VMH, Meijer CJLM, Berkhof J. Re: Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in the
Netherlands. J Natl Cancer Inst 2010; 102(5): 358 (5 / 14.069)
de Sanjose S, Quint WGV, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR,
Vallejos CS, de Ruiz PA, Lima MA, Guimera N, Clavero O, Alejo M, Llombart-Bosch A, Cheng-Yang C, Tatti SA, .. Meijer
CJLM, ... et al.. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective crosssectional worldwide study. Lancet Oncol 2010; 11: 1048-1056 (5 / 14.47)
de Wilde J, Kooter JM, Overmeer RM, Claassen-Kramer D, Meijer CJLM, Snijders PJF, Steenbergen RDM. hTERT
promoter activity and CpG methylation in HPV-induced carcinogenesis. BMC Cancer 2010; 10: art.nr. 271 (3 / 2.736)
Deganello A, Franchi A, Sardi I, Pignataro L, Leemans CR, Gallo O. Genetic Alterations Between Primary Head and
Neck Squamous Cell Carcinoma and Recurrence After Radiotherapy Recurrence, Genetically Related Cancer, or
Second Primary?. Cancer 2010; 116: 1291-1297 (4 / 5.418)
73
Appendix 4: Scientific output
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
74
Dijkstra MG, Heideman DAM, de Roy SC, Rozendaal L, Berkhof J, van Krimpen K, van Groningen K, Snijders PJF, Meijer
CJLM, van Kemenade FJ. p16(INK4a) immunostaining as an alternative to histology review for reliable grading of
cervical intraepithelial lesions. J Clin Pathol 2010; 63: 972-977 (3 / 2.333)
Gok M, Heideman DAM, van Kemenade FJ, Berkhof J, Rozendaal L, Spruyt JWM, Voorhorst F, Belien JAM, Babovic M,
Snijders PJF, Meijer CJLM. HPV testing on self collected cervicovaginal lavage specimens as screening method for
women who do not attend cervical screening: cohort study. Brit Med J 2010; 340: art.nr. c1040 (5 / 13.66)
Hesselink AT, Heideman DAM, Berkhof J, Topal F, Pol RP, Meijer CJLM, Snijders PJF. Comparison of the Clinical
Performance of PapilloCheck Human Papillomavirus Detection with That of the GP5+/6+-PCR-Enzyme Immunoassay in
Population-Based Cervical Screening. J Clin Microbiol 2010; 48: 797-801 (4 / 4.162)
Hovland S, Arbyn M, Lie AK, Ryd W, Borge B, Berle EJ, Skomedal H, Kadima TM, Kyembwa L, Billay EM, Mukwege D,
Chirimwami RB, Mvula TM, Snijders PJF, Meijer CJLM, Karlsen F. A comprehensive evaluation of the accuracy of
cervical pre-cancer detection methods in a high-risk area in East Congo. Brit J Cancer 2010; 102: 957-965 (4 / 4.346)
Koppen IJN, Hermans FJR, Kaspers GJL. Folate related gene polymorphisms and susceptibility to develop childhood
acute lymphoblastic leukaemia. Brit J Haematol 2010; 148: 3-14 (4 / 4.597)
Lim DHK, Rehal PK, Nahorski MS, Macdonald F, Claessens T, Van Geel M, Gijezen L, Gille JJP, Giraud S, Richard S, van
Steensel M, Menko FH, Maher ER. A New Locus-Specific Database (LSDB) for Mutations in the Folliculin (FLCN) Gene.
Hum Mutat 2010; 31: E1043-E1051 (4 / 6.887)
Mahfouz ME, Rodrigo JP, Takes RP, Elsheikh MN, Rinaldo A, Brakenhoff RH, Ferlito A. Current potential and limitations
of molecular diagnostic methods in head and neck cancer. Eur Arch Oto-Rhino-L 2010; 267: 851-860 (3 / 1.167)
Meleti M, Mooi WJ, van der Waal I. Melanotic Pigmentation of Palatal Salivary Glands as a Possible Precursor to
Malignant Melanoma: Report of an Unusual Case. J Oral Maxil Surg 2010; 68: 867-869 (3 / 1.58)
Raza SA, Franceschi S, Pallardy S, Malik FR, Avan BI, Zafar A, Ali SH, Pervez S, Serajuddaula S, Snijders PJF, van
Kemenade FJ, Meijer CJLM, Shershah S, Clifford GM. Human papillomavirus infection in women with and without
cervical cancer in Karachi, Pakistan. Brit J Cancer 2010; 102: 1657-1660 (4 / 4.346)
Rijkaart DC, Berkhof J, van Kemenade FJ, Rozendaal L, Verheijen RHM, Bulk S, Herreilers ME, Verweij WM, Snijders
PJF, Meijer CJLM. Comparison of HPV and cytology triage algorithms for women with borderline or mild dyskaryosis in
population-based cervical screening (VUSA-screen study). Int J Cancer 2010; 126: 2175-2181 (4 / 4.722)
Ruijs MWG, Verhoef S, Rookus MA, Pruntel R, van der Hout AH, Hogervorst FBL, Kluijt I, Sijmons RH, Aalfs CM, Wagner
A, Ausems MGEM, Hoogerbrugge N, van Asperen CJ, Garcia EBG, Meijers-Heijboer EJ, ten Kate LP, Menko FH, van't
Veer LJ. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate
and relative frequency of cancers in different familial phenotypes. J Med Genet 2010; 47: 421-428 (4 / 5.751)
Schaaij-Visser TBM, Bremmer JF, Braakhuis BJM, Heck AJR, Slijper M, van der Waal I, Brakenhoff RH. Evaluation of
cornulin, keratin 4, keratin 13 expression and grade of dysplasia for predicting malignant progression of oral
leukoplakia. Oral Oncol 2010; 46: 123-127 (5 / 3.123)
Schaaij-Visser TBM, Brakenhoff RH, Leemans CR, Heck AJR, Slijper M. Protein biomarker discovery for head and neck
cancer. J Proteomics 2010; 73: 1790-1803 (1 / 3.851)
Schook RM, Postmus BBM, Van den Berg RM, Sutedja TG, de Man FS, Smit EF, Postmus PE. The Finding of Premalignant
Lesions is Not Associated with Smoking Cessation in Chemoprevention Study Volunteers. J Thorac Oncol 2010; 5: 12401245 (4 / 4.547)
Sherpa ATL, Clifford GM, Vaccarella S, Shrestha S, Nygard M, Karki BS, Snijders PJF, Meijer CJLM, Franceschi S.
Human papillomavirus infection in women with and without cervical cancer in Nepal. Cancer Causes Control 2010; 21:
323-330 (4 / 3.199)
Smith JS, Moses S, Hudgens MG, Parker CB, Agot K, Maclean I, Ndinya-Achola JO, Snijders PJF, Meijer CJLM, Bailey
RC. Increased Risk of HIV Acquisition among Kenyan Men with Human Papillomavirus Infection. J Infect Dis 2010; 201:
1677-1685 (5 / 5.865)
Smith JS, Backes DM, Hudgens MG, Bailey RC, Veronesi G, Bogaarts M, Agot K, Ndinya-Achola JO, Maclean I, Agingu W,
Meijer CJLM, Moses S, Snijders PJF. Prevalence and risk factors of human papillomavirus infection by penile site in
uncircumcised Kenyan men. Int J Cancer 2010; 126: 572-577 (4 / 4.722)
Snijders PJF, Heideman DAM, Meijer CJLM. Methods for HPV detection in exfoliated cell and tissue specimens. Apmis
2010; 118: 520-528 (2 / 1.745)
Vaccarella S, Franceschi S, Clifford GM, Touze A, Hsu CC, de Sanjose S, Pham THA, Nguyen TH, Matos E, Shin HR,
Sukvirach S, Thomas JO, Boursaghin L, Gaitan J, Snijders PJF, Meijer CJLM, Munoz N, Herrero R, Coursaget P.
Seroprevalence of Antibodies against Human Papillomavirus (HPV) Types 16 and 18 in Four Continents: the
International Agency for Research on Cancer HPV Prevalence Surveys. Cancer Epidem Biomar 2010; 19: 2379-2388 (5 /
4.31)
Vaccarella S, Franceschi S, Snijders PJF, Herrero R, Meijer CJLM, Plummer M. Concurrent Infection with Multiple
Human Papillomavirus Types: Pooled Analysis of the IARC HPV Prevalence Surveys. Cancer Epidem Biomar 2010; 19:
503-510 (5 / 4.31)
Van den Berg RM, Brokx H, Vesin A, Field JK, Brambilla C, Meijer CJLM, Sutedja GT, Heideman DAM, Postmus PE, Smit
EF, Snijders PJF. Prognostic value of hTERT mRNA expression in surgical samples of lung cancer patients: the
European Early Lung Cancer Project. Int J Oncol 2010; 37: 455-461 (3 / 2.447)
van der Lelij P, Chrzanowska KH, Godthelp BC, Rooimans MA, Ostra AB, Stumm M, Zdzienicka MZ, Joenje H, de Winter
JP. Warsaw Breakage Syndrome, a Cohesinopathy Associated with Mutations in the XPD Helicase Family Member
DDX11/ChIR1. Am J Hum Genet 2010; 86: 262-266 (5 / 12.303)
van Engen-van Grunsven A, van Dijk MCRF, Ruiter DJ, Klaasen A, Mooi WJ, Blokx WAM. HRAS-mutated Spitz Tumors A
Subtype of Spitz Tumors With Distinct Features. Am J Surg Pathol 2010; 34: 1436-1441 (5 / 4.062)
van Harn T, Foijer F, van Vugt M, Banerjee R, Yang FT, Oostra AB, Joenje H, te Riele H. Loss of Rb proteins causes
genomic instability in the absence of mitogenic signaling. Genes Dev 2010; 24: 1377-1388 (5 / 12.075)
van Riel E, Ausems MGEM, Hogervorst FBL, Kluijt I, van Gijn ME, van Echtelt J, Scheidel-Jacobse K, Hennekam EFAM,
Stulp RP, Vos YJ, Offerhaus GJA, Menko FH, Gille JJP. A novel pathogenic MLH1 missense mutation, c.112A > C,
p.Asn38His, in six families with Lynch syndrome. Hered Cancer Clin Pr 2010; 8: art.nr. 7 (1 / 0.276)
van Zeeburg HJT, van Beusechem VW, Huizenga A, Haisma HJ, Korokhov N, Gibbs S, Leemans CR, Brakenhoff RH.
Adenovirus retargeting to surface expressed antigens on oral mucosa. J Gene Med 2010; 12: 365-376 (3 / 2.968)
Appendix 4: Scientific output
45.
46.
47.
48.
49.
van Zeeburg HJT, Huizenga A, Brink A, van den Doel PB, Zhu ZB, McCormick F, Brakenhoff RH, van Beusechem VW.
Comparison of oncolytic adenoviruses for selective eradication of oral cancer and pre-cancerous lesions. Gene Ther
2010; 17: 1517-1524 (4 / 4.745)
Veldhuijzen MJ, Snijders PJF, Reiss P, Meijer CJLM, van de Wijgert JH. Factors affecting transmission of mucosal
human papillomavirus; 2010, pp 862-874.. Lancet Infect Dis 2010; 10(12): 862-874 (5 / 15.583)
Wasielewski M, Riaz M, Vermeulen J, van den Ouweland A, Labrijn-Marks I, Olmer R, van der Spaa L, Klijn JG,
Meijers-Heijboer EJ, Dooijes D, Schutte M. Association of rare MSH6 variants with familial breast cancer. Breast
Cancer Res Tr 2010; 123(2): 315-320 (4 / 4.696)
Wilting SM, van Boerdonk RAA, Henken FE, Meijer CJLM, Diosdado B, Meijer GA, le Sage C, Agami R, Snijders PJF,
Steenbergen RDM. Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer.
Mol Cancer 2010; 9: art.nr. 167 (4 / 4.16)
Yan ZJ, Delannoy M, Ling C, Daee D, Osman F, Muniandy PA, Shen X, Oostra AB, Du HS, Steltenpool J, Lin T, Schuster
B, Decaillet C, Stasiak A, Stasiak AZ, Stone S, Hoatlin ME, Schindler D, Woodcock CL, Joenje H, Sen R, de Winter JP,
Li L, Seidman MM, Whitb. A Histone-Fold Complex and FANCM Form a Conserved DNA-Remodeling Complex to Maintain
Genome Stability. Mol Cell 2010; 37: 865-878 (5 / 14.608)
Scientific papers non-refereed
1.
2.
3.
4.
5.
Braakhuis BJM, Brakenhoff RH, Leemans CR. Gene expression profiling in head and neck squamous cell carcinoma.
Curr Opin Otolaryngol Head Neck Surg 2010; 18: 67-71
Louwers JA, Kocken M, van der Biji JC, Berkhof J, Snijders PJF, Meijer CJLM, Verheijen RHM. Colposcopic
Characteristics of High-Risk Human Papillomavirus-Related Cervical Lesions. J Low Genit Tract Dis 2010; 14: 49-55
Okolo C, Franceschi S, Adewole I, Thomas JO, Follen M, Snijders PJF, Meijer CJLM, Clifford GM. Human papillomavirus
infection in women with and without cervical cancer in Ibadan, Nigeria. Infect Agent Cancer 2010; 5: 24
Smetsers SE, Zwaan CM, Sonnevelt MC, Brakenhoff RH, Smiers FJ, Best JD, Joenje H, Bierings MB. Fanconi anaemie:
uit de kinderschoenen. Ned Tijdschr Hematol 2010; 7: 258-263
van der Waal I. Een ongewone radiolucentie. Tandartspraktijk 2010; 31: 34-35
Dissertations
1.
2.
3.
4.
5.
6.
Aarts M - Gene targeting by single-stranded DNA oligonucleotides in mouse embryonic stem cells. Vrije Universiteit
Amsterdam, 4/8/2010. (Co-)promotores: HPJ te Riele (cat B)
de Wilde J - Molecular insights in HPV-mediated transformation with emphasis on hTERT. Vrije Universiteit
Amsterdam, 2/25/2010. (Co-)promotores: PJF Snijders, CJLM Meijer, RDM Steenbergen (cat A)
Ruijs MWG - Li-Fraumeni syndrome, clinical and molecular genetics. Vrije Universiteit Amsterdam, 2/5/2010. (Co)promotores: LP ter Kate, H Meijers-Heijboer, L van 't Veer, FH Menko (cat A)
van der Lelij P - The role of sister chromatoid cohesion in cohesinopathies, DNA damage response and carcinogenesis.
Vrije Universiteit Amsterdam, 10/7/2010. (Co-)promotores: H Joenje, JP de Winter (cat A)
van Zeeburg HJT - Oncolytic adenoviruses for treatment of oral cancer and precancer in sporadic and genetically
predisposed patients. Vrije Universiteit Amsterdam, 11/16/2010. (Co-)promotores: RH Brakenhoff, CR Leemans, VW
van Beusechem (cat A)
Vormer TL - Tumor suppression by retinoblastoma proteins: interacting proteins and cooperating. Vrije Universiteit
Amsterdam, 11/26/2010. (Co-)promotores: HPJ te Riele (cat A)
Program 2: Immunopathogenesis
Scientific papers refereed
1.
2.
3.
4.
5.
6.
7.
Ammerlaan H, Seifert H, Harbarth S, Brun-Buisson C, Torres A, Antonelli M, Kluytmans J, Bonten M. Should We Be
Debating the Importance of Timely Adequate Antimicrobial Therapy? Reply. Clinical Infectious Diseases 2010; 50: 618620 (5 / 8.195)
Aronica E, Fluiter K, Iyer A, Zurolo E, Vreijling J, van Vliet EA, Baayen JC, Gorter JA. Expression pattern of miR-146a,
an inflammation-associated microRNA, in experimental and human temporal lobe epilepsy. European Journal of
Neuroscience 2010; 31: 1100-1107 (3 / 3.418)
van Dommelen L, van Tiel FH, Ouburg S, Brouwers EE, Terporten PH, Savelkoul PH, Morré SA, Bruggeman CA, Hoebe
CJ. Alarmingly poor performance in Chlamydia trachomatis point-of-care testing. Sex Transm Infect 2010; 86(5): 355359 (2 / 2.175)
Shrestha UK, Karimi O, Crusius JB, Zhou F, Wang Z, Chen Z, van Bodegraven AA, Xiao J, Morré SA, Wang H, Li J, Xia B.
Distribution of peroxisome proliferator-activated receptor-gamma polymorphisms in Chinese and Dutch patients with
inflammatory bowel disease. Inflamm Bowel Dis 2010; 16(2): 312-319 (4 / 4.643)
Oort FA, Terhaar Sive Droste JS, van der Hulst RWM, van Heukelem HA, Loffeld RJLF, Wesdorp ICE, van Wanrooij RLJ,
de Baaij L, Mutsaers ER, van der Reijt S, Coupe VMH, Berkhof J, Bouman AA, Meijer GA, Mulder CJJ. Colonoscopycontrolled intra-individual comparisons to screen relevant neoplasia: faecal immunochemical test vs. guaiac-based
faecal occult blood test. Aliment Pharmacol Ther 2010; 31(3): 432-439 (4 / 4.357)
Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, van Eijndhoven MAJ, Hopmans ES, Lindenberg JL, de Gruijl TD,
Wurdinger T, Middeldorp JM. Functional delivery of viral miRNAs via exosomes. P Natl Acad Sci USA 2010; 107: 63286333 (5 / 9.432)
Alkemade FE, van Vliet P, Henneman P, van Dijk KW, Hierck BP, van Munsteren JC, Scheerman JA, Goeman JJ,
Havekes LM, Gittenberger-de Groot AC, van den Elsen PJ, DeRuiter MC. Prenatal Exposure to apoE Deficiency and
Postnatal Hypercholesterolemia Are Associated with Altered Cell-Specific Lysine Methyltransferase and Histone
Methylation Patterns in the Vasculature. Am J Pathol 2010; 176: 542-548 (5 / 5.673)
75
Appendix 4: Scientific output
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
76
Ang CW, Dijkstra JR, de Klerk MA, Endtz HP, van Doorn PA, Jacobs BC, Jeurissen SHM, Wagenaar JA. Host Factors
Determine Anti-GM1 Response Following Oral Challenge of Chickens with Guillain-Barre Syndrome Derived
Campylobacter jejuni Strain GB11. Plos one 2010; 5: art.nr. e9820 (4 / 4.351)
Arnold L, Tyagi RK, Mejia P, van Rooijen N, Perignon JL, Druilhe P. Analysis of innate defences against Plasmodium
falciparum in immunodeficient mice. Malaria J 2010; 9: art.nr. 197 (4 / 3.002)
Arwert EN, Lal R, Quist S, Rosewell I, van Rooijen N, Watt FM. Tumor formation initiated by nondividing epidermal
cells via an inflammatory infiltrate. P Natl Acad Sci USA 2010; 107: 19903-19908 (5 / 9.432)
Backer R, Schwandt T, Greuter M, Oosting M, Jungerkes F, Tuting T, Boon L, O'Toole T, Kraal G, Limmer A, den Haan
JMM. Effective collaboration between marginal metallophilic macrophages and CD8(+) dendritic cells in the
generation of cytotoxic T cells. P Natl Acad Sci USA 2010; 107: 216-221 (5 / 9.432)
Bakema JE, Hiemstra IH, Bakker J, de Haij S, Kok Y, Adema G, van Egmond M, Coffer PJ, van de Winkel JGJ, Leusen
JHW. c-Jun activating binding protein 1 binds to the IgA receptor and modulates protein levels of Fc alpha RI and FcR
gamma-chain. Eur J Immunol 2010; 40: 2035-2040 (4 / 5.179)
Barral P, Polzella P, Bruckbauer A, van Rooijen N, Besra GS, Cerundolo V, Batista FD. CD169(+) macrophages present
lipid antigens to mediate early activation of iNKT cells in lymph nodes. Nat Immunol 2010; 11: 303-U48 (5 / 26.0)
Beumer JH, Franke NE, Tolboom R, Buckle T, Rosing H, Lopez-Lazaro L, Schellens JHM, Beijnen JH, van Tellingen O.
Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice. Invest New Drugs
2010; 28: 145-155 (3 / 3.072)
Birch HL, Alderwick LJ, Appelmelk BJ, Maaskant JJ, Bhatt A, Singh A, Nigou J, Eggeling L, Geurtsen J, Besra GS. A
truncated lipoglycan from mycobacteria with altered immunological properties. P Natl Acad Sci USA 2010; 107: 26342639 (5 / 9.432)
Bolscher JGM, Brevoord J, Nazmi K, Ju TZ, Veerman ECI, van Wijk JAE, Cummings RD, van Die I. Solid-phase synthesis
of a pentavalent GalNAc-containing glycopeptide (Tn antigen) representing the nephropathy-associated IgA hinge
region. Carbohyd Res 2010; 345: 1998-2003 (3 / 2.025)
Bontkes HJ, Moreno M, Hangalapura BN, Lindenberg JJ, de Groot J, Lougheed SM, van der Vliet HJJ, van den
Eertwegh AJM, de Gruijl TD, von Blomberg BME, Scheper RJ. Attenuation of invariant Natural Killer T-cell anergy
induction through intradermal delivery of alpha-galactosylceramide. Clin Immunol 2010; 136: 364-374 (4 / 3.863)
Bosch T, de Neeling AJ, Schouls LM, van der Zwaluw KW, Kluytmans JAJW, Grundmann H, Huijsdens XW. PFGE
diversity within the methicillin-resistant Staphylococcus aureus clonal lineage ST398. BMC Microbiol 2010; 10: art.nr.
40 (3 / 2.89)
Bradshaw AC, Parker AL, Duffy MR, Coughlan L, van Rooijen N, Kahari VM, Nicklin SA, Baker AH. Requirements for
Receptor Engagement during Infection by Adenovirus Complexed with Blood Coagulation Factor X. PLoS Pathog 2010;
6 (10): art.nr. e1001142 (5 / 8.978)
Broekhuizen CAN, Sta M, Vandenbroucke-Grauls CMJE, Zaat SAJ. Microscopic Detection of Viable Staphylococcus
epidermidis in Peri-Implant Tissue in Experimental Biomaterial-Associated Infection, Identified by Bromodeoxyuridine
Incorporation. Infect Immun 2010; 78: 954-962 (4 / 4.205)
Szeles L, Poliska S, Nagy G, Szatmari I, Szanto A, Pap A, Lindstedt M, Santegoets SJAM, Ruhl R, Dezso B, Nagy L.
Research Resource: Transcriptome Profiling of Genes Regulated by RXR and Its Permissive and Nonpermissive Partners
in Differentiating Monocyte-Derived Dendritic Cells. Mol Endocrinol 2010; 24: 2218-2231 (4 / 5.257)
Alba R, Bradshaw AC, Coughlan L, Denby L, McDonald RA, Waddington SN, Buckley SMK, Greig JA, Parker AL, Miller
AM, Wang HJ, Lieber A, van Rooijen N, Mcvey JH, Nicklin SA, Baker AH. Biodistribution and retargeting of FX-binding
ablated adenovirus serotype 5 vectors. Blood 2010; 116: 2656-2664 (5 / 10.555)
Budding AE, Grasman ME, Lin F, Bogaards JA, Soeltan-Kaersenhout DJ, Vandenbroucke-Grauls CMJE, Van Bodegraven
AA, Savelkoul PHM. IS-pro: high-throughput molecular fingerprinting of the intestinal microbiota. Faseb J 2010; 24:
4556-4564 (5 / 6.401)
Budding AE, Vandenbroucke-Grauls CMJE, Melles DC, van Duijkeren E, Kluytmans JAJW, Savelkoul PHM. Binary IS
Typing for Staphylococcus aureus. Plos one 2010; 5(10): art.nr. e13671 (4 / 4.351)
Cameron B, Flamand L, Juwana H, Middeldorp J, Naing Z, Rawlinson W, Ablashi D, Lloyd A. Serological and Virological
Investigation of the Role of the Herpesviruses EBV, CMV and HHV-6 in Post-Infective Fatigue Syndrome. J Med Virol
2010; 82: 1684-1688 (2 / 2.47)
De Jong MAWP, de Witte L, Taylor ME, Geijtenbeek TBH. Herpes Simplex Virus Type 2 Enhances HIV-1 Susceptibility
by Affecting Langerhans Cell Function. J Immunol 2010; 185: 1633-1641 (4 / 5.646)
De Jong MAWP, Vriend LEM, Theelen B, Taylor ME, Fluitsma D, Boekhout T, Geijtenbeek TBH. C-type lectin Langerin
is a beta-glucan receptor on human Langerhans cells that recognizes opportunistic and pathogenic fungi. Mol Immunol
2010; 47: 1216-1225 (3 / 3.202)
den Dunnen J, Gringhuis SI, Geijtenbeek TBH. Dusting the sugar fingerprint: C-type lectin signaling in adaptive
immunity. Immunology Letters 2010; 128: 12-16 (3 / 2.906)
Gringhuis SI, van der Vlist M, van den Berg LM, den Dunnen J, Litjens M, Geijtenbeek TBH. HIV-1 exploits innate
signaling by TLR8 and DC-SIGN for productive infection of dendritic cells. NATURE IMMUNOLOGY 2010; 11: 419-U81 (5
/ 26.0)
Schilder AM. Wegener's Granulomatosis vasculitis and granuloma. Autoimmunity Reviews 2010; 9: 483-487 (4 / 6.368)
Triantis V, Saeland E, Bijl N, Oude-Elferink RP, Jansen PLM. Glycosylation of Fibroblast Growth Factor Receptor 4 Is a
Key Regulator of Fibroblast Growth Factor 19-Mediated Down-Regulation of Cytochrome P450 7A1. Hepatology 2010;
52: 656-666 (5 / 10.84)
Schrama AJJ, Elferink JGR, Hack CE, de Beaufort AJ, Berger HM, Walther FJ. Pulmonary Secretory Phospholipase A(2)
in Infants with Respiratory Distress Syndrome Stimulates in vitro Neutrophil Migration. Neonatology 2010; 97: 1-9 (3 /
1.984)
Cantaert T, van Baarsen LGM, Wijbrandts CA, Thurlings RM, van de Sande MG, Bos C, van der Pouw TK, Verweij CL,
Tak PP, Baeten DL. Type I interferons have no major influence on humoral autoimmunity in rheumatoid arthritis.
Rheumatology 2010; 49: 156-166 (4 / 4.236)
Carlos CP, Mendes GEF, Miquelin AR, Luz MAM, da Silva CGA, van Rooijen N, Coimbra TM, Burdmann EA. Macrophage
Depletion Attenuates Chronic Cyclosporine A Nephrotoxicity. Transplantation 2010; 89: 1362-1370 (5 / 3.498)
Catron DM, Pape KA, Fife BT, van Rooijen N, Jenkins MK. A Protease-Dependent Mechanism for Initiating T-Dependent
B Cell Responses to Large Particulate Antigens. J Immunol 2010; 184: 3609-3617 (4 / 5.646)
Appendix 4: Scientific output
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
Christerson L, de Vries HJC, de Barbeyrac B, Gaydos CA, Henrich B, Hoffmann S, Schachter J, Thorvaldsen J, VallMayans M, Klint M, Herrmann B, Morre SA. Typing of Lymphogranuloma Venereum Chlamydia trachomatis Strains.
Emerg Infect Dis 2010; 16: 1777-1779 (5 / 6.794)
Claessen FAP, Blaauw GJ, van der Vorst MJDL, Ang CW, van Agtmael MA. Tryps after adventurous trips. Neth J Med
2010; 68: 144-145 (3 / 1.503)
Cockburn IA, Chen YC, Overstreet MG, Lees JR, van Rooijen N, Farber DL, Zavala F. Prolonged Antigen Presentation Is
Required for Optimal CD8+T Cell Responses against Malaria Liver Stage Parasites. PLoS Pathog 2010; 6 (5): art.nr.
e1000877 (5 / 8.978)
Daniels JMA, Schoorl M, Snijders D, Knol DL, Lutter R, Jansen HM, Boersma WG. Procalcitonin vs C-Reactive Protein as
Predictive Markers of Response to Antibiotic Therapy in Acute Exacerbations of COPD. Chest 2010; 138: 1108-1115 (5
/ 6.36)
De Jong MAWP, de Witte L, Santegoets SJAM, Fluitsma D, Taylor ME, de Gruijl TD, Geijtenbeek TBH. Mutz-3-derived
Langerhans cells are a model to study HIV-1 transmission and potential inhibitors. J Leukoc Biol 2010; 87: 637-643 (4 /
4.403)
de Vries HJC, Smelov V, Ouburg S, Pleijster J, Geskus RB, Speksnijder AGCL, Fennema JSA, Morre SA. Anal
Lymphogranuloma Venereum Infection Screening With IgA Anti-Chlamydia trachomatis-Specific Major Outer Membrane
Protein Serology. Sex Transm Dis 2010; 37: 789-795 (3 / 2.579)
Dingemans AMC, van den Boogaart V, Vosse BA, van Suylen RJ, Griffioen AW, Thijssen VL. Integrin expression profiling
identifies integrin alpha5 and beta1 as prognostic factors in early stage non-small cell lung cancer. Mol Cancer 2010;
9: art.nr. 152 (4 / 4.16)
Driessen NN, Stoop EJM, Ummels R, Gurcha SS, Mishra AK, Larrouy-Maumus G, Nigou J, Gilleron M, Puzo G, Maaskant
JJ, Sparrius M, Besra GS, Bitter W, Vandenbroucke-Grauls CMJE, Appelmelk BJ. Mycobacterium marinum MMAR_2380,
a predicted transmembrane acyltransferase, is essential for the presence of the mannose cap on lipoarabinomannan.
Microbiology+ 2010; 156: 3492-3502 (1 / 0.638)
Dubois PCA, Trynka G, Franke L, Hunt KA, Romanos J, Curtotti A, Zhernakova A, Heap GAR, Adany R, Aromaa A,
Bardella MT, van den Berg LH, Bockett NA, de la Concha EG, Dema B, Fehrmann RSN, Fernandez-Arquero M, Fiatal S,
Grandone E, … Mulder CJ, … et al.. Multiple common variants for celiac disease influencing immune gene expression
(vol 42, pg 295, 2010). Nature Genet 2010; 42: 465 (5 / 32.284)
Ellett JD, Atkinson C, Evans ZP, Amani Z, Balish E, Schmidt MG, van Rooijen N, Schnellmann RG, Chavin KD. Murine
Kupffer Cells Are Protective in Total Hepatic Ischemia/Reperfusion Injury with Bowel Congestion through IL-10. J
Immunol 2010; 184: 5849-5858 (4 / 5.646)
Fabrizio K, Manix C, Tian HJ, van Rooijen N, Pirofski LA. The efficacy of pneumococcal capsular polysaccharidespecific antibodies to serotype 3 Streptococcus pneumoniae requires macrophages. Vaccine 2010; 28: 7542-7550 (4 /
3.616)
Fachiroh J, Stevens SJC, Haryana SM, Middeldorp JM. Combination of Epstein-Barr virus scaffold (BdRF1/VCA-p40) and
small capsid protein (BFRF3/VCA-p18) into a single molecule for improved serodiagnosis of acute and malignant EBVdriven disease. J Virol Methods 2010; 169: 79-86 (3 / 2.133)
Frimpong-Boateng K, van Rooijen N, Geiben-Lynn R. Regulatory T Cells Suppress Natural Killer Cells during Plasmid
DNA Vaccination in Mice, Blunting the CD8(+) T Cell Immune Response by the Cytokine TGF beta. Plos one 2010; 5(8):
art.nr. e12281 (4 / 4.351)
Garcia MR, Ledgerwood L, Yang Y, Xu JN, Lal G, Burrell B, Ma G, Hashimoto D, Li YS, Boros P, Grisotto M, van Rooijen
N, Matesanz R, Tacke F, Ginhoux F, Ding YZ, Chen SH, Randolph GJ, Merad M, Bromberg JS, Ochando JC. Monocytic
suppressive cells mediate cardiovascular transplantation tolerance in mice. J Clin Invest 2010; 120: 2486-2496 (5 /
15.387)
Hangalapura BN, Oosterhoff D, Aggarwal S, Wijnands PGJT, van de Ven R, Santegoets SJAM, van den Tol MP,
Hooijberg E, Pereboev A, van den Eertwegh AJM, Curiel DT, Scheper RJ, de Gruijl TD. Selective Transduction of
Dendritic Cells in Human Lymph Nodes and Superior Induction of High-avidity Melanoma-reactive Cytotoxic T Cells by
a CD40-targeted Adenovirus. J Immunother 2010; 33: 706-715 (3 / 3.203)
Hazlett LD, McClellan SA, Barrett RP, Huang X, Zhang YF, Wu MH, van Rooijen N, Szliter E. IL-33 Shifts Macrophage
Polarization, Promoting Resistance against Pseudomonas aeruginosa Keratitis. Invest Ophth Vis Sci 2010; 51: 15241532 (4 / 3.431)
Huch JH, Cunningham AL, Arvin AM, Nasr N, Santegoets SJAM, Slobedman E, Slobedman B, Abendroth A. Impact of
Varicella-Zoster Virus on Dendritic Cell Subsets in Human Skin during Natural Infection. J Virol 2010; 84: 4060-4072 (4
/ 5.15)
Hunter MM, Wang A, Parhar KS, Johnston MJG, van Rooijen N, Beck PL, Mckay DM. In Vitro-Derived Alternatively
Activated Macrophages Reduce Colonic Inflammation in Mice. Gastroenterology 2010; 138: 1395-1405 (5 / 12.899)
Ishida W, Fukuda K, Kajisako M, Takahashi A, Sumi T, van Rooijen N, Fukushima A. Conjunctival macrophages act as
antigen-presenting cells in the conjunctiva during the development of experimental allergic conjunctivitis. Mol Vis
2010; 16: 1280-1285 (4 / 2.541)
Jafari N, van Nierop GP, Verjans GMGM, Osterhaus ADME, Middeldorp JM, Hintzen RQ. No evidence for intrathecal IgG
synthesis to Epstein Barr virus nuclear antigen-1 in multiple sclerosis. J Clin Virol 2010; 49: 26-31 (3 / 3.124)
Jager MM, Murk JLAN, Pique R, Wulf MWH, Leenders ACAP, Buiting AG, Bogaards JA, Kluytmans JAJW,
Vandenbroucke-Grauls CMJE. Prevalence of carriage of meticillin-susceptible and meticillin-resistant Staphylococcus
aureus in employees of five microbiology laboratories in The Netherlands. J Hosp Infect 2010; 74: 292-294 (3 / 3.012)
Kaiser AM, Haenen AJP, de Neeling AJ, Vandenbroucke-Grauls CMJE. Prevalence of Methicillin-Resistant
Staphylococcus aureus and Risk Factors for Carriage in Dutch Hospitals. Infect Control Hosp Ep 2010; 31: 1188-1190 (4
/ 2.768)
Kluytmans JAJW. Methicillin-resistant Staphylococcus aureus in food products: cause for concern or case for
complacency?. Clin Microbiol Infec 2010; 16: 11-15 (4 / 4.014)
Kluza E, van der Schaft DWJ, Hautvast PAI, Mulder WJM, Mayo KH, Griffioen AW, Strijkers GJ, Nicolay K. Synergistic
Targeting of alpha(v)beta(3) Integrin and Galectin-1 with Heteromultivalent Paramagnetic Liposomes for Combined
MR Imaging and Treatment of Angiogenesis. Nano Lett 2010; 10: 52-58 (5 / 9.991)
Kremer M, Thomas E, Milton RJ, Perry AW, van Rooijen N, Wheeler MD, Zacks S, Fried M, Rippe RA, Hines IN. Kupffer
Cell and Interleukin-12-Dependent Loss of Natural Killer T Cells in Hepatosteatosis. Hepatology 2010; 51: 130-141 (5 /
10.84)
77
Appendix 4: Scientific output
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
78
Krieckaert CLM, Bartelds GM, Lems WF, Wolbink GJJ. The effect of immunomodulators on the immunogenicity of TNFblocking therapeutic monoclonal antibodies: a review. Arthritis Res Ther 2010; 12(5): art.nr. 217 (4 / 4.271)
Kuijf ML, Samsom JN, van Rijs W, Bax M, Huizinga R, Heikema AP, van Doorn PA, van Belkum A, van Kooyk Y, Burgers
PC, Luider TM, Endtz HP, Nieuwenhuis EES, Jacobs BC. TLR4-Mediated Sensing of Campylobacter jejuni by Dendritic
Cells Is Determined by Sialylation. J Immunol 2010; 185: 748-755 (4 / 5.646)
Kuijk LM, van Die I. Worms to the Rescue: Can Worm Glycans Protect from Autoimmune Diseases?. Iubmb life 2010;
62: 303-312 (3 / 3.578)
Kulah C, Mooij MJ, Comert F, Aktas E, Celebi G, Ozlu N, Rijnsburger MC, Savelkoul PHM. Characterisation of
carbapenem-resistant Acinetobacter baumannii outbreak strains producing OXA-58 in Turkey. Int J Antimicrob Ag
2010; 36: 114-118 (3 / 3.032)
Kwakman PHS, te Velde AA, de Boer L, Speijer D, Vandenbroucke-Grauls CMJE, Zaat SAJ. How honey kills bacteria.
Faseb J 2010; 24: 2576-2582 (5 / 6.401)
Land JA, Van Bergen JEAM, Morre SA, Postma MJ. Epidemiology of Chlamydia trachomatis infection in women and the
cost-effectiveness of screening. Hum Reprod Update 2010; 16(2): 189-204 (5 / 7.042)
Lang PA, Recher M, Honke N, Scheu S, Borkens S, Gailus N, Krings C, Meryk A, Kulawik A, Cervantes-Barragan L, van
Rooijen N, Kalinke U, Ludewig B, Hengartner H, Harris N, Haussinger D, Ohashi PS, Zinkernagel RM, Lang KS. Tissue
Macrophages Suppress Viral Replication and Prevent Severe Immunopathology in an Interferon-I-Dependent Manner in
Mice. Hepatology 2010; 52: 25-32 (5 / 10.84)
Lanthier N, Molendi-Coste O, Horsmans Y, van Rooijen N, Cani PD, Leclercq IA. Kupffer cell activation is a causal
factor for hepatic insulin resistance. Am J Physiol-Gastr L 2010; 298: G107-G116 (3 / 3.258)
Lauro C, Cipriani R, Catalano M, Trettel F, Chece G, Brusadin V, Antonilli L, van Rooijen N, Eusebi F, Fredholm BB,
Limatola C. Adenosine A(1) Receptors and Microglial Cells Mediate CX3CL1-Induced Protection of Hippocampal
Neurons Against Glu-Induced Death. Neuropsychopharmacol 2010; 35: 1550-1559 (5 / 6.993)
Lee WY, Moriarty TJ, Wong CHY, Zhou H, Strieter RM, van Rooijen N, Chaconas G, Kubes P. An intravascular immune
response to Borrelia burgdorferi involves Kupffer cells and iNKT cells. Nat Immunol 2010; 11: 295-U36 (5 / 26.0)
Lotzer K, Dopping S, Connert S, Grabner R, Spanbroek R, Lemser B, Beer M, Hildner M, Hehlgans T, van der Wall M,
Mebius RE, Lovas A, Randolph GJ, Weih F, Habenicht AJR. Mouse Aorta Smooth Muscle Cells Differentiate Into
Lymphoid Tissue Organizer-Like Cells on Combined Tumor Necrosis Factor Receptor-1/Lymphotoxin beta-Receptor NFkappa B Signaling. Arterioscl Throm Vas 2010; 30: 395-402 (5 / 7.235)
Loureiro J, Schilte MN, Aguilera A, Albar-Vizcaino P, Ramirez-Huesca M, Perez-Lozano ML, Gonzalez-Mateo G, Aroeira
LS, Selgas R, Mendoza L, Ortiz A, Ruiz-Ortega M, van den Born J, Beelen RHJ, Lopez-Cabrera M. BMP-7 blocks
mesenchymal conversion of mesothelial cells and prevents peritoneal damage induced by dialysis fluid exposure.
Nephrol Dial Transpl 2010; 25: 1098-1108 (4 / 3.306)
Ly LV, Baghat A, Versluis M, Jordanova ES, Luyten GPM, van Rooijen N, van Hall T, van der Velden PA, Jager MJ. In
Aged Mice, Outgrowth of Intraocular Melanoma Depends on Proangiogenic M2-Type Macrophages. J Immunol 2010;
185: 3481-3488 (4 / 5.646)
Machnik A, Dahlmann A, Kopp C, Goss J, Wagner H, van Rooijen N, Eckardt KU, Muller DN, Park JK, Luft FC,
Kerjaschki D, Titze J. Mononuclear Phagocyte System Depletion Blocks Interstitial Tonicity-Responsive Enhancer
Binding Protein/Vascular Endothelial Growth Factor C Expression and Induces Salt-Sensitive Hypertension in Rats.
Hypertension 2010; 55: 755-U76 (5 / 6.614)
Martin SF, Esser PR, Schmucker S, Dietz L, Naisbitt DJ, Park BK, Vocanson M, Nicolas JF, Keller M, Pichler WJ, Peiser
M, Luch A, Wanner R, Maggi E, Cavani A, Rustemeyer T, Richter A, Thierse HJ, Sallusto F. T-cell recognition of
chemicals, protein allergens and drugs: towards the development of in vitro assays. Cell Mol Life Sci 2010; 67: 41714184 (4 / 6.09)
McGill J, van Rooijen N, Legge KL. IL-15 trans-presentation by pulmonary dendritic cells promotes effector CD8 T cell
survival during influenza virus infection. J Exp Med 2010; 207: 521-534 (5 / 14.505)
Meissner TB, Li A, Biswas A, Lee KH, Liu YJ, Bayir E, Iliopoulos D, van den Elsen PJ, Kobayashi KS. NLR family member
NLRC5 is a transcriptional regulator of MHC class I genes. P Natl Acad Sci USA 2010; 107: 13794-13799 (5 / 9.432)
Mooney JE, Rolfe BE, Osborne GW, Sester DP, van Rooijen N, Campbell GR, Hume DA, Campbell JH. Cellular Plasticity
of Inflammatory Myeloid Cells in the Peritoneal Foreign Body Response. Am J Pathol 2010; 176: 369-380 (5 / 5.673)
Mount AM, Masson F, Kupresanin F, Smith CM, May JS, van Rooijen N, Stevenson PG, Belz GT. Interference with
Dendritic Cell Populations Limits Early Antigen Presentation in Chronic gamma-Herpesvirus-68 Infection. J Immunol
2010; 185: 3669-3676 (4 / 5.646)
Nielsen HM, Mulder SD, Belien JAM, Musters RJP, Eikelenboom P, Veerhuis R. Astrocytic A beta 1-42 Uptake Is
Determined by A beta-Aggregation State and the Presence of Amyloid-Associated Proteins. Glia 2010; 58: 1235-1246
(4 / 4.932)
Nieuwland R, van der Post JAM, Gemma CARL, Kenter G, Sturk A. Microparticles and Exosomes in Gynecologic
Neoplasias. Semin Thromb Hemost 2010; 36: 925-929 (4 / 3.214)
Oostdijk EAN, De Smet AMGA, Blok HEM, Groen EST, van Asselt GJ, Benus RFJ, Bernards SAT, Frenay IHME, Jansz AR,
de Jongh BM, Kaan JA, Leverstein-van Hall MA, Mascini EM, Pauw W, Sturm PDJ, Thijsen SFT, Kluytmans JAJW, Bonten
MJM. Ecological Effects of Selective Decontamination on Resistant Gram-negative Bacterial Colonization. Am J Resp
Crit Care Med 2010; 181: 452-457 (5 / 10.689)
Ouwehand K, Scheper RJ, de Gruijl TD, Gibbs S. Epidermis-to-dermis migration of immature Langerhans cells upon
topical irritant exposure is dependent on CCL2 and CCL5. Eur J Immunol 2010; 40: 2026-2034 (4 / 5.179)
Ouwehand K, Spiekstra SW, Reinders J, Scheper RJ, de Gruijl TD, Gibbs S. Comparison of a novel CXCL12/CCL5
dependent migration assay with CXCL8 secretion and CD86 expression for distinguishing sensitizers from nonsensitizers using MUTZ-3 Langerhans cells. Toxicol Vitro 2010; 24: 578-585 (2 / 2.06)
Reijmers RM, Vondenhoff MFR, Roozendaal R, Kuil A, Li JP, Spaargaren M, Pals ST, Mebius RE. Impaired Lymphoid
Organ Development in Mice Lacking the Heparan Sulfate Modifying Enzyme Glucuronyl C5-Epimerase. J Immunol 2010;
184: 3656-3664 (4 / 5.646)
Relyveld GN, Westerhof W, Woudenberg J, Kingswijk M, Langenberg MHG, Vandenbroucke-Grauls CMJE, Bos JD,
Savelkoul PHM. Progressive Macular Hypomelanosis Is Associated with a Putative Propionibacterium Species. J Invest
Dermatol 2010; 130: 1182-1184 (5 / 5.543)
Appendix 4: Scientific output
87.
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
107.
108.
109.
110.
111.
112.
113.
114.
Reyes JL, Terrazas CA, Alonso-Trujillo J, van Rooijen N, Satoskar AR, Terrazas LI. Early removal of alternatively
activated macrophages leads to Taenia crassiceps cysticercosis clearance in vivo. Int J Parasitology 2010; 40: 731-742
(1 / 3.819)
Rosenberger S, Arce JDC, Langbein L, Steenbergen RDM, Rosl F. Alternative splicing of human papillomavirus type-16
E6/E6*early mRNA is coupled to EGF signaling via Erk1/2 activation. P Natl Acad Sci USA 2010; 107: 7006-7011 (5 /
9.432)
Sani M, Houben ENG, Geurtsen J, Pierson J, de Punder K, van Zon M, Wever B, Piersma SR, Jimenez CR, Daffe M,
Appelmelk BJ, Bitter W, van der Wel N, Peters PJ. Direct Visualization by Cryo-EM of the Mycobacterial Capsular
Layer: A Labile Structure Containing ESX-1-Secreted Proteins. PLoS Pathog 2010; 6(3): art.nr. e1000794 (5 / 8.978)
Saridin CP, Raijmakers PGHM, Slootweg PJ, Tuinzing DB, Becking AG, van der Waal I. Unilateral Condylar
Hyperactivity: A Histopathologic Analysis of 47 Patients. J Oral Maxil Surg 2010; 68: 47-53 (3 / 1.58)
Schilte MN, Fabbrini P, Ter Wee PM, Keuning ED, Zareie M, Tangelder GJ, Van Lambalgen AA, Beelen RHJ, van den
Born J. Peritoneal Dialysis Fluid Bioincompatibility and New Vessel Formation Promote Leukocyte-Endothelium
Interactions in a Chronic Rat Model for Peritoneal Dialysis. Microcirculation 2010; 17: 271-280 (3 / 2.368)
Scholten KBJ, Ruizendaal JJ, Graf M, Schoedl T, Kramer D, Meijer CJLM, Man S, Hooijberg E. Promiscuous behavior of
HPV16E6 specific T cell receptor beta chains hampers functional expression in TCR transgenic T cells, which can be
restored in part by genetic modification. Cell Oncol 2010; 32: 43-56 (4 / 4.169)
Serrats J, Schiltz JC, Garcia-Bueno B, van Rooijen N, Reyes TM, Sawchenko PE. Dual Roles for Perivascular
Macrophages in Immune-to-Brain Signaling. Neuron 2010; 65: 94-106 (5 / 13.26)
Simon ID, van Rooijen N, Rose JK. Vesicular Stomatitis Virus Genomic RNA Persists In Vivo in the Absence of Viral
Replication. J Virol 2010; 84: 3280-3286 (4 / 5.15)
Sluijter BJR, van den Hout MFCM, Stam AGM, Lougheed SM, Suhoski MM, van den Eertwegh AJM, van den Tol MP, van
Leeuwen PAM, Meijer S, Scheper RJ, June CH, de Gruijl TD, Santegoets SJAM. 4-1BB-mediated expansion affords
superior detection of in vivo primed effector memory CD8(+) T cells from melanoma sentinel lymph nodes. Clin
Immunol 2010; 137: 221-233 (4 / 3.863)
Snijders D, Daniels JMA, de Graaff CS, van der Werf TS, Boersma WG. Efficacy of Corticosteroids in Communityacquired Pneumonia A Randomized Double-Blinded Clinical Trial. Am J Resp Crit Care Med 2010; 181: 975-982 (5 /
10.689)
Stienstra R, Saudale F, Duval C, Keshtkar S, Groener JEM, van Rooijen N, Staels B, Kersten S, Muller M. Kupffer Cells
Promote Hepatic Steatosis Via Interleukin-1 beta-Dependent Suppression of Peroxisome Proliferator-Activated
Receptor alpha Activity. Hepatology 2010; 51: 511-522 (5 / 10.84)
Stritzker J, Weibel S, Seubert C, Gotz A, Tresch A, van Rooijen N, Oelschlaeger TA, Hill PJ, Gentschev I, Szalay AA.
Enterobacterial tumor colonization in mice depends on bacterial metabolism and macrophages but is independent of
chemotaxis and motility. Int J Med Microbiol 2010; 300: 449-456 (3 / 2.802)
Stuart J, Leverstein-van Hall MA. Guideline for phenotypic screening and confirmation of carbapenemases in
Enterobacteriaceae. Int J Antimicrob Ag 2010; 36: 205-210 (3 / 3.032)
ten Brinke A, van Schijndel G, Visser R, de Gruijl TD, Zwaginga JJ, van Ham SM. Monophosphoryl lipid A plus IFN
gamma maturation of dendritic cells induces antigen-specific CD8(+) cytotoxic T cells with high cytolytic potential.
Cancer Immunol Immun 2010; 59: 1185-1195 (4 / 3.791)
Traag BA, Driks A, Stragier P, Bitter W, Broussard G, Hatfull G, Chu F, Adams KN, Ramakrishnan L, Losick R. Do
mycobacteria produce endospores?. P Natl Acad Sci USA 2010; 107: 878-881 (5 / 9.432)
Triantafyllopoulou A, Franzke CW, Seshan SV, Perino G, Kalliolias GD, Ramanujam M, van Rooijen N, Davidson A,
Ivashkiv LB. Proliferative lesions and metalloproteinase activity in murine lupus nephritis mediated by type I
interferons and macrophages. P Natl Acad Sci USA 2010; 107: 3012-3017 (5 / 9.432)
Tsang CM, Zhang GT, Seto E, Takada K, Deng W, Yip YL, Man C, Hau PM, Chen HL, Cao Y, Lo KW, Middeldorp JM,
Cheung ALM, Tsao SW. Epstein-Barr virus infection in immortalized nasopharyngeal epithelial cells: regulation of
infection and phenotypic characterization. Int J Cancer 2010; 127: 1570-1583 (4 / 4.722)
Unoki N, Murakami T, Nishijima K, Ogino K, van Rooijen N, Yoshimura N. SDF-1/CXCR4 Contributes to the Activation
of Tip Cells and Microglia in Retinal Angiogenesis. Invest Ophth Vis Sci 2010; 51: 3362-3371 (4 / 3.431)
Valdivia IM, Aguayo F, Pruyas M, Snijders PJF, Corvalan A, Ferreccio C. Human papillomavirus (HPV) genotypes in
cervix uterine cancer patients in a public hospital and private clinic from Santiago, Chile. Rev Chil Infectol 2010; 27:
11-16 (1 / 0.41)
van Beek EM, van Bruggen R, Schornagel K, Tool A, Matozaki T, Kraal G, Roos D, van den Berg TK. SIRP alpha controls
phagocyte NADPH oxidase function by limiting the expression of gp91(phox). Eur J Clin Invest 2010; 40: 34 (4 / 2.643)
van de Pavert SA, Mebius RE. New insights into the development of lymphoid tissues. Nat Rev Immunol 2010; 10: 664U24 (5 / 32.245)
van den Berg H, Greuter M, Kraal G, den Haan JMM. Different mechanisms regulate CD4(+) T cell independent
induction of oral and nasal tolerance of CD8(+) T cells. Immunobiology 2010; 215: 163-171 (3 / 3.586)
van den Hende M, Redeker A, Kwappenberg KM, Franken KL, Drijfhout JW, Oostendorp J, Valentijn AR, Fathers LM,
Welters MJ, Melief CJ, Kenter GG, van der Burg SH, Offringa R. Evaluation of immunological cross-reactivity between
clade A9 high-risk human papillomavirus types on the basis of E6-Specific CD4+ memory T cell responses. J Infect Dis
2010; 8: 12--00-1211 (5 / 5.865)
van der Horst-Bruinsma I, Crusius JBA. New insights in understanding the pathogenesis of spondyloarthropathies.
Arthritis Res Ther 2010; 12 (1): art.nr. 102 (4 / 4.271)
van Die I, van Stijn CMW, Geyer H, Geyer R. Structural and Functional Analysis of Glycosphingolipids of Schistosoma
Mansoni. Methods Enzymology 2010; 480: 117-140 (2 / 1.904)
van Die I, Cummings RD. Glycan gimmickry by parasitic helminths: A strategy for modulating the host immune
response?. Glycobiology 2010; 20: 2-12 (3 / 3.929)
van Luijn MM, van den Ancker W, Chamuleau MED, Ossenkoppele GJ, van Ham SM, van de Loosdrecht AA. Impaired
antigen presentation in neoplasia: basic mechanisms and implications for acute myeloid leukemia. Immunotherapy
2010; 2: 85-97 (1 / 0.0)
van Luijn MM, Chamuleau MED, Ressing ME, Wiertz EJ, Ostrand-Rosenberg S, Souwer Y, Zevenbergen A, Ossenkoppele
GJ, van de Loosdrecht AA, van Ham SM. Alternative Ii-independent antigen-processing pathway in leukemic blasts
involves TAP-dependent peptide loading of HLA class II complexes. Cancer Immunol Immun 2010; 59: 1825-1838 (4 /
3.791)
79
Appendix 4: Scientific output
115.
116.
117.
118.
119.
120.
121.
122.
123.
124.
125.
126.
127.
128.
van Luijn MM, Chamuleau MED, Thompson JA, Ostrand-Rosenberg S, Westers TM, Souwer Y, Ossenkoppele GJ, van
Ham SM, van de Loosdrecht AA. Class II-associated invariant chain peptide down-modulation enhances the
immunogenicity of myeloid leukemic blasts resulting in increased CD4(+) T-cell responses. Haematol-Hematol J 2010;
95: 485-493 (4 / 6.416)
van Steenwijk PJD, Heusinkveld M, Ramwadhdoebe TH, Lowik MJ, van der Hulst JM, Goedemans R, Piersma SJ, Kenter
GG, van der Burg SH. An Unexpectedly Large Polyclonal Repertoire of HPV-Specific T Cells Is Poised for Action in
Patients with Cervical Cancer. Cancer Res 2010; 70: 2707-2717 (5 / 7.543)
van Stijn CMW, van den Broek M, Vervelde L, Alvarez RA, Cummings RD, Tefsen B, van Die I. Vaccination-induced IgG
response to Gal alpha 1-3GalNAc glycan epitopes in lambs protected against Haemonchus contortus challenge
infection. Int J Parasit 2010; 40: 215-222 (1 / 3.819)
van Stijn CMW, Meyer S, van den Broek M, Bruijns SCM, van Kooyk Y, Geyer R, van Die I. Schistosoma mansoni worm
glycolipids induce an inflammatory phenotype in human dendritic cells by cooperation of TLR4 and DC-SIGN. Mol
Immunol 2010; 47: 1544-1552 (3 / 3.202)
van Wijk XMR, Oosterhof A, van den Broek SAMW, Griffioen AW, ten Dam GB, Rutjes FPJT, van Delft FL, van
Kuppevelt TH. A 4-deoxy analogue of N-acetyl-D-glucosamine inhibits heparan sulphate expression and growth factor
binding in vitro. Exp Cell Res 2010; 316: 2504-2512 (3 / 3.589)
Verheul HMW, van Erp K, Homs MYV, Yoon GS, van Der Groep P, Rogers C, Hansel DE, Netto GJ, Pili R. The
Relationship of Vascular Endothelial Growth Factor and Coagulation Factor (Fibrin and Fibrinogen) Expression in Clear
Cell Renal Cell Carcinoma. Urology 2010; 75: 608-614 (3 / 2.365)
von Mensdorff-Pouilly S. Vaccine-induced antibody responses in patients with carcinoma. Expert Rev Vaccines 2010; 9:
579-594 (4 / 4.214)
Wauben MHM, Toes REM, Bos NA, Damoiseaux J, van Ham SM, van de Loosdrecht AA, Samsom JN. Sensing and
signaling by the immune system NVVI-Dutch Society for Immunology Course, Lunteren, April 2-3, 2009. Immunol Lett
2010; 128: 1-3 (3 / 2.906)
Weersma RK, Crusius JBA, Roberts RL, Koeleman BPC, Palomino-Morales R, Wolfkamp S, Hollis-Moffatt JE, Festen
EAM, Meisneris S, Heijmans R, Noble CL, Gearry RB, Barclay ML, Gomez-Garcia M, Lopez-Nevot MA, Nieto A, Rodrigo
L, Radstake TRDJ, Van Bodegraven A. Association of FcgR2a, but Not FcgR3a, with Inflammatory Bowel Diseases
Across Three Caucasian Populations. Inflamm Bowel Dis 2010; 16: 2080-2089 (4 / 4.643)
Weisel FJ, Appelt UK, Schneider AM, Horlitz JU, van Rooijen N, Korner H, Mach M, Winkler TH. Unique Requirements
for Reactivation of Virus-Specific Memory B Lymphocytes. J Immunol 2010; 185: 4011-4021 (4 / 5.646)
Welters MJP, Kenter GG, van Steenwijk PJD, Lowik MJG, Berends-van der Meer D, Essahsah F, Stynenbosch LFM, Vloon
APG, Ramwadhdoebe TH, Piersma SJ, van der Hulst JM, Valentijn ARPM, Fathers LM, Drijfhout JW, Franken KLMC,
Oostendorp J, Fleuren GJ, Melief C. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with
kinetics and phenotype of induced T-cell responses. P Natl Acad Sci USA 2010; 107: 11895-11899 (5 / 9.432)
Wierda RJ, Geutskens SB, Jukema JW, Quax PHA, van den Elsen PJ. Epigenetics in atherosclerosis and inflammation. J
Cell Mol Med 2010; 14: 1225-1240 (5 / 5.228)
Willemsen I, Cooper B, van Buitenen C, Winters M, Andriesse G, Kluytmans JAJW. Improving Quinolone Use in
Hospitals by Using a Bundle of Interventions in an Interrupted Time Series Analysis. Antimicrob Agents Ch 2010; 54:
3763-3769 (4 / 4.802)
Winkler IG, Sims NA, Pettit AR, Barbier V, Nowlan B, Helwani F, Poulton IJ, van Rooijen N, Alexander KA, Raggatt LJ,
Levesque JP. Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes
HSCs. Blood 2010; 116: 4815-4828 (5 / 10.555)
Scientific papers non-refereed
1.
2.
3.
4.
5.
6.
7.
8.
9.
Cornelissen LH, Bronneberg D, Gibbs S, Bouten CV, Oomens CW. Cytokine release in tissue-engineered epidermal
equivalents after prolonged mechanical loading. Methods Mol Biol 2010; 585: 335-344
Gunawan J, Linardi P, Tawaluyan K, Mantik MFJ, Veerman AJP. Varicella outbreak in Pediatric Oncology Ward: the
Manado Experience. Asian Pacific J Cancer Prev 2010; 11: 289-292
Hutajulu SH, Hoebe EK, Verkuijlen SAWM, Fachiroh J, Hariwijanto B, Haryana SM, Stevens SJC, Greijer A.E.,
Middeldorp J. Conserved mutation of Epstein-Barr virus-encoded BamHI-A Rightward Frame-1 (BARF1) gene in
Indonesian nasopharyngeal carcinoma. Infect Agent Cancer 2010; 5: 16
Kluytmans JAJW, Vandenbroucke-Grauls CMJE, van der Meer JW. Antibiotic resistance: measures urgently needed.
Nederlands tijdschrift voor geneeskunde 2010; 154: 2261
Kluytmans JAJW. Beschouwing pandemie van Nieuwe Influenza-A-virus (H1N1). Ned Tijdsch Med Microbiol 2010; 18: 89
Kock R, Becker K, Cookson B, van Gemert-Pijnen JE, Harbarth S, Kluytmans JAJW, Mielke M, Peters GJ, Skov RL,
Struelens MJ, Tacconelli E, Torne AN, Witte W, Friedrich AW. Methicillin-resistant Staphylococcus aureus (MRSA):
burden of disease and control challenges in Europe. Eurosurveillance 2010; 15: 12-20
van der Beek EM, van Bruggen R, Schornagel J, Tool A, Matozaki T, Kraal G, et al. SIRP alpha controls phagocyte
NADPH oxidase function by limiting the expression of gp91(phox). Eur J Clin Invest 2010; 40: 34
van Rooijen N, Hendrikx E. Liposomes for specific depletion of macrophages from organs tissues. Methods Mol Biol
2010; 605: 189-203
Zomer SF, Vendrig T, Hopmans ES, van Eijndhoven MAJ, Middeldorp JM, Pegtel DM. Exosomes: Fit to deliver small
RNA. Communicative & Integative Biology 2010; 3: 447-450
Scientific publications (books, book chapters, proceedings)
1.
2.
80
Ammerlaan H, Kluytmans JAJWl. Methicillin-resistant Staphylococcus aureus (MRSA) colonization. Infectious Diseases
2010; : 769-771
van den Elsen PJ, van Eggermond MCJA, Wierda RJl. Epigenetic control in immune function; in Ballestar E, (ed):
Epigenetic contributions in autoimmune disease. Austin, Tx, USA, Landes Bioscience. 2010; : 1-14
Appendix 4: Scientific output
Professional publications
1.
Schmaderer C, Eissler R, Seibel S, van Rooijen N, Baumann Ml. Blood Pressure Control: A Facelift for Macrophages?.
Hypertension 2010; 56: E23
Popular publications
1.
2.
3.
4.
5.
Gibbs Sl.
Gibbs Sl.
Gibbs Sl.
Gibbs Sl.
Gibbs Sl.
DC migration assay. Sens-it-iv Newsletter 2010
Two tiered assay. Sens-it-iv Newsletter 2010
Epidermal equivalent assay to determine the potency of a sensitizer. Sens-it-iv Newsletter 2010
The Sens-it-iv toolbox and scientific spin-offs. Sens-it-iv Newsletter 2010; 42
Ready for pre-validation: a two-tiered in vitro test to assess sinsitization. Sens-it-iv Newsletter 2010; 36
Patents
1.
Scheper RJl. Bioengineered skin regeneration; USA and Australia. 2010; :
Dissertations
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
Abdi K - IL-12: The role of p40 versus p75. Vrije Universiteit Amsterdam, 5/11/2010. (Co-)promotores: CD Dijkstra, HL
Ploegh (cat B)
Bax M - Functional consequences of glycosylation on dendritic cell biology. Vrije Universiteit Amsterdam, 1/27/2010.
(Co-)promotores: Y van Kooyk, SJ van Vliet, JJ Garcia-Vallejo (cat A)
Bloemers B - Severe RSV infections in children with down syndrome. Universiteit van Utrecht, 9/9/2010. (Co)promotores: JLL Kimpen, AM van Furth (cat C)
Cazander G - How do maggots operate? The underlying mechanisms of action of maggot debridement therapy. Vrije
Universiteit Amsterdam, 4/7/2010. (Co-)promotores: HJ Bonjer, MWJ Schreurs (cat A)
de Jong MAWP - The role of dendritic cells in innate defense against pathogens. Vrije Universiteit Amsterdam,
4/29/2010. (Co-)promotores: Y van Kooyk, TBH Geijtenbeek (cat A)
Michaloglou C - The role and mechanism of BRAFE600-induced senescence-like proliferative arrest of melanocytic
naevi in preventing melanoma-genesis.. Vrije Universiteit Amsterdam, 6/21/2010. (Co-)promotores: WJ Mooi, DS
Peeper (cat B)
Molenaar R - Control of the mucosal immune system by vitamin A. Vrije Universiteit Amsterdam, 10/12/2010. (Co)promotores: RE Mebius, G Kraal (cat A)
Olivier BJ - Formation and function of organized gut associated lymphoid tissue in health and disease. Vrije
Universiteit Amsterdam, 12/14/2010. (Co-)promotores: RE Mebius, G Bouma (cat A)
Paramita D - Humoral immune responses to Epstein-Barr Virus early antigen and tumor associated antigen in
nasopharyngeal carcinoma. Vrije Universiteit Amsterdam, 6/9/2010. (Co-)promotores: JM Middeldorp, SM Haryana, B
Tan (cat A)
Schilte MN - Anti-inflammatory therapy and biomarker analysis during peritoneal dialysis. Vrije Universiteit
Amsterdam, 11/24/2010. (Co-)promotores: RHJ Beelen, RM ter Wee, J van den Born (cat A)
Scholten KBJ - Adoptive transfer of tumor specific T-cells for the treatment of cervical cancer: Generation of HPV
specific T-cells. Vrije Universiteit Amsterdam, 12/2/2010. (Co-)promotores: CJLM Meijer, MWJ Schreurs, E Hooijberg
(cat A)
Singh SK - Glycan-lectin duet. A novel strategy for DC targeting. Vrije Universiteit Amsterdam, 12/8/2010. (Co)promotores: Y van Kooyk, E Saeland (cat A)
Steen KSS - Decline of NSAID gastropathy in rheumatoid arthritis. Vrije Universiteit Amsterdam, 3/26/2010. (Co)promotores: BAC Dijkmans, WF Lems, M Boers, MT Nurmohamed (cat A)
van den Berg H - The balancing mucosal immune system. Vrije Universiteit Amsterdam, 3/30/2010. (Co-)promotores:
G Kraal, J den Haan (cat A)
Program 3: Disease profiling
Scientific papers refereed
1.
2.
3.
4.
5.
Chen C, Skog J, Hsu CH, Lessard RT, Balaj L, Wurdinger T, Carter BS, Breakefield XO, Toner M, Irimia D. Microfluidic
isolation and transcriptome analysis of serum microvesicles. Lab Chip 2010; 10: 505-511 (5 / 6.342)
Saydam O, Senol O, Schaaij-Visser TBM, Pham TV, Piersma SR, Stemmer-Rachamimov AO, Wurdinger T, Peerdeman
SM, Jimenez CR. Comparative Protein Profiling Reveals Minichromosome Maintenance (MCM) Proteins As Novel
Potential Tumor Markers for Meningiomas. J Proteome Res 2010; 9: 485-494 (4 / 5.132)
Albrethsen J, Knol JC, Piersma SR, Pham TV, de Wit M, Mongera S, Carvalho B, Verheul HMW, Fijneman RJA, Meijer
GA, Jimenez CR. Subnuclear Proteomics in Colorectal Cancer: Identification of proteins enriched in the nuclear
matrix fraction and regulation in adenoma to carcinoma progression. Mol Cell Proteomics 2010; 9: 988-1005 (5 /
8.791)
Balgobind BV, Lugthart S, Hollink IH, Arentsen-Peters STJC, van Wering ER, de Graaf SSN, Reinhardt D, Creutzig U,
Kaspers GJL, De Bont ESJM, Stary J, Trka J, Zimmermann M, Beverloo HB, Pieters R, Delwel R, Zwaan CM, van den
Heuvel-Eibrink M. EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia. Leukemia 2010; 24:
942-949 (5 / 8.296)
Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, Oyen WJG, Kotzerke J, Hoekstra
OS, Pruim J, Marsden PK, Tatsch K, Hoekstra CJ, Visser EP, Arends B, Verzijlbergen FJ, Zijlstra JM, Comans EFI,
81
Appendix 4: Scientific output
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
82
Lammertsma AA, Paans AM, et al.. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version
1.0. Eur J Nucl Med Mol I 2010; 37: 181-200 (5 / 4.531)
Boellaard R, O'Doherty MJ, Chiti A, Krause BJ. Reply to: FDG PET and PET/CT: EANM procedure guideline for tumour
PET imaging. Eur J Nucl Med Mol I 2010; 37: 1432-1433 (5 / 4.531)
Brisse HJ, European Retinoblastoma Imaging Co. Retinoblastoma Imaging. Ophthalmology 2010; 117(5): 1051-1051.e1
(5 / 5.491)
Deenik W, van der Holt B, Janssen JJWM, Chu IWT, Valk PJM, Ossenkoppele GJ, van der Heiden IP, Sonneveld P, van
Schaik RHN, Cornelissen JJ. Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular
resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib. Blood 2010; 95(6):
1036-1037 (5 / 10.555)
Scheinin I, Ferreira JA, Knuutila S, Meijer GA, van de Wiel MA, Ylstra B. CGHpower: exploring sample size calculations
for chromosomal copy number experiments. BMC Bioinformatics 2010; 11: 331 (4 / 3.428)
van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJB, Wesseling P, Frenay M, Tijssen CC, Lacombe D,
Idbaih A, van Marion R, Kros JM, Dinjens WNM, Gorlia T, Sanson M. IDH1 and IDH2 Mutations Are Prognostic but not
Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research
and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 2010; 16(5): 1597-1604 (5 / 6.747)
Brosens RPM, Haan JC, Carvalho B, Rustenburg F, Grabsch H, Quirke P, Engel AF, Cuesta MA, Maughan N, Flens M,
Meijer GA, Ylstra B. Candidate driver genes in focal chromosomal aberrations of stage II colon cancer. J Pathol 2010;
221: 411-424 (5 / 6.466)
Broyl A, Hose D, Lokhorst H, de Knegt Y, Peeters J, Jauch A, Bertsch U, Buijs A, Stevens-Kroef M, Beverloo HB,
Vellenga E, Zweegman S, Kersten MJ, van der Holt B, el Jarari L, Mulligan G, Goldschmidt H, van Duin M, Sonneveld P.
Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood 2010;
116: 2543-2553 (5 / 10.555)
Engel C, Versmold B, Wappenschmidt B, Simard J, Easton DF, Peock S, Cook M, Oliver C, Frost D, Mayes R, Evans DG,
Eeles R, Paterson J, Brewer C, McGuffog L, Antoniou AC, Stoppa-Lyonnet D, Sinilnikova OM, Barjhoux L, Frenay M,
Michel C, Leroux D, Dreyfus H. Association of the Variants CASP8 D302H and CASP10 V410I with Breast and Ovarian
Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiol Biomarkers Prev 2010; 19: 2859-2868 (5 / 4.31)
Hadithi M, Pena AS. Current methods to diagnose the unresponsive and complicated forms of coeliac disease. Eur J Int
Med 2010; 21: 247-253 (3 / 1.385)
Capelle LG, de Vries AC, Haringsma J, ter Borg F, de Vries RA, Bruno MJ, van Dekken H, Meijer J, van Grieken NCT,
Kuipers EJ. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for
atrophic gastritis. Gastrointest Endosc 2010; 71: 1150-1158 (5 / 6.713)
Cohen DB, Zijlstra EE, Mukaka M, Reiss M, Kamphambale S, Scholing M, Waitt PI, Neuhann F. Diagnosis of cryptococcal
and tuberculous meningitis in a resource-limited African setting. Tropical Medicine & International Health 2010; 15:
910-917 (3 / 2.328)
Pas S, Rossen JWA, Schoener D, Thamke D, Pettersson A, Babiel R, Schutten M. Performance Evaluation of the New
Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 Test Version 2.0 for Quantification of Human Immunodeficiency Virus
Type 1 RNA. J Clin Microbiol 2010; 48: 1195-1200 (4 / 4.162)
Poirel L, Rodriguez-Martinez JM, Al Naiemi N, Ossenkopp YJ, ordmann P. Characterization of DIM-1, an IntegronEncoded Metallo-beta-Lactamase from a Pseudomonas stutzeri Clinical Isolate in the Netherlands. Antimicrob Agents
Ch 2010; 54: 2420-2424 (4 / 4.802)
Poortman P, Lohle PNM, Schoemaker CM, Cuesta MA, Oostvogel HJM, de Lange-de Klerk E, Hamming JF. Improving the
false-negative rate of CT in acute appendicitis-Reassessment of CT images by body imaging radiologists: A blinded
prospective study. European Journal of Radiology 2010; 74: 67-70 (3 / 2.645)
Stuart JC, Dierikx C, Al Naiemi N, Karczmarek A, Van Hoek AHAM, Vos P, Fluit AC, Scharringa J, Duim B, Mevius D,
Hall MALV. Rapid detection of TEM, SHV and CTX-M extended-spectrum beta-lactamases in Enterobacteriaceae using
ligation-mediated amplification with microarray analysis. J Antimicrob Chemoth 2010; 65: 1377-1381 (4 / 4.352)
Stuart JC, Mouton JW, Diederen BMW, Al Naiemi N, Thijsen S, Vlaminckx BJM, Fluit AC, Leverstein-van Hall MA.
Evaluation of Etest To Determine Tigecycline MICs for Enterobacter Species. Antimicrob Agents Ch 2010; 54: 27462747 (4 / 4.802)
van Ufford HQ, Hoekstra OS, de Haas M, Fijnheer R, Wittebol S, Tieks B, Kramer MHH, de Klerk J. On the Added Value
of Baseline FDG-PET in Malignant Lymphoma. Molecular Imaging and Biology 2010; 12: 225-232 (3 / 2.467)
Pena AS, Hadithi M. Antibody testing in coeliac disease. Eur J Int Med 2010; 21: 468 (3 / 1.385)
Peters GJ, Hodzic J, Ortega B, Giovannetti E, Adema AD. Promoter methylation of deoxycytidine kinase in cancer
cells. Nucleosides Nucleotides Nucleic Acids 2010; 29: 408-413 (1 / 0.768)
Snaebjornsson P, Jonasson L, Jonsson T, Moller PH, Theodors A, Jonasson JG. Colon cancer in Iceland-a nationwide
comparative study on various pathology parameters with respect to right and left tumor location and patients age. Int
J Cancer 2010; 127: 2645-2653 (4 / 4.722)
Chen W, Jarzyna PA, Van Tilborg GAF, Nguyen VA, Cormode DP, Klink A, Griffioen AW, Randolph GJ, Fisher EA, Mulder
WJM, Fayad ZA. RGD peptide functionalized and reconstituted high-density lipoprotein nanoparticles as a versatile
and multimodal tumor targeting molecular imaging probe. Faseb J 2010; 24: 1689-1699 (5 / 6.401)
Daniels JMA, de Graaff CS, Vlaspolder F, Snijders D, Jansen HM, Boersma WG. Sputum colour reported by patients is
not a reliable marker of the presence of bacteria in acute exacerbations of chronic obstructive pulmonary disease.
Clin Microbiol Infec 2010; 16: 583-588 (4 / 4.014)
de Boer R, Peters RPH, Gierveld S, Schuurman T, Kooistra-Smid M, Savelkoul PHM. Improved detection of microbial
DNA after bead-beating before DNA isolation. J Microbiol Meth 2010; 80: 209-211 (3 / 2.427)
de Bree R. The real additional value of FDG-PET in detecting the occult primary tumour in patients with cervical
lymph node metastases of unknown primary tumour. Eur Arch Oto-Rhino-L 2010; 267: 1653-1655 (3 / 1.167)
de Graaf P, van der Valk P, Moll AC, Imhof SM, Meeteren AYNS, Knol DL, Castelijns JA. Contrast-Enhancement of the
Anterior Eye Segment in Patients with Retinoblastoma: Correlation between Clinical, MR Imaging, and Histopathologic
Findings. Am J Neuroradiol 2010; 31: 237-245 (4 / 3.296)
de Groot M, Toering ST, Boer K, Spliet WGM, Heimans JJ, Aronica E, Reijneveld JC. Expression of synaptic vesicle
protein 2A in epilepsy-associated brain tumors and in the peritumoral cortex. Neuro-Oncology 2010; 12: 265-273 (4 /
4.984)
Appendix 4: Scientific output
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
de Jonge HJM, Valk PJM, Veeger NJGM, ter Elst A, den Boer ML, Cloos J, de Haas V, van den Heuvel-Eibrink M,
Kaspers GJL, Zwaan CM, Kamps WA, Lowenberg B, De Bont ESJM. High VEGFC expression is associated with unique
gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia. Blood 2010;
116: 1747-1754 (5 / 10.555)
De Vries MK, van Drumpt AS, van Royen BJ, van Denderen JC, Manoliu RA, van der Horst-Bruinsma I. Discovertebral
(Andersson) lesions in severe ankylosing spondylitis: a study using MRI and conventional radiography. Clin Rheumatol
2010; 29: 1433-1438 (2 / 1.668)
Dijkers EC, Munnink THO, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, van Dongen GAMS, Schroder CP, Lub-de
Hooge MN, de Vries EGE. Biodistribution of Zr-89-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients
With Metastatic Breast Cancer. Clin Pharmacol Ther 2010; 87: 586-592 (5 / 6.961)
Diosdado B, Buffart TE, Watkins R, Carvalho B, Ylstra B, Tijssen M, Bolijn AS, Lewis F, Maude K, Verbeke C, Nagtegaal
ID, Grabsch H, Mulder CJJ, Quirke P, Howdle P, Meijer GA. High-Resolution Array Comparative Genomic Hybridization
in Sporadic and Celiac Disease-Related Small Bowel Adenocarcinomas. Clin Cancer Res 2010; 16: 1391-1401 (5 /
6.747)
Esch CEH, Csizmadia GDS, Van Hoogstraten IMW, Schreurs MWJ, Mearin ML, von Blomberg BME. Childhood coeliac
disease: towards an improved serological mass screening strategy. Aliment Pharmacol Ther 2010; 31: 760-766 (4 /
4.357)
Festen EAM, Stokkers PCF, van Diemen CC, Van Bodegraven AA, Boezen HM, Crusius JBA, Hommes DW, van der Woude
JC, Balschun T, Verspaget HW, Schreiber S, de Jong DJ, Franke A, Dijkstra G, Wijmenga C, Weersma RK. Genetic
Analysis in A Dutch Study Sample Identifies More Ulcerative Colitis Susceptibility Loci and Shows Their Additive Role in
Disease Risk. Am J Gastroenterol 2010; 105: 395-402 (5 / 6.012)
Fransen K, Visschedijk MC, van Sommeren S, Fu JYY, Franke L, Festen EAM, Stokkers PCF, Van Bodegraven AA, Crusius
JBA, Hommes DW, Zanen P, de Jong DJ, Wijmenga C, van Diemen CC, Weersma RK. Analysis of SNPs with an effect on
gene expression identifies UBE2L3 and BCL3 as potential new risk genes for Crohn's disease. Hum Mol Genet 2010; 19:
3482-3488 (5 / 7.386)
Fratantoni SA, Piersma SR, Jimenez CR. Comparison of the performance of two affinity depletion spin filters for
quantitative proteomics of CSF: Evaluation of sensitivity and reproducibility of CSF analysis using GeLC-MS/MS and
spectral counting. Proteom Clin Appl 2010; 4: 613-617 (2 / 1.875)
Frings V, de Langen AJ, Smit EF, van Velden FHP, Hoekstra OS, van Tinteren H, Boellaard R. Repeatability of
Metabolically Active Volume Measurements with F-18-FDG and F-18-FLT PET in Non-Small Cell Lung Cancer. J Nucl
Med 2010; 51: 1870-1877 (5 / 6.424)
Harvey RA, Mitchell HDC, Stenman UH, Blankenstein MA, Nustad K, Stieber P, Stewart W, Savage PM, Seckl MJ,
Braunstein GD. Differences in Total Human Chorionic Gonadotropin Immunoassay Analytical Specificity and Ability to
Measure Human Chorionic Gonadotropin in Gestational Trophoblastic Disease and Germ Cell Tumors. J Reprod Med
2010; 55: 285-295 (1 / 0.696)
Hoeben BAW, Kaanders JHAM, Franssen GM, Troost EGC, Rijken PFJW, Oosterwijk E, van Dongen GAMS, Oyen WJG,
Boerman OC, Bussink J. PET of Hypoxia with Zr-89-Labeled cG250-F(ab ')(2) in Head and Neck Tumors. J Nucl Med
2010; 51: 1076-1083 (5 / 6.424)
Hoetjes NJ, van Velden FHP, Hoekstra OS, Hoekstra CJ, Krak NC, Lammertsma AA, Boellaard R. Partial volume
correction strategies for quantitative FDG PET in oncology. Eur J Nucl Med Mol I 2010; 37: 1679-1687 (5 / 4.531)
Janssen JJWM, Denkers F, Valk P, Cornelissen JJ, Schuurhuis GJ, Ossenkoppele GJ. Methylation patterns in CD34
positive chronic myeloid leukemia blast crisis cells. Haematol-Hematol J 2010; 95: 1036-1037 (4 / 6.416)
Jimenez CR, Knol JC, Meijer GA, Fijneman RJA. Proteomics of colorectal cancer: Overview of discovery studies and
identification of commonly identified cancer-associated proteins and candidate CRC serum markers. J Proteomics
2010; 73: 1873-1895 (1 / 3.851)
Jimenez CR, Slijper M. Current status of cancer proteomics, how far are we from clinical applications?. J Proteomics
2010; 73: 1787-1789 (1 / 3.851)
Kuijper EAM, Blankenstein MA, Luttikhof LJ, Roek SJM, Overbeek A, Hompes PG, Twisk JWR, Lambalk CB. Frequency
distribution of polymorphisms in the FSH receptor gene in infertility patients of different ethnicity. Reprod Biomed
Online 2010; 20: 588-593 (4 / 2.38)
Martin-Trujillo A, van Rietschoten JGI, Timmer TCG, Rodriguez FM, Huizinga TWJ, Tak PP, Marsal S, Ibrahim SM,
Dijkmans BAC, Kraan TCTM, Verweij CL. Loss of imprinting of IGF2 characterises high IGF2 mRNA-expressing type of
fibroblast-like synoviocytes in rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1239-1242 (5 / 8.111)
Mendes RA, Carvalho JFC, van der Waal I. Biological pathways involved in the aggressive behavior of the keratocystic
odontogenic tumor and possible implications for molecular oriented treatment - An overview. Oral Oncol 2010; 46:
19-24 (5 / 3.123)
Mendes RA, Carvalho JFC, van der Waal I. Characterization and management of the keratocystic odontogenic tumor in
relation to its histopathological and biological features. Oral Oncol 2010; 46: 219-225 (5 / 3.123)
Mitchell AJ, Pradel LC, Chasson L, van Rooijen N, Grau GE, Hunt NH, Chimini G. Technical Advance: Autofluorescence
as a tool for myeloid cell analysis. J Leukoc Biol 2010; 88: 597-603 (4 / 4.403)
Munnink THO, de Korte MA, Nagengast WB, Timmer-Bosscha H, Schroder CP, de Jong JR, van Dongen GAMS, Jensen
MR, Quadt C, Lub-de Hooge MN, de Vries EGE. Zr-89-trastuzumab PET visualises HER2 downregulation by the HSP90
inhibitor NVP-AUY922 in a human tumour xenograft. Eur J Cancer 2010; 46: 678-684 (3 / 4.121)
Nagengast WB, de Korte MA, Munnink THO, Timmer-Bosscha H, den Dunnen WF, Hollema H, de Jong JR, Jensen MR,
Quadt C, Garcia-Echeverria C, van Dongen GAMS, Lub-de Hooge MN, Schroder CP, de Vries EGE. Zr-89-Bevacizumab
PET of Early Antiangiogenic Tumor Response to Treatment with HSP90 Inhibitor NVP-AUY922. J Nucl Med 2010; 51:
761-767 (5 / 6.424)
Nota B, Verweij RA, Molenaar D, Ylstra B, van Straalen NM, Roelofs D. Gene Expression Analysis Reveals a Gene Set
Discriminatory to Different Metals in Soil. Toxicol Sci 2010; 115: 34-40 (5 / 4.814)
Nota B, van Straalen NM, Ylstra B, Roelofs D. Gene expression microarray analysis of heat stress in the soil
invertebrate Folsomia candida. Insect Mol Biol 2010; 19: 315-322 (5 / 2.568)
Nowee ME, Seeber LMS, Horree N, Snijders AM, van Diest PJ, Verheijen RHM, Dorsman JC. Array comparative genomic
hybridization analysis indicates that serous carcinomas of the ovary, fallopian tube and endometrium are distinct
entities. Histopathology 2010; 57: 634-637 (4 / 3.855)
83
Appendix 4: Scientific output
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84
Perk LR, Vosjan MJWD, Visser GWM, Budde M, Jurek P, Kiefer GE, van Dongen GAMS. p-Isothiocyanatobenzyldesferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for
immuno-PET imaging. Eur J Nucl Med Mol I 2010; 37: 250-259 (5 / 4.531)
Peters RPH, Savelkoul PHM, Vandenbroucke-Grauls CMJE. Future diagnosis of sepsis. Lancet 2010; 375: 1779-1780 (5 /
30.758)
Pham TV, Piersma SR, Warmoes M, Jimenez CR. On the beta-binomial model for analysis of spectral count data in
label-free tandem mass spectrometry-based proteomics. Bioinformatics 2010; 26: 363-369 (5 / 4.926)
Piersma SR, Labots M, Verheul HMW, Jimenez CR. Strategies for kinome profiling in cancer and potential clinical
applications: chemical proteomics and array-based methods. Anal Bioanal Chem 2010; 397: 3163-3171 (5 / 3.48)
Piersma SR, Fiedler U, Span S, Lingnau A, Pham TV, Hoffmann S, Kubbutat MHG, Jimenez CR. Workflow Comparison
for Label-Free, Quantitative Secretome Proteomics for Cancer Biomarker Discovery: Method Evaluation, Differential
Analysis, and Verification in Serum. J Proteome Res 2010; 9: 1913-1922 (4 / 5.132)
Quint KD, Bom RJM, Bruisten SM, van Doorn LJ, Hajipour NN, Melchers WJG, de Vries HJC, Morre SA, Quint WGV.
Comparison of three genotyping methods to identify Chlamydia trachomatis genotypes in positive men and women.
Mol Cell Probe 2010; 24: 266-270 (3 / 1.899)
Rijkaart DC, Coupe VMH, van Kemenade FJ, Heideman DAM, Hesselink AT, Verweij W, Rozendaal L, Verheijen RHM,
Snijders PJF, Berkhof J, Meijer CJLM. Comparison of Hybrid capture 2 testing at different thresholds with cytology as
primary cervical screening test. Brit J Cancer 2010; 103: 939-946 (4 / 4.346)
Rizvi SNF, Comans EFI, Boellaard R, van Tinteren H, Hoekstra OS. Two decades at the cross-roads of biology, physics
and epidemiology: Lessons learned in [18F-]FDG positron emission tomography in oncology. Eur J Cancer 2010; 46:
2150-2158 (3 / 4.121)
Roef MJ, van der Poel H, van der Laken CJ, Vogel WV. Colchicine must be stopped before imaging with [F-18]methylcholine PET/CT. Nucl Med Commun 2010; 31: 1075-1077 (2 / 1.315)
Rood IGH, Pettersson AM, Savelkoul PHM, de Korte D. Development of a reverse transcription-polymerase chain
reaction assay for eubacterial RNA detection in platelet concentrates. Transfusion 2010; 50: 1352-1358 (3 / 2.982)
Sillars-Hardebol AH, Carvalho B, de Wit M, Postma C, Delis-van Diemen PM, Mongera S, Ylstra B, van de Wiel MA,
Meijer GA, Fijneman RJA. Identification of key genes for carcinogenic pathways associated with colorectal adenomato-carcinoma progression. Tumor Biol 2010; 31: 89-96 (2 / 1.94)
Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S, Thomson BP, Li YH, Kurreeman FAS, Zhernakova A, Hinks A,
Guiducci C, Chen R, Alfredsson L, Amos CI, Ardlie KG, Barton A, Bowes J, Brouwer E, Burtt NP, … Crusius JBA, … van
der Horst-Bruinsma IE,… et al.. Genome-wide association study meta-analysis identifies seven new rheumatoid
arthritis risk loci. Nature Genet 2010; 42: 508-U56 (5 / 32.284)
Tack GJ, Verbeek WHM, van de Water JMW, von Blomberg BME, Bhola SL, Ylstra B, Mulder CJJ, Schreurs MWJ.
Phenotypic and genomic analysis of an exceptional case of enteropathy associated T-cell lymphoma. Leuk Res 2010;
34: E183-E189 (2 / 2.358)
Tilburg JJHC, Melchers WJG, Pettersson AM, Rossen JWA, Hermans MHA, van Hannen EJ, Nabuurs-Franssen MH, de
Vries MC, Horrevorts AM, Klaassen CHW. Interlaboratory Evaluation of Different Extraction and Real-Time PCR
Methods for Detection of Coxiella burnetii DNA in Serum. J Clin Microbiol 2010; 48: 3923-3927 (4 / 4.162)
Ursum J, van der Weijden MAC, van Schaardenburg D, Prins APA, Dijkmans BAC, Twisk JWR, Crusius JBA, van der
Horst-Bruinsma I. IL10 GGC Haplotype Is Positively and HLA-DQA1*05-DQB1*02 Is Negatively Associated with
Radiographic Progression in Undifferentiated Arthritis. J Rheumatol 2010; 37: 1431-1438 (3 / 3.854)
Ursum J, Bos WH, van Dillen N, Dijkmans BAC, van Schaardenburg D. Levels of anti-citrullinated protein antibodies
and IgM rheumatoid factor are not associated with outcome in early arthritis patients: a cohort study. Arthritis Res
Ther 2010; 12: art.nr. R8 (4 / 4.271)
van de Stadt LA, Bos WH, Reynders MM, Wieringa H, Turkstra F, van der Laken CJ, van Schaardenburg D. The value of
ultrasonography in predicting arthritis in auto-antibody positive arthralgia patients: a prospective cohort study.
Arthritis Res Ther 2010; 12(3): R98 (4 / 4.271)
van der Drift MA, Hol BEA, Klaassen CHW, Prinsen CFM, van Aarssen YAWG, Donders R, van der Stappen JWJ,
Dekhuijzen PNR, van der Heijden HFM, Thunnissen FBJM. Circulating DNA is a non-invasive prognostic factor for
survival in non-small cell lung cancer. Lung Cancer 2010; 68: 283-287 (4 / 3.14)
van der Veldt AAM, Hendrikse NH, Smit EF, Mooijer MPJ, Rijnders AY, Gerritsen WR, van der Hoeven JJM, Windhorst
AD, Lammertsma AA, Lubberink M. Biodistribution and radiation dosimetry of C-11-labelled docetaxel in cancer
patients. Eur J Nucl Med Mol I 2010; 37: 1950-1958 (5 / 4.531)
van der Veldt AAM, Comans EFI, Thunnissen FBJM, Hendrikse NH, Smit EF, van der Hoeven JJM. Re: Sarcoid-like
reaction to malignancy on whole-body integrated (18)F-FDG PET/CT: prevalence and disease pattern. Clin Radiol
2010; 65: 94-96 (2 / 1.645)
van der Veldt AAM, Hendrikse NH, Harms HJ, Comans EFI, Postmus PE, Smit EF, Lammertsma AA, Lubberink M.
Quantitative Parametric Perfusion Images Using O-15-Labeled Water and a Clinical PET/CT Scanner: Test-Retest
Variability in Lung Cancer. J Nucl Med 2010; 51: 1684-1690 (5 / 6.424)
van Geenen EJM, van der Peet DL, Bhagirath P, Mulder CJJ, Bruno MJ. Etiology and diagnosis of acute biliary
pancreatitis. Nat Rev Gastro Hepat 2010; 7: 495-502 (1 / 0.0)
van Loon J, Janssen MHM, Ollers MC, Aerts HJWL, Dubois L, Hochstenbag M, Dingemans AMC, Lalisang R, Brans B,
Windhorst B, van Dongen GAMS, Kolb H, Zhang J, de Ruysscher D, Lambin P. PET imaging of hypoxia using [F-18]HX4:
a phase I trial. Eur J Nucl Med Mol I 2010; 37: 1663-1668 (5 / 4.531)
van Wanrooij RLJ, Schreurs MWJ, Bouma G, von Blomberg BME, Tack GJ, Verbeek WHM, Mulder CJJ. Accurate
classification of RCD requires flow cytometry. Gut 2010; 59: 1732 (5 / 9.357)
Van Weyenberg SJB, Meijerink MR, Jacobs MAJM, van der Peet DL, van Kuijk C, Mulder CJJ, van Waesberghe JHTM.
MR Enteroclysis in the Diagnosis of Small-Bowel Neoplasms. Radiology 2010; 254: 765-773 (5 / 6.341)
Vosjan MJWD, Perk LR, Visser GWM, Budde M, Jurek P, Kiefer GE, van Dongen GAMS. Conjugation and radiolabeling of
monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyldesferrioxamine. Nat Protoc 2010; 5: 739-743 (5 / 6.335)
Wu T, Boezen HM, Postma DS, Los H, Postmus PE, Snieder H, Boomsma DI. Genetic and environmental influences on
objective intermediate asthma phenotypes in Dutch twins. Eur Respir J 2010; 36: 261-268 (5 / 5.527)
Appendix 4: Scientific output
Scientific papers non-refereed
1.
2.
3.
4.
5.
Brosens RPM, Belt EJTH, Haan JC, Buffart TE, Carvalho B, Grabsch H, Quirke P, Cuesta MA, Engel AF, Ylstra B, Meijer
GA. Deletion of chromosome 4q predicts outcome in stage II colon cancer patients. Anal Cell Pathol 2010; 33: 95-104
Flach GB, de Bree R, van Schie A, Hoekstra OS, Bloemena E, Castelijns JA, van der Waal I, Leemans Cr. Sentinel node
procedure in oral carcinoma. First experience with this method. Ned Tijdschr Geneeskd 2010; 154: A1254
Mulder WJM, Griffioen AW. Imaging of angiogenesis. Angiogenesis 2010; 13: 71-74
Mulder WJM, Strijkers GJ, Nicolay K, Griffioen AW. Quantum dots for multimodal molecular imaging of angiogenesis.
Angiogenesis 2010; 13: 131-134
Schuurhuis GJ, Ossenkoppele GJ. Minimal residual disease in acute myeloid leukemia: already predicting a safe
haven?. Expert Rev Hematol 2010; 3: 1-5
Scientific publications
1.
Boven E, Meijerink MR, Vroling L, van der Veldt AAMl. Surrogate markers of anti-angiogenic therapies. In Chatterjee M
(ed): Angiogenesis & Therapeutic Targets of Cancer. Bentham Science Publication. 2010; : 330-353
Professional publications
1.
2.
3.
4.
5.
de Bree R, Leemans CRl. Veranderingen in de TNM-classificatie van hoofd-halstumoren: een nieuwe editie. Hoofd-hals
Journaal 2010; 22: 22-23
de Bree R, Leemans CRl. Improvements in de TNM-classification for head and neck tumours. Ned Tijdschr KNO-Heelk
2010; 16: 7-13
Meijer GAl. Op weg naar een nationaal weefselarchief voor translationeel onderzoek. NPPV Bulletin 2010; 19: 5-7
Struys EA, Heijboer AC, van Moorselaar J, Jakobs C, Blankenstein MAl. Serum sarcosine is not a marker for prostate
cancer. Ann Clin Biochem 2010; 47: 282
van der Laken CJ, de Greeuw I, Voskuyl AE, Jansen G, Dijkmans BAC, Lammertsma AA, Kularatne S, Low PS,
Windhorst AD, Molthoff CFMl. Beeldvorming van experimentele artritis met Positron Emissie Tomografie en een
nieuwe macrofagen tracer [18F]PEG-folaat. Nederlands Tijdschrift voor Reumatologie 2010; 4: 75-76
Dissertations
1.
2.
3.
4.
5.
Borjesson PKE - Radioimmunodetection and radioimmunotherapy of head and neck cancer. Vrije Universiteit
Amsterdam, 2/15/2010. (Co-)promotores: GAMS van Dongen, CR Leemans, R de Bree (cat A)
Bosma I - Cognitive dysfunction in glioma. Underlying mechanisms and consequences. Vrije Universiteit Amsterdam,
5/7/2010. (Co-)promotores: JJ Heimans, CJ Stam, M Klein, JC Reijneveld (cat A)
Douw L - Neural networks and brain tumors: the interplay between tumor, epilepsy and cognition. Vrije Universiteit
Amsterdam, 11/8/2010. (Co-)promotores: CJ Stam, JJ Heimans, JC Reijneveld, M Klein (cat A)
Ljumanovic - Prognostic value of MRI in head and neck oncology. Vrije Universiteit Amsterdam, 11/23/2010. (Co-)
promotores: JA Castelijns, CR Leemans, JA Langendijk, OS Hoekstra (cat A)
Postma C - Chromosomal instability in Colorectal Cancer. Vrije Universiteit Amsterdam, 11/12/2010. (Co-)
promotores: GA Meijer, B Carvalho, B Ylstra (cat A)
Program 4: Innovative therapy
Scientific papers refereed
1.
2.
3.
4.
5.
6.
7.
8.
Axwijk PH, Kluijt I, de Jong D, Gille JJP, Teertstra J, Horenblas S. Hereditary causes of kidney tumours. European
Journal of Clinical Investigation 2010; 40: 433-439 (4 / 2.643)
Baselga J, Cervantes A, Martinelli E, Chirivella I, Hoekman K, Hurwitz HI, Jodrell DI, Hamberg P, Casado E, Elvin P,
Swaisland A, Iacona R, Tabernero J. Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of
Saracatinib in Patients with Solid Tumors. Clinical Cancer Research 2010; 16: 4876-4883 (5 / 6.747)
Biere SSAY, van der Peet DL, Cuesta MA. Minimally Invasive Esophagectomy. Annals of Surgery 2010; 251: 178-179 (5 /
7.9)
Mir SE, Hamer PCD, Krawczyk PM, Balaj L, Claes A, Niers JM, Van Tilborg AAG, Zwinderman AH, Geerts D, Kaspers
GJL, Vandertop WP, Cloos J, Tannous BA, Wesseling P, Aten JA, Noske DP, Van Noorden CJF, Wurdinger T. In Silico
Analysis of Kinase Expression Identifies WEE1 as a Gatekeeper against Mitotic Catastrophe in Glioblastoma. Cancer
Cell 2010; 18: 244-257 (5 / 25.288)
Adema AD, Losekoot N, Smid K, Kathmann I, Myhren F, Sandvold ML, Peters GJ. Induction of Resistance to the
Lipophilic Cytarabine Prodrug Elacytarabine (CP-4055) in CEM Leukemic Cells. Nucleos Nucleot Nucl 2010; 29: 394-399
(1 / 0.768)
Adema AD, Laan AC, Myhren F, Fichtner I, Verheul HMW, Sandvold ML, Peters GJ. Cell cycle effects of fatty acid
derivatives of cytarabine, CP-4055, and of gemcitabine, CP-4126, as basis for the interaction with oxaliplatin and
docetaxel. Int J Oncol 2010; 36: 285-294 (3 / 2.447)
Bachas C, Schuurhuis GJ, Hollink IHIM, Kwidama ZJ, Goemans BF, Zwaan CM, van den Heuvel-Eibrink M, De Bont ESJM,
Reinhardt D, Creutzig U, de Haas V, Assaraf YG, Kaspers GJL, Cloos J. High-frequency type I/II mutational shifts
between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine.
Blood 2010; 116: 2752-2758 (5 / 10.555)
Banerji U, Camidge DR, Verheul HMW, Agarwal R, Sarker D, Kaye SB, Desar IME, Timmer-Bonte JNH, Eckhardt SG,
Lewis KD, Brown KH, Cantarini MV, Morris C, George SMA, Smith PD, van Herpen CML. The First-in-Human Study of the
85
Appendix 4: Scientific output
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
86
Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label
Multicenter Trial in Patients with Advanced Cancer. Clin Cancer Res 2010; 16: 1613-1623 (5 / 6.747)
Barnhill RL, Cerroni L, Cook M, Elder DE, Kerl H, Leboit PE, McCarthy SW, Mihm MC, Mooi WJ, Piepkorn MW, Prieto
VG, Scolyer RA. State of the Art, Nomenclature, and Points of Consensus and Controversy Concerning Benign
Melanocytic Lesions: Outcome of an International Workshop. Adv Anat Pathol 2010; 17: 73-90 (4 / 3.221)
Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BAC, Tak PP, Wolbink GJJ.
Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and
anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis 2010; 69: 817-821 (5 / 8.111)
Basu N, Watts R, Bajema I, Baslund B, Bley T, Boers M, Brogan P, Calabrese L, Cid MC, Cohen-Tervaert JW, FloresSuarez LF, Fujimoto S, de Groot K, Guillevin L, Hatemi G, Hauser T, Jayne D, Jennette C, Kallenberg CGM, Kobayashi
S, Little MA, Mahr A, et al.. EULAR points to consider in the development of classification and diagnostic criteria in
systemic vasculitis. Ann Rheum Dis 2010; 69: 1744-1750 (5 / 8.111)
Becker A, van Wijk A, Smit EF, Postmus PE. Side-Effects of Long-Term Administration of Erlotinib in Patients with
Non-small Cell Lung Cancer. J Thorac Oncol 2010; 5: 1477-1480 (4 / 4.547)
Belt EJT, van Stijn MFM, Bril H, de Lange-de Klerk E, Meijer GA, Meijer S, Stockmann HBAC. Lymph Node Negative
Colorectal Cancers with Isolated Tumor Deposits Should Be Classified and Treated As Stage III. Ann Surg Oncol 2010;
17: 3203-3211 (5 / 4.13)
Bergman GJD, Hochberg MC, Boers M, Wintfeld N, Kielhorn A, Jansen JP. Indirect Comparison of Tocilizumab and
Other Biologic Agents in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying
Antirheumatic Drugs. Semin Arthritis Rheu 2010; 39: 425-441 (4 / 4.724)
Bex A, van der Veldt AAM, Blank C, Meijerink MR, Boven E, Haanen JBAG. Progression of a caval vein thrombus in two
patients with primary renal cell carcinoma on pretreatment with sunitinib. Acta Oncol 2010; 49: 520-U124 (2 / 2.265)
Bex A, van der Veldt AAM, Boven E, Haanen JBAG. Re: Surgical Resection of Renal Cell Carcinoma After Targeted
Therapy. J Urology 2010; 183: 1646-1647 (4 / 4.016)
Bierman WFW, Scheffer GL, Schoonderwoerd A, Jansen G, van Agtmael MA, Danner SA, Scheper RJ. Protease
inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad
panel of ABC transporter-overexpressing cell lines. J Antimicrob Chemoth 2010; 65: 1672-1680 (4 / 4.352)
Bijnsdorp IV, Azijli K, Jansen EE, Wamelink MM, Jakobs C, Struys EA, Fukushima M, Kruyt FAE, Peters GJ.
Accumulation of thymidine-derived sugars in thymidine phosphorylase overexpressing cells. Biochem Pharmacol 2010;
80: 786-792 (4 / 4.254)
Bijnsdorp IV, Vrijland K, Vroling L, Fukushima M, Peters GJ. Increased Migration by Stimulation of Thymidine
Phosphorylase in Endothelial Cells of Different Origin. Nucleos Nucleot Nucl 2010; 29: 482-487 (1 / 0.768)
Bijnsdorp IV, Peters GJ, Temmink OH, Fukushima M, Kruyt FA. Differential activation of cell death and autophagy
results in an increased cytotoxic potential for trifluorothymidine compared to 5-fluorouracil in colon cancer cells. Int
J Cancer 2010; 126: 2457-2468 (4 / 4.722)
Bijnsdorp IV, Kruyt FAE, Fukushima M, Smid K, Gokoel S, Peters GJ. Molecular mechanism underlying the synergistic
interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human
colorectal cancer cell lines. Cancer Sci 2010; 101: 440-447 (3 / 3.771)
Bloemers BLP, Broers CJM, Bont L, Weijerman ME, Gemke RJBJ, van Furth AM. Increased risk of respiratory tract
infections in children with Down syndrome: the consequence of an altered immune system. Microbes Infect 2010; 12:
799-808 (3 / 2.757)
Bloemers BLP, van Furth AM, Weijerman ME, Gemke RJBJ, Broers CJM, Kimpen JLL, Bont L. High Incidence of
Recurrent Wheeze in Children With Down Syndrome With and Without Previous Respiratory Syncytial Virus Lower
Respiratory Tract Infection. Pediatr Infect Dis J 2010; 29: 39-42 (5 / 2.854)
Bode LGM, Kluytmans JAJW, Wertheim HFL, Bogaers D, Vandenbroucke-Grauls CMJE, Roosendaal R, Troelstra A, Box
ATA, Voss A, van der Tweel I, van Belkum A, Verbrugh HA, Vos MC. Preventing Surgical-Site Infections in Nasal
Carriers of Staphylococcus aureus. N Engl J Med 2010; 362: 9-17 (5 / 47.05)
Boers M. Standing on the promises: First wave validation reports of the Patient-Reported Outcome Measurement
Information System. J Clin Epidemiol 2010; 63: 1167-1168 (4 / 2.956)
Boers M. Updated Consolidated Standards of Reporting Trials (CONSORT): it just gets better. J Clin Epidemiol 2010;
63: 813-814 (4 / 2.956)
Boers M, Brooks P, Fries JF, Simon LS, Strand V, Tugwell P. A first step to assess harm and benefit in clinical trials in
one scale. J Clin Epidemiol 2010; 63: 627-632 (4 / 2.956)
Boers M, Berkhof J, Twisk JWR, Ader HJ, Bezemer D, Knol DL, Kostense PJ, Kuik DJ, Uitdehaag BMJ. A new graph and
scoring system simplified analysis of changing states: disease remissions in a rheumatoid arthritis clinical trial. J Clin
Epidemiol 2010; 63: 633-637 (4 / 2.956)
Boers M. A new design for registration trials in rheumatoid arthritis allowing secondary head-to-head comparisons
with standard of care treatment including biologicals. Ann Rheum Dis 2010; 69: 4-6 (5 / 8.111)
Boers M. The time has come to limit the placebo period in rheumatoid arthritis trials to 3 months: a systematic
comparison of 3-and 6-month response rates in trials of biological agents. Ann Rheum Dis 2010; 69: 186-192 (5 /
8.111)
Boers M, Kostense PJ. Non-Overlapping American College of Rheumatology Response Rates: A Better Way to Report
Response in Rheumatoid Arthritis Clinical Trials COMMENTARY. Arthrit Rheum-Arthr 2010; 62: 3524-3527 (3 / 4.152)
Boers M. Cost-Effectiveness of Biologics in Early Rheumatoid Arthritis RESPONSE. Ann Intern Med 2010; 152: 334 (5 /
16.225)
Boomsma MF, Garssen B, Slot E, Berbee M, Berkhof J, Meezenbroek ED, Slieker W, Visser A, Meijer S, Beelen RHJ.
Breast Cancer Surgery-Induced Immunomodulation. J Surg Oncol 2010; 102: 640-648 (4 / 2.502)
Bos WH, Wolbink GJJ, Boers M, Tijhuis GJ, de Vries N, van der Horst-Bruinsma I, Tak PP, van de Stadt RJ, van der
Laken CJ, Dijkmans BAC, van Schaardenburg D. Arthritis development in patients with arthralgia is strongly associated
with anti-citrullinated protein antibody status: a prospective cohort study. Ann Rheum Dis 2010; 69: 490-494 (5 /
8.111)
Bos WH, Dijkmans BAC, Boers M, van de Stadt RJ, van Schaardenburg D. Effect of dexamethasone on autoantibody
levels and arthritis development in patients with arthralgia: a randomised trial. Ann Rheum Dis 2010; 69: 571-574 (5 /
8.111)
Appendix 4: Scientific output
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
Boven E, Massard C, Armand JP, Tillier C, Hartog V, Brega NM, Countouriotis AM, Ruiz-Garcia A, Soria JC. A phase I,
dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours. Brit J Cancer
2010; 103: 993-1000 (4 / 4.346)
Pillay J, Ramakers BP, Kamp VM, Loi ALT, Lam SW, Hietbrink F, Leenen LP, Tool AT, Pickkers P, Koenderman L.
Functional heterogeneity and differential priming of circulating neutrophils in human experimental endotoxemia. J
Leukocyte Biology 2010; 88: 211-220 (4 / 4.403)
Lam SW, Teraa M, Leenen LPH, van der Heijden GJMG. Systematic review shows lowered risk of nonunion after
reamed nailing in patients with closed tibial shaft fractures. Injury - Int J Care Injured 2010; 41(7): 703-707 (4 /
2.383)
Ong CL, Palma D, Verbakel WFAR, Slotman BJ, Senan S. Treatment of large stage I-II lung tumors using stereotactic
body radiotherapy (SBRT): Planning considerations and early toxicity. Radiother Oncol 2010; 97(3): 431-436 (5 /
4.343)
van Leeuwen RWF, Swart EL, Boom FA, Schuitenmaker MS, Hugtenburg JG. Potential drug interactions and duplicate
prescriptions among ambulatory cancer patients: a prevalence study using an advanced screening method. BMC
Cancer 2010; 13(10): 679 (3 / 2.736)
Adema AY, Schilder AM, Schreuder TCMA, Grunberg K, Bultink IEM, Mulder CJJ. Ascites as the Presenting Symptom in
a Patient with Churg-Strauss Syndrome. J Gastrointest Liver Dis 2010; 19: 199-201 (1 / 1.265)
Barreiro-de Acosta M, Ouburg S, Morre SA, Crusius JBA, Lorenzo A, Potel J, Salvador-Pena A, Dominguez-Munoz JE.
NOD2, CD14 and TLR4 mutations do not influence response to adalimumab in patients with Crohn's disease: a
preliminary report. Revista Espanola de Enfermedades Digestivas 2010; 102: 591-595 (1 / 0.994)
Boparai KS, Mathus-Vliegen EMH, Koornstra JJ, Nagengast FM, van Leerdam M, van Noesel CJM, Houben M, Cats A, van
Hest LP, Fockens P, Dekker E. Increased colorectal cancer risk during follow-up in patients with hyperplastic polyposis
syndrome: a multicentre cohort study. Gut 2010; 59: 1094-1100 (5 / 9.357)
Boparai KS, Reitsma JB, Lemmens V, Van Os TAM, Mathus-Vliegen EMH, Koornstra JJ, Nagengast FM, van Hest LP,
Keller JJ, Dekker E. Increased colorectal cancer risk in first-degree relatives of patients with hyperplastic polyposis
syndrome. Gut 2010; 59: 1222-1225 (5 / 9.357)
Cauberg ECC, Salomons MA, Kummerlin IPED, de Reijke TM, Zwinderman AH, de la Rosette JJMC, Kate FJW, Pes MPL.
Trends in epidemiology and treatment of upper urinary tract tumours in the Netherlands 1995-2005: an analysis of
PALGA, the Dutch national histopathology registry. BJU International 2010; 105: 922-927 (4 / 2.865)
De Bie CI, Hummel TZ, Kinderman A, Kokke FTM, Damen GM, Kneepkens CMF, Van Rheenen PF, Schweizer JJ,
Hoekstra JH, Norbruis OF, Tjon AT, Vreugdenhil AC, ckers-Kocken JM, Gijsbers CFM, Escher JC, de Ridder L. The
duration of effect of infliximab maintenance treatment in paediatric Crohn's disease is limited. Alimentary
Pharmacology & Therapeutics 2010; 33: 243-250 (4 / 4.357)
de Bruijne J, Bergmann JF, Weegink CJ, van Nieuwkerk CMJ, de Knegt RJ, Komoda Y, de Rooij-van de Wetering, van
Vliet A, Jansen PLM, Molenkamp R, Schinkel J, Reesink H, Janssen HLA. Safety and antiviral activity of JTK-652: a
novel HCV infection inhibitor. Antiviral Therapy 2010; 15: 765-773 (4 / 4.322)
Buijs N, de van der Schueren M, Langius JAE, Leemans CR, Kuik DJ, Vermeulen MAR, van Leeuwen PAM. Perioperative
arginine-supplemented nutrition in malnourished patients with head and neck cancer improves long-term survival. Am
J Clin Nutr 2010; 92: 1151-1156 (5 / 6.307)
de Vries R, Kretzschmar M, Schellekens JFP, Versteegh FGA, Westra TA, Roord JJ, Postma MJ. Cost-Effectiveness of
Adolescent Pertussis Vaccination for The Netherlands: Using an Individual-Based Dynamic Model. Plos one 2010; 5: (4
/ 4.351)
de Vries RR, Visser O, Nieuwenhuijzen JA, Horenblas S. Outcome of treatment of bladder cancer: a comparison
between low-volume hospitals and an oncology centre. World J Urol 2010; 28: 431-437 (3 / 2.629)
de Witt Hamer PC. Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies. NeuroOncology 2010; 12: 304-316 (4 / 4.4984)
Douw L, van Dellen E, Baayen JC, Klein M, Velis DN, Alpherts WCJ, Heimans JJ, Reijneveld JC, Stam CJ. The lesioned
brain: still a small-world?. Front Hum Neurosc 2010; 4: (2 / 1.548)
Haasnoot PJ, Boeting TE, Kuney MO, van Roosmalen J. Knowledge, Attitudes, and Practice of Tuberculosis among
Maasai in Simanjiro District, Tanzania. Am J Trop Med Hyg 2010; 83: 902-905 (4 / 2.795)
Hartemink KJ, Hepp SM, van den Bos IC, van Weyenberg SJB. Gallstone ileus: correlation between computed
tomography, double-balloon enteroscopy and intra-operative findings. Wiener Klinische Wochenschrift 2010; 122: 720722 (2 / 0.955)
Kneepkens CMF, Brand PLP. Clinical practice - Breastfeeding and the prevention of allergy. Eur J Pediatr 2010; 169:
911-917 (3 / 1.634)
Koutroubakis IE, Pena AS. Disease activity and venous thromboembolism in inflammatory bowel disease. Lancet 2010;
375: 1689 (5 / 30.758)
Kummerlin IPED, ten Kate FJW, Wijkstra H, Zwinderman A, de la Rosette JJMC, Laguna MP. A Decade of Surgically
Removed Small Renal Masses in The Netherlands: Characteristics and Trends in Type of Surgery and Pathologic
Reporting. J Endourol 2010; 24: 1675-1679 (2 / 1.754)
Bobardt MD, Chatterji U, Schaffer L, de Witte LD, Gallay PA. Syndecan-Fc Hybrid Molecule as a Potent In Vitro
Microbicidal Anti-HIV-1 Agent. Antimicrob Agents Ch 2010; 54: 2753-2766 (4 / 4.802)
Cardillo G, Treggiari S, Paul MA, Carleo F, De Massimi AR, Remotti D, Graziano P, Martelli M. Primary neuroendocrine
tumours of the thymus: a clinicopathologic and prognostic study in 19 patients. European Journal of Cardio-Thoracic
Surgery 2010; 37: 814-818 (4 / 2.397)
Gaujoux-Viala C, Smolen JS, Landewe R, Dougados M, Kvien TK, Mola EM, Scholte-Voshaar M, van Riel P, Gossec L.
Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs:
a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.
Annals of the Rheumatic Diseases 2010; 69: 1004-1009 (5 / 8.111)
Gudlaugsson E, Skaland I, Janssen EAM, van Diest PJ, Voorhorst FJ, Kjellevold K, zur Hausen A, Baak JPA. Prospective
multicenter comparison of proliferation and other prognostic factors in lymph node negative lobular invasive breast
cancer. Breast Cancer Research and Treatment 2010; 121: 35-40 (4 / 4.696)
Jansen JP, O'Sullivan AK, Lugtenburg E, Span LFR, Janssen JJWM, Stam WB. Economic evaluation of posaconazole
versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands. Ann Hematol
2010; 89: 919-926 (3 / 2.919)
87
Appendix 4: Scientific output
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88
Klarenbeek BR, Samuels M, van der Wal MA, van der Peet DL, Meijerink WJ, Cuesta MA. Indications for Elective
Sigmoid Resection in Diverticular Disease. Annals of Surgery 2010; 251: 670-674 (5 / 7.9)
Kneppers E, Lokhorst HM, Eeltink CM, Huls G, Kersten MJ, Koedam J, Minnema MC, van Oers MHJ, Raymakers RAP,
Schaafsma MR, Vellenga E, Wijermans PW, Wittebol S, Sonneveld P, Zweegman S. Analysis of Efficacy and Prognostic
Factors of Lenalidomide Treatment as Part of a Dutch Compassionate Use Program. Clinical Lymphoma Myeloma &
Leukemia 2010; 10: 138-143 (1 / 1.13)
Lecluse LLA, Driessen RJB, Spuls PI, De Jong EMGJ, Stapel SO, van Doorn MBA, Bos JD, Wolbink GJ. Extent and Clinical
Consequences of Antibody Formation Against Adalimumab in Patients With Plaque Psoriasis. Archives of Dermatology
2010; 146: 127-132 (5 / 4.76)
Morks AN, Klarenbeek BR, Flikweert ER, van der Peet DL, Karsten TM, Eddes EH, Cuesta MA, de Graaf PW. Current
surgical treatment of diverticular disease in the Netherlands. World Journal of Gastroenterology 2010; 16: 1742-1746
(2 / 2.092)
Oonk MH, van Hemel BM, Hollema H, de Hullu JA, Ansink AC, Vergote I, Verheijen RHM, Maggioni A, Gaarenstroom
KN, Baldwin PJ, van Dorst EB, van der Velden J, Hermans RH, van der Putten HW, Drouin P, Runnebaum IB, Sluiter
WJ, van der Zee AG. Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in
early stage vulvar cancer: results from GROINSS-V, a multicentre observational study. Lancet Oncology 2010; 11: 646652 (5 / 14.47)
Pastina I, Giovannetti E, Chioni A, Sissung TM, Crea F, Orlandini C, Price DK, Cianci C, Figg WD, Ricci S, Danesi R.
Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate
Cancer (CRPC) patients. BMC Cancer 2010; 10: (3 / 2.736)
Peters MJL, Nurmohamed MT, Kitas GD, Sattar N. Statin treatment of rheumatoid arthritis: comment on the editorial
by Ridker and Solomon. Arthritis and Rheumatism 2010; 62: 302-303 (3 / 4.152)
Sandvold ML, Galmarini C, Myhren F, Peters GJ. The Activity of the Lipophilic Nucleoside Derivatives Elacytarabine
and CP-4126 in a Panel of Tumor Cell Lines Resistant to Nucleoside Analogues. Nucleos Nucleot Nucl 2010; 29: 386393 (1 / 0.768)
Sanz MA, Montesinos P, Rayon C, Holowiecka A, de la Serna J, Milone G, de Lisa E, Brunet S, Rubio V, Ribera JM, Rivas
C, Krsnik I, Bergua J, Gonzalez J, az-Mediavilla J, Rojas R, Manso F, Ossenkoppele G, Gonzalez JD, Lowenberg B,
Pethema G, Hovon G. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and
anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in
treatment outcome. Blood 2010; 115: 5137-5146 (5 / 10.555)
Snoeren N, Voest EE, Bergman AM, Dalesio O, Verheul HM, Tollenaar RAEM, van der Sijp JRM, Schouten SB, Rinkes
IHMB, van Hillegersberg R. A randomized two arm phase III study in patients post radical resection of liver metastases
of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX
alone as adjuvant treatment. BMC Cancer 2010; 10: (3 / 2.736)
Thomson M, Venkatesh K, Elmalik K, van der Veer W, Jacobs MAJM. Double balloon enteroscopy in children: Diagnosis,
treatment, and safety. World Journal of Gastroenterology 2010; 16: 56-62 (2 / 2.092)
Toffalorio F, De Pas T, Giovannetti E. Differences of Gene Expression in Non-small Cell Lung Cancer Are Histology,
Tumor Site, and Methodology Relevant?. J Thorac Oncol 2010; 5: 1310-1311 (4 / 4.547)
van Meurs T, Van Doorn R, Kirtschig G. Treatment of Lentigo Maligna with Imiquimod Cream: A Long-Term Follow-Up
Study of 10 Patients. Dermatologic Surgery 2010; 36: 853-858 (3 / 2.343)
Welsh P, Sattar N, Peters MJL. Association of inflammatory mediators with premature atherosclerosis in rheumatoid
arthritis and healthy controls: comment on the article by Rho et al. Arthritis Care & Research 2010; 62: 1052-1053 (3
/ 4.152)
Wijermans P, Schaafsma M, Termorshuizen F, Ammerlaan R, Wittebol S, Sinnige H, Zweegman S, Kooy MV, van der
Griend R, Lokhorst H, Sonneveld P. Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in
Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study. J Clin Oncol 2010; 28: 3160-3166 (5 /
17.793)
Wu WC, Chan CL, Wong YW, Cuijpers JP. A study on the influence of breathing phases in intensity-modulated
radiotherapy of lung tumours using four-dimensional CT. British journal of radiology 2010; 83: 252-256 (3 / 2.105)
Lokhorst HM, van der Holt B, Zweegman S, Vellenga E, Croockewit S, van Oers MH, Borne PV, Wijermans P, Schaafsma
R, de Weerdt O, Wittebol S, Delforge M, Berenschot H, Bos GM, et al.. A randomized phase 3 study on the effect of
thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide
maintenance in patients with multiple myeloma. Blood 2010; 115: 1113-1120 (5 / 10.555)
Menke HE, Faber WR, Pieters T. Charles Louis Drognat Landre and Gerhard Henrik Armauer Hansen; Contribution from
A Dutch Colony to the Discovery of the Leprosy Bacterium. Leprosy Review 2010; 81: 82-86 (2 / 1.165)
Mulder CJJ, Puri AS, Reddy DN. Gastroenterology training in private hospitals: India vs South Africa. World J
Gastroenterol 2010; 16: 948-952 (2 / 2.092)
Neerincx M, Droste JSTS, Mulder CJJ, Rakers M, Bartelsman JFWM, Loffeld RJ, Tuynman HARE, Brohet RM, Van der
Hulst RWM. Colonic work-up after incomplete colonoscopy: significant new findings during follow-up. Endoscopy 2010;
42: 730-735 (5 / 5.545)
Obdeijn IMA, Loo CE, Rijnsburger AJ, Wasser MNJM, Bergers E, Kok T, Klijn JGM, Boetes C. Assessment of falsenegative cases of breast MR imaging in women with a familial or genetic predisposition. Breast Cancer Research and
Treatment 2010; 119: 399-407 (4 / 4.696)
Pijpe A, Manders P, Mulder RL, van Leeuwen FE, Rookus MA. Reliability of self-reported diagnostic radiation history in
BRCA1/2 mutation carriers. Eur J Epidemiol 2010; 25: 103-113 (5 / 3.718)
Sardanelli F, Boetes C, Borisch B, Decker T, Federico M, Gilbert FJ, Helbich T, Heywang-Kobrunner SH, Kaiser WA,
Kerin MJ, Mansel RE, Marotti L, Martincich L, Mauriac L, Meijers-Heijboer EJ, Orecchia R, Panizza P, Ponti A,
Purushotham AD, Regitnig P, Del. Magnetic resonance imaging of the breast: Recommendations from the EUSOMA
working group. European Journal of Cancer 2010; 46: 1296-1316 (3 / 4.121)
van Dillen J, Zwart J, Schutte J, van Roosmalen J. Maternal sepsis: epidemiology, etiology and outcome. Curr Opin
Infect Dis 2010; 23: 249-254 (4 / 4.723)
van Gool WA, van de Beek D, Eikelenboom P. Systemic infection and delirium: when cytokines and acetylcholine
collide. Lancet 2010; 375: 773-775 (5 / 30.758)
Appendix 4: Scientific output
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
107.
108.
109.
110.
111.
112.
113.
114.
115.
116.
Van Turenhout ST, Jacobs MAJM, Van Weyenberg SJ, Herdes E, Stant F, Mulder CJJ, Bouma G. Diagnostic Yield of
Capsule Endoscopy in a Tertiary Hospital in Patients with Obscure Gastrointestinal Bleeding. J Gastrointest Liver Dis
2010; 19: 141-145 (1 / 1.265)
Buikhuisen WA, Burgers JA, Vincent AD, Schellens JHM, Beijnen JH, Smit EF, Joerger M. Pemetrexed PathwayAssociated Germline Polymorphisms: A Useful Tool for Treatment Individualization?. J Clin Oncol 2010; 28: E482-E483
(5 / 17.793)
Buis DR, Meijer OWM, van den Berg R, Lagerwaard FJ, Bot JCJ, Slotman BJ, Vandertop WP. Clinical outcome after
repeated radiosurgery for brain arteriovenous malformations. Radiother Oncol 2010; 95: 250-256 (5 / 4.343)
Capelle LG, van Grieken NCT, Lingsma HF, Steyerberg EW, Klokman WJ, Bruno MJ, Vasen HFA, Kuipers EJ. Risk and
Epidemiological Time Trends of Gastric Cancer in Lynch Syndrome Carriers in The Netherlands. Gastroenterology
2010; 138: 487-492 (5 / 12.899)
Carmichael MD, Davis JM, Murphy EA, Carson JA, van Rooijen N, Mayer E, Ghaffar A. Role of brain macrophages on IL1 beta and fatigue following eccentric exercise-induced muscle damage. Brain Behav Immun 2010; 24: 564-568 (2 /
2.733)
Casal C, Torres-Collado AX, Plaza-Calonge MD, Martino-Echarri E, Cajal SRY, Rojo F, Griffioen AW, RodriguezManzaneque JC. ADAMTS1 Contributes to the Acquisition of an Endothelial-like Phenotype in Plastic Tumor Cells.
Cancer Res 2010; 70: 4676-4686 (5 / 7.543)
Cazander G, van de Veerdonk MC, Vandenbroucke-Grauls CMJE, Schreurs MWJ, Jukema GN. Maggot Excretions Inhibit
Biofilm Formation on Biomaterials. Clin Orthop Rel Res 2010; 468: 2789-2796 (4 / 2.065)
Cazander G, Pawiroredjo JS, Vandenbroucke-Grauls CMJE, Schreurs MWJ, Jukema GN. Synergism between maggot
excretions and antibiotics. Wound Repair Regen 2010; 18: 637-642 (4 / 2.781)
Chandeck C, Mooi WJ. Oncogene-induced Cellular Senescence. Adv Anat Pathol 2010; 17: 42-48 (4 / 3.221)
Charni S, de Bettignies G, Rathore MG, Aguilo JI, van den Elsen PJ, Haouzi D, Hipskind RA, Enriquez JA, SanchezBeato M, Pardo J, Anel A, Villalba M. Oxidative Phosphorylation Induces De Novo Expression of the MHC Class I in
Tumor Cells through the ERK5 Pathway. J Immunol 2010; 185: 3498-3503 (4 / 5.646)
Cillessen SAGM, Meijer CJLM, Notoya M, Ossenkoppele GJ, Oudejans JJ. Molecular targeted therapies for diffuse large
B-cell lymphoma based on apoptosis profiles. J Pathol 2010; 220: 509-520 (5 / 6.466)
Civantos FJ, Stoeckli SJ, Takes RP, Woolgar JA, de Bree R, Paleri V, Devaney KO, Rinaldo A, Silver CE, Mondin V,
Werner JA, Ferlito A. What is the role of sentinel lymph node biopsy in the management of oral cancer in 2010?. Eur
Arch Oto-Rhino-L 2010; 267: 839-844 (3 / 1.167)
Cui J, Saevarsdottir S, Thomson B, Padyukov L, van der Helm-van Mil A, Nititham J, Hughes LB, de Vries N,
Raychaudhuri S, Alfredsson L, Askling J, Wedren S, Ding B, Guiducci C, Wolbink GJJ, Crusius JBA, van der HorstBruinsma I, Herenius M, Weinblatt ME,. Rheumatoid Arthritis Risk Allele PTPRC Is Also Associated With Response to
Anti-Tumor Necrosis Factor alpha Therapy. Arthrit Rheum-Arthr 2010; 62: 1849-1861 (3 / 4.152)
Cuijpers JP, Verbakel WFAR, Slotman BJ, Senan S. A novel simple approach for incorporation of respiratory motion in
stereotactic treatments of lung tumors. Radiother Oncol 2010; 97: 443-448 (5 / 4.343)
Curvers WL, ten Kate FJ, Krishnadath KK, Visser M, Elzer B, Baak LC, Bohmer C, Mallant-Hent RC, van Oijen A, Naber
AH, Scholten P, Busch OR, Blaauwgeers HGT, Meijer GA, Bergman JJGH. Low-Grade Dysplasia in Barrett's Esophagus:
Overdiagnosed and Underestimated. Am J Gastroenterol 2010; 105: 1523-1530 (5 / 6.012)
Daniels JMA, Snijders D, de Graaff CS, Vlaspolder F, Jansen HM, Boersma WG. Antibiotics in Addition to Systemic
Corticosteroids for Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Am J Resp Crit Care Med 2010;
181: 150-157 (5 / 10.689)
de Boer MP, van der Veldt AAM, Lankheet NA, Wijnstok NJ, van den Eertwegh AJM, Boven E, Serne EH. Sunitinibinduced reduction in skin microvascular density is a reversible phenomenon. Ann Oncol 2010; 21: 1923 (4 / 5.647)
de Bree R, van der Waal I, de Bree E, Leemans CR. Management of adult soft tissue sarcomas of the head and neck.
Oral Oncol 2010; 46: 786-790 (5 / 3.123)
de Bree R, Hoekstra OS. Predictive value of fluorodeoxyglucose uptake in head and neck cancer: importance of
standardization Editorial on EAORL-D-10-00277. Eur Arch Oto-Rhino-L 2010; 267: 1491-1493 (3 / 1.167)
de Bree R, Leemans CR. Recent advances in surgery for head and neck cancer. Curr Opin Oncol 2010; 22: 186-193 (3 /
4.088)
De Cesare M, Sfondrini L, Campiglio M, Sommariva M, Bianchi F, Perego P, van Rooijen N, Supino R, Rumio C, Zunino
F, Pratesi G, Tagliabue E, Balsari A. Ascites Regression and Survival Increase in Mice Bearing Advanced-stage Human
Ovarian Carcinomas and Repeatedly Treated Intraperitoneally With CpG-ODN. J Immunother 2010; 33: 8-15 (3 /
3.203)
De Falco L, Totaro F, Nai A, Pagani A, Girelli D, Silvestri L, Piscopo C, Campostrini N, Dufour C, Manjomi FAL, Minkov
M, Van Vuurden DG, Feliu A, Kattamis A, Camaschella C, Iolascon A. Novel TMPRSS6 Mutations Associated with Ironrefractory Iron Deficiency Anemia (IRIDA). Hum Mutat 2010; 31: E1390-+ (4 / 6.887)
de Graaf P, Vos RM, de Boer NHK, Sinjewel A, Jharap B, Mulder CJJ, Van Bodegraven AA, Veldkamp AI. Limited
stability of thiopurine metabolites in blood samples: Relevant in research and clinical practise. J Chromatogr B 2010;
878: 1437-1442 (4 / 2.777)
de Graaf P, De Boer NKH, Wong DR, Karner S, Jharap B, Hooymans PM, Veldkamp AI, Mulder CJJ, Van Bodegraven AA,
Schwab M. Influence of 5-aminosalicylic acid on 6-thioguanosine phosphate metabolite levels: a prospective study in
patients under steady thiopurine therapy. Brit J Pharmacol 2010; 160: 1083-1091 (5 / 5.204)
de Jonge PJF, van Blankenstein M, Looman CWN, Casparie MK, Meijer GA, Kuipers EJ. Risk of malignant progression in
patients with Barrett's oesophagus: a Dutch nationwide cohort study. Gut 2010; 59: 1030-1036 (5 / 9.357)
de Jonge PJF, van Blankenstein M, Looman CWN, Casparie MK, Meijer GA, Kuipers EJ. Risk of Colorectal Cancer in
Patients With Barrett's Esophagus: A Dutch Population-Based Study. Am J Gastroenterol 2010; 105: 77-83 (5 / 6.012)
de Jonge RCJ, van Furth AM, Wassenaar M, Gemke RJBJ, Terwee CB. Predicting sequelae and death after bacterial
meningitis in childhood: A systematic review of prognostic studies. BMC Infect Dis 2010; 10: art.nr. 232 (3 / 2.55)
de Kruijf EM, Sajet A, van Nes JGH, Natanov R, Putter H, Smit VTHB, Liefers GJ, van den Elsen PJ, van de Velde CJH,
Kuppen PJK. HLA-E and HLA-G Expression in Classical HLA Class I-Negative Tumors Is of Prognostic Value for Clinical
Outcome of Early Breast Cancer Patients. J Immunol 2010; 185: 7452-7459 (4 / 5.646)
de Ruysscher D, Faivre-Finn C, Nestle U, Hurkmans CW, Le Pechoux C, Price A, Senan S. European Organisation for
Research and Treatment of Cancer Recommendations for Planning and Delivery of High-Dose, High-Precision
Radiotherapy for Lung Cancer. J Clin Oncol 2010; 28: 5301-5310 (5 / 17.793)
89
Appendix 4: Scientific output
117.
118.
119.
120.
121.
122.
123.
124.
125.
126.
127.
128.
129.
130.
131.
132.
133.
134.
135.
136.
137.
138.
139.
140.
141.
90
de Vries AC, Haringsma J, de Vries RA, ter Borg F, van Grieken NCT, Meijer GA, van Dekken H, Kuipers EJ. Biopsy
Strategies for Endoscopic Surveillance of Pre-malignant Gastric Lesions. Helicobacter 2010; 15: 259-264 (3 / 2.851)
de Vries HJC, Morre SA, White JA, Moi H. European guideline for the management of lymphogranuloma venereum,
2010. Int J Std Aids 2010; 21: 533-536 (1 / 1.05)
de Vries M, Horst-Bruinsma I, Van Hoogstraten IMW, Van Bodegraven AA, von Blomberg BME, Ratnawati H, Dijkmans
BAC. pANCA, ASCA, and OmpC antibodies in patients with ankylosing spondylitis without inflammatory bowel disease
(vol 37, pg 2340, 2010). J Rheumatol 2010; 37: 2639 (3 / 3.854)
Deenik W, Janssen JJWM, van der Holt B, Verhoef GEG, Smit WM, Kersten MJ, Daenen SMGJ, Verdouck LF, Ferrant A,
Schattenberg AVMB, Sonneveld P, Kooy MV, Wittebol S, Willemze R, Wijermans PW, Beverloo HB, Lowenberg B, Valk
PJM, Ossenkoppele GJ, Cornelissen. Efficacy of escalated imatinib combined with cytarabine in newly diagnosed
patients with chronic myeloid leukemia. Haematol-Hematol J 2010; 95: 914-921 (4 / 6.416)
den Bakker MA, Willemsen S, Grunberg K, Noorduijn LA, van Oosterhout MFM, van Suylen RJ, Timens W, Vrugt B,
Wiersma-van Tilburg A, Thunnissen FBJM. Small cell carcinoma of the lung and large cell neuroendocrine carcinoma
interobserver variability. Histopathology 2010; 56: 356-363 (4 / 3.855)
Di Maio M, Lama N, Morabito A, Smit EF, Georgoulias V, Takeda K, Quoix E, Hatzidaki D, Wachters FM, Gebbia V, Tsai
CM, Camps C, Schuette W, Chiodini P, Piccirillo MC, Perrone F, Gallo C, Gridelli C. Clinical assessment of patients
with advanced non-small-cell lung cancer eligible for second-line chemotherapy: A prognostic score from individual
data of nine randomised trials. Eur J Cancer 2010; 46: 735-743 (3 / 4.121)
Dik VK, Peters MJL, Dijkmans PA, van der Weijden MAC, De Vries MK, Dijkmans BAC, van der Horst-Bruinsma I,
Nurmohamed MT. The relationship between disease-related characteristics and conduction disturbances in ankylosing
spondylitis. Scand J Rheumatol 2010; 39: 38-41 (2 / 2.507)
Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson
RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Lowenberg B, Bloomfield
CD. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert
panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474 (5 / 10.555)
Douw L, van Dellen E, de Groot M, Heimans JJ, Klein M, Stam CJ, Reijneveld JC. Epilepsy is related to theta band
brain connectivity and network topology in brain tumor patients. BMC Neurosci 2010; 11: art.nr. 103 (2 / 2.744)
Engelhardt M, Udi J, Kleber M, Spencer A, Rocci A, Knop S, Bruno B, Bringhen S, Perez-Simon JA, Zweegman S,
Driessen C, Patriarca F, Gramatzki M, Terpos E, Sezer O, Kropff M, Straka C, Johnsen HE, Waage A, Boegsted M,
Lokhorst H, Hajek R, Morgan G, Boccad. European Myeloma Network: the 3rd Trialist Forum Consensus Statement
from the European experts meeting on multiple myeloma. Leuk Lymphoma 2010; 51: 2006-2011 (2 / 2.397)
Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sokler M, Zijlstra JM, Sturm I, Topp MS, Rank A, Zenz T,
Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V. Epoetin Alfa in Patients With Advanced-Stage
Hodgkin's Lymphoma: Results of the Randomized Placebo-Controlled GHSG HD15EPO Trial. J Clin Oncol 2010; 28:
2239-2245 (5 / 17.793)
Eppinga W, Lagerwaard FJ, Verbakel WFAR, Slotman BJ, Senan S. Volumetric Modulated Arc Therapy for Advanced
Pancreatic Cancer. Strahlenther Onkol 2010; 186: 382-387 (4 / 3.776)
Eriksson S, Peters GJ. Purine and Pyrimidine Metabolism in the Fist Decade of the 21St Century - Highlights and
Perspectives. Nucleos Nucleot Nucl 2010; 29: 1-11 (1 / 0.768)
Eshuis EJ, Slors JFM, Stokkers PCF, Sprangers MAG, Ubbink DT, Cuesta MA, Pierik EGJM, Bemelman WA. Long-term
outcomes following laparoscopically assisted versus open ileocolic resection for Crohn's disease. Brit J Surg 2010; 97:
563-568 (5 / 4.077)
Faaij CMJM, Willemze AJ, Revesz T, Balzarolo M, Tensen CP, Hoogeboom M, Vermeer MH, van Wering ER, Zwaan CM,
Kaspers GJL, Story C, van Halteren AGS, Vossen JM, Egeler RM, van Tol MJD, Annels NE. Chemokine/Chemokine
Receptor Interactions in Extramedullary Leukaemia of the Skin in Childhood AML: Differential Roles for CCR2, CCR5,
CXCR4 and CXCR7. Pediatr Blood Cancer 2010; 55: 344-348 (3 / 2.134)
Gaetani P, Hulleman E, Levi D, Quarto M, Scorsetti M, Helin K, Simonelli M, Colombo P, Baena RRY. Expression of the
transcription factor HEY1 in glioblastoma: a preliminary clinical study. Tumori 2010; 96: 97-102 (1 / 0.863)
Giovannetti E, Zucali PA, Peters GJ, Cortesi F, D'Incecco A, Smit EF, Falcone A, Burgers JA, Santoro A, Danesi R,
Giaccone G, Tibaldi C. Association of Polymorphisms in AKT1 and EGFR with Clinical Outcome and Toxicity in NonSmall Cell Lung Cancer Patients Treated with Gefitinib. Mol Cancer Ther 2010; 9: 581-593 (4 / 4.953)
Giovannetti E, Honeywell RJ, Hanauske AR, Tekle C, Kuenen B, Sigmond J, Giaccone G, Peters GJ. Pharmacological
Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer (NSCLC). Curr Drug Targets 2010;
11: 12-28 (4 / 3.932)
Giovannetti E, Leon LG, Bertini S, Macchia M, Minutolo F, Funel N, Alecci C, Giancola F, Danesi R, Peters GJ. Study of
Apoptosis Induction and Deoxycytidine Kinase/Cytidine Deaminase Modulation in the Synergistic Interaction of a Novel
Ceramide Analog and Gemcitabine in Pancreatic Cancer Cells. Nucleos Nucleot Nucl 2010; 29: 419-426 (1 / 0.768)
Giovannetti E, Funel N, Peters GJ, Del Chiaro M, Erozenci LA, Vasile E, Leon LG, Pollina LE, Groen A, Falcone A,
Danesi R, Campani D, Verheul HMW, Boggi U. MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome
and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity. Cancer Res 2010; 70: 45284538 (5 / 7.543)
Godbout C, Bilodeau R, van Rooijen N, Bouchard P, Frenette J. Transient Neutropenia Increases Macrophage
Accumulation and Cell Proliferation but Does Not Improve Repair following Intratendinous Rupture of Achilles Tendon.
J Orthop Res 2010; 28: 1084-1091 (5 / 3.112)
Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Kerstens PJSM, Nielen MMJ, Vos K, van Schaardenburg D, Speyer I,
Seys PEH, Breedveld FC, Allaart CF, Dijkmans BAC. DAS-driven therapy versus routine care in patients with recentonset active rheumatoid arthritis. Ann Rheum Dis 2010; 69: 65-69 (5 / 8.111)
Goemans BF, Zwaan CM, Cloos J, de Lange D, Loonen AH, Reinhardt D, Hahlen K, Gibson BES, Creutzig U, Kaspers
GJL. FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine
kinase inhibitor SU11657. Leuk Res 2010; 34: 1302-1307 (2 / 2.358)
Grijsen ML, Vrouenraets SME, Steingrover R, Lips P, Reiss P, Wit FWNM, Prins JM. High prevalence of reduced bone
mineral density in primary HIV-1-infected men. AIDS 2010; 24: 2233-2238 (5 / 4.909)
Groschel S, Lugthart S, Schlenk RF, Valk PJM, Eiwen K, Goudswaard C, van Putten WJL, Kayser S, Verdonck LF,
Lubbert M, Ossenkoppele GJ, Germing U, Schmidt-Wolf I, Schlegelberger B, Krauter J, Ganser A, Dohner H,
Lowenberg B, Dohner K, Delwel R. High EVI1 Expression Predicts Outcome in Younger Adult Patients With Acute
Appendix 4: Scientific output
142.
143.
144.
145.
146.
147.
148.
149.
150.
151.
152.
153.
154.
155.
156.
157.
158.
159.
160.
161.
162.
163.
164.
Myeloid Leukemia and Is Associated With Distinct Cytogenetic Abnormalities. J Clin Oncol 2010; 28: 2101-2107 (5 /
17.793)
Guler-Yuksel M, Allaart CF, Watt I, Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, van Schaardenburg D, van Krugten
MV, Dijkmans BAC, Huizinga TWJ, Lems WF, Kloppenburg M. Treatment with TNF-alpha inhibitor infliximab might
reduce hand osteoarthritis in patients with rheumatoid arthritis. Osteoarthr Cartilage 2010; 18: 1256-1262 (5 / 3.888)
Guler-Yuksel M, Klarenbeek NB, Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, van der Kooij SM, Gerards AH,
Ronday HK, Huizinga TWJ, Dijkmans BAC, Allaart CF, Lems WF. Accelerated hand bone mineral density loss is
associated with progressive joint damage in hands and feet in recent-onset rheumatoid arthritis. Arthritis Res Ther
2010; 12(3): art.nr. R96 (4 / 4.271)
Haasbeek CJA, Lagerwaard FJ, Antonisse ME, Slotman BJ, Senan S. Stage I Nonsmall Cell Lung Cancer in Patients Aged
>= 75 Years Outcomes After Stereotactic Radiotherapy. Cancer 2010; 116: 406-414 (4 / 5.418)
Hammers HJ, Verheul HMW, Salumbides B, Sharma R, Rudek M, Jaspers J, Shah P, Ellis L, Shen L, Paesante S, Dykema
K, Furge K, Teh B, Netto G, Pili R. Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to
Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study. Mol Cancer Ther 2010; 9: 15251535 (4 / 4.953)
Hamoir M, Leemans CR, Dolivet G, Schmitz S, Gregoire V, Andry G. Selective Neck Dissection in the Management of
the Neck After (Chemo)Radiotherapy for Advanced Head and Neck Cancer. Proposal for A Classification Update. Head
Neck-J Sci Spec 2010; 32: 816-819 (5 / 2.283)
Hertog D, van der Waal I. Ameloblastoma of the jaws: A critical reappraisal based on a 40-years single institution
experience. Oral Oncol 2010; 46: 61-64 (5 / 3.123)
Heusschen R, van Gink M, Griffioen AW, Thijssen VL. MicroRNAs in the tumor endothelium: Novel controls on the
angioregulatory switchboard. BBA-Rev Cancer 2010; 1805: 87-96 (5 / 11.685)
Hilverda K, Bosma I, Heimans JJ, Postma TJ, Vandertop WP, Slotman BJ, Buter J, Reijneveld JC, Klein M. Cognitive
functioning in glioblastoma patients during radiotherapy and temozolomide treatment: initial findings. J Neuro-Oncol
2010; 97: 89-94 (3 / 2.752)
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel
JC, Akerley W, van den Eertwegh AJM, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C,
Peschel C, Quirt I, et al.. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N Engl J Med
2010; 363: 711-723 (5 / 47.05)
Hoff M, Boyesen P, Haugeberg G, Vis M, Woolf AD, Havaardsholm EA, Dijkmans BAC, Kvien TK, Uhlig T, Lems WF. High
disease activity is a predictor of cortical hand bone loss in post-menopausal patients with established rheumatoid
arthritis: a 5-year multicentre longitudinal study. Rheumatology 2010; 49: 1676-1682 (4 / 4.236)
Hollink IHIM, van den Heuvel-Eibrink M, Zimmermann M, Balgobind BV, Arentsen-Peters STCJ, Alders M, Willasch A,
Kaspers GJL, Trka J, Baruchel A, Creutzig U, Pieters R, Reinhardt D, Zwaan CM. No Prognostic Impact of the WT1
Gene Single Nucleotide Polymorphism rs16754 in Pediatric Acute Myeloid Leukemia. J Clin Oncol 2010; 28: E523-E526
(5 / 17.793)
Honeywell RJ, Yarzadah K, Giovannetti E, Losekoot N, Smit EF, Walraven M, Lind JSW, Tibaldi C, Verheul HMW,
Peters GJ. Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical
setting by liquid chromatography tandem mass spectrometry. J Chromatogr B 2010; 878: 1059-1068 (4 / 2.777)
Horsten NCA, Ursum J, Roorda LD, van Schaardenburg D, Dekker J, Hoeksma AF. Prevalence of Hand Symptoms,
Impairments and Activity Limitations in Rheumatoid Arthritis in Relation to Disease Duration. J Rehabil Med 2010; 42:
916-921 (4 / 1.882)
Hwang JH, Voortman J, Giovannetti E, Steinberg SM, Leon LG, Kim YT, Funel N, Park JK, Kim MA, Kang GH, Kim SW,
Del Chiaro M, Peters GJ, Giaccone G. Identification of MicroRNA-21 as a Biomarker for Chemoresistance and Clinical
Outcome Following Adjuvant Therapy in Resectable Pancreatic Cancer. Plos one 2010; 5 (5): art.nr. e10630 (4 /
4.351)
Idema S, Dirven CMF, van Beusechem VW, Carette JE, Planque R, Noske DP, Lamfers MLM, Vandertop WP. Objective
determination of the oncolytic potency of conditionally-replicating adenoviruses using mathematical modeling. J
Gene Med 2010; 12: 564-571 (3 / 2.968)
Jamnitski A, Visman IM, Peters MJL, Dijkmans BAC, Voskuyl AE, Nurmohamed MT. Beneficial effect of 1-year
etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: the ETRA study. Ann
Rheum Dis 2010; 69: 1929-1933 (5 / 8.111)
Jharap B, Seinen ML, De Boer NKH, van Ginkel JR, Linskens RK, Kneppelhout JC, Mulder CJJ, Van Bodegraven AA.
Thiopurine Therapy in Inflammatory Bowel Disease Patients: Analyses of Two 8-Year Intercept Cohorts. Inflamm
Bowel Dis 2010; 16: 1541-1549 (4 / 4.643)
Jongerden IP, De Smet AMGA, Kluytmans JAJW, Velde LFT, Dennesen PJ, Wesselink RM, Bouw MP, Spanjersberg R,
Bogaers-Hofman D, van der Meer NJ, de Vries JW, Kaasjager K, van Iterson M, Kluge GH, van der Werf TS, Harinck HI,
Bindels AJ, Pickkers P, Bonten MJ. Physicians' and nurses' opinions on selective decontamination of the digestive tract
and selective oropharyngeal decontamination: a survey. Critical Care 2010; 14(4): art.nr. R132 (4 / 4.931)
Kamps WA, van der Pal-de Bruin K, Veerman AJP, Fiocco M, Bierings M, Pieters R. Long-term results of Dutch
Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004. Leukemia 2010;
24: 309-319 (5 / 8.296)
Klarenbeek NB, Guler-Yuksel M, van der Heijde DMFM, Hulsmans HMJ, Kerstens PJSM, Molenaar THE, de Sonnaville
PBJ, Huizinga TWJ, Dijkmans BAC, Allaart CF. Clinical synovitis in a particular joint is associated with progression of
erosions and joint space narrowing in that same joint, but not in patients initially treated with infliximab. Ann Rheum
Dis 2010; 69: 2107-2113 (5 / 8.111)
Klarenbeek NB, Kerstens PJSM, Huizinga TWJ, Dijkmans BAC, Allaart CF. Recent advances in the management of
rheumatoid arthritis. Brit Med J 2010; 341: art.nr. c6942 (5 / 13.66)
Klarenbeek NB, van der Kooij SM, Huizinga TJW, Goekoop-Ruiterman YPM, Hulsmans HMJ, van Krugten MV, Speyer I,
de Vries-Bouwstra JK, Kerstens PJSM, Huizinga TWJ, Dijkmans BAC, Allaart CF. Blood pressure changes in patients
with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the
BeSt trial. Ann Rheum Dis 2010; 69: 1342-1345 (5 / 8.111)
Konings IRHM, van der Gaast A, van der Wijk LJ, de Jongh FE, Eskens FA, Sleijfer S. The addition of pravastatin to
chemotherapy in advanced gastric carcinoma: a randomised phase II trial. Eur J Cancer 2010; 46(18): 3200-3204 (3 /
4.121)
91
Appendix 4: Scientific output
165.
166.
167.
168.
169.
170.
171.
172.
173.
174.
175.
176.
177.
178.
179.
180.
181.
182.
183.
184.
185.
186.
187.
92
Konings IRHM, de Jonge MJA, Burger H, van der Gaast A, van Beijsterveldt LEC, Winkler H, Verweij J, Yuan Z,
Hellemans P, Eskens FALM. Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ26483327 in patients with advanced solid tumours. Brit J Cancer 2010; 103: 987-992 (4 / 4.346)
Koppen IJN, Hermans FJR, Kaspers GJL. Acute lymphoblastic leukaemia in children - is there a role for MTHFR? response to Lightfoot et al. Brit J Haematol 2010; 149: 799-800 (4 / 4.597)
Kragelund C, Reibel J, Hadler-Olsen ES, Hietanen J, Johannessen AC, Kenrad B, Nylander K, Puranen M, Rozell B, Salo
T, Syrjanen S, Soland TM, van der Waal I, van der Wal JE, Warfvinge G. Scandinavian Fellowship for Oral Pathology
and Oral Medicine: statement on oral pathology and oral medicine in the European Dental Curriculum. J Oral Pathol
Med 2010; 39(10): art.nr. 800-e1 (4 / 2.144)
Kroep JR, Linn SC, Boven E, Bloemendal HJ, Baas J, Mandjes IAM, van den Bosch J, Smit WM, de Graaf H, Schroder
CP, Vermeulen GJ, Hop WCJ, Nortier JWR. Lapatinib: clinical benefit in patients with HER2-positive advanced breast
cancer. Neth J Med 2010; 68: 371-376 (3 / 1.503)
Kuijper IT, Dahele M, Senan S, Verbakel WFAR. Volumetric modulated arc therapy versus conventional intensity
modulated radiation therapy for stereotactic spine radiotherapy: A planning study and early clinical data. Radiother
Oncol 2010; 94: 224-228 (5 / 4.343)
Kuilman T, Michaloglou C, Mooi WJ, Peeper DS. The essence of senescence. Genes Dev 2010; 24: 2463-2479 (5 /
12.075)
Kuiper RP, Waanders E, van der Velden VHJ, van Reijmersdal SV, Venkatachalam R, Scheijen B, Sonneveld E, van
Dongen JJM, Veerman AJP, van Leeuwen FN, van Kessel AG, Hoogerbrugge PM. IKZF1 deletions predict relapse in
uniformly treated pediatric precursor B-ALL. Leukemia 2010; 24: 1258-1264 (5 / 8.296)
Lacerda HM, Richiardi L, Pettersson AM, Corbin M, Merletti F, Akre O. Cancer Risk in Mothers of Men Operated for
Undescended Testis. Plos one 2010; 5(12): art.nr. e14285 (4 / 4.351)
Lagerwaard FJ, van der Hoorn EA, Verbakel WFAR, Haasbeek CJA, Slotman BJ, Senan S. Simultaneous In-Field Boost
for Brain Metastases: in Regard to Lagerwaard et Al. (Int J Radiat Oncol Biol Phys 2009;75:253-259) Reply. Int J Radiat
Oncol 2010; 78: 965 (5 / 4.592)
Lam TJ, Meurs-Szojda MM, Gundlach L, Belien JAM, Meijer GA, Mulder CJJ, Felt-Bersma RJF. There is no increased
risk for colorectal cancer and adenomas in patients with diverticulitis: a retrospective longitudinal study. Colorectal
Dis 2010; 12: 1122-1126 (3 / 2.41)
Lambin P, Petit SF, Aerts HJWL, van Elmpt WJC, Oberije CJG, Starmans MHW, van Stiphout RGPM, van Dongen GAMS,
Muylle K, Flamen P, Dekker ALAJ, de Ruysscher D. The ESTRO Breur Lecture 2009. From population to voxel-based
radiotherapy: Exploiting intra-tumour and intra-organ heterogeneity for advanced treatment of non-small cell lung
cancer. Radiother Oncol 2010; 96: 145-152 (5 / 4.343)
Landewe RBM, Houbiers JGA, Van den Bosch F, in't Hout J, Verschueren PCPM, Meijerink JH, van den Hoogen FHJ,
Masek BA, Bruyn GAW, Wouters JMGW, Voskuyl AE, van Laar JM, Bijlsma JJW, van der Heijde DMFM, Breedveld FC,
van de Putte LBA, et al.. Intranasal administration of recombinant human cartilage glycoprotein-39 as a treatment for
rheumatoid arthritis: a phase II, multicentre, double-blind, randomised, placebo-controlled, parallel-group, dosefinding trial. Ann Rheum Dis 2010; 69: 1655-1659 (5 / 8.111)
Langenberg MHG, Witteveen PO, Roodhart JM, Verheul HMW, Mergui-Roelvink M, van der Sar J, Brendel E, Laferriere
N, Schellens JHM, Voest EE. Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine
Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors. Clin
Cancer Res 2010; 16: 2187-2197 (5 / 6.747)
Lems WF, den Uyl D. Exercise-induced changes in interleukin-10 in patients with knee osteoarthritis: new
perspectives?. Arthritis Res Ther 2010; 12(4): art.nr. 131 (4 / 4.271)
Li XM, Wood TE, Sprangers R, Jansen G, Franke NE, Mao XL, Wang XM, Zhang YF, Verbrugge SE, Adomat H, Li ZH,
Trudel S, Chen C, Religa TL, Jamal N, Messner H, Cloos J, Rose DR, Navon A, Guns E, Batey RA, Kay LE, Schimmer AD.
Effect of Noncompetitive Proteasome Inhibition on Bortezomib Resistance. J Natl Cancer Inst 2010; 102: 1069-1082 (5
/ 14.069)
Lind JSW, Dingemans AMC, Groen HJM, Thunnissen FBJM, Bekers O, Heideman DAM, Honeywell RJ, Giovannetti E,
Peters GJ, Postmus PE, van Suylen RJ, Smit EF. A Multicenter Phase II Study of Erlotinib and Sorafenib in
Chemotherapy-Naive Patients with Advanced Non-Small Cell Lung Cancer. Clin Cancer Res 2010; 16: 3078-3087 (5 /
6.747)
Lind JSW, Postmus PE, Smit EF. Osteoblastic Bone Lesions Developing During Treatment with Erlotinib Indicate Major
Response in Patients with Non-small Cell Lung Cancer A Brief Report. J Thorac Oncol 2010; 5: 554-557 (4 / 4.547)
Lind JSW, Meijerink MR, Dingemans AMC, van Kuijk C, Ollers MC, de Ruysscher D, Postmus PE, Smit EF. Dynamic
contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of
monitoring treatment?. Eur Radiol 2010; 20: 2890-2898 (4 / 3.589)
Lo Galbo AM, de Bree R, Kuik DJ, Lips P, Leemans CR. Paratracheal lymph node dissection does not negatively affect
thyroid dysfunction in patients undergoing laryngectomy. Eur Arch Oto-Rhino-L 2010; 267: 807-810 (3 / 1.167)
Lowenberg B, Morgan G, Ossenkoppele GJ, Burnett AK, Zachee P, Duhrsen U, Dierickx D, Muller-Tidow C, Sonneveld
P, Krug U, Bone E, Flores N, Richardson AF, Hooftman L, Jenkins C, Zweegman S, Davies F. Phase I/II Clinical Study of
Tosedostat, an Inhibitor of Aminopeptidases, in Patients With Acute Myeloid Leukemia and Myelodysplasia. J Clin
Oncol 2010; 28: 4333-4338 (5 / 17.793)
Lowenberg B, Beck J, Graux C, van Putten W, Schouten HC, Verdonck LF, Ferrant A, Sonneveld P, Jongen-Lavrencic
M, von Lilienfeld-Toal M, Biemond BJ, Vellenga E, Breems D, de Muijnck H, Schaafsma R, Verhoef G, Dohner H, ..
Ossenkoppele GJ, .. et al.. Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more:
results of a multicenter phase 3 study. Blood 2010; 115: 2586-2591 (5 / 10.555)
Ludwig H, Beksac M, Blade J, Boccadoro M, Cavenagh J, Cavo M, Dimopoulos M, Drach J, Einsele H, Facon T,
Goldschmidt H, Harousseau JL, Hess U, Ketterer N, Kropff M, Mendeleeva L, Morgan G, Palumbo A, Plesner T, San
Miguel J, Shpilberg O, Sondergeld P, Son. Current Multiple Myeloma Treatment Strategies with Novel Agents: A
European Perspective. Oncologist 2010; 15: 6-25 (4 / 6.701)
Lugthart S, Groschel S, Beverloo HB, Kayser S, Valk PJM, Van Zelderen-Bhola SL, Ossenkoppele GJ, Vellenga E, van
den Berg-de Ruiter, Schanz U, Verhoef G, Vandenberghe P, Ferrant A, Koohne CH, Pfreundschuh M, Horst HA, Koller
E, et al….. Clinical, Molecular, and Prognostic Significance of WHO Type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and
Various Other 3q Abnormalities in Acute Myeloid Leukemia. J Clin Oncol 2010; 28: 3890-3898 (5 / 17.793)
Appendix 4: Scientific output
188.
189.
190.
191.
192.
193.
194.
195.
196.
197.
198.
199.
200.
201.
202.
203.
204.
205.
206.
207.
208.
209.
210.
211.
212.
213.
214.
Luttjeboer M, Lafleur MVM, Kwidama ZJ, Van Rijn J, Van Den Berg J, Slotman BJ, Kaspers GJL, Cloos J. Strategies for
the analysis of in vitro radiation sensitivity and prediction of interaction with potential radiation modifying agents. Int
J Radiat Biol 2010; 86: 458-466 (5 / 1.842)
Maas KW, El Sharouni SY, Phernambucq ECJ, Stigt JA, Groen HJM, Herder GJM, Van den Borne BEEM, Senan S, Paul
MA, Smit EF, Schramel FMNH. Weekly Chemoradiation (Docetaxel/Cisplatin) Followed by Surgery in Stage III NSCLC; a
Multicentre Phase II Study. Anticancer Res 2010; 30: 4237-4243 (1 / 1.428)
Malinowski KT, Pantarotto JR, Senan S, Mcavoy TJ, D'Souza WD. Inferring Positions of Tumor and Nodes in Stage Iii
Lung Cancer from Multiple Anatomical Surrogates Using Four-Dimensional Computed Tomography. Int J Radiat Oncol
2010; 77: 1553-1560 (5 / 4.592)
Mandl ES, Meijer OWM, Slotman BJ, Vandertop WP, Peerdeman SM. Stereotactic radiation therapy for large vestibular
schwannomas. Radiother Oncol 2010; 95: 94-98 (5 / 4.343)
Marees T, van Leeuwen FE, Schaapveld M, Imhof SM, de Boer MR, Kors WA, Ringens PJ, Moll AC. Risk of third
malignancies and death after a second malignancy in retinoblastoma survivors. Eur J Cancer 2010; 46: 2052-2058 (3 /
4.121)
Marees T, Moll AC, Imhof SM, de Boer MR, Ringens PJ, van Leeuwen FE. Re: More About Second Cancers After
Retinoblastoma. J Natl Cancer Inst 2010; 102: 831-832 (5 / 14.069)
Martens HA, Gross S, van der Steege G, Brouwer E, Berden JHM, de Sevaux R, Derksen RHWM, Voskuyl AE, Berger SP,
Navis GJ, Kallenberg CGM, Bijl M. Lack of Association of C-C Chemokine Receptor 5 Delta 32 Deletion Status with
Rheumatoid Arthritis, Systemic Lupus Erythematosus, Lupus Nephritis, and Disease Severity. J Rheumatol 2010; 37:
2226-2231 (3 / 3.854)
Martin-Mola E, Sieper J, Leirisalo-Repo M, Dijkmans BAC, Vlahos B, Pedersen R, Koenig AS, Freundlich B. Sustained
efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with
ankylosing spondylitis. Clin Exp Rheumatol 2010; 28: 238-245 (2 / 2.396)
Marttila-Ichihara F, Castermans K, Auvinen K, Egbrink MGAO, Jalkanen S, Griffioen AW, Salmi M. Small-Molecule
Inhibitors of Vascular Adhesion Protein-1 Reduce the Accumulation of Myeloid Cells into Tumors and Attenuate Tumor
Growth in Mice. J Immunol 2010; 184: 3164-3173 (4 / 5.646)
Meijer GA. What makes CRCs metastasise?. Gut 2010; 59: 1164-1165 (5 / 9.357)
Meijerink MR, van Waesberghe JHTM, van Schaik C, Boven E, van der Veldt AAM, van den Tol P, Meijer S, van Kuijk C.
Perfusion Ct and Us of Colorectal Cancer Liver Metastases: A Correlative Study of Two Dynamic Imaging Modalities.
Ultrasound Med Biol 2010; 36: 1626-1636 (4 / 2.021)
Meijerink MR, van Waesberghe JHTM, Golding RP, van der Weide L, van den Tol P, Meijer S, van Kuijk C. Subtractionmultiphase-CT unbeneficial for early detection of colorectal liver metastases. Eur J Radiol 2010; 74: E133-E138 (3 /
2.645)
Meng YR, Beckett MA, Liang H, Mauceri HJ, van Rooijen N, Cohen KS, Weichselbaum RR. Blockade of Tumor Necrosis
Factor alpha Signaling in Tumor-Associated Macrophages as a Radiosensitizing Strategy. Cancer Res 2010; 70: 15341543 (5 / 7.543)
Moman MR, van der Heide UA, Kotte ANTJ, van Moorselaar RJA, Bol GH, Franken SPG, van Vulpen M. Long-term
experience with transrectal and transperineal implantations of fiducial gold markers in the prostate for position
verification in external beam radiotherapy; feasibility, toxicity and quality of life. Radiother Oncol 2010; 96: 38-42 (5
/ 4.343)
Montesinos P, Gonzalez JD, Gonzalez J, Rayon C, de Lisa E, Amigo ML, Ossenkoppele GJ, Penarrubia MJ, PerezEncinas M, Bergua J, Deben G, Sayas MJ, de la Serna J, Ribera JM, Bueno J, Milone G, Rivas C, Brunet S, Lowenberg B,
Sanz MA. Therapy-Related Myeloid Neoplasms in Patients With Acute Promyelocytic Leukemia Treated With All-TransRetinoic Acid and Anthracycline-Based Chemotherapy. J Clin Oncol 2010; 28: 3872-3879 (5 / 17.793)
Moro-Sibilot D, Vergnenegre A, Smit EF, Toy E, Parente B, Schmitz S, Kraaij K, Visseren-Grul C, Soldatenkova V,
Arellano J, Leteneux C. Second-line therapy for NSCLC in clinical practice: baseline results of the European
SELECTTION observational study. Curr Med Res Opin 2010; 26: 2661-2672 (4 / 2.498)
Mukherji SK, Castelijns JA. CT Perfusion of Head and Neck Cancer: Why We Should Care versus Why Should We Care!.
Am J Neuroradiol 2010; 31: 391-393 (4 / 3.296)
Nannizzi S, Veal GJ, Giovannetti E, Mey V, Ricciardi S, Ottley CJ, Tacca MD, Danesi R. Cellular and molecular
mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines. Cancer
Chemoth Pharm 2010; 66: 547-558 (3 / 2.654)
Neervoort FW, Van Ouwerkerk WJR, Folkersma H, Kaspers GJL, Vandertop WP. Surgical morbidity and mortality of
pediatric brain tumors: a single center audit. Childs Nerv Syst 2010; 26: 1583-1592 (2 / 1.214)
Niewerth D, Creutzig U, Bierings MB, Kaspers GJL. A review on allogeneic stem cell transplantation for newly
diagnosed pediatric acute myeloid leukemia. Blood 2010; 116: 2205-2214 (5 / 10.555)
Nowak-Sliwinska P, Wagnieres G, van den Bergh H, Griffioen AW. Angiostasis-induced vascular normalization can
improve photodynamic therapy. Cell Mol Life Sci 2010; 67: 1559-1560 (4 / 6.09)
Ong CL, Verbakel WFAR, Cuijpers JP, Slotman BJ, Lagerwaard FJ, Senan S. Stereotactic radiotherapy for peripheral
lung tumors: A comparison of volumetric modulated arc therapy with 3 other delivery techniques. Radiother Oncol
2010; 97: 437-442 (5 / 4.343)
Ong CL, Palma DA, Verbakel WFAR, Slotman BJ, Senan S. Stereotactic Body Radiotherapy (SBRT) for Stage I Lung
Cancer > 80 cm(3): Correlation of Early Toxicity with Planning Parameters. Int J Radiat Oncol 2010; 78: S502 (5 /
4.592)
Oostlander AE, Bravenboer N, Sohl E, Holzmann PJ, van der Woude CJ, Dijkstra G, et al.. Histomorphometric analysis
reveals reduced bone mass and bone formation in patients with quiescent Crohn's disease. Gastroenterology 2010;
140: 116-123 (5 / 12.899)
Palma DA, Tyldesley S, Sheehan F, Mohamed IG, Smith S, Wai E, Murray N, Senan S. Stage I Non-small Cell Lung
Cancer (NSCLC) in Patients Aged 75 Years and Older Does Age Determine Survival After Radical Treatment?. J Thorac
Oncol 2010; 5: 818-824 (4 / 4.547)
Palma DA, Visser O, Lagerwaard FJ, Belderbos J, Slotman BJ, Senan S. Impact of Introducing Stereotactic Lung
Radiotherapy for Elderly Patients With Stage I Non-Small-Cell Lung Cancer: A Population-Based Time-Trend Analysis. J
Clin Oncol 2010; 28: 5153-5159 (5 / 17.793)
Palma DA, Verbakel WFAR, Otto K, Senan S. New developments in arc radiation therapy: A review. Cancer Treat Rev
2010; 36: 393-399 (4 / 5.295)
93
Appendix 4: Scientific output
215.
216.
217.
218.
219.
220.
221.
222.
223.
224.
225.
226.
227.
228.
229.
230.
231.
232.
233.
234.
235.
236.
237.
238.
239.
240.
241.
242.
94
Paulis YWJ, Soetekouw PMMB, Verheul HMW, Tjan-Heijnen VCG, Griffioen AW. Signalling pathways in vasculogenic
mimicry. BBA-Rev Cancer 2010; 1806: 18-28 (5 / 11.685)
Peters GJ, Hodzic J, Ortega B, Giovannetti E, Adema AD, Broekhuizen R, Kaspers GJL, Hubeek I. Methylation Specific
PCR to Characterize Methylation of the Promoter of Deoxycytidine Kinase. Nucleos Nucleot Nucl 2010; 29: 408-413 (1
/ 0.768)
Peters MJL, Voskuyl AE, Sattar N, Dijkmans BAC, Smulders YM, Nurmohamed MT. The interplay between
inflammation, lipids and cardiovascular risk in rheumatoid arthritis: why ratios may be better. Int J Clin Pract 2010;
64: 1440-1443 (4 / 2.245)
Peters MJL, Watt P, Cherry L, Welsh P, Henninger E, Dijkmans BAC, McInnes IB, Nurmohamed MT, Sattar N. Lack of
effect of TNF alpha blockade therapy on circulating adiponectin levels in patients with autoimmune disease: results
from two independent prospective studies. Ann Rheum Dis 2010; 69: 1687-1690 (5 / 8.111)
Peters MJL, Welsh P, McInnes IB, Wolbink GJJ, Dijkmans BAC, Sattar N, Nurmohamed MT. Tumour necrosis factor a
blockade reduces circulating N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid
arthritis: results from a prospective cohort study. Ann Rheum Dis 2010; 69: 1281-1285 (5 / 8.111)
Peters MJL, Visman I, Nielen MMJ, van Dillen N, Verheij RA, van der Horst-Bruinsma I, Dijkmans BAC, Nurmohamed
MT. Ankylosing spondylitis: a risk factor for myocardial infarction?. Ann Rheum Dis 2010; 69: 579-581 (5 / 8.111)
Peters MJL, Symmons DPM, McCarey D, Dijkmans BAC, Nicola P, Kvien TK, McInnes IB, Haentzschel H, Gonzalez-Gay
MA, Provan S, Semb A, Sidiropoulos P, Kitas G, Smulders YM, Soubrier M, Szekanecz Z, Sattar N, Nurmohamed MT.
EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis
and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69: 325-331 (5 / 8.111)
Peters MJL, van Eijk IC, Smulders YM, Serne EH, Dijkmans BAC, van der Horst-Bruinsma I, Nurmohamed MT. Signs of
Accelerated Preclinical Atherosclerosis in Patients with Ankylosing Spondylitis. J Rheumatol 2010; 37: 161-166 (3 /
3.854)
Peters MJL, Voskuyl AE, Smulders YM, Dijkmans BAC, Nurmohamed MT. Rheumatoid arthritis and diabetes mellitus:
two faces of one coin? Comment on the article by Peters et al Reply. Arthrit Rheum-Arthr 2010; 62: 1202 (3 / 4.152)
Rasch CRN, Hauptmann M, Schornagel J, Wijers O, Buter J, Gregor T, Wiggenraad R, de Boer JP, Ackerstaff AH,
Kroger R, Hoebers FJP, Balm AJM. Intra-arterial Versus Intravenous Chemoradiation for Advanced Head and Neck
Cancer: Results of a Randomized Phase 3 Trial. Cancer 2010; 116: 2159-2165 (4 / 5.418)
Raterman HG, van Eijk IC, Voskuyl AE, Peters MJL, Dijkmans BAC, van Halm VP, Simsek S, Lems WF, Nurmohamed MT.
The metabolic syndrome is amplified in hypothyroid rheumatoid arthritis patients: a cross-sectional study. Ann Rheum
Dis 2010; 69: 39-42 (5 / 8.111)
Regelink JC, van Roessel CHM, van Galen KPM, Ossenkoppele GJ, Huijgens PC, Zweegman S. Long-Term Follow-Up of
Tandem Autologous Stem-Cell Transplantation in Multiple Myeloma. J Clin Oncol 2010; 28: E741-E743 (5 / 17.793)
Regelink JC, Tack GJ, Huijgens PC, Mulder CJJ, Janssen JJWM, Visser O. Disappointing outcome of allogeneic
hematopoietic SCT in two EATL patients. Bone Marrow Transpl 2010; 45: 959-960 (3 / 2.998)
Rijnsburger AJ, Obdeijn IM, Kaas R, Tilanus-Linthorst MM, Boetes C, Loo CE, Wasser MN, Bergers E, Kok T, Muller SH,
Peterse H, Tollenaar RA, Hoogerbrugge N, Meijer S, Bartels CC, Seynaeve C, Hooning MJ, Kriege M, Schmitz PI,
Oosterwijk JC, .. et al …. BRCA1-associated breast cancers present differently from BRCA2-associated and familial
cases: long-term follow-up of the Dutch MRISC Screening Study. J Clin Oncol 2010; 28: 5265-5273 (5 / 17.793)
Rodjan F, de Graaf P, Moll AC, Imhof SM, Verbeke JIML, Sanchez E, Castelijns JA. Brain Abnormalities on MR Imaging
in Patients with Retinoblastoma. Am J Neuroradiol 2010; 31: 1385-1389 (4 / 3.296)
Rostami-Nejad M, Rostami K, Sanaei M, Mohebbi SR, Al-Dulaimi D, Nazemalhosseini-Mojarad E, Collin P, Mulder CJ,
Zali MR. Rotavirus and coeliac autoimmunity among adults with non-specific gastrointestinal symptoms. Saudi Med J
2010; 31(8): 891-894 (1 / 0.51)
Sander A, Zimmermann M, Dworzak M, Fleischhack G, von Neuhoff C, Reinhardt D, Kaspers GJL, Creutzig U.
Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379
patients of three consecutive AML-BFM trials. Leukemia 2010; 24: 1422-1428 (5 / 8.296)
Schaapveld M, Visser O, Siesling S, Schaar CG, Zweegman S, Vellenga E. Improved survival among younger but not
among older patients with Multiple Myeloma in the Netherlands, a population-based study since 1989. Eur J Cancer
2010; 46: 160-169 (3 / 4.121)
Scheepers JJG, van der Peet DL, Veenhof AAFA, Heijnen B, Cuesta MA. Systematic approach of postoperative gastric
conduit complications after esophageal resection. Dis Esophagus 2010; 23: 117-121 (2 / 1.493)
Schoonbeek A, Monshouwer R, Hanssens P, Raaijmakers E, Nowak P, Marijnissen JPA, Lagerwaard FJ, Cuijpers JP,
Vonk EJA, van der Maazen RWM. Intracranial Radiosurgery in the Netherlands. A Planning Comparison of Available
Systems with Regard to Physical Aspects and Workload. Technol Cancer Res T 2010; 9: 279-289 (2 / 2.023)
Schuurmans M, Bromberg JEC, Doorduijn J, Poortmans P, Taphoorn MJB, Seute T, Enting R, van Imhoff G, van Norden
Y, van den Bent MJ. Primary central nervous system lymphoma in the elderly: a multicentre retrospective analysis.
Brit J Haematol 2010; 151: 179-184 (4 / 4.597)
Seinen ML, Van Asseldonk DP, Mulder CJJ, De Boer NKH. Dosing 6-Thioguanine in Inflammatory Bowel Disease: ExpertBased Guidelines for Daily Practice. J Gastrointest Liver 2010; 19: 291-294 (1 / 1.265)
Senan S, Lagerwaard FJ. Stereotactic radiotherapy for stage I lung cancer: Current results and new developments.
Cancer Radiother 2010; 14: 115-118 (2 / 1.438)
Sietses C, Meijerink MR, Meijer S, van den Tol MP. The impact of intraoperative ultrasonography on the surgical
treatment of patients with colorectal liver metastases. Surg Endosc 2010; 24: 1917-1922 (4 / 3.307)
Sigmond J, Bergman AM, Leon LG, Loves WJP, Hoebe EK, Peters GJ. Staurosporine increases toxicity of gemcitabine in
non-small cell lung cancer cells: role of protein kinase C, deoxycytidine kinase and ribonucleotide reductase. AntiCancer Drug 2010; 21: 591-599 (2 / 2.23)
Sikkens ECM, Schreuder TCMA, Fronczek J, Mulder CJJ, Bouma G. Lymphocytic Myopericarditis in a Patient With
Previously Undiagnosed Crohn's Disease. Am J Gastroenterol 2010; 105: 236-237 (5 / 6.012)
Smit EF, Dingemans AMC, Thunnissen FBJM, Hochstenbach MM, van Suylen RJ, Postmus PE. Sorafenib in Patients with
Advanced Non-small Cell Lung Cancer that Harbor K-Ras Mutations A Brief Report. J Thorac Oncol 2010; 5: 719-720 (4
/ 4.547)
Soffietti R, Baumert BG, Bello L, von Deimling A, Duffau H, Frenay M, Grisold W, Grant R, Graus F, Hoang-Xuan K,
Klein M, Melin B, Rees J, Siegal T, Smits A, Stupp R, Wick W. Guidelines on management of low-grade gliomas: report
of an EFNS-EANO* Task Force. Eur J Neurol 2010; 17: 1124-1133 (3 / 2.51)
Appendix 4: Scientific output
243.
244.
245.
246.
247.
248.
249.
250.
251.
252.
253.
254.
255.
256.
257.
258.
259.
260.
261.
262.
263.
264.
265.
266.
267.
Soria JC, Smit EF, Khayat D, Besse B, Yang XQ, Hsu CP, Reese D, Wiezorek J, Blackhall F. Phase 1b Study of
Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in
Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer. J Clin Oncol 2010; 28: 1527-1533 (5 / 17.793)
Spoelstra FOB, Senan S, Le Pechoux C, Ishikura S, Casas F, Ball D, Price A, de Ruysscher D, de Koste JRV. Variations in
Target Volume Definition for Postoperative Radiotherapy in Stage Iii Non-Small-Cell Lung Cancer: Analysis of An
International Contouring Study. Int J Radiat Oncol 2010; 76: 1106-1113 (5 / 4.592)
Steingrover R, Garcia EF, van Valkengoed IGM, Bekker V, Bezemer D, Kroon FP, Dekker L, Prins M, de Wolf F, Lange
JMA, Prins JM. Transient Lowering of the Viral Set Point After Temporary Antiretroviral Therapy of Primary HIV Type 1
Infection. AIDS Res Hum Retrov 2010; 26: 379-387 (2 / 2.178)
Surmont V, Smit EF, de Jonge M, Aerts JG, Nackaerts K, Vernhout R, Gras J, van Wijk A, Phernambucq ECJ, van
Meerbeeck JP, Senan S, Kraaij CJ, Chouaki N, Praag J, van Klaveren RJ. Pemetrexed and cisplatin with concurrent
radiotherapy for locally advanced non-small cell and limited disease small cell lung cancer: Results from 2 phase I
studies. Lung Cancer 2010; 69: 302-306 (4 / 3.14)
Sutherland MK, Yu CP, Anderson M, Zeng WP, van Rooijen N, Sievers EL, Grewal IS, Law CL. 5-azacytidine enhances
the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia. MABS 2010; 2:
440-448 (1 / 0.0)
Tack GJ, Verbeek WHM, Schreurs MWJ, Mulder CJJ. The spectrum of celiac disease: epidemiology, clinical aspects
and treatment. Nat Rev Gastro Hepat 2010; 7: 204-213 (1 / 0.0)
Tallen G, Ratei R, Mann G, Kaspers GJL, Niggli F, Karachunsky A, Ebell W, Escherich G, Schrappe M, Klingebiel T,
Fengler R, Henze G, von Stackelberg A. Long-Term Outcome in Children With Relapsed Acute Lymphoblastic Leukemia
After Time-Point and Site-of-Relapse Stratification and Intensified Short-Course Multidrug Chemotherapy: Results of
Trial ALL-REZ BFM 90. J Clin Oncol 2010; 28: 2339-2347 (5 / 17.793)
Tate MD, Pickett DL, van Rooijen N, Brooks AG, Reading PC. Critical Role of Airway Macrophages in Modulating
Disease Severity during Influenza Virus Infection of Mice. J Virol 2010; 84: 7569-7580 (4 / 5.15)
Temmink OH, Bijnsdorp IV, Prins HJ, Losekoot N, Adema AD, Smid K, Honeywell RJ, Ylstra B, Eijk PP, Fukushima M,
Peters GJ. Trifluorothymidine Resistance Is Associated with Decreased Thymidine Kinase and Equilibrative Nucleoside
Transporter Expression or Increased Secretory Phospholipase A2. Mol Cancer Ther 2010; 9: 1047-1057 (4 / 4.953)
Thijssen VL, Barkan B, Shoji H, Aries IM, Mathieu V, Deltour L, Hackeng TM, Kiss R, Kloog Y, Poirier F, Griffioen AW.
Tumor Cells Secrete Galectin-1 to Enhance Endothelial Cell Activity. Cancer Res 2010; 70: 6216-6224 (5 / 7.543)
Thurlings RM, Boumans M, Tekstra J, van Roon JA, Vos K, van Westing DM, van Baarsen LGM, Bos C, Kirou KA, Gerlag
DM, Crow MK, Bijlsma JW, Verweij CL, Tak PP. Relationship Between the Type I Interferon Signature and the
Response to Rituximab in Rheumatoid Arthritis Patients. Arthrit Rheum-Arthr 2010; 62: 3607-3614 (3 / 4.152)
Toffalorio F, Giovannetti E, De Pas T, Radice D, Pelosi G, Manzotti M, Minocci D, Spaggiari L, Spitaleri G, Noberasco C,
Catania C, Boselli S, Danesi R, de Braud F. Expression of gemcitabine- and cisplatin-related genes in non-small-cell
lung cancer. Pharmacogenomics J 2010; 10: 180-190 (4 / 4.398)
Uyl-de Groot CA, Senft A, de Bree R, Leemans CR, Hoekstra OS. Chest CT and Whole-Body F-18-FDG PET Are CostEffective in Screening for Distant Metastases in Head and Neck Cancer Patients. J Nucl Med 2010; 51: 176-182 (5 /
6.424)
Van Asseldonk DP, De Boer NKH, Smid K, Mulder CJJ, Van Bodegraven AA, Peters GJ. Limited Intra-Individual
Variability in Hypoxanthine-Guanine Phosphoribosyl Transferase, Thiopurine S-Methyl Transferase, and Xanthine
Oxidase Activity in Inflammatory Bowel Disease Patients During 6-Thioguanine Therapy. Nucleos Nucleot Nucl 2010;
29: 284-290 (1 / 0.768)
van Assen S, Holvast A, Benne CA, Posthumus MD, van Leeuwen MA, Voskuyl AE, Blom M, Risselada AP, de Haan A,
Westra J, Kallenberg CGM, Bijl M. Humoral Responses After Influenza Vaccination Are Severely Reduced in Patients
With Rheumatoid Arthritis Treated With Rituximab. Arthrit Rheum-Arthr 2010; 62: 75-81 (3 / 4.152)
van Baarsen LGM, Wijbrandts CA, Gerlag DM, Rustenburg F, Kraan TCTM, Dijkmans BAC, Tak PP, Verweij CL.
Pharmacogenomics of infliximab treatment using peripheral blood cells of patients with rheumatoid arthritis. Genes
Immun 2010; 11: 622-629 (4 / 4.222)
van Baarsen LGM, Bos WH, Rustenburg F, Kraan TCTM, Wolbink GJJ, Dijkmans BAC, van Schaardenburg D, Verweij CL.
Gene Expression Profiling in Autoantibody-Positive Patients With Arthralgia Predicts Development of Arthritis. Arthrit
Rheum-Arthr 2010; 62: 694-704 (3 / 4.152)
van Baarsen LGM, Wijbrandts CA, Rustenburg F, Cantaert T, Kraan TCTM, Baeten DL, Dijkmans BAC, Tak PP, Verweij
CL. Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with
clinical response to treatment. Arthritis Res Ther 2010; 12: art.nr. R11 (4 / 4.271)
van Baarsen LGM, Wijbrandts CA, Timmer TCG, Kraan TCTM, Tak PP, Verweij CL. Synovial Tissue Heterogeneity in
Rheumatoid Arthritis in Relation to Disease Activity and Biomarkers in Peripheral Blood. Arthrit Rheum-Arthr 2010;
62: 1602-1607 (3 / 4.152)
van Cleef BAGL, Broens EM, Voss A, Huijsdens XW, Zuchner L, van Benthem BHB, Kluytmans JAJW, Mulders MN, van de
Giessen AW. High prevalence of nasal MRSA carriage in slaughterhouse workers in contact with live pigs in The
Netherlands. Epidemiol Infect 2010; 138: 756-763 (4 / 2.365)
van Cleef BAGL, Verkade EJM, Wulf MWH, Buiting AG, Voss A, Huijsdens XW, van Pelt W, Mulders MN, Kluytmans
JAJW. Prevalence of Livestock-Associated MRSA in Communities with High Pig-Densities in The Netherlands. Plos one
2010; 5(2): art.nr. e9385 (4 / 4.351)
van Cruijsen H, Voest EE, Punt CJA, Hoekman K, Witteveen PO, Meijerink MR, Puchalski TA, Robertson J, Saunders O,
Jurgensmeier JM, van Herpen CML, Giaccone G. Phase I evaluation of cediranib, a selective VEGFR signalling
inhibitor, in combination with gefitinib in patients with advanced tumours. Eur J Cancer 2010; 46: 901-911 (3 / 4.121)
van Dam IE, de Koste JRV, Hanna GG, Muirhead R, Slotman BJ, Senan S. Improving target delineation on 4dimensional CT scans in stage I NSCLC using a deformable registration tool. Radiother Oncol 2010; 96: 67-72 (5 /
4.343)
van de Water JMW, Cillessen SAGM, Visser OJ, Verbeek WHM, Meijer CJLM, Mulder CJJ. Enteropathy associated T-cell
lymphoma and its precursor lesions. Best Pract Res Clin Ga 2010; 24: 43-56 (3 / 2.48)
van den Ancker W, van Luijn MM, Westers TM, Bontkes HJ, Ruben JM, de Gruijl TD, Ossenkoppele GJ, van de
Loosdrecht AA. Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual
disease in acute myeloid leukemia. Immunotherapy 2010; 2: 69-83 (1 / 0.0)
95
Appendix 4: Scientific output
268.
269.
270.
271.
272.
273.
274.
275.
276.
277.
278.
279.
280.
281.
282.
283.
284.
285.
286.
287.
288.
289.
290.
291.
292.
293.
96
van den Ancker W, Terwijn M, Westers TM, Merle PA, van Beckhoven E, Drager AM, Ossenkoppele GJ, van de
Loosdrecht AA. Acute leukemias of ambiguous lineage: diagnostic consequences of the WHO2008 classification.
Leukemia 2010; 24: 1392-1396 (5 / 8.296)
van den Berg L, Delemarre-van de Waa H, Han JC, Ylstra B, Eijk P, Nesterova M, Heutink P, Stratakis CA. Investigation
of a Patient With a Partial Trisomy 16q Including the Fat Mass and Obesity Associated Gene (FTO): Fine Mapping and
FTO Gene Expression Study. Am J Med Genet A 2010; 152A: 630-637 (2 / 2.404)
van den Berg MH, Van Dulmen-den Broeder E, Overbeek A, Twisk JWR, Schats R, van Leeuwen FE, Kaspers GJL,
Lambalk CB. Comparison of ovarian function markers in users of hormonal contraceptives during the hormone-free
interval and subsequent natural early follicular phases. Hum Reprod 2010; 25: 1520-1527 (5 / 3.859)
van der Bij GJ, Bogels M, Otten MA, Oosterling SJ, Kuppen PJ, Meijer S, Beelen RHJ, van Egmond M. Experimentally
induced liver metastases from colorectal cancer can be prevented by mononuclear phagocyte-mediated monoclonal
antibody therapy. J Hepatol 2010; 53: 677-685 (5 / 7.818)
van der Goes MC, Jacobs JWG, Boers M, Andrews T, Blom-Bakkers MAM, Buttgereit F, Caeyers N, Cutolo M, Da Silva
JAP, Guillevin L, Kirwan JR, Rovensky J, Severijns G, Webber S, Westhovens R, Bijlsma JWJ. Monitoring adverse
events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum
Dis 2010; 69: 1913-1919 (5 / 8.111)
van der Goes MC, Jacobs JWG, Boers M, Andrews T, Blom-Bakkers MAM, Buttgereit F, Caeyers N, Choy EH, Cutolo M,
Da Silva JAP, Guillevin L, Holland M, Kirwan JR, Rovensky J, Saag KG, Severijns G, Webber S, Westhovens R, Bijlsma
JWJ. Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the
European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid
therapy in rheumatic diseases. Ann Rheum Dis 2010; 69: 1015-1021 (5 / 8.111)
Van der Leeden M, Dahmen R, Ursum J, Roorda LD, van Schaardenburg D, Knol DL, Dekker J, Steultjens MPM.
Prediction of Walking Disability by Disease-Related Factors in Patients with Rheumatoid Arthritis. J Rehabil Med 2010;
42: 506-510 (4 / 1.882)
van der Pas MHGM, van Dongen GAMS, Cailler F, Pelegrin A, Meijerink WJHJ. Sentinel node procedure of the sigmoid
using indocyanine green: feasibility study in a goat model. Surg Endosc 2010; 24: 2182-2187 (4 / 3.307)
van der Putten L, de Bree R, Kuik DJ, Rietveld DHF, Langendijk JA, Leemans CR. Hypopharyngeal carcinoma after
radiation for tuberculosis: Radiation-induced carcinoma. Oral Oncol 2010; 46: 672-677 (5 / 3.123)
van der Rhee JI, Mooi WJ, Kukutsch NA, De Snoo FA, Bergman W. Iatrogenic melanoma. Comment on: Melanoma
epidemic: a midsummer night's dream?. Brit J Dermatol 2010; 162: 457-458 (5 / 4.26)
van der Velden VHJ, Sluijs-Geling A, Gibson BES, Marvelde JGT, Hoogeveen PG, Hop WCJ, Wheatley K, Bierings MB,
Schuurhuis GJ, de Graaf SSN, van Wering ER, van Dongen JJM. Clinical significance of flowcytometric minimal residual
disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12
protocol. Leukemia 2010; 24: 1599-1606 (5 / 8.296)
van der Veldt AAM, Meijerink MR, van den Eertwegh AJM, Haanen JBAG, Boven E. Choi response criteria for early
prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Brit J Cancer 2010;
102: 803-809 (4 / 4.346)
van der Veldt AAM, Meijerink MR, van den Eertwegh AJM, Boven E. Targeted therapies in renal cell cancer: recent
developments in imaging. Target Oncol 2010; 5: 95-112 (1 / 0.455)
van der Veldt AAM, de Boer MP, Boven E, Eringa EC, van den Eertwegh AJM, van Hinsbergh VWM, Smulders YM, Serne
EH. Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib. AntiCancer Drug 2010; 21: 439-446 (2 / 2.23)
van der Vorst MJDL, Bleeker MCG, Boven E. Unusual Presentation of Granulosa Cell Tumor of the Ovary. J Clin Oncol
2010; 28: E554-E556 (5 / 17.793)
van der Waal I, de Bree R. Second primary tumours in oral cancer. Oral Oncol 2010; 46: 426-428 (5 / 3.123)
van der Waal I. Potentially malignant disorders of the oral and oropharyngeal mucosa; present concepts of
management. Oral Oncol 2010; 46: 423-425 (5 / 3.123)
van der Woude CJ, Stokkers P, Van Bodegraven AA, Van Assche G, Hebzda Z, Paradowski L, D'Haens G, Ghosh S,
Feagan B, Rutgeerts P, Dijkstra G, de Jong DJ, Oldenburg B, Farhan M, Richard T, Dean Y, Hommes DW. Phase I,
Double-blind, Randomized, Placebo-controlled, Dose-escalation Study of NI-0401 (a Fully Human Anti-CD3 Monoclonal
Antibody) in Patients with Moderate to Severe Active Crohn's Disease. Inflamm Bowel Dis 2010; 16: 1708-1716 (4 /
4.643)
van Dongen GAMS, Vosjan MJWD. Immuno-Positron Emission Tomography: Shedding Light on Clinical Antibody
Therapy. Cancer Biother Radio 2010; 25: 375-385 (2 / 1.443)
van Eijk IC, Tushuizen ME, Sturk A, Dijkmans BAC, Boers M, Voskuyl AE, Diamant M, Wolbink GJJ, Nieuwland R,
Nurmohamed MT. Circulating microparticles remain associated with complement activation despite intensive antiinflammatory therapy in early rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1378-1382 (5 / 8.111)
van Erp NP, Mathijssen RHJ, van der Veldt AAM, Haanen JB, Reyners AKL, Eechoute K, Boven E, Wessels JAM,
Guchelaar HJ, Gelderblom H. Myelosuppression by sunitinib is flt-3 genotype dependent. Brit J Cancer 2010; 103: 757758 (4 / 4.346)
van Geenen EJM, Smits MM, Schreuder TCMA, van der Peet DL, Bloemena E, Mulder CJJ. Nonalcoholic Fatty Liver
Disease Is Related to Nonalcoholic Fatty Pancreas Disease. Pancreas 2010; 39: 1185-1190 (3 / 2.733)
van Geenen EJM, Mulder CJJ, van der Peet DL, Fockens P, Bruno MJ. Endoscopic treatment of acute biliary
pancreatitis: A national survey among Dutch gastroenterologists. Scand J Gastroentero 2010; 45: 1116-1120 (2 /
2.084)
van Geenen EJM, De Boer NKH, Stassen P, Linskens RK, Bruno MJ, Mulder CJJ, Stegeman CA, Van Bodegraven AA.
Azathioprine or mercaptopurine-induced acute pancreatitis is not a disease-specific phenomenon. Aliment Pharmacol
Ther 2010; 31: 1322-1329 (4 / 4.357)
van Heijl M, Omloo JM, Henegouwen MIV, van Lanschot JJ, Sloof GW, Boellaard R. Influence of ROI definition, partial
volume correction and SUV normalization on SUV-survival correlation in oesophageal cancer. Nucl Med Commun 2010;
31: 652-658 (2 / 1.315)
van Kuijk AWR, de Groot M, Stapel SO, Dijkmans BAC, Wolbink GJJ, Tak PP. Relationship between the clinical
response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with
psoriatic arthritis. Ann Rheum Dis 2010; 69: 624-U187 (5 / 8.111)
Appendix 4: Scientific output
294.
295.
296.
297.
298.
299.
300.
301.
302.
303.
304.
305.
306.
307.
308.
309.
310.
311.
312.
313.
314.
315.
316.
317.
318.
van Nifterik KA, Van Den Berg J, van der Meide WF, Ameziane N, Wedekind LE, Steenbergen RDM, Leenstra S, Lafleur
MVM, Slotman BJ, Stalpers LJA, Sminia P. Absence of the MGMT protein as well as methylation of the MGMT promoter
predict the sensitivity for temozolomide. Brit J Cancer 2010; 103: 29-35 (4 / 4.346)
van Schaardenburg D, Dijkmans BAC. A welcome address for the new criteria. Ann Rheum Dis 2010; 69: 1577-1579 (5 /
8.111)
van Spil WE, DeGroot J, Lems WF, Oostveen JCM, Lafeber FPJG. Serum and urinary biochemical markers for knee and
hip-osteoarthritis: a systematic review applying the consensus BIPED criteria. Osteoarthr Cartilage 2010; 18: 605-612
(5 / 3.888)
van Tuyl LHD, Felson DT, Wells G, Smolen J, Zhang B, Boers M. Evidence for Predictive Validity of Remission on LongTerm Outcome in Rheumatoid Arthritis: A Systematic Review. Arthrit Rheum-Arthr 2010; 62: 108-117 (3 / 4.152)
van Tuyl LHD, Boers M, Lems WF, Landewe RBM, Han H, van der Linden S, van de Laar M, Westhovens R, van
Denderen JC, Westedt ML, Peeters AJ, Jacobs P, Huizinga TWJ, van de Brink H, Dijkmans BAC, Voskuyl AE. Survival,
comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Ann
Rheum Dis 2010; 69: 807-812 (5 / 8.111)
van Ufford HMEQ, van Tinteren H, Stroobants SG, Riphagen II, Hoekstra OS. Added Value of Baseline F-18-FDG Uptake
in Serial F-18-FDG PET for Evaluation of Response of Solid Extracerebral Tumors to Systemic Cytotoxic Neoadjuvant
Treatment: A Meta-Analysis. J Nucl Med 2010; 51: 1507-1516 (5 / 6.424)
van Vollenhoven RF, Houbiers JGA, Buttgereit F, in't Hout J, Boers M, Leij S, Kvien TK, Dijkmans BAC, Szczepanski L,
Szombati I, Sierakowski S, Miltenburg AMM. The Selective Estrogen Receptor alpha Agonist Org 37663 Induces
Estrogenic Effects but Lacks Antirheumatic Activity. Arthrit Rheum-Arthr 2010; 62: 351-358 (3 / 4.152)
van Vonderen MGA, Blumer RME, Hassink EAM, Sutinen J, Ackermans MT, van Agtmael MA, Yki-Jarvinen H, Danner SA,
Serlie MJ, Sauerwein HP, Reiss P. Insulin Sensitivity in Multiple Pathways Is Differently Affected During
Zidovudine/Lamivudine-Containing Compared With NRTI-Sparing Combination Antiretroviral Therapy. Jaids 2010; 53:
186-193 (4 / 4.207)
Van Weyenberg SJ, Van Turenhout ST, Bouma G, van Waesberghe JH, van der Peet DL, Mulder CJ, Jacobs MA. Doubleballoon endoscopy as the primary method for small-bowel video capsule endoscope retrieval. Gastrointest Endosc
2010; 71: 535-541 (5 / 6.713)
Vasen HFA, Abdirahman M, Brohet R, Langers AMJ, Kleibeuker JH, van Kouwen M, Koornstra JJ, Boot H, Cats A,
Dekker E, Sanduleanu S, Poley JW, Hardwick JCH, Cappel WHDT, van der Meulen-de Jong A, Tan TG, Jacobs MAJM,
Mohamed FLA, de Boer SY, van de Meeberg. One to 2-Year Surveillance Intervals Reduce Risk of Colorectal Cancer in
Families With Lynch Syndrome. Gastroenterology 2010; 138: 2300-2306 (5 / 12.899)
Veening MA, Verbeke JI, Witbreuk MM, Kaspers GJL. Kaposiform (Spindle Cell) Hemangioendotelioma in a Child With
an Unusual Presentation. J Pediatr Hematol Oncol 2010; 32: 240-242 (2 / 1.022)
Veerman AJP, Kaspers GJL. Towards individualised treatment in childhood leukaemia. Lancet Oncol 2010; 11: 502-503
(5 / 14.47)
Verbakel WFAR, Lagerwaard FJ, Verduin AJE, Heukelom S, Slotman BJ, Cuijpers JP. The accuracy of frameless
stereotactic intracranial radiosurgery. Radiother Oncol 2010; 97: 390-394 (5 / 4.343)
Vergeer MR, Doornaert PAH, Jonkman A, Kaanders JHAM, van den Ende PLA, de Jong MA, Leemans CR, Slotman BJ,
Langendijk JA. Ipsilateral Irradiation for Oral and Oropharyngeal Carcinoma Treated with Primary Surgery and
Postoperative Radiotherapy. Int J Radiat Oncol 2010; 78: 682-688 (5 / 4.592)
Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RHM, van der Burg MEL, Lacave AJ,
Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GCE, Pecorelli S, Reed NS. Neoadjuvant
Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer. N Engl J Med 2010; 363: 943-953 (5 / 47.05)
Verhagen AF, Bulten J, Shirango H, Thunnissen FBJM, van der Drift MA, van der Bruggen W, Tjan-Heijnen VCG, van
Swieten HA. The Clinical Value of Lymphatic Micrometastases in Patients with Non-small Cell Lung Cancer. J Thorac
Oncol 2010; 5: 1201-1205 (4 / 4.547)
Verhoeff JJC, Lavini C, van Linde ME, Stalpers LJA, Majoie CBLM, Reijneveld JC, van Furth WR, Richel DJ.
Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. Ann Oncol 2010; 21: 1723-1727 (4 /
5.647)
Verkade EJM, Verhulst CJMM, Huijsdens XW, Kluytmans JAJW. In vitro activity of tigecycline against methicillinresistant Staphylococcus aureus, including livestock-associated strains. Eur J Nucl Med Mol I 2010; 29: 503-507 (5 /
4.531)
Villaran RF, Espinosa-Oliva AM, Sarmiento M, de Pablos RM, Arguelles S, Delgado-Cortes MJ, Sobrino V, van Rooijen N,
Venero JL, Herrera AJ, Cano J, Machado A. Ulcerative colitis exacerbates lipopolysaccharide-induced damage to the
nigral dopaminergic system: potential risk factor in Parkinson's disease. J Neurochem 2010; 114: 1687-1700 (3 /
3.999)
Visser K, Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Ronday HK, Seys PEH, Kerstens PJSM, Huizinga TWJ,
Dijkmans BAC, Allaart CF. A matrix risk model for the prediction of rapid radiographic progression in patients with
rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. Ann
Rheum Dis 2010; 69: 1333-1337 (5 / 8.111)
Voortman J, Goto A, Mendiboure J, Sohn JJ, Schetter AJ, Saito M, Dunant A, Pham TC, Petrini I, Lee A, Khan MA,
Hainaut P, Pignon JP, Brambilla E, Popper HH, Filipits M, Harris CC, Giaccone G. MicroRNA Expression and Clinical
Outcomes in Patients Treated with Adjuvant Chemotherapy after Complete Resection of Non-Small Cell Lung
Carcinoma. Cancer Res 2010; 70: 8288-8298 (5 / 7.543)
Vroling L, Lind JSW, de Haas RR, Verheul HMW, van Hinsbergh VWM, Broxterman HJ, Smit EF. CD133(+) circulating
haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients.
Brit J Cancer 2010; 102: 268-275 (4 / 4.346)
Waaijman T, Breetveld M, Ulrich M, Middelkoop E, Scheper RJ, Gibbs S. Use of A Collagen/Elastin Matrix As Transport
Carrier System to Transfer Proliferating Epidermal Cells to Human Dermis in Vitro. Wound Repair Regen 2010; 18: 089
(4 / 2.781)
Walenkamp AME, Bestebroer J, Boer IGJ, Kruizinga R, Verheul HMW, van Strijp JAG, de Haas CJC. Staphylococcal SSL5
binding to human leukemia cells inhibits cell adhesion to endothelial cells and platelets. Cell Oncol 2010; 32: 1-10 (4
/ 4.169)
Wang H, Douw L, Hernandez JM, Reijneveld JC, Stam CJ, Van Mieghem P. Effect of tumor resection on the
characteristics of functional brain networks. Phys Rev E 2010; 82(2): art.nr. 021924 (4 / 2.4)
97
Appendix 4: Scientific output
319.
320.
321.
322.
323.
324.
325.
326.
327.
328.
329.
330.
331.
332.
Wassenberg MWM, Kluytmans JAJW, Box ATA, Bosboom RW, Buiting AGM, van Elzakker EPM, Melchers WJG, van Rijen
MML, Thijsen SFT, Troelstra A, Vandenbroucke-Grauls CMJE, Visser CE, Voss A, Wolffs PFG, Wulf MWH, van Zwet AA,
de Wit GA, Bonten MJM. Rapid screening of methicillin-resistant Staphylococcus aureus using PCR and chromogenic
agar: a prospective study to evaluate costs and effects. Clin Microbiol Infec 2010; 16: 1754-1761 (4 / 4.014)
Westers TM, Alhan C, Chamuleau MED, van der Vorst MJDL, Eeltink C, Ossenkoppele GJ, van de Loosdrecht AA.
Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting
response to growth factor treatment. Blood 2010; 115: 1779-1784 (5 / 10.555)
Westgeest HM, Akol H, Schreuder TCMA. Pure naratriptan-induced ischemic colitis: A case report. Turk J
Gastroenterol 2010; 21: 42-44 (1 / 0.484)
Wever K, van Agtmael MA, Carr A. Incomplete Reversibility of Tenofovir-Related Renal Toxicity in HIV-Infected Men.
Jaids 2010; 55: 78-81 (4 / 4.207)
Wiering B, Adang EMM, van der Sijp JRM, Roumen RM, de Jong KP, Comans EFI, Pruim J, Dekker HM, Ruers TJM,
Krabbe PFM, Oyen WJG. Added value of positron emission tomography imaging in the surgical treatment of colorectal
liver metastases. Nucl Med Commun 2010; 31: 938-944 (2 / 1.315)
Wolters VM, Alizadeh BZ, Weijerman ME, Zhernakova A, Van Hoogstraten IMW, Mearin ML, Wapenaar MC, Wijmenga C,
Schreurs MWJ. Intestinal barrier gene variants may not explain the increased levels of antigliadin antibodies,
suggesting other mechanisms than altered permeability. Hum Immunol 2010; 71: 392-396 (2 / 2.55)
Wu J, Xia B, von Blomberg BME, Zhao C, Yang XW, Crusius JBA, Pena AS. Coeliac disease in China, a field waiting for
exploration. Rev Esp Enferm Dig 2010; 102: 472-477 (1 / 0.994)
Wu J, Xia B, von Blomberg BME, Zhao C, Yang XW, Crusius JBA, Pena AS. Coeliac disease: emerging in China?. Gut
2010; 59: 418-419 (5 / 9.357)
Wunderlich FT, Strohle P, Konner AC, Gruber S, Tovar S, Bronneke HS, Juntti-Berggren L, Li LS, van Rooijen N, Libert
C, Berggren PO, Bruning JC. Interleukin-6 Signaling in Liver-Parenchymal Cells Suppresses Hepatic Inflammation and
Improves Systemic Insulin Action. Cell Metab 2010; 12: 237-249 (5 / 17.35)
Zecha JAEM, Mendes RA, Lindeboom VB, van der Waal I. Recurrence rate of keratocystic odontogenic tumor after
conservative surgical treatment without adjunctive therapies - A 35-year single institution experience. Oral Oncol
2010; 46: 740-742 (5 / 3.123)
Zucali PA, Giovannetti E, Assaraf YG, Ceresoli GL, Peters GJ, Santoro A. New tricks for old biomarkers: thymidylate
synthase expression as a predictor of pemetrexed activity in malignant mesothelioma. Ann Oncol 2010; 21: 1560-1561
(4 / 5.647)
Zuurbier L, Homminga I, Calvert V, Winkel MLT, Buijs-Gladdines JGCA, Kooi C, Smits WK, Sonneveld E, Veerman AJP,
Kamps WA, Horstmann M, Petricoin EF, Pieters R, Meijerink JPP. NOTCH1 and/or FBXW7 mutations predict for initial
good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients
treated on DCOG or COALL protocols. Leukemia 2010; 24: 2014-2022 (5 / 8.296)
Zwaan CM, Reinhardt D, Zimmerman M, Hasle H, Stary J, Stark B, Dworzak M, Creutzig U, Kaspers GJL. Salvage
treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab
ozogamicin: results of a phase II study. Brit J Haematol 2010; 148: 768-776 (4 / 4.597)
Zwijnenburg PJG, Meijers-Heijboer EJ, Boomsma DI. Identical But Not the Same: The Value of Discordant Monozygotic
Twins in Genetic Research. Am J Med Genet B 2010; 153B: 1134-1149 (4 / 3.481)
Scientific papers non-refereed
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
98
Bakker OJ, Go PNMYH, Puylaert JBCM, Kazemier G, Heij HA. Richtlijn voor diagnostiek en behandeling van acute
appendicitis. Nederlands tijdschrift voor geneeskunde 2010; 154: A303
Boers M, Felson DT, Wells G, van Tuyl LHD, Zhang B, Funovits J, Smolen J. Progress toward the development of a new
definition of remission in rheumatoid arthritis. Bull NYU Hosp Jt Dis 2010; 68: 140-142
Chansky K, Sculier JP, Crowley JJ, Giroux D, Van Meerbeeck J, Goldstraw P. [The International Association for the
Study of Lung Cancer Staging Project. Prognostic factors and pathologic TNM stage in surgically managed non-small
cell lung cancer]. Chinese Journal of Lung Cancer 2010; 13: 9-18
de Graaf P, Vos RM, de Boer NHK, Sinjewel A, Jharap B, Mulder CJJ, Van Bodegraven AA, Veldkamp AI. Chemical
stability of thiopurine metabolites in erythrocytes during 6-mercaptopurine and azathioprine treatment. J
Chromatogr B Analyt Technol Biomed Life Sci 2010; 878: 1437-1442
de Vries RR, Nieuwenhuijzen JA, Vincent A, van Tinteren H, Horenblas S. Survival after cystectomy for invasive
bladder cancer. Eur J Surg Onc 2010; 36: 292-297
de Wilt LHAM, Stegehuis JH, Groen HJ, Peters GJ, De Jong S, Kruyt FAE. TRAIL-receptor-gerichte behandelingen in
niet-kleincellig longcarcinoom. Ned Tijdschr Oncol 2010; 3: 346-353
Dijkstra G, Derijks LJ, Houwert GJ, de Wolf H, van Bodegraven A. Guideline 'Diagnosis and treatment of inflammatory
bowel disease in adults', II. Special situations and organisation of medical care.. Nederlands Tijschrift voor
Geneeskunde 2010; 154: A1900
Gotink KJ, Verheul HMW. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?. Angiogenesis
2010; 13: 1-14
Ham JC, Janssen JJWM, Boers JE, Kluin PhM, Verdonck LF. Blastair plasmacytoid dendritische celneoplasma;
casuistiek en behandeling. Ned Tijdschr Hematol 2010; 7: 245-248
Haverkort ME, van Thiel PPAM, de Vries HJC. Uw diagnose?. Tijdschrift voor infectieziekten 2010; 5: 36-37
Nieuwenhuis WP, Kneepkens CMF, Houwen RH, de Beer HJ, Mulder CJJ, Mearin ML. Guideline 'Coeliac disease and
dermatitis herpetiformis'. Ned Tijdschr Geneeskd 2010; 154: A1904
Nowak-Sliwinska P, van Beijnum JR, van Berkel M, van den Bergh H, Griffioen AW. Vascular regrowth following
photodynamic therapy in the chicken embryo chorioallantoic membrane. Angiogenesis 2010; 13: 281-292
Olcay E, Giovannetti E, Peters GJ. Drug delivery and drug resistance: EGFR-tyrosine kinase inhibitors in non-small cell
lung cancer. The Open Lung Cancer Journal 2010; 3: 25-32
Ossenkoppele GJ, Janssen JJWM, Posthuma EFM, Falkenburg JHF, Bos GMJ, Petersen EJ, Schattenberg AVMB, Verhoef
GEG. Aanbevelingen voor de behandeling van chronische myelo´de leukemie namens de HOVON Leukemie Werkgroep.
Ned Tijdschr Hematol 2010; 7: 198-206
Slotman BJ. Radiotherapy for Extensive Stage Small Cell Lung Cancer. Front Radiat Ther Oncol 2010; 42: 187-192
Appendix 4: Scientific output
16.
17.
18.
19.
20.
21.
22.
23.
24.
Smits M, Nilsson J, Mir SE, van der Stoop PM, Hulleman E, Niers JM, de Witt Hamer PC, Marquez VE, Cloos J,
Krichevsky AM, Noske DP, Tannous BA, Würdinger T. miR-101 is down-regulated in glioblastoma resulting in EZH2induced proliferation, migration, and angiogenesis. Oncotarget 2010; 1(8): 710-720
Strijkers GJ, Kluza E, Van Tilborg GAF, van der Schaft DWJ, Griffioen AW, Mulder WJM, Nicolay K. Paramagnetic and
fluorescent liposomes for target-specific imaging and therapy of tumor angiogenesis. Angiogenesis 2010; 13: 161-173
Unlu C, de Korte N, Daniels L, Consten ECJ, Cuesta MA, Gerhards MF, van Geloven AAW, van der Zaag ES, van der
Hoeven JAB, Klicks R, Cense HA, Roumen RMH, Eijsbouts QAJ, Lange JF, Fockens P, de Borgie CAJM, Bemelman MA,
Reitsma JB, Stockmann HBAC, et al.. A multicenter randomized clinical trial investigating the cost-effectiveness of
treatment strategies with or without antibiotics for incomplicated acute diverticulitis (DIABOLO trial). BMC Surgery
2010; 23:
van Bodegraven A, van Everdingen JJ, Dijkstra G, Jong DJ, Oldenburg B, Hommes DW, et al. Guideline 'Diagnosis and
treatment of inflammatory bowel disease in adults' I. Diagnosis and treatment. Nederlands tijdschrift voor
geneeskunde 2010; 154: A1899
van den Eertwegh AJM, Bloemena E, Hoentjen F, Van Bodegraven AA. Behandeling van auto-immuun reacties ten
gevolge van een immuuntherapie met een atistof tegen CTLA-4 (ipilimumab) bij patiÙnten met een gemetastaseerd
melonoom. Ned Tijdschr Oncol 2010; 7: 258-263
Vliet H, Roon K, Jeurissen FJF, Taphoorn MJB, Hop WCJ, Vecht CHJ, et al. Temozolomide and implications for
interventions by the nurse practitioner in neuro-oncology. European Journal of Oncology Nursing 2010; 14: S36-S37
Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RM, Menon R, Maier S, Soltermann A, Moch.H.,
et al, Thunnissen FBJM, Smit EF, Heideman DAM, et al. Frequent and focal FGFR1 amplification Associates with
Therapeutically tractable FRGFR1 amplification associates with therapeutically fractable FGFR1 dependency in
squamous cell lung cancer. Sci Transl Med 2010; 2: 62ra93
Wilde JCH, Lameris W, van Hasselt EH, Molyneux EM, Heij HA, Borgstein EG.. Challanges and outcome of Wilms'
tumour managment in a resource-constrained setting. African Journal of Paediatric Surgery 2010; 7: 159-162
Willemsen I, van der Kooij T, van Benthem BHB, Wille J, Kluytmans JAJW. Appropriateness of antimicrobial therapy: a
multicentre prevalence survey in the Netherlands, 2008-2009. Eurosurveillance 2010; 15: 42-48
Scientific publications (books, book chapters, proceedings)
1.
2.
3.
4.
5.
6.
Luqmani R, Pincus T, Boers Ml. Rheumatoid arthritis; Oxford, Oxford University Press.. 2010; :
Reijneveld JCl. Neuro-oncologie; in Bohn SevL, (ed): Het neurologie formularium; een praktische leidraad. Houten.
2010; : 201-217
Schramel FMNH, Postmus PE, Thunnissen FBJM, Vanderschueren RGJRA, Seldenrijk CAl. Tumoren van long, pleura en
mediastinum; in van de Velde CJH, van Krieken JHJM, de Mulder PHM, Vermorken JB, (eds): Oncologie. Bohn Stafleu,
van Loghem. 2010; : 251-274
Smit EF, Dingemans ACl. Een patient met longkanker en dyspneu, hoesten en hemoptoe; in van Wanrooije BS, (ed):
Palliatieve zorg in de praktijk. 2010; : 143-156
van der Horst-Bruinsma Il. De ziekte van Bechterew; in Lems WF, van Royen BJ, (eds): Reumatologie & Orthopedie
formularium, een praktische leidraad. Houten, Bohn Stafleu van Loghum. 2010; : 89-99
van der Horst-Bruinsma Il. De ziekte van Bechterew, buitenbeen binnen de reumatologie. In: van Riel P, (ed): Reuma,
bestaat dat nog? Leusden. 2010
Professional publications
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
Baart JA, van der Waal Il. Bespiegelingen vanuit een universitaire afdeling mondziekten, kaak- en
aangezichtschirurgie. De relatie tussen tandarts en kaakchirurg.. Ned Tandartsen blad 2010; 8: 18-19
Boven El. De behandeling van het gemetastaseerde mammacarcinoom. Farmacotherapie - Online 2010; : 1-32
De Boer NKH, Van Asseldonk DP, van Bodegraven Al. ECCO consensus: Evidence-based use of 6-thioguanine therapy in
Crohn's disease?. J Crohns Colitis 2010; 4: 484-485
De Vet HCW, Jellema P, van der Windt DAWM, Bruinvels DJ, Mallen CD, Van Weyenberg SJB, Mulder CJl. Colorectal
cancer Authors' reply. BRITISH MEDICAL JOURNAL 2010; 340: c2504
Giovannetti E, Tibaldi C, Falcone A, Danesi R, Peters GJl. Impact of Cytidine Deaminase Polymorphisms on Toxicity
After Gemcitabine: The Question Is Still Ongoing. J Clin Oncol 2010; 28: E221-E222
Kruitwagen R, Pelikan H, Trum Hl. Para-aortic lymphadenectomy in endometrial cancer. Lancet 2010; 376: 511
Oerlemans Rl. Molecular mechanisms of resistance to classical and experimental anti-rheumatic drugs. Nederlands
Tijdschrift voor Reumatologie 2010; 4: 33-36
Overkleeft ENM, Goldschmeding R, van Reekum F, Voest EE, Verheul HMWl. Nephrotic syndrome caused by the
angiogenesis inhibitor sorafenib. Ann Oncol 2010; 21: 184-185
Smit EF, Groen HJM, van Zandwijk Nl. Platinum-Based Second-Line Treatment in Non-Small-Cell Lung Cancer: An Old
New Kid on the Block? Reply. Journal of Clinical Oncology 2010; 28: E26
Stegehuis JH, de Wilt LHAM, de Vries EG, Groen HJ, De Jong S, Kruyt FAEl. TRAIL receptor targeting therapies for
non-small cell lung cancer: current status and perspectives. Drug Resist Updat 2010; 13: 2-15
ter Wengel PV, Reijneveld JC, Lagerwaard FJ, Peerdeman SMl. Meningeomen deel 1: biologisch gedrag en
behandelstrategieÙn. Tijdschr Neurol Neurochir 2010; 111: 200-209
van der Veldt AAM, Boven El. Responsmeting bij patiÙnten met niercelcarcinoom tijdens behandeling met
angiogeneseremmers. Angiogenese Journaal 2010; 5: 2-5
van der Waal Il. Een opaciteit in de onderkaak. Tandartspraktijk 2010; 31: 32-33
van der Waal Il. Hoe ziet een normal tong eruit en wat zijn de meest voorkomende afwijkingen?. Mondhygienisten
Vademecum 2010; 8(2):
Van Weyenberg SJ, Mulder CJ, van Waesberghe JHl. Small intestinal diverticulitis. Clin Gastroenterol Hepatol 2010; 8:
e123
99
Appendix 4: Scientific output
Popular publication
1.
Belien JAM, Verheul HMW, Meijer GAl. De ICT-standaard voor klinisch onderzoek. Oncologie up-to-date 2010; augustus
Patents
1.
2.
3.
4.
van Beusechem VW, Carette JE, Vermeulen Cl. Replication competent viruses capable of silencing virus inhibitory
factor expression. 2010
van Beusechem VW, van Ginkel JWHl. MicroRNA and miRNA inhibitors that modulate adenovirus replication and/or
adenovirus induced cell death. 2010
Vermeulen C, Tol N, van Beusechem VWl. Replication-competent adenoviruses. 2010
Wurdinger Tl. Holder of thrombocyte RNA analysis provisional patent. 2010
Dissertations
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
Badr C - Biolumenescence imaging in glioblastoma: monitoring of biological processes and novel therapeutics. Vrije
Universiteit Amsterdam, 9/23/2010. (Co-)promotores: WP Vandertop, T Wurdinger, BA Tannous (cat A)
Bierman WFW - Strengths and weaknesses of HIV-1 protease inhibitor therapy. Vrije Universiteit Amsterdam,
10/26/2010. (Co-)promotores: SA Danner, RJ Scheper, MA van Agtmael (cat A)
Bijnsdorp IV - Mechanism of trifluorothymidine cytotoxicity and thymidine phosphorylase induced angiogenesis. Vrije
Universiteit Amsterdam, 6/9/2010. (Co-)promotores: GJ Peters, FAE Kruyt (cat A)
Buis DR - Stereotactic radiosurgery for brain arteriovenous malformations.. Vrije Universiteit Amsterdam,
11/11/2010. (Co-)promotores: WP Vandertop, BJ Slotman, CMF Dirven, F Barkhof (cat A)
Haasbeek CJA - Image-guided stereotactic radiotherapy for early stage lung cancer: techniques and clinical outcomes.
Vrije Universiteit Amsterdan, 3/3/2010. (Co-)promotores: S Senan, BJ Slotman, FJ Lagerwaard (cat A)
Jansen EPM - Chemoradiotherapy in gastric cancer. Vrije Universiteit Amsterdam, 4/14/2010. (Co-)promotores: M
Verheij, GMM Bartelink, A Cats (cat B)
Klarenbeek B - Surgical challenges in diverticular disease. Vrije Universiteit Amsterdam, 5/12/2010. (Co-)promotores:
MA Cuesta, CL van der Peet (cat A)
Kuijk AWR - Clinical and synovial tissue studies in psoriatic arthritis. Universiteit van Amsterdam, 9/17/2010. (Co)promotores: P Tak, BAC Dijkmans (cat C)
Marees T - Second primary malignancies and excess mortality after retinoblastoma. Vrije Universiteit Amsterdam,
1/29/2010. (Co-)promotores: FE van Leeuwen, PJ Ringens, AC Moll, SM Imhof (cat A)
Meijerink M - Novel dynamic imaging methods and image-guided ablative therapies of liver tumors. Vrije Universiteit
Amsterdam, 6/18/2010. (Co-)promotores: C van Kuijk, JHTM van Waesberghe, MP van Tol (cat A)
Nieuwenhuijzen JA - Surgical treatment of bladder cancer. Vrije Universiteit Amsterdam, 4/28/2010. (Co)promotores: S Horenblas (cat A)
Noordhuis P - Molecular aspects of 5-fluorouracil and oxaliplatin activity. Vrije Universiteit Amsterdam, 10/21/2010.
(Co-)promotores: GJ Peters, CJ van Groeningen (cat A)
Oerlemans R - Molecular mechanisms of resistance to classical and experimental antirheumatic drugs. Vrije
Universiteit Amsterdam, 6/25/2010. (Co-)promotores: BAC Dijkmans, RJ Scheper, G Jansen, WF Lems, (cat A)
Overbeek MJ - Pulmonary arterial hypertension in systemic sclerosis. Vrije Universiteit Amsterdam, 9/9/2010. (Co)promotores: EF Smit, BAC Dijkmans, A Boonstra, AE Voskuyl (cat A)
Schaaij-Visser TB - Biomarker discovery for head and neck cancer. A proteomics approach. Universiteit van Utrecht,
1/20/2010. (Co-)promotores: AJR Heck, RH Brakenhoff, Slijpers M (cat C)
Spoelstra FOB - Optimization of image-guidede radiotherapy (IGRT) for lung cancer. Vrije Universiteit Amsterdam,
1/15/2010. (Co-)promotores: S Senan, BJ Slotman, JR Sörnsen de Koste (cat A)
Steegerda MJ - I-125 seed implants for prostate brachy therapy. Vrije Universiteit Amsterdam, 10/21/2010. (Co)promotores: M Verheij, LMF Moonen (cat B)
Tijink BM - Targeted therapies in head and neck cancer. Vrije Universiteit Amsterdam, 2/19/2010. (Co-)promotores:
GAMS van Dongen, CR Leemans, R de Bree (cat A)
van Riel JMGH - Hepatic arterial chemotherapy for liver metastases of colorectal cancer. Vrije Universiteit
Amsterdaqm, 9/17/2010. (Co-)promotores: E Boven, GJ Peters, CJ van Groeningen (cat A)
Willemsen LE - Improving antimicrobial use in hospitals. Vrije Universiteit Amsterdam, 9/22/2010. (Co-)promotores:
JAJW Kluytmans, PHM Savelkoul (cat A)
Program 5: Quality of life
Scientific papers refereed
1.
2.
3.
100
Albers G, Echteld MA, De Vet HCW, Onwuteaka-Philipsen BD, van der Linden MHM, Deliens L. Content and Spiritual
Items of Quality-of-Life Instruments Appropriate for Use in Palliative Care: A Review. J Pain Sympt Manag 2010; 40:
290-300 (4 / 2.423)
Albers G, Echteld MA, De Vet HCW, Onwuteaka-Philipsen BD, van der Linden MHM, Deliens L. Evaluation of quality-oflife measures for use in palliative care: a systematic review. Palliative Med 2010; 24: 17-37 (3 / 2.031)
Braam KI, Van Dijk EM, Veening MA, Bierings MB, Merks JHM, Grootenhuis MA, Chinapaw MJM, Sinnema G, Takken T,
Huisman J, Kaspers GJL, Van Dulmen-den Broeder E. Design of the Quality of Life in Motion (QLIM) study: a
randomized controlled trial to evaluate the effectiveness and cost-effectiveness of a combined physical exercise and
psychosocial training program to improve physical fitness in children with cancer. BMC Cancer 2010; 10: art.nr. 624 (3
/ 2.736)
Appendix 4: Scientific output
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
Braamse AMJ, van Meijel B, Visser O, van Oppen P, Boenink AD, Eeltink C, Cuijpers P, Huijgens PC, Beekman ATF,
Dekker J. Distress and quality of life after autologous stem cell transplantation: a randomized clinical trial to
evaluate the outcome of a web-based stepped care intervention. BMC Cancer 2010; 10: art.nr. 361 (3 / 2.736)
Lammens CRM, Aaronson NK, Wagner A, Sijmons RH, Ausems MGEM, Vriends AHJT, Ruijs MWG, Van Os TAM, Spruijt L,
Garcia EBG, Kluijt I, Nagtegaal T, Verhoef S, Bleiker EMA. Genetic Testing in Li-Fraumeni Syndrome: Uptake and
Psychosocial Consequences. J Clin Oncol 2010; 28: 3008-3014 (5 / 17.793)
de Vries J, van der Steeg AFW, Roukema JA. Psychometric properties of the Fatique Assessment Scale (FAS) in women
with breast problems. Int J Clin Hlth Psyc 2010; 10: 125-139 (3 / 1.792)
de Vries MC, Wit JM, Engberts DP, Kaspers GJL, van Leeuwen E. Pediatric Oncologists' Attitudes Towards Involving
Adolescents in Decision-Making Concerning Research Participation. Pediatr Blood Cancer 2010; 55: 123-128 (3 / 2.134)
Den Oudsten BL, Van Heck GL, van der Steeg AFW, Roukema JA, de Vries J. Clinical factors are not the best
predictors of quality of sexual life and sexual functioning in women with early stage breast cancer. Psycho-Oncoly
2010; 19: 646-656 (4 / 2.684)
Den Oudsten BL, Van Heck GL, van der Steeg AFW, Roukema JA, de Vries J. Personality predicts perceived availability
of social support and satisfaction with social support in women with early stage breast cancer. Support Care Cancer
2010; 18: 499-508 (4 / 2.089)
Den Oudsten BL, Van Heck GL, van der Steeg AFW, Roukema JA, de Vries J. Second operation is not related to
psychological outcome in breast cancer patients. Int J Cancer 2010; 126: 1487-1493 (4 / 4.722)
Dommering CJ, van den Heuvel MR, Acmoll AC, Imhof SM, Meijers-Heijboer EJ, Henneman L. Reproductive decisionmaking: a qualitative study among couples at increased risk of having a child with retinoblastoma. Clin Genet 2010;
78: 334-341 (3 / 3.304)
Engelen V, Haverman L, Koopman H, Schouten-van Meeteren N, Meijer-van den Bergh E, Vrijmoet-Wiersma J, Van
Dijk EM, Last B, Detmar S, Grootenhuis M. Development and implementation of a patient reported outcome
intervention (QLIC-ON PROfile) in clinical paediatric oncology practice. Patient Educ Couns 2010; 81: 235-244 (5 /
1.975)
Garssen B, Boomsma MF, Beelen RHJ. Psychological factors in immunomodulation induced by cancer surgery: A
review. Biol Psychol 2010; 85: 1-13 (5 / 4.363)
Gehring K, Aaronson NK, Taphoorn MJB, Sitskoorn MM. Interventions for cognitive deficits in patients with a brain
tumor: an update. Exp Rev Anticanc 2010; 10: 1779-1795 (3 / 2.493)
Giesbers J, Verdonck-de Leeuw IM, van Zuuren FJ, Kleverlaan N, van der Linden MHM. Coping with parental cancer:
web-based peer support in children. Psycho-Oncoly 2010; 19: 887-892 (4 / 2.684)
Herenius MMJ, Hoving JL, Sluiter JK, Raterman HG, Lems WF, Dijkmans BAC, Tak PP, Nurmohamed MT, Voskuyl AE,
Frings-Dresen MHW. Improvement of Work Ability, Quality of Life, and Fatigue in Patients With Rheumatoid Arthritis
Treated With Adalimumab. J Occup Environ Med 2010; 52: 618-621 (3 / 1.882)
Hurkmans EJ, van den Berg MH, Ronday HK, Peeters AJ, le Cessie S, Vlieland TPMV. Maintenance of physical activity
after Internet-based physical activity interventions in patients with rheumatoid arthritis. Rheumatology 2010; 49:
167-172 (4 / 4.236)
Knijnenburg SL, Kremer LC, van den Bos C, Braam KI, Jaspers MWM. Health Information Needs of Childhood Cancer
Survivors and Their Family. Pediatr Blood Cancer 2010; 54: 123-127 (3 / 2.134)
Langius JAE, Doornaert P, Spreeuwenberg MD, Langendijk JA, Leemans CR, van Bokhorst-de van der Schueren M.
Radiotherapy on the neck nodes predicts severe weight loss in patients with early stage laryngeal cancer. Radiother
Oncol 2010; 97: 80-85 (5 / 4.343)
Mostert S, Sitaresmi MN, Gundy CM, Janes V, Sutaryo, Veerman AJP. Comparing childhood leukaemia treatment
before and after the introduction of a parental education programme in Indonesia. Arch Dis Child 2010; 95: 20-25 (4 /
2.657)
Oskam IM, Verdonck-de Leeuw IM, Aaronson NK, Kuik DJ, de Bree R, Doornaert P, Langendijk JA, Leemans CR. Quality
of life as predictor of survival: A prospective study on patients treated with combined surgery and radiotherapy for
advanced oral and oropharyngeal cancer. Radiother Oncol 2010; 97: 258-262 (5 / 4.343)
Raterman HG, Hoving JL, Nurmohamed MT, Herenius MMJ, Sluiter JK, Lems WF, Tak PP, Dijkmans BAC, Twisk JWR,
Frings-Dresen MHW, Voskuyl AE. Work ability: a new outcome measure in rheumatoid arthritis?. Scand J Rheumatol
2010; 39: 127-131 (2 / 2.507)
Sitaresmi MN, Mostert S, Schook RM, Sutaryo, Veerman AJP. Treatment refusal and abandonment in childhood acute
lymphoblastic leukemia in Indonesia: an analysis of causes and consequences. Psycho-Oncoly 2010; 19: 361-367 (4 /
2.684)
Sizoo EM, Braam L, Postma TJ, Pasman HRW, Heimans JJ, Klein M, Reijneveld JC, Taphoorn MJB. Symptoms and
problems in the end-of-life phase of high-grade glioma patients. Neuro-Oncology 2010; 12: 1162-1166 (4 / 4.984)
Stol YH, Menko FH, Westerman MJ, Janssens RMJP. Informing family members about a hereditary predisposition to
cancer: attitudes and practices among clinical geneticists. J Med Ethics 2010; 36: 391-395 (4 / 1.206)
Taphoorn MJB, Sizoo EM, Bottomley A. Review on Quality of Life Issues in Patients with Primary Brain Tumors.
Oncologist 2010; 15: 618-626 (4 / 6.701)
Taphoorn MJB, Claassens L, Aaronson NK, Coens C, Mauer M, Osoba D, Stupp R, Mirimanoff RO, van den Bent MJ,
Bottomley A. An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing
health-related quality of life and symptoms in brain cancer patients. Eur J Cancer 2010; 46: 1033-1040 (3 / 4.121)
Uhlig T, Lems WF, Dijkmans BAC, Kvien TK, Woolf AD. Differences in utility and other disease severity levels in
patients with rheumatoid arthritis from three European countries. Scand J Rheumatol 2010; 39: 433-434 (2 / 2.507)
van der Meij BS, Langius JAE, Smit EF, Spreeuwenberg MD, von Blomberg BME, Aarden L, Heijboer AC, Paul MA, van
Leeuwen PAM. Oral nutritional supplements containing (n-3) polyunsaturated fatty acids affect the nutritional status
of patients with stage III non-small cell lung cancer during multimodality treatment. J Nutr 2010; 140: 1774-1780 (4 /
4.091)
van der Steeg AFW, de Vries J, Roukema JA. Anxious personality and breast cancer: possible negative impact on
quality of life after breast-conservind therapy. World J Surg 2010; 34: 1453-1460 (4 / 2.696)
van Nieuwenhuizen AJ, Rinkel RNPM, de Bree R, Leemans CR, Leeuw IMVD. Patient Reported Voice Outcome in
Recurrent Respiratory Papillomatosis. Laryngoscope 2010; 120: 188-192 (4 / 2.018)
van Straten A, Geraedts A, Verdonck-de Leeuw IM, Andersson G, Cuijpers P. Psychological treatment of depressive
symptoms in patients with medical disorders: A meta-analysis. J Psychosomatic Res 2010; 69: 23-32 (3 / 2.908)
101
Appendix 4: Scientific output
33.
Verdonck-de Leeuw IM, van Bleek WJ, Leemans CR, de Bree R. Employment and return to work in head and neck
cancer survivors. Oral Oncol 2010; 46: 56-60 (5 / 3.123)
Scientific papers non-refereed
1.
2.
3.
4.
Braamse AMJ, Meijel Bv, Marwijk Kooij Mv, Visser O, Dekker J. Distress en kwaliteit van leven bij
hematologiepatiÙnten na autologe stamceltransplantatie: de effectiviteit van een internet en stepped-care
interventie. Nederlands Tijdschrift voor Hematologie 2010; 7: 31-37
Heij HA, Wijnen MHWA. Cancer care in the pediatric surgical patient: A paradigm to abolish volume-outcome
disparities in surgery. Surgery 2010; 147: 467-468
Kruizenga HM, Evers AM, Schilp J, de Bont M. Ondervoeding, we moeten sneller ingrijpen. Oncologica 2010; :
Sizoo EM, Taphoorn MJB. Symptom control and quality of life in the end-of-life phase of brain tumour patients.
Magazine of European Medical Oncology 2010; : 18-20
Dissertations
1.
2.
102
Pijpe A - Modifiers of breast cancer risk in BRCA1/2 mutation carriers; physical activity, body weight, and diagnostic
radiation. Vrije Universiteit Amsterdam, 7/2/2010. (Co-)promotores: FE van Leeuwen, MA Rookus (cat B)
Pisters MF - Exercise Therapy in Patients with Osteoarthritis: Long-term effectiveness and the role of exercise
adherence. Vrije Universiteit Amsterdam, 10/15/2010. (Co-)promotores: J Dekker, DH Bakker, C Veenhof (cat A)
Appendix 5: Indicators of esteem
Appendix 5. Indicators of esteem
In this appendix an overview is given of the memberships of editorial boards, (inter)national functions, lectures given and obtained
awards. In addition, newly obtained grants are listed to show the recruitment capacity of CCA/V-ICI, and news items are shown.
Memberships of editorial boards
Associate
Journal
Ang CW
• Nederlands Tijdschrift voor Medische Microbiologie (editor-in-chief)
Appelmelk BJ
• Innate Immunity
Beelen RHJ
• Perit Dial Int
Beliën JAM
• Analytical Cellualr Pathology
Bitter W
• SGM Microbiology
Blankenstein MA
• Annals of Clinical Biochemistry
Boers M
•
•
•
•
•
•
Braakhuis BJM
• Oral Oncology
• The Open Pathology Journal
Brakenhoff RH
• Clinical Cancer Research
• Current Cancer Therapy Reviews
• Oral Oncology
Broxterman HJ
• Drug Resistance Updates
• Molecular Cancer Therapeutics
• World Journal of Pharmacology
Castelijns JA
• European Radiology
• American Journal of Neuroradiology
de Bree R
•
•
•
•
de Winter JP
• The Open Genetics Journal
Dekker J
• Editor in Chief International Journal of Behavioral Medicine
Dijkmans BAC
• Arthritis Research and Therapy
Griffioen AW
•
•
•
•
Jansen G
• The Open Arthritis Journal
Jimenez CD
• Journal of Proteomics
• Molecular and Cellular Proteomics
• Journal of Proteomics, special issue, aug. 2010, ‘Cancer Proteomics’
Joenje H
•
•
•
•
•
Kluytmans JAJM
• Journal of Infectious Disease
Leemans CR
• Hoofd-hals Journaal (Head and Neck Journal of the NWHHT)
Arthritis and Rheumatism
Letter to the Editor in Rheumatology
Annals of Internal Medicine
Journal for Clinical Epidemiology (Policy Advisory Board)
Annals of Rheumatic Diseases
Journal of Rheumatology
European Archives of Otorhinolaryngology
The Open Otorhinolaryngology Journal
Oral Oncology
Nederlands Tijdschrift voor Oncologie
Angiogenesis
Journal of Biology
Vascular Cell
Biochemical Journal
The Open Genomics Journal
Cellular Oncology
Anemia
Familial Cancer
Open Genetics Reviews
103
Apendix 5: Indicators of esteem
Associate
Journal
•
•
•
•
•
•
•
•
•
Nederlands Tijdschrift voor Keel-Neus-Oorheelkunde (Netherlands Journal of Otorhinolaryngology)
European Archives of Oto-Rhino-Laryngology Head and Neck
Nederlands Tijdschrift voor Oncologie (Netherlands Journal of Oncology)
Oral Oncology
Head & Neck
Oral Diseases
Surgical Oncology
Italian Journal of Maxillofacial Surgery
Acta Otorrinolaringología Española
Lems WF
• Therapeutic Advances in Musculoskeletal Disease
• Nederlands Tijdschrift Reumatologie
• Osteoporose Journal
Meijer GA
•
•
•
•
Menko FH
• Familial Cancer
Mooi WJ
• Advanced in Anatomic Pathology
• Pathology research international
Nurmohamed MT
• Annals of the Rheumatic Diseases
Peters GJ
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Rustemeyer T
• Contact Dermatitis
• Dermatologie in Beruf und Umwelt (Wissenschaftlicher Beirat)
• Nederlands Tijdschrift voor Allergologie
Scheper RJ
• Contact Dermatitis
Schuurhui s GJ
• Open Hematology Journal
• International Scholarly Research Network (ISRN) Hematology
• World Journal of Stem Cells (WJSC): upcoming
Senan S
• The Oncologist
• Radiation Oncology
Slotman BJ
• Journal of Radiosurgery and Stereotactic Body Radiotherapy
Stoof TJ
• Allergie Actueel
• Nederlands Tijdschrift voor Dermatologie en Venereologie
Vandenbroucke-Grauls CMJE
• Farmacotherapeutisch Kompas
van Beusechem VW
• Human Gene Therapy
• Genetics Research International
van de Loosdrecht AA
• Ned Tijdschrift voor Hematologie
van den Elsen P
• Immunogenetics
104
Cellular Oncology
Oncology News International
Oncology Up-to-date
World Journal of Gastrointestinal Oncology (WJGO)
American Journal of Cancer research
Annals of Oncology
Cancer Chemotherapy and Pharmacology
Cancer Therapy
Chemotherapy Research and Practice
Chinese Journal of Clinicians
Clinical Colorectal Cancer
European Journal of Cancer
Gastrointestinal Cancer Reviews
International Journal of Oncology
Journal of Chemotherapy
Journal of Chinese Clinical Medicine
Journal of Pharmacology and Toxicology
Journal of Epithelial Biology and Pharmacology
World Journal of Clinical Oncology
World Journal of Gastrointestinal Oncology
World Journal of Gastrointestinal Pharmacology and Therapeutics
The Open Lung Cancer Journal
Appendix 5: Indicators of esteem
Associate
Journal
•
•
•
•
The Open Immunology Journal
Section Editor ''Current Opinion in Immunology'' on Antigen processing 23/1
Frontiers in Molecular Innate Immunity
Contact Dermatitis
van der Waal I
•
•
•
•
•
•
•
•
•
•
•
•
•
ACTA Stomatologica Croatica
European Journal of Cancer
Padjadjaran Journal of Dentistry
Medicina Oral
Oral and Maxillofacial Surgery
Oral Health & Preventive Dentistry
Oral Oncology
Revista de Odontologia da Universidade de São Paolo (Journal of Dentistry, University of São Paolo)
STOMA
Nederlands Tandartsenblad
Nederlands Tijdschrift voor Geneeskunde
Journal of Stomatological Investigation
Minerva Stomatologica
van Die I
• Glycoconjugate Journal
• Open Glycoscience Journal
van Dongen GAMS
• Journal of Oncology
van Schaardenburg D
• Advisory editor, Arthritis & Rheumatism 2010-2012
Veerman AJP
• Pediatric Blood and Cancer
Verdonck-de Leeuw IM
• Voice-, Speech- en Language Pathology (Dutch)
• World Journal of Clinical Oncology (WJCO
Verweij CL
•
•
•
•
•
Ylstra, B
• International Journal of Cellular Oncology
The Open Rheumatology Journal
Genes and Immunity
Arthritis Research & Therapy
Arthritis
Frontiers in Immunology
105
Apendix 5: Indicators of esteem
(Inter)national functions
Associate
Function
Organisation
Ang W
Member
• Consensusberaad Borrelia
Appelmelk BJ
Scientific councilor Microbiology
• The International endotoxin and
innate immunity society
Beelen RHJ
Scientific Board
• European Macrophage Dendritic Cell
Society
Beliën JAM
MemBer
• Dutch Society of Pattern Recognition
and Image Processing (NVPHBV)
Dutch Society of Microscopy (NVVM)
Bitter W
Member Scientific Committee
• Nederlandse vereniging voor
Medische Microbiologie (NvMM)
Boers M
Co-chair
• OMERACT Executive Committee. (see
www.omeract.org)
• American College of Rheumatology
subcommittee on the definition of
remission in rheumatoid arthritis
Chair
• Trial Steering Committee: ZIPP
(zoledronate in prevetion of Paget)
trial. P.I. S Ralston, Edinburgh, UK
Member
• EULAR Committee on disease activity
measurement in rheumatoid
arthritis.
• EULAR Committee on monitoring of
glucocorticoid therapy in rheumatoid
arthritis.
• OMERACT Task Force on imaging in
rheumatoid arthritis.
• ASAS, international consensus group
on guidelines for outcome measures
in ankylosing spondylitis
• COMET Steering Group. International
initiative to create measurement
core sets for trials across diseases
Braakhuis BJM
Founding Member and member of
Research Commitee
• International Academy of Oral
Oncology
Brakenhoff RH
Member
• Fanconi anemia workshop on head
and neck cancer
Castelijns JA
Member
• Concilium Radiologicum
• MSRC
• Radiological Society of Northern
America
• American Society of Neuroradiology
• American Society of Head and Neck
Radiology
• Executive Com. European Society of
Head and Neck Radiology
• European Society of Neuroradiology
• Neuro Section, NVvR (Dutch Society
of Radiology)
Chair
• Head and Neck Section, NVvR (Dutch
Society of Radiology)
Member of Immuno-dermatology
Advisory Board
• Sanofi-Pasteur MSD
member of Advisory Board
• DCPrime BV
member of Grant Review Committee
• Melanoma Research Alliance
Member
• Open Programma
beoordelingscommissie 22,
de Gruijl TD
de Winter JP
106
Appendix 5: Indicators of esteem
Associate
Function
Organisation
NWO/ALW
Dekker J
Associate Professor
• Physiotherapy – Psychological aspects
of rehabilitation; Faculty of Sports
and Health Sciences, University of
Jyväskylä, Finland
President Elect and member of the
Member of Governing Council
• International Society of Behavioral
Medicine
Board member
• Netherlands Behavioral Medicine
Federation
Member
• Committee on Medical Technology
Assessment, Health Council of the
Netherlands (Gezondheidsraad)
• International Advisory Board,
Behaviour Change Technique
Taxonomy Project
Dijkmans BAC
Chair
• Dutch Society for Rheumatology
• Continuous Medical Education
Rheumatology Boerhaave
• STRO-FARR
• Scientific board Arthron
Eeltink C
Member
• research sub committee, Late
Effects Working Party, EBMT
Garcia-Vallejo JJ
Participating Investigator
• Consortium for Functional Glycomics
(CFG)
Gibbs S
Program committee
• Nederlandse vereniging voor
Experimentele Dermatologie
Member
• Dutch Program for Tissue Engineering
Consortium
Work Package Leader
• EU integrated FP6 project: Sens-it-iv
Member
• American Association for Cancer
Research (AACR)
• American Pancreas Club
• European Organisation for Research
and Treatment of Cancer (EORTC)
PAMM group
• European Pancreatic Club (EPC)
• Italian Society of Chemotherapy (SIC)
• Italian Society of Pharmacology (SIF)
• Italian Society for the Study of the
Pancreas (AISP)
Principal investigator
• International project “GEM Profile.
Expression of gemcitabine and
cisplatin-related genes in NSCLC”.
www.pharmgkb.org/views/project
Auditor
• Austrian Science Foundation (FWF)
to advice on a large-scale
angiogenesis consortium (NFN)
Advisor
• Canadian Foundation for Innovation,
since 2001
Jury member
• Finish Academy of Sciences
Member
• Quality Control advisary panel of the
Werkgroep Moleculaire Diagnostiek
in de Pathologie - Nederlandse
Vereniging Voor Pathologie (QC
committee WMDP NVVP)
• IASLC
• AACR
Giovannetti E
Griffioen AW
Heideman DAM
107
Apendix 5: Indicators of esteem
Associate
Function
Organisation
• NVGE
• VMDG
Chair
• Scientific Session SS21: Molecular
testing methods: new trends,
EUROGIN 2010 meeting, February
20th, 2010, Monte Carlo, Monaco
Janssen JJWM
Member
• American Society of Hematology
• HOVON Stem cell Transplantation
Working Party
• Dutch Society of Hematology
• European Blood and Marrow
Transplantation group (EBMT)
• Nederlandse Internisten Vereniging
(Dutch Internist Society)
• European Hematology Association
Jiménez CR
Coördinator
• Netherlands Proteomics Platform
• Colon proteomics team,
International Cancer Biomarker
Consortium
General Council Member
• European Proteomics Association
(EuPA)
Secretary
• Proteomics werkgroep, Ned. Ver.
Klin. Chemie
WP-co-leader
• EU kp7 project MEFOPA
Member
•
•
•
•
•
EU kp7 project AngioTOX
WP1 CTMM-Airforce consortium
WPB CTMM-DeCoDe consortium
Human Proteome Organisation
American Society for Mass
Spectrometry
• American Society for Biochemistry
and Molecular Biology
• Dutch Society for Biochemistry and
Molecular Biology
• Dutch Society for Mass spectrometry
Member Scientific Advisory Board
• Fanconi Anemia Research Fund, Inc.,
Eugene, Oregon, USA
Session chair
• 22nd Annual Fanconi Anemia Research
Fund Scientific Symposium, October
21-24, Minneapolis, Minnesota, USA,
Fanconi Anemia Research Fund, Inc.,
Eugene, Oregon, USA
Chair
• VUmc Onderzoek Naar Kinderkanker
(VONK)
• Scientific Committee Department of
Pediatrics, Vumc
• Disease Committee Myeloid
Malignancies, DCOG
• Protocol committees Relapsed AML
1999/2001 and 2005 and APL, DCOG
Program co-leader
• “Quality of Life” of CCA/V-ICI, VU
University Medical Center,
Amsterdam
• Working Group “shared care”, DCOG
• AML Relapse Working Group,
International BFM Study Group
Co-chair
• IKA – Werkgroep indertumoren
Member
• Supervisory Board SKION = Dutch
Childhood Oncology Group (DCOG)
Joenje H
Kaspers GJL
108
Appendix 5: Indicators of esteem
Associate
Function
Organisation
• Protocol committee ALL-10 and
AML2007 (DB-AML01), DCOG
• Scientific Committee, DCOG
• LAD, NVK, NVvO, KNMG; AACR, ASH,
EHA, SIOP
• Scientific Committee “Lymphoid
Neoplasia” of the American Society
ofHematology, 2008-2012 (2010 vicechairman, 2011 chairman)
Kirtschig G
Kluytmans JAJW
Lagerwaard FJ
International coordinator
• I-BFM-SG Phase III studies “Relapsed
AML 2001/01” and “Relapsed AML
2010/01”
• Phase III study on Pediatric APL (ICC
APL 01)
Member
• UK Dermatology Clinical Trials
Network
• EADV / EDF task force
• Werkgroep lichen sclerosus en lichen
planus
• Nederlandse Vereniging voor Vulva
Pathologie
European co-ordinator
• International trial on bullous
pemphigoid; HTA grant UK
Scientific Expert
• Medische adviesraad lichen planus
vereniging
Chair
• bestuur Stichting Werkgroep
Infectiepreventie (WIP)
Infectiecommissie Amphia
Ziekenhuis, Breda
• NVMM commissie laboratorium
detectie van MRSA en van BRMO
Board member
• Stichting Amphia Academy infectious
Disease Foundation
Member
• Infectiecommissie Verpleeghuis
Elisabeth, Breda
• Raad van Qualiteit, Amphia
Ziekenhuis, Breda
• Commissie wetenschap bevordering
Amphia Ziekenhuis, Breda
• Adviescommissie PREZIES
• Commissie herstructurering opleiding
medische microbiologie
• Concilium Microbiologicum Medische
Microbiologie
• Organisatie Boerhaave nascholing
infectieziekten
• Outbreak Management Team MRSA in
de veehouderij
• Werkgroep MRSA in de openbare
gezondheidszorg LCI
• Publications Committee van de SHEA
• Scientific Advisory Commmittee van
ESCMID
• European Advisory Board 3M
International Advisory Board Wyeth
European expert group on MRSA van
het ECDC
• European course on hospital
epidemiology and infection control
Oprichter en lid
• ZIEN
Member
• Landelijke werkgroep Richtlijn
109
Apendix 5: Indicators of esteem
Associate
Function
Organisation
hersenmetastasen, VIKC
• TBM college (beoordelaar
projectvoorstellen), Agentschap voor
Innovatie door Wetenschap en
Technologie (IWT), Vlaanderen
Leemans CR
Lems WF
Mebius RE
110
(Vice-)chair
• IKA euro-Oncology
Chair
• Dutch Head and Neck Oncology
Cooperative Group (NWHHT)
• Head and Neck Cancer Cooperative
Group of the European Organization
for Research and Treatment of
Cancer (EORTC)
Member
• Netherlands Society for
Otorhinolaryngology and CervicoFacial Surgery
• American Head and Neck Society
(Fellow-at-large)
• Netherlands Society of Oncology
• American
Academy
of
Otolaryngology-Head
and
Neck
Surgery
• Concilium Oto-rhino-laryngologicum
in the Netherlands
• British Association of Head and Neck
Oncologists
• European Rhinological Society
• Collegium Oto-rhino-laryngologicum
Amicitiae Sacrum (CORLAS)
• European Salivary Gland Society
(ESGS)
• Spanish Society of
Otorhinolaryngology-Head and Neck
Surgery (Sociedad Española y
Pathología Cérvico-Facial; SEORLPCF).
Secretary
• Working Party Head and Neck
Surgery of the Netherlands Society
for Otorhinolaryngology and CervicoFacial Surgery
Board member
• European Head and Neck Society
(General Secretary)
Founding fellow
• International Academy of Oral
Oncology
Member
• OSTRA-group, a collaboration
between OSLO (Prof Kvien), Truro
(Prof Woolf) and Amsterdam (Prof
Dijkmans and Prof) Lems which is
now existing and succesfull for more
than 10 years
• ASBMR-working group on Rheumatic
Disesases
• EULAR working group:
recommendations on osteoporosis in
rheumatic diseases
Chair
• EULAR-EFORT working group on
prevention of subsequent fractures,
after an initial fracture
• The new multidiciplinairy
Osteoporosis Guideline (for general
practitioners, traumatologists,
endorcrinologists, reumatologists,
fracture nurses, etc, www.cbo.nl)
Presedent program committee
• Nederlandse Vereniging voor
Appendix 5: Indicators of esteem
Associate
Function
Organisation
Immunologie
Meijer GA
Member executive committee
• Management Board OOA
Member
• Committee of the Pathological
Society of Great Britain and Ireland
• Research Sub Committee of the
Pathological Society of Great Britain
and Ireland
• Scientific Board of the Dutch Cancer
Society (KWF)
Advisor
• Health Council of the Netherlands,
committee National colorectal
cancer screening programme
President
• Nederlandse Vereniging
Endoscopische Chirugie (NVEC)
• Opleidingscollege Endoscopische
Heelkunde (OCEH)
• Advanced Suturing Course (ASC)
Member reseach committee
• European Association of Endoscopic
Surgery (EAES)
Board member
• Scientific committee Dutch Surgical
Colorectal Audit
Member
• Advisory board Olympus Medical
Tokyo
• Scientific committee European Single
Port Registration Geneva
Chair
• Nederlandse Melanoompanel
Member
• Nederlandse Mesothelioompanel
• Commissie herziening richtlijn
melanoom
Oudgenoeg G
Member
• Dutch Society for Biochemistry and
Molecular Biology
• Dutch Society for Mass spectrometry
• Netherlands Proteomics Platform
Peters GJ
Member of the scientific advisory board
• “Cancéropôle Lyon-Auvergne-RhôneAlpes”, Lyon, France
• Heidelberg Pharma GmbH,
Ladenburg, Germany
• Kucera Pharmaceuticals, WinstonSalem, NC, USA
Member review committee for TCRF
and ACS grants
• UICC, Geneva, Zwitzerland
Member
• European Organization for Research
and treatment of Cancer
• EORTC General Assembly
• EORTC-Translational Research
Advisory Committee (TRAC)
• American Association for Cancer
Research
• International Society on Nucleosides,
Nucleotides and Nucleic Acids (IS3NA)
Chair
• EORTC Pharmacology and Molecular
Mechanisms Group
• EORTC Drug Discovery Committee NCI
compounds task force
Scientific committee member
• Winter EORTC-PAMMmeeting,
Toulouse, France
• Puridine and Pyrimidine Metabolism in
Man, Tokyo, Japan
Meijerink WJHJ
Mooi WJ
111
Apendix 5: Indicators of esteem
Associate
Function
Organisation
Member of the council and publication
secretary
• Purine and Pyrimidine Society (PPS)
Pham TV
Member
• Human Proteome Organisation
• The International Society for
Computational Biology
• The International Association for
Pattern Recognition
• Dutch Society for Pattern
Recognition and Image Processing
• Netherlands Proteomics Platform
Piersma S
Member
• American Society for Mass
Spectrometry
• Dutch Society for Biochemistry and
Molecular Biology
• Dutch Society for Mass spectrometry
• Netherlands Proteomics Platform
Pieters-van den Bos IC
Member
• ESR (European Society of Radiology)
• NVvR (Dutch Society of Radiology)
• Section of Abdominal Imaging, NVvR
(Dutch Society of Radiology)
• KNMG (Royal Netherlands Medical
Association)
• RNSA (Radiological Society of
Northern America)
Rustemeyer T
Board Member
• Member European Environmental and
Contact Dermatitis Research Group
(EECDRG)
• Bestuur en Raad van Toezicht van de
Stichting Nationaal Huidfonds
• Bij- en Nascholingscommissie van de
Nederlandse Vereniging voor
Dermatologie en Venereologie
• European Prevention of Occupational
Skin Diseases (EPOS)
• Stichting Milieu- en
Arbeidsdermatologie
Member
• Domeingroep Allergologie en
Contactdermatosen van de
Nederlandse vereniging voor
Dermatologie en Venereologie
• European Surveillance System on
Contact Allergens (ESSCA)
• Richtlijn “Lichen sclerosus” van de
Nederlandse vereniging voor
Dermatologie en Venereologie
• Werkgroep Allergische
Beroepsziekten Amsterdam &
Omgeving
Scientific Expert
• EU commission group on “Risk
assessment of consumer products’’
• Ministerie voor Volksgezondheid,
Welzijn en Sport (VWS),
• Voedsel en Waren Autoriteit (VWA),
• Rijksinstituut voor Volksgezondheid
en Milieu (RIVM)
Chair
• Richtlijn “Contacteczeem” van de
Nederlandse vereniging voor
Dermatologie en Venereologie
• PMS cosmetica - Nederlandse
Vereniging voor Dermatologie en
Venereologie
• CESES program van het Ministerie
voor Volksgezondheid, Welzijn en
Sport (VWS), Voedsel en Waren
112
Appendix 5: Indicators of esteem
Associate
Function
Organisation
Autoriteit (VWA) en Rijksinstituut
voor Volksgezondheid en Milieu
(RIVM)
Savelkoul PHM
Chair
• European Study Group on Molecular
Diagnostics, European Society of
Clinical Microbiology & Infectious
Diseases (ESCMID)
• Microbial typing Section, Dutch
Society of Microbiology (NvvM)
Board member Scientific committee
• Dutch Society of Microbiology (NvvM)
Board member post-education &
registration committee
• Dutch Society of Medical
Microbiology (NVMM)
Tutor Medical microbiological Scientist
specialization (MMO)
• Dutch Society of Medical
Microbiology (NVMM) & SMBWO
Tutor Medical Molecular Microbiologist
training (MMM)
• Dutch Society of Medical
Microbiology (NVMM)
Schaaij-Visser T
Member
• WP1 CTMM-Airforce consortium
• American Association for Cancer
Research
Scheper RJ
Member
• European Environmental and
Industrial Contact Dermatitis Group
• Tumor Vaccine and Cell Therapy
Working Group (Washington /
Portland)
• Board European Experimental
Contact Dermatitis Research Group
• Wetenschappelijke Adviesraad
Brandwonden Stichting, Beverwijk
• Nederlandse Vereniging voor
Immunologie
• American Association for Cancer
Research
Board member
• A-Skin BV, Amsterdam
• DC-Prime, Amsterdam
• Stichting Milieu- en
Arbeidsdermatologie
Schuurhuis GJ
Chair
• The international working party
flowcytometric assessment of
minimal residual disease in acute
myeloid leukemia
Senan S
Faculty member
• Chest Tumors, European Society for
Medical Oncology
Foundation Council member
• European Thoracic Oncology
Platform
Honorary member
• Belgische Vereniging voor
Radiotherapie en Oncologie
Member Board of key opinion leaders
• Italian Association of Thoracic
Oncology
Member
• accreditation committee, American
Radium Society
Program director
• Novalis Circle Meetings
Secretary-treasurer
• Dutch Society for Radiobiology
(NVRB)
Board member
• Dutch Commission on Radiation
Dosimetry (NCS)
Slotman BJ
Sminia P
113
Apendix 5: Indicators of esteem
Associate
Function
Organisation
Starink TM
Board Member
• International Society of
Dermatopathology
• Nederlandse Werkgroep voor
Dermatopathologie
Member
• Concilium Dermatologicum et
Venereologicum
• Medische Specialisten Registratie
Commissie
Member
• Werkgroep Vulvapathologie van de
Stichting Onderwijs Oncologische
Gynaecologie
• Nederlandse Vereniging voor Vulva
Pathologie
• Nederlandse Werkgroep voor
Dermatopathologie
• Medical advisory board PVN
Medical advisor
• Psoriasis Vereniging Nederland (PVN)
Treasurer, member of the Board,
member of the Science committee
• Netherlands Society of Gene Therapy
Member
• Expert group on Advanced Therapy
Medicinal Products, Medicine
Evaluation Board (CBG)
Member
• Medisch advies college LCH
vereniging Nederland
• Internationale commissie LCH-adults
(LCH-A1 klinisch protocol)
• Medical advisory board Roche BV,
Woerden
• Medical advisory board Novartis BV,
Arnhem
• Medical advisory board Celgene BV,
Utrecht
Lunteren Commissie Immunologie
van NVvI
• Werkgroep Leukemie/MDS HOVONSAKK (Nordics)
• SIHON/Nederlanse Vereniging
Cytometry (NvC)
• Continuüm Oncologicum: na/bij
scholing oncologie en hematologie in
Nederland
• Scientific committee on IPSS revison
in MDS (MDS foundation Inc.)
Chair
• Werkgroep NvC sectie MDS en
flowcytometrie
• Werkgroep MDS en flowyctometrie
European LeukemiaNet (WP8)
Member Scientific Board
• MDS flowyctometrie European
LeukemiaNet (WP8)
Member visitatie commissie
• King’s College London (research
program van prof. G. Mufti)
van den Elsen P
Member
• External advisory board the
Biomedical Research Institute
Dr.L.Willems-Instituut, Limburgs
Universitair Centrum, Diepenbeek,
Belgium
van der Horst-Bruinsma IE
Member
• Commissie wetenschappelijke stages
VICI
• NIAZ accreditatiecommissie
• HASVU: overleg huisartsen-medisch
specialisten
Stoof TJ
van Beusechem VW
van de Loosdrecht AA
114
Appendix 5: Indicators of esteem
Associate
Function
Organisation
• werkgroep patiëntenzorg
samenwerking VU-JBI reumatologie
Chair
• commissie “Rode Loper” VUmc,
coördinatiegroep verwijzers
• werkgroep “Beweegdag
Reumapatiënten Amsterdam “
• Landelijke werkgroep Patient
Partners
• Bestuur Netherlands Rheumatoid
Arthritis Surgical Society (NERASS)
• GENetica Research (GENRA)
Amsterdam
Vice-chair
• Dagelijks Bestuur Stafconvent VUmc
van der Sar AM
External Examiner
• Vivi voce (PhD defence), University
of Sheffield, Sheffield, UK
van der Waal I
Board member
• Centraal College van de Nederlandse
Maatschappij tot bevordering der
Tandheelkunde
• Consilium Chirurgicum Oris
Expert
• UICC Telepathology Consultation
Center for odontogenic tissue
Register
• External Evaluation Experts Hellenic
Quality Assurance Agency for Higher
Education (HQAA), Athene,
Griekenland
van Die
Member
• Jenner Scientific Committee of the
Royal Society of Medicine
• Research Networking Programme
“Euroglycoscience”
• Consortium for Functional Glycomics
(NIH, USA)
van Dongen GAMS
Task Force leader and national
coordinator
• EATRIS: The European Advanced
Translational Research Infrastructure
in Medicine.
Member Supervisory Board
• Spinoza center for neuro-imaging
Member Advisory Board
• Macrocyclics Inc, Dallas, USA
van Dulmen-den Broeder E
Board member
• DCOG-LATER
van Egmond M
Evaluator FP7 grants
• EU
van Furth AM
Member
• European Society of Pediatric
Infectious Diseases
• Infectious Diseases Society of
America
• Merck Sharp & Dome Faculty club
• Medical Ethical Commitee VUmc
Advisor
• Nederlandse Meningitis Stichting
Member
• European Society for Pathology
Representative
• Netherlands Society for Pathology
Scientific committe member
• European Immunology meeting
ECI2012
• International Immunology meeting
Kobe 2010
• International Immunology meeting
Rome 2013
Scientific Board member
• KWF
• Dutch Aids Foundation
van Kemenade FJ
van Kooyk Y
115
Apendix 5: Indicators of esteem
Associate
Function
Organisation
Committee member
• ALW Open “Molecuul tot Organisme”
Board member
• Dutch Society of Immunology (NVVI)
Subgroup leader Immune recognition of
glycans
• Consortium for Functional Glycomics
(CFG)
Participating Investigator
• Consortium for Functional Glycomics
(CFG)
van Schaardenburg
Co-organizer
• first international workshop on
preclinical RA, Reade, Amsterdam
26.1.2011
van Vliet SJ
Participating Investigator
• Consortium for Functional Glycomics
(CFG)
Vandenbroucke-Grauls CJME
Chair
• Adviescommissie Centrum
Infectieziektenbestrijding van het
RIVM
• Bestuur Nederlands Tijdschrift voor
Geneeskunde
• Registratiecommissie ISIS, Centrum
Infectieziektenbestrijding van het
RIVM.
Member
• Programmacommissie
Infectieziektenbestrijding van ZonMw
• Programmacommissie Antimicrobiele
resistentie van ZonMw
• European course on hospital
epidemiology and infection control
• Concilium Microbiologicum Medische
Microbiologie
• KNAW-ECOS Erkenningscommissie
onderzoeksscholen
• Subcommissie medische
Wetenschappen
• Bestuur Nederlandse Vereniging voor
Medische Microbiologie
• Antonie van Leeuwenhoek Stichting
• Commissie Wetenschap Sint Lucas
Andreas Ziekenhuis
Evaluator
• European Commission, FP7-Health2011-single-stage
Verbeke JIML
Member
• NVvR (Dutch Society of Radiology)
met lidmaatschap sectie
kinderradiologie
• KBVR (Koninklijke Belgische
Vereniging Radiologie)
• ESPR (European Society of Paediatric
Radiology)
Verdonk IM
Member
• European Org. of Research and
Treatment of Cancer (EORTC)
Quality of Life Group.
• Dutch Working Group on Psychosocial
Screening in Oncology.
• European COST 2103 project.
• Multinational Association for
Supportive Care in Cancer (MASCC)
• Dutch Psychology Society (NIP).
• Dutch Psychosocial Oncology Society
(NVPO).
• American Psychosocial Oncology
Society (APOS).
• International Psychosocial Oncology
Society (IPOS).
• International Society of Internet
Research (ISRI).
116
Appendix 5: Indicators of esteem
Associate
Function
Organisation
• Dutch ENT Society (KNO).
• Dutch Society of Logopedics and
Phoniatrics (NVLF).
• Dutch Society of Voice, Speech, and
Language Pathology (NVSST).
• Dutch Phonetic Sciences Society
(NVFW)
Verweij CL
Member
• Steering committee, EU integrated
program AUTOCURE
• Organising Committee International
organisation of drug targeting, Dubai
• International Society for
Translational Medicine (ISTM)
• European Association for Predictive
and Personalised Medicine (EPMA)
• Biomarker Qualification Working
Group of the FDA
Waisfisz Q
Member
• Scientific Research Committee CWO,
CCA/V-ICI Vumc
Wintzen M
Member
• Commissie patienteninformatie
(Nederlandse Vereniging voor
Dermatologie en Venerologie
Clinical Assessor Dermatology
• Dutch medicines evaluation board
CBG-MEB and EMEA
Research Fellow
• Massachusetts General
Hospital/Harvard Medical School
Member
• LSH (Ambassador
http://www.lifescienceshealth.com)
• Scientific consultant Thomson
Reuters
• Advisory board member Genomic
Enterprise
• Advisory board member of Stichting
Liefde in de stad
• Board member Stichting Tractor
• Member of cultural science group
Great Apes
• Member RNAi Global Initiative
Ylstra B
President elect
• International Society of Cellular
Oncology
Zweegman S
Chair
• Hematology Working Group, Cancer
Center Amsterdam
• The subcommittee on Patient
Logistics, VU University medical
center, Amsterdam
• Subcommissie myeloproliferatieve
aandoeningen
Member
• HOVON Multiple Myeloma Working
group
• Committee for “Rapid Diagnosis in
Oncology patients”
• Organizing committee of the Dutch
Hematology Conference
• Werkgroep Niet-Oncologische
Hematologie van de Nederlandse
Vereniging voor Hematologie
• Commissie Klinische Studies
• European Multiple Network
biobanking committee
• “Biobank lichaamsmaterialen Vumc”,
VU University medical center,
Amsterdam
Wurdinger T
117
Apendix 5: Indicators of esteem
Associate
118
Function
Organisation
Executive Board member
• European Myeloma Net Trialist Group
Appendix 5: Indicators of esteem
Lectures
Associate
Title
Organisation
Appelmelk BJ
The many DC-SIGN ligands of
Mycobacterium tuberculosis : An
enigma in host-parasite research
Consortium of Functional Glycomics
Meeting, 20-22 May 2010, Bethesda,
MD, USA
Why do all the fishes die?
Frontiers in Tuberculosis Research –The
Granuloma: where Pathology meets
Microbiology, June 23-25 2010,
Borstel, Germany
Analysis of mycobacteria with altered
lipoglycan cell wall composition
New TBVAC meeting, 15 -16 Sep 2010,
Paris, France
Mycobacterium tuberculosis DC-SIGN
ligands galore
11 oct 2010, University of Victoria,
Canada
The multiple DC-SIGN ligands of
Mycobacterium tuberculosis
15 oct 2010, Berkeley UNiversity, CA,
USA
Beelen RHJ
EuTRiPD
EuroPD-meeting, 6-8 oktober,
Strasbourg, France
Boers M
Do we need new points to consider in
trials of RA?
EULAR annual meeting Rome, Italy.
Hard words in diagnostic research:
utility, predictive value, likelihood
ratios......
EULAR annual meeting Rome, Italy.
Burden of morning stiffness in RA
Merck Serono Rheumatologie Experten
Forum; Berlin, Germany
Are glucocorticoids disease-modifying
antirheumatic drugs?
Mundipharma symposium on
optimization of glucocorticoids for
rheumatoid arthritis, Copenhagen,
Denmark
Why do we need new remission criteria
for RA?
American College of Rheumatology
Annual Meeting Atlanta, GA, USA
A simple system to measure benefit
and harm simultaneously: the
OMERACT 3 x 3 table
IsoQoL Symposium, Amsterdam
Pitfalls in clinical trials.
Roche International PEARL meeting
Amsterdam
Uveitis in Spondylarthopathy
ASAS international Educational
Courses, 13 January 2010 Berlin and 30
June 2010 Amsterdam
Gastro-enterologie en reumatische
aandoeningen
8 March 2010, Dutch Surinam clinic of
Rheumatology and Infectious Diseases,
Paramaribo, Suriname
Chair and speaker workshop Diagnosis
and Treatment of (axial)
Spondyloarthritis
Charite Hospital, 25 March 2010 Berlin
Molecular margin analysis of head and
neck cancer
Polish study group of head & neck
cancer. February 19, 2010, Poznan,
Poland
HPV and oral cancer: where, when and
why?
3rd International Symposium “Advances
in oral cancer”, November 18, Bilbao,
Spain
HPV in head and neck cancer: time to
solve the problems
Polish Head and Neck Oncology
Workgroup, Poznan, February 19
Genomics of HPV-mediated HNSCC
Mersey Head and Neck Oncology
Research Group, Liverpool, November
19
Braakhuis BJM
Brakenhoff RH
119
Apendix 5: Indicators of esteem
Associate
Title
Organisation
Progression of HNSCC
Meeting on head and neck cancer,
Fanconi Anemia Research Fund,
Chicago, USA , oct. 21
Summary on the meeting of head and
neck cancer
22nd Annual Fanconi Anemia Research
Fund Scientific Symposium , oct 21
Prediction of local relapse in head and
neck cancer by immunostaining of the
surgical margins using biomarkers
identified in a proteomics screen
AHNS, Washington DC, USA, October 28
AML stem cells
3rd AML-BFM Research Symposium, 2728 October 2010, Hannover, Germany
Relevance of stem cell detection at
MRD
3rd AML-BFM Research Symposium, 2728 October 2010, Hannover, Germany
Cuijpers J
Analysis of Intra-Fractional Variability
of the Internal Target Volume during
Stereotactic Radiotherapy in Peripheral
Lung Tumors
52nd Annual Meeting ASTRO, October 31
– November 4, 2010 San Diego, USA
de Boer EM
Autologous cultured skin for hard to
heal leg ulcers: a revolutionary
approach?
Arterial and Venous ulcers of the lower
legs, 27 / 3 / 2010, Affligem-Essene,
Belgium
Autologous cultured skin for hard to
heal leg ulcers
Deutsche Gesellschaft fuer
Phlebologie, 10-13 November, 2010,
Aken, Deutsland
Screening for distant metastases in
head and neck cancer patients by FDGPET(-CT) to avoid futile treatments
Molecular Imaging in Radiation
Oncology. 19 maart 2010, Bruxelles,
Belgium
PET to avoid futile laryngoscopies in
patients with suspicion of recurrent
laryngeal carcinoma after radiotherapy
Molecular Imaging in Radiation
Oncology.19 maart 2010, Bruxelles,
Belgium
Combining FNA and SNB in the
treatment of oral SCC
Fourth international conference on
sentinel node biopsy and radioguided
head & neck surgery. 28 mei 2010.
Copenhagen, Denmark
Screening for distant metastases in
head and neck cancer patients by FDGPET(-CT) to avoid futile treatments
4th World Congress of the International
federation of Head and Neck Oncologic
Societies. 16 juni 2010 Seoul Korea
PET to avoid futile laryngoscopies in
patients with suspicion of recurrent
laryngeal carcinoma after radiotherapy
4th World Congress of the International
federation of Head and Neck Oncologic
Societies. 16 juni 2010 Seoul Korea
Positron emission tomography (PET) in
head and neck cancer: What are the
indications?
4th World Congress of the International
federation of Head and Neck Oncologic
Societies. 17 juni 2010 Seoul Korea
Response evaluation after
chemoradiation for oropharyngeal
carcinoma
Panel oropharynx. 4th World Congress
of the International federation of Head
and Neck Oncologic Societies. 18 juni
2010 Seoul Korea
Electrochemotherapy in head and neck
cancer
The Amsterdam experiece.
Electrochemotherapy 1st International
Users’ Meeting. 19 november 2010,
Bologna Italy
Sentinel node procedure in head and
neck cancer
November 20, 2010, Barretos, Brazil
Enterovirus remains an important
cause of central nervous system
infection in dutch children
ESPID, May 2010, Nice, France
Real-time PCR is the most reliable
method in dectecting enterovirus
ESPID, May 2010, Nice, France
Cloos J
de Bree R
de Crom S
120
Appendix 5: Indicators of esteem
Associate
Title
Organisation
infection
de Gruijl TD
de Winter JP
Eeltink C
Fijneman RJA
Garcia-Vallejo JJ
Gibbs S
Effects on DC subsets of the melanoma
Sentinel Lymph Node of combined local
GM-CSF and CpG-B administration
5th DC-THERA Annual Meeting, 7 May
2010, Athens, Greece
Immune and clinical response
monitoring in patients with metastatic
Hormone-Refractory Prostate Cancer
receiving combined Prostate GVAX and
anti-CTLA4 immunotherapy
8th Annual Cancer Immunotherapy
Meeting CIMT 2010, 26-28 May 2010,
Mainz, Germany
Novel genomic maintenance pathways
identified by studies on Fanconi
anemia and related syndromes
Research visit Cancer Research UK
(host Helen Walden), January 15,
Lincolns Inn Fields Laboratories,
London, UK
Diagnostic overlap between Fanconi
anemia and related syndromes: Beyond
chromosomal breakage
Symposium 80th birthday Traute
Schroeder-Kurth, May 14-16,
Wuerzburg, Germany
Warsaw Breakage Syndrome, a Fanconi
anemia-like disorder associated with
mutations in the FANCJ-like helicase
DDX11
22nd Annual Fanconi Anemia Research
Fund Scientific Symposium, October
21-24, Minneapolis, USA
Genome maintenance pathways
identified by studies on Fanconi
anemia and related syndromes
Research visit University of St Andrews
(host Joanna Parish), November 25, St
Andrews, Scotland, UK
80 Questions and Answers about Cancer
and Sexuality
European Society of Oncology
Pharmacy (ESOP), 29 jan 2010,
Hamburg
Train the trainer: Cancer and sexuality
European Bone Marrow Transplantation
Nurse group, 21 – 24 March 2010,
Wenen
How to administer azacitidine
MDS colloquium, 7-8 may 2010,
Warschau
80 Questions and Answers about Cancer
and Sexuality
2nd Rotterdam Symposium on Cancer
and Sexuality, 4 June 2010, Rotterdam
Identification of prion protein as a cell
surface candidate biomarker for
colorectal adenoma-to-carcinoma
progression
International Society for Cellular
Oncology, 17-19 March 2010, Dresden,
Germany
Cell Surface Proteomics Identifies Prion
Protein as a Candidate Biomarker for
Colorectal Adenoma-to-Carcinoma
Pathological Society, 29 June - 1 July,
2010, St. Andrews, Scotland
DC-SIGN controls immune homeostasis
in the brain
Workshop on Recognition of host and
pathogen glycans by mammalian GBPs
and Mammalian GBPs in immune cell
communication, 20-21 May 2010,
Bethesda, Maryland (USA)
Dendrimers and liposomes as
multivalent systems
Regular network meeting and workshop
“Structural glycoscience: Methods and
instrumentation”, 29 June – 3 July,
2010, Grenoble, France
Quantitative and dynamic analysis of
DC-SIGN-mediated internalization and
intracellular routing using imaging flow
cytometry
NVVI Annual Meeting 2010, 16-17
December, 2010, Noordwijkerhout, The
Netherlands
Homeostatic interaction of CNS myelin
with DC-SIGN-expressing microglia
prevents neuroinflammation
NVVI Annual Meeting 2010, 16-17
December, 2010, Noordwijkerhout, The
Netherlands
Biological Requirements of In Vitro
Models
Workshop: Biophysical stimuli and mass
transport for tissue development, 18-
121
Apendix 5: Indicators of esteem
Associate
Title
Organisation
19 Nov 2010, Lattrop, The Netherlands
Giovannetti E
Griffioen AW
122
Progress on the development of skin
equivalent based assays to distinguish
sensitizers from non- sensitizers and to
determine sensitizer potency
Skin In Vitro, 8-9 June 2010, Frankfurt,
Germany
Allergen mediated Langerhans Cell
maturation and migration in an
immuno-competent skin-equivalent
ITCASS, 21-22 June 2010, Den Bosch
A potential Epidermal equivalent assay
to determine sensitizer potency
ITCASS, 21-22 June 2010, Den Bosch
Use of a collagen / elastin matrix as
transport carrier system to transfer
proliferating epidermal cells to human
dermis in vitro
ETRS, 16 - 17 Sept 2010, Gent, Belgium
Development of an in vitro full
thickness hypertrophic scar model
3rd International Scar-Club meeting,
25-27 march 2010, Montpellier, France
MicroRNA-21: an oncomir under the
spotlight as a potential biomarker of
clinical outcome and determinant of
chemoresistance in pancreatic cancer
XXXIV National congress of the Italian
Society for Pancreas Study (AISP),
October 7-10 2010, Verona – Italy
Identification of MicroRNA-21 as a
potential biomarker of clinical
outcome and a target to overcome
chemoresistance in pancreatic ductal
adenocarcinoma (PDAC)
European Pancreatic Club Congress
(EPC), June 16-19th, 2010, Stockholm –
Sweden
MicroRNA-21 from bench to bedside
and back: a potential marker of clinical
outcome and a target to overcome
resistance to gemcitabine in pancreatic
cancer
Pancreas Club 2010, May 1-2, 2010,
New Orleans, USA
MicroRNA-21 (miR-21) in pancreatic
adenocarcinoma (PDAC): correlation
with clinical outcome and
pharmacological aspects underlying its
role in the modulation of gemcitabine
activity
101st Annual Meeting American
Association Cancer Research (AACR),
17-21 April, 2011, Washington, USA
MicroRNA-21 (MIR-21) in pancreatic
ductal adenocarcinoma (PDAC):
correlation with clinical outcome and
pharmacological aspects underlying its
role in the modulation of gemcitabine
activity
31th Annual Meeting EORTCPharmacology and Molecular
Mechanisms Group, 27-30 January
2010, Toulouse, France
Pharmacogenetics and new
determinants of chemoresistance in
pancreatic cancer
Karolinska Institute Gatroenterology
Department Lectures, 27 November
2010, Stockholm, Sweden
Angiogenesis inhibitors for the
treatment of angiogenic diseases
Spinoza lecture at the dept of
Ophtalmology, Academic Medical
Center Amsterdam, November 30,
2010, Amsterdam
Pros and cons of angiostatic therapy
Spinoza lecture, Academic Medical
Center Amsterdam, November 30,
2010, Amsterdam
How to convert anti-angiogenesis into
effective cancer therapy?
Spinoza Grand Lecture, Academic
Medical Center Amsterdam, November
30, 2010, Amsterdam
Mechanisms of angiogenesis
Invited lecture at the Course on
Mathematical modeling of
angiogenesis, Lorentz Institute, Leiden,
The Netherlands, October 4-8, 2010,
Appendix 5: Indicators of esteem
Associate
Title
Organisation
Leiden
Novel angiogenesis inhibitors for
treatment of cancer
Invited seminar at Sanquin Institute
Amsterdam, September 20, 2010,
Amsterdam
Novel ways tot target angiogenesis as
treatment for cancer
Invited lecture at the EANO
Educational Day, September 16,
Maastricht
Novel pathways of angiogenesis
inhibition for the treatment of cancer
Invited lecture at the DONAMO
symposium, Netherlands Cancer
Institute, March 12, Amsterdam
Comparison of the clinical performance
of cobas® 4800 HPV detection assay
with Hybrid Capture 2 (hc2) in
population-based cervical screening
Rotkreuz Symposium 2010, November
2010, Luzern/Rotkreuz, Swiss
Symposium Optimal and Optical
Genomics, August 2010, Amsterdam,
The Netherlands
Micro-array CGH and microRNA
Comparison of the clinical performance
of cobas® 4800 HPV detection assay
with Hybrid Capture 2 (hc2) in
population-based cervical screening
Meeting Human Papilloma Virus testing
and cervical cancer, May 2010,
Vilvoorde, Belgium
Comparison of the clinical performance
of cobas® 4800 HPV detection assay
with Hybrid Capture 2 (hc2) in
population-based cervical screening.
Session: cervical cancer screening:
Evolution from cytology to HPV testing
Eurogin, February 2010, Monte Carlo,
Monaco
Triage of HPV-positive women by non
morphological methods. Session SS 8 :
Performance and clinical value of HPV
DNA testing and genotyping
February 2010, Monte Carlo, Monaco
Ilarregui JM
Role of galectin-1 in dendritic cell
physiology
French Society for Dendritic Cells,
December 16th and 17th, 2010, Pasteur
Institute. Paris, France
Jansen G
Bortezomib resistance associated with
mutations in the PSMB5 gene is
overcome by the novel proteasome
inhibitor 5-amino-8-hydroxyquinole
(5AHQ)
EORTC-Pharmacology and Molecular
Mechanism group, January 27, 2010 –
January 30, 2010, - place meeting:
Toulouse, France
Peptide epoxyketone-based
proteasome inhibitors are substrates
for P-glycoprotein (ABCB1) but not for
multidrug resistance-associated protein
1-5 (ABCC1-5) and breast cancer
resistance protein (ABCG2)
3rd FEBS Special Meeting “ATP-Binding
Cassette (ABC) Proteins: From
Multidrug Resistance to Genetic
Diseases”, February 28, 2010 – March 5,
2010, Innsbruck, Austria
The role of multidrug resistance efflux
transporters in cancer and
inflammation
June 16, 2010, University De La
Laguna, Tenerife, Spain
Mechanisms of proteasome inhibitor
resistance (invited lecture)
IV International Workshop On Myeloma
Genetics, Pharmacogenomics & Novel
Therapeutics, September 26-28, 2010,
Cape Cod, Boston, U.S.A.
Resistance to antifolates
3rd International Symposium on Folate
Receptors and Transporters, October
12-15, 2010, Zion National Park, UT,
U.S.A.
Label-free mass spectrometry-based
proteomics for biomarker discovery
and validation in tissues and biofluids
Annual meeting Nederlandse
Vereniging voor Massaspectrometrie:
‘’Mass spectrometry in aMSterdam, 28
Heideman DAM
Jiménez CR
123
Apendix 5: Indicators of esteem
Associate
Title
Organisation
Oct, 2010, Amsterdam
Kaspers GJL
124
Mass spectrometry in aMSterdam
Annual meeting Nederlandse
Vereniging voor Massaspectrometrie:
‘’Mass spectrometry in aMSterdam, 28
Oct, 2010, Amsterdam
Label-free proteomics targeted to subcellular compartments for candidate
biomarker discovery and early
detection of colorectal cancer
1st International Proteomics
Conference on Crete – IPCC01, 8 Oct,
2010, Heraklion, Greece
CSF proteomics for biomarker discovery
in mild cognitive impairment and
Alzheimer’s disease
Workshop on Biomarkers in the early
diagnosis of neurodegenerative
disorders, 4 june, 2010, Assisi, Italy
Targeted mass spectrometry-based
proteomics strategies for biomarker
discovery and validation in colorectal
cancer
Advanced Proteomic Applications in
Clinical and Life Sciences Symposium,
13 april, 2010, Aberdeen, Schotland
Targeted Mass Spectrometry-based
Proteomics Strategies for Biomarkers
Discovery and Validation in Colorectal
Cancer
International Cancer Biomarker
Consortium Conference, 23 march,
2010, Seatlle, USA
Pediatric AML
Amsterdam School of Pediatric
Oncology, 12 January 2010, Amsterdam
Pitfalls in pediatric oncology
First Course on Pediatric Oncology, 18
January 2010, Eldoret, Kenya
Febrile neutropenia and infections in
pediatric oncology
First Course of Pediatric Oncology, 18
January 2010, Eldoret, Kenya
Pediatric relapsed AML
Annual pediatric oncology/hematology
meeting EPHO, 25 March 2010, Cairo,
Egypt
Pediatric APL
Annual pediatric oncology/hematology
meeting EPHO, 26 March 2010, Cairo,
Egypt
Clinical Management of Problems in AML
EHA course on Pediatric
Oncology/Hematology, 8 April 2010,
Sorrento, Italy
Pediatric APL: ICC APL Study 01
Annual I-BFM-SG meeting, 2 October
2010, Antalya, Turkey
Indication for SCT in AML in CR1
Annual I-BFM-SG meeting, 2 October
2010, Antalya, Turkey
Relapsed AML
Annual I-BFM-SG meeting, 2 October
2010, Antalya, Turkye
Bortezomib in relapsed ALL
Annual I-BFM-SG meeting, 3 October
2010, Antalya, Turkey
Round Table: old drugs for AML
Childhood Leukemia Symposium, 5
October 2010, Antalya, Turkey
Cytogenetics in relapsed AML
Annual SIOP meeting, 23 October 2010,
Boston, USA
Pediatric AML
Research Course on Pediatric
Hematology, 10 November 2010,
Billund, Denmark
ICC APL
International Consortium APL of ASH, 2
December 2010, Orlando, USA
CNS involvement in pediatric relapsed
AML
Annual meeting of ASH, 6 December
2010, Orlando, USA
Appendix 5: Indicators of esteem
Associate
Title
Organisation
Kirtschig G
Klinik, Diagnostik und Therapie des
mucosalen Lichen planus
Vorarlberger interdisziplinärerVulvaWorkshop 2010, 23 04 – 24 04, 2010,
Feldkirch, Österreich
The pregnancy dermatoses – patient
education
EADV congress Gothenburg, October
2010, Gothenburg, Sweden
Lichen sclerosus bij Lichen sclerosus in
families, bij kinderen en vulvaire
kanker
Lichen sclerosus informatiedag
(Nederlands patientenvereniging),
30.10.2010, De Bilt
Consequences of antimicrobial class
restriction
Hot Topic Symposium – Healthcare
Associated Infection, 2 februari 2010,
Edinburgh
New strategies to prevent surgical site
infections
Aseptic Surgery Forum, 26-27 maart
2010, Parijs
Decolonisation of carriers
3rd Joint Conference German Society
for Hygiene and Microbiology (DGHM)
and Association for General and
Applied Microbiology (VAAM), 28-31
maart 2010, Hannover
New horizons in the diagnosis of
baceterial sepsis
20th European Congress of Clinical
Microbiology and Infectious Diseases
(ECCMID), 10-13 april 2010, Wenen
MRSA bacteraemia and endocarditis –
treatment considerations
20th European Congress of Clinical
Microbiology and Infectious Diseases
(ECCMID), 10-13 april 2010, Wenen
In the surgical unit: improving patient
safety by ignoring resistance
20th European Congress of Clinical
Microbiology and Infectious Diseases
(ECCMID), 10-13 april 2010, Wenen
From theory to clinical practice
ESCMID-SHEA-ASID Comprehensive
Course in Hospital Epidemiology
Course, 21-25 juni 2010, Port Douglas,
Queensland, Australia
Surgical site infections: new
perspectives for diagnosis and
prevention
50th ICAAC, 12-15 september 2010,
Boston
Prevention of surgical site infections
using antimicrobial strategies: aiming
at zero
50th ICAAC, 12-15 september 2010,
Boston
Kuipers-de Wilt L
Mechanisms of acquired bortezomib
resistance in non-small cell lung cancer
cells: Potential role of autophagy
Pharmacology and Molecular
Mechanisms Group (PAMM), January 2830 2010, Toulouse, France
Ladenius-Lischer L
An improved hybrid IMRT technique for
delivery of high dose radiation to
patients with large St III lung tumours
ESTRO, September 2010, Barcelona
Lagerwaard FJ
Synchronous Brain Metastases From
NSCLC: Time for Reappraisal of
Extracranial Treatment Options?
2nd European Lung Cancer Conference,
30th April 2010, Geneva, Switzerland
New trials in early stage non-small cell
lung cancer comparing surgery and
radiotherapy
2nd European Lung Cancer Conference,
29th April 2010, Geneva, Switzerland
Health-Related Quality of Life (HRQOL)
after Stereotactic Body Radiotherapy
(SBRT) for Stage I Non-Small Cell Lung
Cancer (NSCLC)
ESTRO, September 15th 2010,
Barcelona, Spain
Initial experience with HybridArc™
radiosurgery planning for intracranial
targets
5th International Conference of the
Novalis Circle, June 18th 2010,
Feldkirchen, Germany
Stereotactic radiotherapy for lung
European Respiratory Society, 22nd
Kluytmans JAJW
125
Apendix 5: Indicators of esteem
Associate
Leemans CR
Lems WF
126
Title
Organisation
cancer
September, 2010, Barcelona, Spain
Positron emission tomography (PET) in
head and neck cancer patients: what
are the indications?
4th World Congress of International
Federation of Head and Neck Oncologic
Societies, June 15-19, 2010, Seoul,
Korea
Recent Progress in Management of the
Neck
4th World Congress of International
Federation of Head and Neck Oncologic
Societies, 15-19, 2010, Seoul, Korea
Oral Cancer, Parapharyngeal Tumors
2010 Global CME program “Current
Concepts in Head and Neck Surgery and
Oncology” nternational Federation of
Head and Neck Oncologic Societies,
October 3-5, 2010, Frankfurt, Germany
Oral Cancer. Parapharyngeal Tumors
2010 Global CME program “Current
Concepts in Head and Neck Surgery and
Oncology” nternational Federation of
Head and Neck Oncologic Societies,
October 7-9, 2010, Antalya, Turkey
Oral Cancer. Parapharyngeal Tumors
2010 Global CME program “Current
Concepts in Head and Neck Surgery and
Oncology” nternational Federation of
Head and Neck Oncologic Societies,
October October 10-11, 2010, St.
Petersberg, Russia
Oral Cancer. Parapharyngeal Tumors
2010 Global CME program “Current
Concepts in Head and Neck Surgery and
Oncology” nternational Federation of
Head and Neck Oncologic Societies,
October 13-15, 2010, Bangalore, India
Oral Cancer. Parapharyngeal Tumors
54th Annual Convention of the
Phillippine Society of OtolaryngologyHead and Neck Surgery/2010 Global
CME program “Current Concepts in
Head and Neck Surgery and Oncology”
International Federation of Head and
Neck Oncologic Societies, October 1720, 2010, Manila, Phillippines
Oral Cancer. Parapharyngeal Tumors
2010 Global CME program “Current
Concepts in Head and Neck Surgery and
Oncology” International Federation of
Head and Neck Oncologic Societies,
October 21-23, 2010, Shanghai, China
Oral Cancer. Parapharyngeal Tumors
2010 Global CME program “Current
Concepts in Head and Neck Surgery and
Oncology” International Federation of
Head and Neck Oncologic Societies,
October 25-27, Rio de Janeiro, Brazil
Oral Cancer. Parapharyngeal Tumors
2010 Global CME program “Current
Concepts in Head and Neck Surgery and
Oncology” International Federation of
Head and Neck Oncologic Societies,
October 28-30, 2010, Mexico-City,
Mexico
Treatment of Head and Neck Cancer
Name meeting: Innovative Tumor
Therapies, Master Course Oncology
Vumc, December 3, 2010, Amsterdam,
The Netherlands
Vertebral Fractures
EULAR (Rome), Juni 2010
Imaging of the spine
Biomarker meeting Oslo, October 2010
Denosumab, state of the art
Rumania, 25th of September
Appendix 5: Indicators of esteem
Associate
Mebius RE
Title
Organisation
Teriparatide and quality of life
Hungary, 1th of October
How immune cells talk with stromal
cells in immune-mediated
inflammatory diseases
May 25, 2010, symposium, AMC,
Amsterdam, invited lecture
June 18, SFB 571 "autoimmune
reactions" symposium, Munich, invited
lecture
October 1, 2010, Amsterdam, EMIG
conference, invited lecture
Meijer GA
Meijerink WJHJ
Mooi WJ
Ouwehand I
Peters GJ
Biology and clinic of colorectal cancer
ISCO 2010 Congress, ISCO, Dresden,
March 17 – 19, 2010
Translating colorectal cancer biology
into clinical applications
European Multidisciplinary Colorectal
Cancer Congress, Nice, France, 28-30
March 2010
No polyp, no cancer. Is it that simple?
OMED CRC SC meeting, DDW, New
Orleans, May 1, 2010
CTMM DeCoDe: translational research
on colorectal cancer in the Netherlands
NCI-NRCI joint meeting, Bethesda,
June 21-22, 2010
Peroperative management of leakage
of low colorectal anastomosis
EAES congress, Geneva June 16-19,
2010
Sentinel node in colorectal cancer.
Surgery on the cutting edge
Barcelona December 10, 2010
Salvage of low GI anastomosis
NVEC congress Curacao October 9-12,
2010
Single Port Surgery
NVEC congress Curacao October 9-12,
2010
Melanocytic lesions of the conjunctiva
and upper aerodigestive tract
British Dermatopathology Course, 11
maart 2010, Liverpool, Engeland
Oncogene-induced senescence
Third Science Conclave of nobel
Laurates, 8-14 december, 2010,
Allahabad, India
Oncogene-induced cellular senescence
Indian National Congress of Clinical
Chemistry, 14 december 2010,
Mumbai, India
Pathology of Pulmonary Hypertension
PY Patil medical University Sepcial
International Seminar, 15 december,
2010, Mumbai, India
Glycan modification of OVA alters
interaction with dendritic dells,
enhancing cross-presentation and Th1skewing
Dutch tumor immunology meeting,
June 2010, Breukelen
Glycan modification of OVA alters
interaction with dendritic dells,
enhancing cross-presentation and Th1skewing
NVVI annual meeting, December 2010,
Noordwijkerhout
Introduction to the Lloyd Kelland
Lecture: Herbie Newel: personalized
treatment in oncology
EORTC PAMM Group meeting, January
27-30, 2010, Toulouse, France
What can the PAMM group bring to
EORTC NOCI?
EORTC Group - Annual meeting, March
18-19, 2010, La Hulpe, Belgium
Pharmacogenomics in pancreaskanker
Universiteit van Antwerpen, June 23,
2010, Antwerp, Belgium
MiR-21 in pancreatic adenocarcinoma:
prognostic or predictive?
EORTC PathoBiology Group, September
9-10, 2010, Marseille, France
127
Apendix 5: Indicators of esteem
Associate
Title
Organisation
Pharmacogenetics and genomics to
guide personalized treatment of
gastrointestinal cancer
Universidad Catolica de Chili, October
27, 2010, Santiago, Chili
Multidrug resistant efflux pumps in
tumor resistance; role of localization
and signaling
Chilean Society for Cell Biology,
November 5, 2010, Pucon, Chili
Innovative anti-cancer drugs
National Cancer Center “Giovanni
Paolo II’, 25 years of life of the
National Cancer center of Bari: what’s
new?, December 10, 2010, Bari, Italy
Progress in CSF biomarker discovery for
mild cognitive impairment and
Alzheimer’s disease by label-free
quantitive proteomics
Human Proteome Organisation (HUPO)
9th Annual World Congress, 20
September, 2010, Sydney, Australia
Strategies for analyzing spectral count
data in label-free tandem mass
spectrometry-based proteomics
Fall Meeting Netherlands Proteomics
Platform 2010, 15 October, 2010,
Utrecht
Allergy to insulines
Contact Allergy meeting, 16.01. – 20.01
2010, Lisabon, Portugal
Clinical implications of new insights in
contact allergy
Contact Allergy meeting, 16.01. – 20.01
2010, Lisabon, Portugal
Allergic contact dermatitis
Immunology meeting, 22.01. –
24.01.2010, Gotheburg, Zweden
Pathomechanisms of allergic contact
dermatitis
Hispano-Latin Dermatology course,
22.04. – 25.04.2010, Barcelona, Spain
Sensitivity of the skin: genetics in
allergic skin diseases
ESCD –GERDA, 15. – 18.09.2010,
Strasburg, France
Cross-reactivity: immunological
background
ESCD –GERDA, 15. – 18.09.2010,
Strasburg, France
Immunogenetics in Contact Dermatitis
ESCD –GERDA, 15. – 18.09.2010,
Strasburg, France
Immunologcal mechanisms of insulin
allergy and treatment
EECDRG, 24. – 26. September 2010,
Copenhagen, Denmark
European Patch test data 2005-2009
EECDRG, 24. – 26. September 2010,
Copenhagen, Denmark
Contact allergy to metals
EECDRG, 24. – 26. September 2010,
Copenhagen, Denmark
Modern Techniques in the diagnosis of
allergic contact dermatitis
EADV, 06. – 10.10.2010, Copenhagen,
Denmark
Schuurhuis GJ
Stem Cells in acute myeloid leukemia
7th SICICS National Congress, Sept 24th
2010, Rimini (Italy)
Senan S
Oligometastatic disease: The role of
stereotactic radiotherapy
Treatment of oligometastatic disease
21st January 2010, Institut Gustave
Roussy, Paris
New insights in the treatment of stage
I NSCLC
Western Canadian Lung Cancer
Conference, 29th January 2010,
Vancouver
Novel horizons in radiotherapy of lung
cancer
Symposium on ‘Critical issues in lung
cancer research – the Swedish
Approach and the International
Standards’. Feb 18-19, 2010, Karolinska
Institutet, Stockholm
Treatment of lung cancer using
advanced imaging and RapidArc
British Institute of Radiology Presidents
Conference 2010. Managing Respiratory
Motion in Radiotherapy. 13 - 14 May
Pham TV
Rustemeijer T
128
Appendix 5: Indicators of esteem
Associate
Title
Organisation
2010, London
Slotman BJ
Stereotactic Body Radiation Therapy
(SBRT) versus Surgical Resection in
operable stage I NSCLC
International China-US SBRT trial
meeting. June 8, 2010. University of
Michigan Medical School, Ann Arbor,
Michigan
RapidArc for conventional and
stereotactic radiotherapy: Experience
with the first 750 patients
Eröffnungssymposium Univ. Klinik für
Strahlentherapie-Radioonkologie June
23rd 2010. Graz, Austria
Volumetric modulated radiotherapy:
Applications to Stereotactic
Radiosurgery
Annual meeting of the American
Association of Physicists in Medicine,
Educational Course. 19th July 2010.
Philadelphia
Stereotactic radiosurgery for lung
tumours
24th Annual Meeting of the European Association
For Cardio-Thoracic Surgery . 11 September
2010, Geneva
Stereotactic radiotherapy for lung
cancer: results, toxicities and
implementation
Autumn meeting of the Belgian Society
of Radiation Oncology. 24-25th
September, Limelette, Belgium
Do we need histology before
stereotactic radiotherapy for lung
cancer? Pro and contra.
Autumn meeting of the Belgian Society
of Radiation Oncology, 24-25th
September, Limelette, Belgium
Locally advanced non-small cell lung
cancer: Reasons for failure of two key
(EORTC, Intergroup) to show
differences
Autumn meeting of the Belgian Society
of Radiation Oncology. 24-25th
September, Limelette, Belgium
Early stage NSCLC: Role of stereotactic
radiotherapy
International Symposium on Thoracic
Surgery. 8 Oct 2010, University
Hospital Gasthuisberg, Leuven, Belgium
RapidArc for Stereotactic radiotherapy
and novel indications.
Rapid Arc Symposium. 14th October
2010, University College Hospital,
London
Discussant - Stereotactic radiotherapy
for lung tumors I
52nd Annual meeting of the American
Society for Radiation Oncology.
October 31 - November 4, 2010, San
Diego
Density Changes on Computed
Tomography after Stereotactic Lung
Radiotherapy: An Analysis of the
Relationship between Dose and Lung
Injury in 50 Patients
52nd Annual meeting of the American
Society for Radiation Oncology.
October 31, November 4, 2010, San
Diego
Concurrent chemo-radiotherapy for
stage III NSCLC: A single center
approach outside clinical trials
Symposium on Recent Advance in the
Radiotherapy of Lung Cancer December
2, 2010, Asan Medical Center, Seoul,
Korea
Stereotactic body radiotherapy: A new
standard in stage I NSCLC?
4th AsiaPacific Lung Cancer
Conference. December 3-4th, 2010,
Seoul, Korea
Stereotactic radiotherapy for early
stage NSCLC
MD Anderson Cancer Center, Orlando,
USA, 4-1-2010
Guidelines for radiotherapy staffing
and infrastructure in Europe
Scottish Radiotherapy Group, Stirling,
UK, 11-2-2010
Radiotherapy planning and organization
in the Netherlands
Ministry of Health, Glasgow, Scotland,
11-2-2010
SBRT for Stage I lung tumors
Moores Cancer Center, UCSD, San
Diego, USA, 22-2-2010
Whole brain radiotherapy with
simultaneous integrated boost for
EORTC ROG, Barcelona, Spain, 10-032010
129
Apendix 5: Indicators of esteem
Associate
Title
Organisation
patients with multiple brain
metastases
Sminia P
Stoepker C
van Beusechem VW
130
New technologies for stereotactic
radiotherapy. Radiocirurgia basada en
la evidencia
XII Congress of the Spanish
Radiosurgery Society, Barcelona, Spain,
22-04-2010
Stereotactic radiotherapy: The new
standard
2nd European Lung Cancer Conference
(Int Ass Study of Lung Cancer and Eur
Soc Medical Oncology). Geneva,
Switzerland, 29-04-2010
SBRT for early stage NSCLC
American Radium Society, Cancun,
Mexico, 3-05-2010
Treatment of lung and liver tumors
using BSRT
European Novalis Symposium. Frankfurt
an der Oder, Germany, 18-05-2010
Radiochirurgie spinaler Prozesse
Symposium Neuromedizin, Erfurt,
Germany, 28-05-2010
Role of SRT in Stage I non-small cell
lung cancer
Novalis Circle, Munich, Germany, 1706-2010
Use of Novalis Tx with RapidArc for
treatment of 3 or more brain
metastases
Novalis Circle, Munich, Germany, 1806-2010
RapidArc for stereotactic radiotherapy
Varian Symposium, ESTRO, Barcelona,
Spain, 14-09-2010
Stereotactic radiotherapy of stage I
NSCLCL
AnnMeeting Soc Bras Radioterapia,
Campinas, Brazil, 22-10-2010
SBRT of spinal tumors
AnnMeeting Soc Bras Radioterapia,
Campinas, Brazil, 23-10-2010
First clinical experience with
TrueBeam technology
Varian Users meeting, San Diego, USA,
30-10-2010
Optimal use of radiation in small cell
lung cancer
Excellence in Oncology: Cutting edge
findings into clinical practice, Athens,
Greece, 19-11-2010
Studies on glioma cells: MGMT status
and response to temozolomide,
radiation and nelfinavir
25th Conference on Clinical and
Experimental Research in Radiation
Oncology (CERRO), Les Menuires,
France, January 22, 2010
MGMT status of human glioma cells and
response to temozolomide, irradiation
and Nelfinavir
6th Annual Conference of the
Organisation for Oncology and
Translational Research; “Oncological
Biomarkers and Clinical Applications”;
26-27 February 2010, Kyoto, Japan
Re-Irradiation
29th conference of the European
Society for Radiotherapy and Oncology,
12-16 September 2010, Barcelona,
Spain
SLX4, a coordinator of structurespecific endonucleases, is mutated in a
new Fanconi anemia subtype
DNA repair group, September 10,
Leiden
SLX4, a coordinator of structurespecific endonucleases, is mutated in a
new Fanconi anemia subtype
DNA 22nd Annual Fanconi Anemia
Research Fund Scientific Symposium,
October 21-24, Minneapolis, USA
SLX4, a coordinator of structurespecific endonucleases, is mutated in a
new Fanconi anemia subtype and
possibly associated with hereditary
breast cancer
najaarssymposium NVHG, November
19, Amsterdam
Exploiting RNAi to enhance the cancer
RNAi Global meeting, October 11-13,
Appendix 5: Indicators of esteem
Associate
Title
Organisation
cell killing potency of oncolytic
adenoviruses
2010, London, UK
Identification of miRNAs that modulate
adenovirus replication in cancer cells
RNAi Global Host-Pathogen Working
Group meeting, October 11, 2010,
London, UK
van de Loosdrecht AA
NVvB, NVvH, Expert meeting Leukemia
and Lymphoma, European Dendritic
Cell Society (EMDS), Antibody targeting
Conferences, MDS WP ELNet, European
Clinical Cytometry, MDS foundation
Inc, en seminars in Oxford, London,
Barcelona
van den Elsen P
Regulation of MHC class I and class II
expression
August 25, 2010, 14th International
Congress of Immunology, August 22-27,
2010, Kobe, Japan
van der Lelij P
Warsaw breakage syndrome: a novel
cohesinopathy associated with
mutations in the XPD helicase family
member DDX11/ChlR1
DNA repair group, January 8, Leiden
Warsaw breakage syndrome: a novel
cohesinopathy associated with
mutations in the DNA helicase DDX11
Genetica Retraite Rolduc, March 18-19,
Kerkrade
van der Pas MHGM
Infrared detection of the sentinel node
in colorectal cancer
ISNS Yokohama, November 17-20, 2010
van der Sar AM
Vicious in fish: T7SS deficient
mycobacteria gain virulence
Disease modelling III, Cancer, Blood
Development & Immune Responses,
June 21-24, Boston, USA
van der Waal I
Oral leukoplakia
2nd International Course on Oral
Mucositis, 26 February 2010, Vicenza,
Italy
Premalignant oral disorders
2nd International Course on Oral
Mucositis, 26 February 2010, Vicenza,
Italy
Management of premalignant lesions of
the oral mucosa
Voorjaarsvergadering Koninklijke
Belgische Vereniging voor Stomatologie
en Maxillo-Faciale Heelkunde, 20 March
2010, Brussels, Belgium
Oral cancer; diagnosis and treatment
European Master Degree on Oral Laser
Application (EMDOLA), 5 June 2010,
Parma, Italy
Oral leukoplakia; diagnosis and
management
2nd International Course on Oral
Mucositis, 26 February 2010, Vicenza,
Italy
Potentially malignant disorders
Oral Healthcare for People Living with
Cancer, 11 June 2010, London, United
Kingdom
Second primary tumors
Oral Healthcare for People Living with
Cancer, 11 June 2010, London, United
Kingdom
Milestones and history (BSOM / EAOM)
10th Biennial Conference of the
European Association of Oral Medicine
(EAOM), 21-25 September 2010,
London, United Kingdom
Surgical pathology of the salivary gland
Annual Meeting of the Royal Belgian
Society of ENT, Head and Neck
Surgery, 22-23 October 2010, Genk,
Belgium
Early diagnosis in oral cancer: is it
III International symposium Advances in
131
Apendix 5: Indicators of esteem
Associate
van Die I
van Dongen GAMS
van Egmond M
van Furth AM
132
Title
Organisation
possible?
Oral Cancer. Spanish Society of Oral
Medicine, 18-19 November 2010,
Bilbao, Spain
Parasite glycans as targets for
serodiagnosis and vaccination
strategies
3rd Annual Meeting of Glycoscience
Ireland, 2010, August 31st and
September 1st, University College
Dublin, Ireland
Immune regulation by glycoconjugates
of parasitic helminths
2010 Annual Conference of the
American Society for Glycobiology, 710, 2010, St. Pete Beach, Florida, USA
Brussels, How can imaging technology
contribute to more efficiënt drug
development?
Advancing Biologics from the lab to the
clinic, 11-12/1/2010
The EGFR story from a molecular
imaging point of view
MIRO, international conference on
Imaging in Molecular Radiation
Oncology, Brussels, 18-20/3/2010
ImmunoPET: shedding light on clinical
antibody therapy
IRIST, 20th Meeting of the International
Research group in Immuno-Scintigraphy
and Therapy, 7-10/4/2010, Groningen
The use of PET in drug development
University of Oxford, 9/8/2010, Oxford
Monoclonal and multiclonal targeting:
immunohistochemistry in vivo
Optimal and optical genomics,
13/8/2010, Amsterdam
Open innovation: bridging the gap
MipTec, 23/9/2010, Basel
Immuno-PET: potential applications
Symposium: The Future of Immuno-PET
in Drug Development, 10/10/2010,
Basel
Improved tumor targeting of anti-EGFR
Nanobodies through albumin binding
1th symposium on: Single Domain
Antibodies Come of Age, 1415/10/2010, Ghent, Belgium
IgA and it’s receptor FcαRI in immunity
and autoimmunity
University of Freiburg, January 21st,
2010, Freiburg, Germany
Immunoglobulin A Fc receptor (FcαRI):
a blessing or burden?
University of Dundee, April, 6th, 2010,
Dundee, UK
Targeting the immunoglobulin A Fc
receptor (FcαRI) on neutrophils for
tumour therapy.
Recombinant Antibodies, June 14th17th, 2010, Berlin, Germany
IgA and its receptor FcαRI in chronic
inflammation
University of Limoges, May 20th, 2010,
Limoges, France
IgA and its receptor FcαRI in chronic
inflammation
FASEB ‘Immunoreceptors’, July 5th-9th,
2010, Snowmass, USA
IgA and neutrophil FcaRI in chronic
inflammation
University of Calgary, October 28th ,
2010, Calgary, Canada
Targeting the immunoglobulin A Fc
receptor (FcαRI) on neutrophils for
tumour therapy
f Star Biotech company, November 26th
, 2010, Cambridge, UK
Central nervous system infections in
children
International Dutch Society of
Neuroradiology, april 2010, Groningen,
The Netherlands
Bacterial meningitis
Research meeting Pediatric Neurology,
March 2010, Cape Town, SA
Central nervous system infections in
children
ESCMID bacterial meningitis meeting,
September 2010, Izmir, Turkey
Kinderen en infecties; balanceren op
het slappe koord
Behandeling van lage
luchtweginfecties. Brugge-dagen,
Appendix 5: Indicators of esteem
Associate
Title
Organisation
Vaalsbroek, Alumini lezing TBM
township project
van Kooyk Y
Innate recognition receptors
Sao Paulo Immunology, Graduate
Course, 8-11 February, 2010, Sao
Paolo, Brazil
Dendritic cells and C-type lectin
receptors:coupling innate to adaptive
immune responses
Symposium on Research and Recent
Progress in Immunology, 12 February
2010, Sao Paolo, Brazil
DC targeting using glycan modification
of antigen
Seminars West Scotland Immunology
Group, 23 February, 2010, Glasgow,
Schotland
Glycan modification and the induction
of immune responses
Invited seminar, GSK, Shanghai, China,
24 March 2010, Shanghai, China
DC targeting using anti-DC-SIGN
antibodies
ICA-2010, 26 March, 2010, Beijing,
China
DC targeting to improve anti cancer
therapy
World Vaccine Conference, 28 March,
2010, Beijing, China
Dendritic cell targeting using glycolliposomes
NIH-CFG, US, 20-22 May 2010, 20-22
May 2010, Bethesda, US
Glycosylated tumor antigens and DC
function
Glycomarkers for Disease, 13-15
September 2010, Wierzba, Polen
Dendritic cells in the control of
homeostasis and inflammation in MS
MS-Immunology-Meeting, 31 October
and 1 November 2010, Nottingham,
Great Britain
Glycodendrimers to inhibit pathogen
interaction to DC
Carmusys mid term meeting, 12-14
December 2010, Milaan, Italy
van Schaardenburg
ACPA in very early rheumatoid arthritis
4th biomarker meeting, Oslo 29.10.2010
van Vliet S
Glycosylation-dependent regulation of
T cell function by the C-type lectin
MGL
Workgroup 2 & 3 meeting of the
American Consortium for Functional
Glycomics, 20th and 21st of May 2010,
Bethesda, Maryland (USA)
Glycodendrimers to inhibit pathogen
interaction to DC
Carmusys Milaan, Italy, 12-14
December 2010
Detection of pathogens in sepsis:
molecular detection versus culture
20th ECCMID, April 10-13, 2010, Vienna,
Austria
Surgical site infections
ESCMID-SHEA-ASID Comprehensive
Course in Hospital Epidemiology and
Infection Control, June 18-24, 2010,
Port Douglas, Queensland, Australia
Clinical Experience with RapidArc
ESTRO September 2010, Barcelona
Clinical experience of using RapidArc
(RA) for Stereotactic Body
Radiotherapy
Varian Users Meeting, ESTRO 2010.
September 2010, Barcelona
Disease management, stepped care and
e-health
Symposium Kwaliteit van leven,
overleven en regie bij de patient met
hoofd-halskanker. Erasmus
Universiteit, Rotterdam, December 10,
2010
Disease management and e-health to
facilitate and innovate supportive care
in cancer patients
Symposium Trends and developments
in cancer survivorship care.
Netherlands Cancer Institute,
Amsterdam, November 12, 2010
Aan het werk met het OncoKompas
Congres Kanker en Arbeid 2, CAGA,
Amsterdam, October 8, 2010
Vandenbroucke-Grauls CMJE
Verbakel WFAR
Verdonck I
133
Apendix 5: Indicators of esteem
Associate
Title
Organisation
Psychological distress in cancer
Alpe d’HuZes Cancer Rehabilitation
Research A-CaRe Meeting 2.
Amsterdam, October 4, 2010
Patient reported outcome in clincal
practice: OncoQuest and OncoCompass
EORTC Quality of Life Group. Leipzig,
Germany, September 23, 2010
Cancer survivorship: research and
clinical practice in the Netherlands
Workshop Cancer Survivorship. MASCC,
Vancouver, Canada, June 23, 2010
Computerized monitoring of quality of
life in cancer patients
University Hospital Antwerpen,
Belgium, April 26, 2010
Patient reported outcome and
supportive care
4th European Conference on Head and
Neck Oncology. Athens, 4-6 March,
2010
Disease management in cancer
patients: the development of a
stepped care strategy
Medicine2.0, Maastricht, The
Netherlands, November 29-30, 2010
Patient reported speech and
swallowing outcome after
chemoradiation for head and neck
cancer
IALP, Athens, Greece, August 25, 2010
Neural network analysis to assess
hypernasality in patients treated for
oral or oropharyngeal cancer
IALP, Athens, Greece, August 26, 2010
Objective assessment of speech quality
in patients treated for a tumour in the
oral cavity or oropharynx
IALP, Athens, Greece, August 26, 2010
Vermeulen C
Identification of adenovirus modulator
genes in human cancer cells by
genome-wide RNAi library screening
13th Annual meeting of the American
Society of Gene and Cell Therapy, May
19-22, 2010, Washington, DC, USA
Verweij CL
Chairman: Symposium “Drug discovery
and therapy in Immunology and
Infection”
International organisation of drug
targeting, 1-5 Feb., 2010, Dubai, UAE
Chairman: plenary session
Annual Congress of Rheumatology, 1013 June, 2009, Papendal, NL
Chairman: Session “Genomics,
proteomics and biomarkers”
MS-Research symposium, 14-15 Dec,
2010, Alphen a.d. Rijn
Genomics in preclinical rheumatoid
arthritis
EU-AUTOCURE, 25-26 Jan. 2010, Berlin,
Germany
Drug discovery and therapy in
Immunology and Infection
International organisation of drug
targeting, 1-5 Feb., 2010, Dubai, UAE
Genomic biomarkers in Rheumatoid
Arthritis
GREES symposium on Rheumatoid
Arthritis, 19-21 March, 2010, Paris,
France
Type I interferon system in rheumatoid
arthritis
EULAR congress, 16-19 June, 2010,
Rome, Italy
Relevance of type I interferons in
rheumatoid arthritis
Seminar program “MedImmune”, 4
Nov., 2010, Washington, USA
Transcriptomics and proteomics in
immunology
EFIS-EJI symposium, 1-4 Dec., 2010,
Paris, France
Genomics, proteomics and biomarkers
in multiple sclerosis
MS-research symposium, 14-15 Dec.,
2010, Alphen a.d. Rijn
Pharmacodynamics of B-cell depletion
in Rheumatoid Arthritis”
EU-AUTOCURE, 25-26 Jan, 2010, Berlin,
Germany
Genetic Variation within IRF5 is
Associated with Responsiveness to IFNβ
Symposium Neuroscience Center
Amsterdam (NCA), 1 April, 2010,
Vosslamber S
134
Appendix 5: Indicators of esteem
Associate
Wondergem MJ
Ylstra B
Zweegman S
Title
Organisation
in Multiple Sclerosis
Amsterdam
Responsiveness to IFNβ treatment in
Multiple Sclerosis: role of IFN signature
and IFN genetics in health and disease
Symposium Netherlands Inflammation
Network (NIN), 7 April, 2010, Lunteren
Pharmacodynamics of B cell depletion
in Rheumatoid Arthritis
Symposium Dutch Society for
Rheumatology, 23 Sept., 2010,
Papendal
IRF5 gene variant as biomarker to
predict the IFNβ response in Multiple
Sclerosis
ECTRIMS congress, 13-16 Oct., 2010,
Götenburg, Sweden
Inhibition of the intrinsic apoptosis
pathway in follicular lymphoma is
caused by dysregulation of the
mitochondria
Dutch Hematology Conference January
2010
Different transplantation strategies in
transformed non-Hodgkin’s lymphoma;
a single center experience
Dutch Hematology Congres January
2010
Molecular Cytogenetics in Oncology:
From Technique to Therapeutic Target
Golden Helix Symposium® on Genetic
Analysis in Translational Medicine, dec
2010, Athens (GR)
Array CGH from FFPE tissues
ESHG European Society of Human
Genetics, June 12 – 15, Gothenburg
(SE)
Molecular Cytogenetics in Oncology:
From Technique to Therapeutic Target
3rd Course in the Integration of
Cytogenetics, Microarrays and Massive
Sequencing in Biomedical and Clinical
Research, 16-20 okt 2010, Bologna (I)
Molecular Cytogenetics in Oncology:
From Technique to Therapeutic Target
Methods of DNA analysis: state of the
art, June 2010, Braga (Pt)
A randomized phase III study in MM
comparing MPR versus MPT
Investigator Research meeting Celgene,
June 2010, Frankfurt
135
Apendix 5: Indicators of esteem
Awards
Name
Award
Place and date
Assaraf Y
KNAW visiting award
KNAW, Amsterdam
Beelen RHJ, M. Schilte
Best poster at EuRoPD
EuRoPD, 8 oktober, Strasbourg
Giovannetti E
Travel grant
14th International Symposium on Purine
and Pyrimidine Metabolism in Man,
Tokio, Japan, 2011
EORTC-PAMM Best Poster Grant
(Coauthor of the poster: The regulation
of BCRP expression and localization by
EGFR pathway in NSCLC cells: role of
erlotinib)
31st Winter Meeting of the EORTCPAMM group, Toulose, 31 January – 2
February 2010
AISP Young Investigator Grant (Coauthor
of the abstract “Loss of Heterozygosity
(LOH) status of D9S105 marker is
associated with down-regulation of
Kruppel-Like Factor 4 (KLF4) expression
in Pancreatic Ductal Adenocarcinoma)
XXXIV National congress of the Italian
Society for Pancreas Study (AISP),
Verona, October 7-10, Italy, 2010
Griffioen AW
Spinoza Chair of the Faculty of
Medicine, University of Amsterdam
Academic Medical Center Amsterdam,
November 30, 2010
Kirtschig G
Asia-Pacific Foundation: Clinical paper
publication prize 2010; awarded by La
Roche-Posay for the paper “Safety of
topical corticosteroids in pregnancy”
September 2010
Medical Microbiology and Infection
Control
100,000 euro grant of the Calouste
Gulbenkian Foundation (Portugal)
The project is a collaboration between
the Institute for Molecular and Cell
Biology (IBMC) at the University of Porto
(Portugal), the Department of Medical
Microbiology and Infection Control at
the Vrije Universiteit Medical Center
(the Netherlands) and the Netherlands
Vaccine Institute
van de Broek L
NVED poster prize
Lunteren, January 2010
ETRS poster prize
Lunteren, January 2010
van der Kuip M
ESPID/Wyeth Fellowship Award
Nice, France, May 4-8
van der Waal I
Honorary Membership (2008) of the
European Association of Oral Medicine
(EAOM)
10th Biennial Conference of EAOM.
London, UK. 25 September 2010
Honorary Fellow of the British Society
for Oral Medicine (BSOM)
10th Biennial Conference of EAOM.
London, UK. 25 September 2010
Honorary Member (2009) of the Greek
Association of Oral Medicine
Announced by George Laskaris on 16
March 2010
136
Appendix 5: Indicators of esteem
Grants obtained in 2010
Project leader(s)
Title project
Funding / budget
Appelmelk BJ
Analysis of mycobacteria with altered lipoglycan
cell wall composition
Gulbenkian Foundation/TBVI, 100.000 Euro
Beelen RHJ
Role of macrophages in excessive scarring of the
burned skin
NWO Mozaiek no 017.006.012, AIO + benc
fee € 200.000, PhD student: B. Mahdavian
Delawary
The role of chemokines, macrophages and
fibroblasts in skin and mucosal scar formation
MOVE, PhD student; € 200.000
Preservatie van de peritoneale membraan door
verveterde macrofaagfunctie onder invloed
vitDreceptor activatie
Nierstichting C09.2331, PhD student +
bench fee, PhD student: A. Stavenuiter
Fibrose en ontstekingsremmende middelen voor de
verbetering van wondgenezing bij brandwonden
Nederlandse Brandwonden stichting no
10.109, PhDstudent + bench fee; € 360.000
Bitter W
Regulation of virulence factors in Pseudomonas
aeruginosa: the surface connection
NWO CW ECHO, 253 kEuro, PhD student:
Karlijn Bastiaansen
Boers M
Translation of PROMIS item bank into Universal
Dutch: project registered in EMGO+ research
Institute
Reumafonds, € 80.000
Byrne, Verheul, Scherer,
Griffioen
Angiotox, 2010 – 2014
EU 7th framework, € 3.000.000
Castelijns JA
Wetenschappelijk onderzoek MRI contrastmiddelen
€ 55.000
Cillessen SAGM, Meijer
CJLM, Ossenkoppele GJ
Identification of targeted therapies for anaplastic
large cell lymphoma based on apoptosis expression
profiles
KWF grant, 517.000 euro, NWP en WP
Cloos J, Kaspers GJL
Protein tyrosine phosphatome sequencing in
childhood acute myeloid leukemia
KiKa/Children Cancer-free, 66.000,-, M.
Irandoust (postdoc)
de Gruijl TD, van de
Loosdrecht AA
A safety and feasibility study of a novel type of
dendritic cell vaccine (DCOne) in patients with
Acute Myeloid Leukemia (AML)
ZonMW Translational Research Grant 4041200-98-9106, € 500,000.-
de Vries, 12 partner
consortium
CTMM MAMMOTH - Imaging of breast cancer, 2010 –
2014
Dutch government 03O-201, CTMM, €
15.000.000
de Winter JP, Dorsman JC,
den Dunnen JT
Identification of novel players in the Fanconi
anemia pathway
KWF VU2010-4767, € 351.000 (Post-doc +
benchfee)
de Winter JP, Van Attikum
H, Te Riele H
Sister chromatid cohesion: lessons from yeast, mice
and men
TOP-GO 854.10.013, € 750.000 (PhD student
+ two post-docs + benchfee)
Dekker J
Future Functional Status in Osteoarthritis of the
Knee: Impact of Neuromuscular, Psychological and
Clinical Factors
Move-Age Grant
Garcia-Vallejo JJ
Productie en analyse van glyco-varianten van Derp1
die de immuunrespons onderdrukken in Astma
Astma Fonds (3.2.10.040), € 240.841, PostDoc: Juan Martín Ilarregui (from 1 January,
2010)
Gibbs S
A Human, In Vitro, Full-Thickness TissueEngineered Skin Model To Investigate Hypertrophic
Scar Formation
Ned. Brandwonden Stichting; (project
number: WO/P08.103), 2nd half of project
granted: € 294.000
Gibbs S (VUMC), Ulrich M
(ADBC Beverwijk)
Application of cultured autologous keratinocytes in
combination with a meshed split skin autograft for
burn wound healing
Ned. Brandwonden Stichting; (project
number: WO/P07.116); (2010-1011)
Gibbs S, Niessen F, Scheper
RJ (CEO A-Skin)
AgentschapNL IS (planned start 2011)
€ 750,000
Gibbs S, Scheper RJ (CEO ASkin)
Development of a novel wound healing formulation
for advanced wound management
EuroTransBio (2010-2013), € 700,000 /
PostDoc/ arts onderzoeker / analist +
benchfee)
137
Apendix 5: Indicators of esteem
Project leader(s)
Title project
Funding / budget
Gibbs S, Scheper RJ (CEO ASkin), Veerman E (ACTA)
Novel saliva-derived peptides for state-of-the-art
clinical wound-healing applications
STW (2010-2014), € 600,000 / OIO + 2
technicians + benchfee)
Gibbs S, Teunis M, Casati S,
Corsini E
Pre-validation of a two tiered approach to
determine the skin sensitizing capacity and
potential of chemicals
Zon Mw PAD(2010-2012), € 432,000
Gibbs S, van Bree JWM,
Pemen AJM
Commercialization of Enhanced Cell Proliferation
Reactor (ECPR) for the culture of Skin Substitutes
Zon Mw PreSeed grant (2010-2012), €
250,000 / analist + benchfee
Gibbs S, Vriens BP
Mucosa
Zon Mw Preseed grant (2010-2012), €
250,000 / PostDoc + benchfee)
Giovanetti E
Targeting key microRNA & signaling pathways to
fight pancreas cancer aggressive behaviour and
chemoresistance
AIRC-Marie Curie, € 85.000,-
Targeting c-Met and related signalling networks in
distinct cell subpopulations to fight pancreatic
cancer invasion and chemoresistance
NWO – VENI (number 91611046), obtained
July 20th 2010, project starts on January 1st
2011, 200.000 for salary, 50.000 bench fee
Giovannetti E, Peters GJ,
in collaboration with
Minutolo and Leon
Synthesis and Biological Evaluation of Inhibitors of
Human Lactate Dehydrogenase-5 as Cancer
Starvation Agents
EORTC-PAMM Mini grant, 5000 euro for
bench fee
Jansen G
The visiting professorship of prof.dr Y.G. Assaraf
Royal Netherlands Academy of Arts and
Sciences (23.000 Euro), Netherlands
Organization for Scientific Research/NWO
(22.300 Euro), Dutch Arthritis Association
(19.000 Euro), and KiKa (21.000 Euro)
Janssen JJWM
Immunophenotypic stem cell identification and
quantification in chronic myeloid leukemia and its
role in predicting response to tyrosine kinase
inhibitor treatment
Novartis, 1 NWP
Jimenez CR
Diagnose en prognose van Alzheimer door
massaspectrometrische detectie van specifieke
amyloid-bèta peptide fragmenten in liquor
combinatie met patroon analyse
Hersenstichting Nederland, 35K, NWP
Validation of a panel of novel candidate biomarkers
for the non-invasive early detection of colorectal
cancer: Innovative multiplex MRM mass
spectrometry essay development and evaluation of
diagnostic performance in faeces and blood
Life Science Validation Fund, 55K, WP
Kaspers GJ, Assaraf YG,
Cloos J, Peters GJ, Jansen G
The role of impaired FPGS splicing in methotrexate
response in childhood ALL
KiKa, 156.000 Euro, PhD student: Drs. A.
Wojtuszkiewicz
Kaspers GJL
Translational research in low-income
countries on treatment compliance in
pediatric oncology
VONK, 60.000,-, S. Mostert (postdoc)
Translational research in diffuse intrinsic pontine
gliomas
Stichting Semmy, 100.000,-, E.H. Hulleman
Kaspers GJL, Gemke RJ
Glucocorticoid induced HPA axis
suppression in childhood acute
lymphoblastic leukemia and lymphoma
KWF Kankerbestrijding/Dutch Cancer,
Society (VU 2010-4859), 260.900,-, Suzanne
Gordijn (PhD student)
Klein M, Reijneveld J,
Verdonck-de Leeuw IM
Internet-based treatment of low-grade glioma
patients with depression and fatigue: randomized
controlled trial VU 2010-480
KWF Dutch Cancer Society:, € 288.300.
Kluytmans J
Assessing the need for isolation in a single room of
patients colonized with highly resistant
Enterobacteriaceae: a cluster-randomized trial
ZON MW, € 498.270
Kruyt FAE, Peters GJ,
Jansen G
Mechanisms of acquired bortezomib resistance in
non-small cell lung cancer cells: Potential role of
autophagy
EORTC-PAMM fellowship (travel grant), €
800,-, PhD student:Leonie Kuipers-de Wilt
Meijer CJLM, Snijders PJF,
Heideman DAM,
Self-Screen: biomarker-based companion diagnostic
of HPV positive women to detect cervical cancer
ZON-MW Life Sciences Pre-seed Grant. 235
k€
138
Appendix 5: Indicators of esteem
Project leader(s)
Title project
Funding / budget
Meijer CJLM, Snijders PJF,
Heideman DAM, van
Kemenade FJ
Schadelastreductie baarmoederhalskanker (BMHK)
door vernieuwend beleid t.a.v. niet-deelneemsters
BVO BMHK
Zorgproject Stichting Achmea
Gezondheidszorg.. 323.1 k€
Meijer GA
Translation research IT infrastruture
CTMM-TraITT, initially 8M€ max 20M€ (total
budget will be established in 2011)
Meijer GA, Heideman DAM,
Smit EF, Verheul H
Doelmatige medicatiebehandeling van oncologische
patiënten door moleculaire tumor-fijndiagnostiek
voor pre-therapeutische stratificatie
LPT grant. 150 k€
Meijerink WJHJ
Near Infrared Fluorescent Imaging of the Sentinel
Node
CCA/V-ICI (toekenningsnummer CCA2010401) € 250.000, PhD students: MHGM van der
Pas, M Ankersmit
Peters GJ
Mechanism of action of RX3117
Rexahn, NWP
Peters GJ, Giovannetti E
Development of LDH inhibitors
EORTC PAMM group
Savelkoul PHM
IS-pro: A molecular tool for clinical diagnostics of
inflammatory bowel disease (NGI
Life Sciences Pre-seed Grant (93610005),
total € 237.500,00 (24 mdn)
Bacterial DNA Load (BDL)
ZonMw 205100007, total € 391.966,00 (36
mdn), PhD student: Marre v.d. Brand
Sminia P (Radiotherapy
VUmc), Stalpers LJA
(Radiotherapy AMC),
Baumert BG (Radiotherapy
MUMC)
Targeting resistance to radio-chemotherapy by
inhibition of the PI3Kinase-Akt signaling pathway
Dutch Cancer Society # VU2010-4874, 1 WP
4, 1 NWP 4, 459,400 euro
Unger WJ
Antigen-specific inhibition of encephalitogenic Tcells by selective targeting of corticosteroid/
antigen-loaded liposomes to cervical lymph node
dendritic cells
MS Research Stichting (10 – 725 MS), €
50.000
van den Elsen PJ
Monocyte dysregulation in MS
€ 49.473,-
van der Horst I
Kwaliteitsonderzoek verbetering patiëntenzorg M.
Bechterew
Educational Grant Wyeth 25.000 euro, PhD
student S van Weelij
Fundraising for the organisation of the
Reumabeweegdag Amsterdam
40.000 euro
Prevention of the progression of very early
symptoms into Ankylosing
Spondylitis: a placebo controlled trial with
etanercept (PREVAS)
Investigator initiated study: 350.000 euro,
Phd Student S Weismann
A phase 0 single microdose study to evaluate the
pharmacokinetics/-dynamics and specific targeting
properties of 124-I-F*IL10 in patients with active
rheumatoid arthritis
Philogen, Zwitserland € 50.000,
Promovendus: Y.Y.J. Gent
PET-CT of biodistribution of rituximab in relation
to therapeutic outcome and histological response
of lymphoid tissue in rheumatoid arthritis patients
Roche Nederland, € 255.850 (plus € 60.000
voor samenwerkende groep Reumatologie in
AMC), H.G. Raterman, S.T. Bruijnen (PhD
students)
van Dulmen-den Broeder E
(VUmc), van den Berg MH
(VUmc), Hilders C (NNF),
ter Kuile M (LUmc)
Knowledge, attitudes and practices
regarding fertility preservation in young
females with cancer
KiKa and VONK, 68.862,- euro, A.Overbeek
(PhD student)
van Egmond M
Novel Antibody-Based Therapy for Ulcerative Colitis
AgentschapNL: ‘anti-UC’, € 500.000
van Egmond M, Vidarsson G
(Sanquin)
Increasing Therapeutic Efficacy of IgG’s in
Melanoma
LSCA Validatiefonds, € 50.000
van Furth AM, Smulders Y,
Van Agtmael M
HIV research grant
Nuffic, € 85.000, PhD: Titus Msoka (KCMC,
Tanzania)
Steenbergen RDM
van der Laken J
139
Apendix 5: Indicators of esteem
Project leader(s)
Title project
Funding / budget
van Kemenade FJ
Prohtect -3 in collab with CJLM Meijer, DAM
Heideman & PFJ Snijders
VWS, PhD student V. Verhoef
van Kooyk Y / Kruisbeek A
Novel DC-based vaccine for breast cancer
Eurotransbio, € 625.200, Post-Doc and
technician
van Vliet S
Spatial dynamics of lectin-carbohydrate
interactions
NWO VENI (ALW nr. 863.10.017), € 250.000
(WP)
Verdonck-de Leeuw IM,
Eerenstein S, Leemans CR,
de Bree R
LARiNX: a web-based self-help programme for
laryngectomized patients during and after
treatment
Michel Keijzer Foundation:, € 199.600. PhD
student: Ingrid Cnossen
Verdonck-de Leeuw IM,
Ganzevoort R
Spiritual Autobiographic writing for cancer patients
Addessium Foundation / RCOAK:, €
175.500. PhD student: Jannette Delver
Verdonck-de Leeuw IM,
Gerritsen WR, Leemans CR,
de Bree R, van Kalken C,
Kraaijenhagen RA, Cuijpers
P
OncoCompass: Development and pilot testing of an
e-health management platform to optimise disease
management in cancer patients
NDDO Foundation:, € 375.000. Postdoc: dr
N van Uden-Kraan
Verdonck-de Leeuw IM,
Steunenberg B
Structured life review using autobiographical
retrieval practice in depressed palliative head and
neck cancer patients
ZonMw: 1151.0003, € 228.642, PhD student:
Irene Riepma
Vos J, Tollenaar R (LUMC),
Verdonck-de Leeuw IM
The development, implementation and evaluation
of the meaning-centered group psychotherapy
'Living Meaningfully with Cancer' in the Netherlands
KWF Dutch Cancer Society:, € 596.500
Waisfisz Q, Meijers H, de
Winter JP, Verheul H
Towards targeted treatment of (familial) breast
cancer
CCA/V-ICI PV10/13, 4 years salary for a PhD
student + € 22,000 bench fee, PhD student:
Janine L Bakker
Windhorst AD, Ussi A, van
Dongen GAMS
Financing Laboratory for Good Manufacturing
Practice (GPM2) for tracer productions
6.4 M€. Subsidy: EFRO, “Kansen voor West”:
2.6 M€, Roche research grant: 150.000 k€
Wurdinger T
Cross-talk in the brain tumor micro-environment
NWO-VIDI, WP 600k€/benchfee 200k€,
2xPhD, Dr. Petra van der Stoop and Dr.
Jordi Berenguer
Wurdinger T, Jeuken J
Elucidation of Temozolomide resistance in
glioblastoma
Stophersentumoren.nl2010, Benchfee 98k€
Wurdinger T, van der Stoop
P
RNAi screening to inhibit glioblastoma migrationinduced radiation resistance
Stophersentumoren.nl2010, Benchfee 90k€,
Ylstra B
Identification of Chromosomal Aberrations Driving
Metastatic Colorectal Cancer Development
Stichting Sacha Swarttouw-Heijmans, euro
25K, Leonie Mekenkamp (UMC St
Radboud)(PhD student)
Ylstra B, Reijneveld JC, vd
Valk P
Prediction of early progression in low-grade glioma
patients
KWF (VU-2009-4470), euro 246K, Hinke
Thuijl (PhD student)
140
Appendix 5: Indicators of esteem
Meeting organization
Project leader(s)
Meeting
Place / date
Ang W
Course Serologisch Diagnostiek van Infectieziekten
June 2010, Amsterdam
Bitter W
NvMM, NvvM voorjaarsvergadering
19-21 april, Papendal
Dekker J
Member of the program committee of the Eleventh
International Congress of Behavioral Medicine
Augustus 2010, Washington
Jansen G
3rd International Symposium on Folate Receptors
and Transporters
October 12/15, 2010, Zion National Part,
US, U.S.A.
Jimenez CR
Fall meeting Netherlands Proteomics Platform
Oct 15, 2010, Utrecht
Kaspers GJL
First Workshop on Pediatric Oncology
18-19 January 2010, Eldoret, Kenya
Meeting of the International Pediatric AML Steering
Committee
2 October 2010, Antalya, Turkye
Annual meeting of the International Pediatric AML
Group
5 December 2010, Orlando, USA
Biomarker meeting
Oslo. 28th October 2010
ASBMR Working Group”Osteoporosis in Rheumatic
Diseases”
17th October 2010, Toronto
The osteoporosis lesson (de osteoporose les)
10 december, Leiden, Symposium
IWO meetings, 2 scientific evenings
Utrecht (7 april and 6 october)
scientific meeting weekend
27th of November
Meijer GA
ISCO Congress
March 17-19, 2010, Dresden
Meijerink WJHJ
NVEC Congress: Voorsprong door techniek
Amersfoort, March 15-16
NVEC Congress
October 9-12, Curacao
Peters GJ
EORTC PAMM meeting
Januari, Toulouse
Rustemeyer T
Themadag NVDV
18.1.2010, Utrecht, Nederland
Dermatologendag NVDV
16.-18.03.2010, Arnhem
Voorjaarsvergadering NVvA 2009
19.3.2010, Amersfoort
Huidveroudering
21.4.2010, Utrecht
EECDRG
04/06.05.2010, Heidelberg, Duitsland
ESCD
15/18.09/2010, Strasburg, Nederland
Bijscholing NVDV
04/10/2010, Noordwijkerhout
Dermatologendag
15/10/2010, Amsterdam
EECDRG
23-25.10.2010, Barcelona, Spain
Themadag NVDV
26-10-2010, Utrecht
Najaarsvergadering NvvA
20-11-2010, Amersfoort
Compendium Dermatologie
14-12-2010, Utrecht
Symposium Stereotactic Body Radiotherapy
27-29 January 2010, Amsterdam
Novalis Circle Meeting
Munich, Germany
Unger WWJ
Advanced Immunology Symposium
22-9-2010, Amsterdam
van Furth AM
ESPID
Juni 2011, Den Haag
van Kooyk Y
Workshop host and pathogen glycans by mammalian
Glycan binding proteins, CFG, NIH
20-21 May, 2010, Bethesda, USA
Keystone Carbohydrates and the Immune system ,
6-11 March, 2011
Lems WF
Slotman BJ
141
Apendix 5: Indicators of esteem
Lake Louis, Canada
Verdonk I
Ylstra B
142
Living with cancer: mobility of knowledge
21-4-2010, Amsterdam
Fatigue in cancer patients
9-6-2010, Amsterdam
Sexuality and fertility in cancer patients
1-12-2010, Amsterdam
ISCO 2010
March 17-19, 2010, Dresden
Appendix 5: Indicators of esteem
News
G.A.M.S. van Dongen had several press-releases: Announcement strategic partnership VUmc-Philips,
Announcement strategic partnership VUmc-Roche-Genentech, Announcement EATRIS Coordination and
Support office at Vumc. Publication: EATRIS, a Vision for Translational Research in Europe (R Becker,
GAMS van Dongen)
S.A.G.M. Cillessen: VIVA 44, page 37, 2010, one of the 400 young talented women of 2010, category:
smart ☺, Amsterdam, 28 October 2010.
June 2010. Nomination for Amsterdam Invention Award. Invention title: ‘Novel panel of candidate
biomarkers for early detection of colon cancer’. Inventors: Dr. CR. Jimenez (Dept. Med. Onc.), Dr. R.J.A.
Fijneman (Dept. PA), Prof. G.A. Meijer (Dept. PA).
H. Joenje: Synaps 16 April: Zeldzame ziekte geeft inzicht in ontstaan van kanker: Chaotische
chromosomen
C.R. Jimenez: Jan 2010. Installation of new state-of-the-art tandem mass spectrometer (ABI-QTrap 5500)
for multiplexed targeted detection of panels of protein biomarker candidates
143
144
Appendix 6: Societal impact
Appendix 6: Societal Impact
Social-cultural relevance
Professional publications and products
Bosch L
Stool DNA test voor de vroege detectie van dikkedarmkanker, KWF
journaal/tracer/VUmc website artikel
Carvalho B
Key players op chromosome 20 in dikkedarmkankerprogressie, Nieuwsbrief
van Stichting VUmc CCA
Kaspers GJL
Participation in Doctor2Doctor, a collaboration between VU University
Medical Center and KLM Aircares on the one hand, and Moi Teaching &
Referral Hospital, Eldoret, Kenya on the other hand
Kemenade FJ
Bevolkingsonderzoek baarmoederhalskanker: oude problemen en nieuwe
kansen. Oncology update 2010. vol 1 nr 3.
Advisory board publicity HPV vaccination RIVM
Guideline 3.1 cervical cytology for NVVP
BVO BMHK: oude problemen en nieuwe kansen, overzichtsstuk op verzoek,
Oncologie up to date 2010, vol 3, nr 1, pag 5-7
Meijer GA
Veelbelovende resultaten dikkedarmkanker screening programma,
OncoMethylome Sciences
Ylstra B
Array CGH using DNA from Formalin-Fixed Paraffin-Embedded (FFPE) Tissue
Samples, protocol Roche-Nimblegen, Technical Note
MegaPool reference DNA Cat. Numbers EA-100M and EA-100F, product
datasheet Kreatech
Memberships of an advice council in the public field
Ang W
Consensusberaad Diagnostiek Borrelia
Bultink IEM
Membership of the medical advice council of the “Nationale vereniging voor
lupus, sclerodermie en MCTD patiënten (NVLE)”
Membership of the scientific committee of the network for “Patient research
partners” from the “Reuma Patiëntenbond”
Meijer GA
Health Council of the Netherlands, committee National colorectal cancer
screening programme
RIVM: adviescommissie uitvoeringstoets bevolkingsonderzoek darmkanker
Rustemeyer T
EU commission on Comsumers´Health VWS en VWA
Slotman BJ
Commissie Radiotherapie Gezondheidsraad
Voorzitter Taskforce Radiotherapie
CvB, Nederlandse Vereniging Radiotherapie en Oncologie
van Beusechem VW
Netherlands Committee on Genetic Modification (COGEM) review committee
of study report on “non-human viruses as oncolytic agents”
User committee ZonMw Translational Gene Therapeutic Research project on
“oncolytic adenovirus therapy as a neoadjuvant treatment for localized
prostate cancer” at Erasmus Medical Center, Rotterdam
User committee Technology Foundation STW project on “Directed evolution
of artificial viruses” at University of Utrecht, Utrecht
van der Horst IE
Reumafonds
Organisator Beweegdag voor reumapatiënten regio 30 oktober 2010
Amsterdam Sporthal Zuid opkomst ruim 300 patienten
van Dongen GAMS
Member Advisory Board: Macrocyclics Inc, Dallas, USA
145
Appendix 6: Societal impact
van Kooyk Y
Member of the scientific Advisory Board Twincore, Center for Experimental
and Clinical Infection Research GmbH, Hannover
Member of the Scientific Advisory Board Infection Institute, Taiwan
PR representative of Dutch Society of Immunology and Developper of
Immunologisch a bi-annual Newspaper Immunologisch to promote
Immunology in the within the general public in the Netherlands
Indications in a directive, protocol or policy note
Rustemeyer T
Richtlijnen `Lichen sclerosus` en `Contacteczeem`
Contributions, based on research, to post initial education
Ang W
Teaching courses on Molecular Diagnostics in Pathology, Training pathology
residents and clinical pathologists in molecular diagnostics in pathology
Smetsers S, Joenje H
Two lectures, by, to educate the Dutch Fanconi anemia patient support
organization (VOKK working group on FA), 6 November, Driebergen
van der Horst IE
ASAS-course: nascholing internationale reumatologen op gebied van
M.Bechterew, 2-3 maal per jaar
Onderwijs patient Partners
Nieuwe ontwikkelingen bij de ziekte van Bechterew. Nationale Patienten
dagen, 8 oktober 2010, RAI Amsterdam
van Kemenade FJ
Publication Br Med Journal, Volkskrant, trouw
van Kooyk Y
Patent filed: Inventors Y. van Kooyk and W. Unger title “’Methods to suppress
an immune response”’
Media attention
Ang W
Interview/article Heideman DAM. Voorlopers van longkanker te zien in DNA.
Eigen-wijs, 2010, 1:8-9
Beliën JAM/Meijer GA
caBIG: de ICT standaard voor translationeel onderzoek, interview Oncologie up
to date 2010, vol. 1, nr 4
Braakhuis BJM
Interview: http://www.medscape.com/viewarticle/730979
Cillessen SAGM
Viva 400, jonge talentvolle vrouwen 2010, artikel Viva
Geurts J
Groeiende hang naar mystiek vs feitelijke kennis, interview EOS Psyche en
Brein
Heideman DAM
Voorlopers van longkanker te zien in DNA, artikel/interview in the Lancer
Oncology
Jimenez CR
Parool, feb. 2010. Interview met CRJ. Publication title: ‘’Sneller speuren naar
kankereiwit’’
Tracer, feb. 2010. Interview met CRJ. Publication title: ‘’Nieuwe
massaspectrometer gaat jaren tijdswinst opleveren’’
Ziekenhuiskrant, feb. 2010, Pag. 3. Interview met CRJ. Title: ‘’Tijdswinst van
jaren in kankeronderzoek’’
DeCoDe-project, nieuwe massaspectrometer, artikel in Het Parool
Meijer CJLM
Wetenschap zweert bij thuistest, artikel in Telegraaf
HPV thuistest, interview in TROS Nieuwsshow
Aantal kankergevallen daalt door thuistest, artikel in De Volkskrant
Minder sterfte door baarmoederhalskanker door HPV-vaccinatie en beter
bevolkingsonderzoek, artikel/interview in het NRC Handelsblad
HPV vaccinatie, interview/artikel in het NCR Handelsblad
146
Appendix 6: Societal impact
Thuistest vertrouwder dan uitstrijkje, artikel in De Telegraaf
Niet één vrouw in Nederland hoeft baarmoederhalskanker te krijgen, interview
Margriet
Meijer GA
Translating biology into medicine: That’s a challenge, interview caBIG
Middeldorp JM
Kanker in Indonesië, interview in Kracht (kanker magazine)
Nieuwe test voor vroegtijdige detectie van nasopharyngeal carcinoma, press
release/interview
Savelkoul PHM
Nominated for Amsterdam inventor award 2009 (winner in 2008)
Snijders PJF
HPV en keelkanker, interview Radio Amsterdam FM
Steenbergen RDM
Verbeterde controle patienten met baarmoederhalsafwijkingen, interview in
KWF jourmaal
van Beusechem VW
Parool, feb. 2010. Interview met CRJ. Publication title: ‘’Sneller speuren naar
kankereiwit’’
Tracer, feb. 2010. Interview met CRJ. Publication title: ‘’Nieuwe
massaspectrometer gaat jaren tijdswinst opleveren’’
Ziekenhuiskrant, feb. 2010, Pag. 3. Interview met CRJ. Title: ‘’Tijdswinst van
jaren in kankeronderzoek’’
van der Horst IE
TV-presentaties over Reuma: video M.Bechterew 2010
van der Valk P
Pathologen werken amper met doden, interview in Arts in Spe
Vandenbroucke-Grauls CMJE
Was interviewed extensively by NOS because of her expertise on antimicrobial
resistance. This resulted in the dedication of an item of NOS TV- news, of NOS
–radio news, and of the NOS website to antimicrobial resistance. A few months
later a second interview followed, wich again led to an item on NOS TV
journaal. In the same period, prof. dr. P. Savelkoul and prof. dr. J.A.J.M.
Kluytmans were interviewed for Uitgresproken EO and prof. dr. C.M.J.E.
Vandenbroucke-Grauls for RTV-Noord Holland News. Finally, prof. C.M.J.E.
Vandenbroucke-Grauls participated in a programme of Teleac (Helder) on
antimicrobial resistance
Verdonck IM
Oba Live. TV uitzending IKON, 18 oktober 2010
Leven met kanker. Radio-uitzending BNR Gezond, 11 oktober 2010.
Kanker overleefd, maar
vu.onlinetouch.nl/18
doodmoe.
Interview
VU
Magazine,
2010#3.
Het gesprek van de dag. Radio uitzending Radio West, 6 september 2010
De terreur van het positief denken. TV uitzending EenVandaag, 3 augustus
2010.
www.eenvandaag.nl/gezondheid/36215/de_terreur_van_het_positief_denken
De geest beïnvloedt kanker. Maar hoe dan? De Volkskrant, Opinie, 20 juli 2010
Fictieve scheiding tussen lichaam en geest. Interview Tijdschrift Synaps, juni
2010
Wat te doen bij kanker en depressie. Interview Tijdschrift Ode, juni 2010
Leven met kanker. Presentatie tijdens avondprogramma Geldbesteding Alpe
d’HuZes, 2 juni 2010, Alpe d’Huez, Frankrijk.
Een doel maakt gelukkig. Interview Trouw, 2 juni 2010
Alpe d’HuZes professor fietst voor haar geld. NoordHollands Dagblad
Bijna half miljoen Nederlanders leeft met kanker. Radio Uitzending AVRO
Radio 1, 28 april 2010.
Psychosocialeorg. Presentatie Patienteninformatiedag
Amsterdam, 19 april 2010, VUmc, Amsterdam
Cancer
Center
Leven met kanker. Presentatie Vrijwilligersdag KWF Kankerbestrijding, 17 april
2010, Beatrixtheater, Utrecht.
147
Appendix 6: Societal impact
Bergen verzetten. Interview Psychosociale Oncologie 2010, jaargang 18,
nummer 1.
Kanker kan ook een nieuw begin zijn. Interview Parool, 28 april 2010
Leven met kanker. Radio-uitzending NCRV Knoopppunt Kranenbarg, 21 april
2010.
von Blomberg M
Coeliakie wordt vaak over ’t hoofd gezien, artikel in de Synaps
Wurdinger T
Cancer Cell publication media attention: Most Dutch newspapers, and NOS
(Radio and TV), RTL Nieuws (TV), Hart van Nederland (TV)
Perceptible impact on public informing and/or authoritative websites
Ang W
Humaan Papillomavirus - cervixkanker. LCI-richtlijnen
Infectieziektebestrijding, 2008, revised 2010,
http://www.rivm.nl/cib/infectieziekten-A-Z/infectieziekten/ humaan_
papillomavirus _cervixkanker/index.jsp
Rustemeyer T
www.sens-it-iv.eu
www.A-skin.nl
www.mucosa.nl
www.NECOD.nl
Technical or economic impact
Memberships of an advice council in the commercial field
Vandenbroucke-Grauls CMJE
DiagNed
Patent applications
Fijneman RJA, de Wit M, Jimenez CR,
Meijer GA
Patent 2010: PROTEIN-BASED METHODS AND COMPOSITION FOR THE
DIAGNOSIS OF COLORECTAL CANCER. Subject of the invention: The present
invention relates to contrast agents, diagnostic markers and methods for
detecting colorectal adenocarcinomas.
Griffioen AW
Start of Somantix BV. – a dutch biotech company
Jimenez CR
Patent 2010: PROTEIN-BASED METHODS AND COMPOSITION FOR THE
DIAGNOSIS OF COLORECTAL CANCER. Subject of the invention: The present
invention relates to contrast agents, diagnostic markers and methods for
detecting colorectal adenocarcinomas. Inventors:Dr. Remond JA. Fijneman,
Drs. Meike de Wit, Dr. CR Jimenez, Prof. Gerrit A. Meijer
van Beusechem VW
Patent applications: 6 active patent families in 2010, 2 of which were filed in
2010.
Vandenbroucke-Grauls CMJE
Microbial profiling of bacteria
Spin off” start-ups
Ang W
Company Self-screen BV
Gibbs S
CSO of A-Skin BV (see www.A-skin.nl)
Gibbs S
CSO of Mucosa BV (see www.mucosa.nl)
Vandenbroucke-Grauls CMJE
Microbiome Ltd
148
Appendix 7: Ongoing projects
Appendix 7: Ongoing projects
Program 1
Characterization of DNA stability genes and proteins and their role in cancer predisposition
1. Breast cancer predisposition
M. Adank, M.P.G. Massink, Q. Waisfisz, H. Meijers-Heijboer
Dept. of Clinical Genetics, VU University Medical Center, Amsterdam
NWO -VIDI
2. Regulation of replication-coupled DNA maintenance
S. Agarwal, J.P. de Winter
Dept. of Clinical Genetics, VU University Medical Center Amsterdam
NWO/A.L.W.
3. Significance of the Fanconi anemia caretaker pathway in development and treatment of cancer
S.T. Bakker, J.P. de Winter, H. Joenje, H.P.J. te Riele
Dept. of Clinical Genetics, VU University Medical Center, Amsterdam
KWF
4. The Fanconi anemial/BRCA pathway in head and neck squamous cell carcinomas
C.Stoepker1, N. Ameziane1, A.B. Oostra1, M.A. Rooimans1, J.Steltenpool1, S. Martens-de Kemp2, R.H. Brakenhoff2, H.
Joenje1, J.P. de Winter1
1Department of Clinical genetics and 2Department of Otolaryngology/Head-Neck Surgery, VU University Medical Center
5. The role of sister chromatid cohesion in the maintenance of genetic stability
P. van der Lelij, C. Fehres, J. Steltenpool, M.A. Rooimans, A.B. Oostra, H. Joenje, J.P. de Winter
Dept. of Clinical Genetics and Human Genetics, VU University Medical Center, Amsterdam
CCA/V-ICI PV05/05 Prom
Detection and treatment of oral preneoplasia
6. Clinical validation of a non-invasive screening method to detect oral precursor lesions
R.H. Brakenhoff
Dept. Otolaryngology/Head and Neck Surgery, VU University Medical Center, Amsterdam
7. Development of virotherapy using retargeted adenoviruses to eradicate preneoplastic lesions of the oral cavity and
oropharynx
H.J.T. van Zeeburg1, A. Brink1, B.J.M. Braakhuis1, I. van der Waal2, V.W. van Beusechem4, C.R. Leemans1, R.H.
Brakenhoff1
1Section Tumor Biology, Dept. of Otolaryngology/Head-Neck Surgery, 2Dept. of Oral and Maxillofacial Surgery, 3Dept. of
Pathology, 4Dept. Medical Oncology, VU University Medical Center, Amster¬dam
KWF 2004-3045, Fanconi hilfe and CCA 2004-3045
8. Diagnosis and therapy of genetically altered mucosal lesions in the oral cavity and oropharynx
J.F. Bremmer2, A. Brink1,2, J.A.M. Belien3, E. Bloemena3, B.J.M. Braakhuis1, C.R. Leemans1, I. van der Waal2, R.H.
Brakenhoff1
Depts of 1Otolaryngology/Head-Neck Surgery, 2Oral and Maxillofacial Surgery and 3Pathology, VU University Medical
Center
ACTA
9. Fanconi anemia: course of disease in the Dutch patient cohort and early recognition of cancer
S. Smetsers1,3, Brakenhoff RH1, H. Joenje1, J.C. Dorsman1, C.M. Zwaan2, M. Bierings3
3University Medical Centre Utrecht, Erasmus MC/2Sophia Children’s Hospital Rotterdam; 1Department of Clinical
Genetics, VU University Medical Center, Amsterdam
Kika
EBV oncogenesis
10. Physiological role of EBV-LMP exosomes for tumor immune escape across the immunological synaps
F. Verweij, M. van Eijndhoven, D.M. Pegtel, J.M. Middeldorp
Department of Pathology, VU University Medical Center
KWF 2007-3775
Head and neck cancer predisposition
11. Genetic characterization of HNSCC of young adults
B.J.M. Braakhuis1, R.H. Brakenhoff1
1Sect. Tumor Biol, Dept. Otolaryngol/Head-Neck Surg
Intramural support
12. High sensitivity to DNA damage in the aetiology of head and neck squamous cell carcinoma in young adults and
individuals not exposed to tobacco smoke and excessive alcohol (SenseDNA)
B.J.M. Braakhuis1, H. Joenje2, A. Nieuwint2, P. Graveland1, G. Flach1, R.H. Brakenhoff1
1Section Tumor Biol, Dept. of Otolaryngology/Head-Neck Surg, 2Dept of Clin Gen, VU University Medical Center,
Amster¬dam, and 4Dept. Biomolecular Mass Spectrometry, University Utrecht
Intramural support
Head and neck carcinogenesis and cancer genes
13. Clinical significance of human papillomavirus infection in oropharyngeal squamous cell carcinoma
M. Rietbergen, C.R. Leemans, P.J.F. Snijders, B.J.M. Braakhuis, E. Bloemena, R.H. Brakenhoff
1Dept Otolaryngology/Head-Neck Surgery and dept. of Pathology, VU University Medical Center
KWF grant VU 2009-4531
14. Functional characterization of TP53 mutations in head and neck squamous cell carcinoma, and association with
clinical outcome
Technician, R.H. Brakenhoff, C.R. Leemans, M. Buize, B.J.M. Braakhuis
Dept Otolaryngology/Head-Neck Surgery, VU University Medical Center, VU University Medical Center, Amsterdam
CCA/V-ICI, Avanti STR Foundation
149
Appendix 7: Ongoing projects
15. Identification of oncogenic microRNAs and classical cancer genes involved in head and neck squamous cell
carcinoma by a functional genomics approach
M. van der Plas, M. de Maaker, S.J. Smeets, M. Buijze, B.J.M. Braakhuis, C.R. Leemans, R.H. Brakenhoff
1Section Tumor Biology, Dept. of Otolaryngology/Head-Neck Surgery, VU University Medical Center, Amsterdam
CCA/V-ICI, InteRNA,, KWF grant VU 2009-4531 2009-4531
16. MicroRNA in head and neck cancer
R.H. Brakenhoff
Dept. Otolaryngol/Head-Neck Surg, VU Univ Med Center, Amsterdam
HPV-induced tumors
17. A retrospective longitudinal clinical cohort study to investigate HPV testing post-treatment and the risk of
recurrence of (cervical) disease
M. Kocken1, J.A. Louwers1, A. Zaal1, J. Berkhof1 P.J.F. Snijders1, R.H.M. Verheijen2, W.A. ter Harmsel3 ,Th.J.M
Helmerhorst4 ,C.J.L.M. Meijer1
1) VU University Medical Center, Amsterdam, 2) University Medical Center Utrecht, Utrecht, 3) Reinier de Graaf groep,
Delft/Voorburg, 4) Erasmus University Medical Center, Rotterdam
HumaVac
18. Comprehensive analysis of the long-term oncogenic capacity and in vitro transforming property of the 15 high-risk
human papillomavirus types (hrHPVs)
D.M. Schütze, D.A.M. Heideman, C.J.L.M. Meijer, P.J.F. Snijders, R.D.M. Steenbergen
Dept. of Pathology, VU University Medical Center, Amsterdam
HUMAVAC
19. Defining the essential molecular pathways involved in cervical carcinogenesis
F.E. Henken, P.J.F. Snijders, D.A.M. Heideman, C.J.L.M. Meijer, R.D.M. Steenbergen
Dept. of Pathology, VU University Medical Center, Amsterdam
CCA/V-ICI
20. Genetic profiling of CIN 3 lesions diagnosed in the subsequent screening round following screening by HPV testing
and cytology
M. Bierkens, R.D.M. Steenbergen, D.A.M. Heideman, C.J.L.M. Meijer, P.J.F. Snijders
Dept. of Pathology, VU University Medical Center, Amsterdam
CCA/V-ICI
21. HPV self-sampling offered to screening non-attendees
V. Verhoef , M. Gök , D.A.M. Heideman, F.J. van Kemenade A.T. Hesselink, R.D.M. Steenbergen L. Rozendaal , H.
Berkhof, P.J.F. Snijders C.J.L.M. Meijer
Dept. of Pathology Biostatistiek&Epidemiologie, VU University Medical Center, Amsterdam
SAG / RIVM / IKA / SO
22. Human papillomavirus infection and cervical cancer: epidemiology and screening
D. Rijkaard, D.A.M. Heideman, F.J. van Kemenade, B. Hesselink, L. Rozendaal, H. Berkhof, PJF Snijders, CJLM Meijer
Dept. of Pathology, VU University Medical Center, Amsterdam
ZON-MW 22000147 and 6200.0013; RIVM 22000147 / 6200.0013
23. Identification of miRNAs and other ncRNAs as biomarkers for cervical cancer and assessment of their potential
functional relevance in HPV-mediated transformation
S.Wilting , C.J.L.M. Meijer, P.J.F. Snijders, R.D.M. Steenbergen
Dept. of Pathology, VU University Medical Center, Amsterdam
CCA/V-ICI 20085-04
24. Immunogenicity and efficacy of HPV 16/18 l1/AS04 vaccine
J.A. Louwers1, M. Kocken1, A. Zaal1, J. Berkhof1 P.J.F. Snijders1, R.H.M. Verheijen2, W.A. ter Harmsel3 ,Th.J.M
Helmerhorst4 ,C.J.L.M. Meijer1, GSK-Biologicals
1) VU University Medical Center, Amsterdam, 2) University Medical Center Utrecht, Utrecht, 3) Reinier de Graaf groep,
Delft/Voorburg, 4) Erasmus University Medical Center, Rotterdam
GSK Biologicals, Rixensart 104820
25. ix cancer proteomics. Unraveling protein expression changes during HPV-induced transformation using a label-free
proteomics approach
C.R. Jimenez1, C. van Alphen1, T.V. Pham1, S.R. Piersma1, P.J.F. Snijders2, R.D.M. Steenbergen2
1OncoProteomics Laboratory, Dept. Medical Oncology, and 2Dept. Pathology, VUmc Cancer Center Amsterdam, VU
University Medical Center, Amsterdam
CCA
26. PREHDICT: Health-economic modelling of prevention strategies for HPV-related diseases in European countries
H. Berkhof, A.T. Hesselink, D.A.M. Heideman, P.J.F. Snijders, C.J.L.M. Meijer
Dept. of Pathology and Biostatistiek&Epidemiologie, VU University Medical Center, Amsterdam
EU
27. Simplified monitoring post-treatment CIN 2/3 women by molecular testing for hrHPV and methylationmarkers
(SiMoNaTh)
M. Uijterwaal1, M. Kocken1, R.D.M. Steenbergen1, J. Berkhof1 P.J.F. Snijders1, R.H.M. Verheijen2, P. Graziosi3,
C.J.L.M. Meijer1,Th.J.M Helmerhorst4
1) VU University Medical Center, Amsterdam, 2) University Medical Center Utrecht, Utrecht, 3) St. Antonius
Hospital,Nieuwegein, 4) Erasmus University Medical Center, Rotterdam
KWF 2009-4413
28. Stratifying high-risk HPV positive women for risk of CIN 3 and cervical carcinoma by HPV transcript analysis
M. Dijkstra, D.A.M. Heideman, R.H.M. Verheijen, C.J.L.M. Meijer, P.J.F. Snijders
Dept. of Pathology, VU University Medical Center, Amsterdam
KWF VU 2006-3570
29. Stratifying high-risk HPV positive women for risk of CIN 3 and cervical carcinoma by methylation analysis
L. de Strooper, C.J.L.M. Meijer, P.J.F. Snijders, D.A.M. Heideman
Dept. Of Pathology, VU University Medical Center Amsterdam
KWF 2009-4522
150
Appendix 7: Ongoing projects
30. The role of human papilloma virus in non-cervical cancer
R.D.M. Steenbergen, D.A.M. Heideman, M.C.G. Bleeker, S. Wilting, C.J.L.M. Meijer, P.J.F. Snijders
Dept. of Pathology, VU University Medical Center, Amsterdam
NIH R01 CA 114773-01
Lung cancer
31. Evaluation of molecular sputum test diagnostic for lung cancer
A.J. Hubers, D.A.M. Heideman, E.F. Smit, F.B.J.M. Thunnissen
Dept. of Pathology1 and Pulmonology2, VU University Medical Center, Amsterdam
KWF VU 2008-4220
32. Genetic profiling for risk assessment of preneoplastic endobronchial lesions
R. van Boerdonk1, T.G. Sutedja2, P.J.F. Snijders1, S. Wilting1, M. vd Wiel, F.B.J.M. Thunnissen1, S. Duin1, B. Ylstra1,
CJLM Meijer1, GA Meijer1, K Grünberg1, JMA Daniels2, P.E. Postmus2, E.F. Smit2, D.A.M. Heideman1.
Dept. of 1Pathology and 2Pulmonary Diseases, VU University Medical Center, Amsterdam
KWF VU 2007 3898
33. Lung cancer: guiding treatment response with biomarkers
M Doeleman1, M van Moorsel1, S. Duin1, P.E. Postmus2, E.F. Smit2, G.A. Meijer, P.J.F. Snijders1, F.B.J.M. Thunnissen1,
D.A.M. Heideman1
Dept. of Pathology1 and Pulmonary Diseases2, VU University Medical Center, Amsterdam
LPT grant / SRP
Molecular diagnosis and genomics-based staging of head and neck cancer
34. Improving molecular staging of surgically treated head and neck cancer patients: towards rationalized adjuvant
treatment
A.P. Graveland1, M. de Maaker1, E. Bloemena2, B.J.M. Braakhuis1, C.R. Leemans1, R.H. Brakenhoff1
Depts. 1Otolaryngology/Head-Neck Surgery and 2Pathology, VU University Medical Center, Amster¬dam, 3Dept.
Biomolecular Mass Spectrometry, University Utrecht
NKB/KWF 2005-3285
35. Molecular diagnosis of lymph node metastasis in primary head and neck squamous cell carcinoma
S.J. Smeets, C.R. Leemans, B. Ylstra, R.H. Brakenhoff, B.J.M. Braakhuis
Dept. Otolaryngology/Head and Neck Surgery, VU University Medical Center, Amsterdam
NKB/KWF 2006-3694
Personalizing therapy of head and neck cancer
36. Determinants of chemotherapy sensitivity
S.R. de Kemp, C.R. Leemans, B.J.M. Braakhuis, R.H. Brakenhoff
Department of Otolaryngology/Head-Neck Surgery, VU University Medical Center
CCA/V-ICI grant
37. Determinants of radio and EGFR-mediated therapy sensitivity
C.R. Nagel, C.R. Leemans, B.J.M.Braakhuis, R.H. Brakenhoff
Department of Otolaryngology/Head-Neck Surgery, VU University Medical Center
Airforce
Other projects:
38. Cervix cancer proteomics. Unraveling protein expression changes during HPV-induced transformation using a labelfree proteomics approach
C.R. Jimenez1, C. van Alphen1, T.V. Pham1, S.R. Piersma1, P.J.F. Snijders2, R.D.M. Steenbergen2
1OncoProteomics Laboratory, Dept. Medical Oncology, and 2Dept. Pathology, VUmc Cancer Center Amsterdam, VU
University Medical Center, Amsterdam
CCA
39. Characterization and prognostication of salivary gland tumours
H Matse1, GA Meijer2, B Ylstra3, I van der Waal1, E Bloemena1,2
Depts of 1Oral and Maxillofacial Surgery/Oral Pathology, Academic Centre for Dentistry (ACTA), 2Pathology and 3Microarray Unit, VU University Medical Center, Amsterdam
Interuniversitaire Onderzoeksschool Tandheelkunde (IOT)
40. Chromosomal aberrations associated with progression characteristics of low-grade glioma patients
H.F. van Thuijl, J.C. Reijneveld, B. Ylstra, S.J. Smeets, P. van der Valk, J.J. Heimans
Dept. Of Pathology, VU University Medical Center Amsterdam
KWF
41. Clinical and biological relevance of focal aberrations in colorectal cancer
O. Krijgsman1, G.A. Meijer1, B. Carvalho1, R.D. Steenbergen1, B. Ylstra1
Dept. of Pathology, VU University Medical Center, Amsterdam
42. Deep-sequencing non-coding RNAs in cancer exosomes
D. Koppers-Lalic, J.M. Middeldorp and D.M. Pegtel
Department of Pathology, VU University Medical Center
KNAW Beijerinck premium
43. Diagnostic markers for screening and early detection of Nasopharyngeal carcinoma
S. Hutajulu, D.K. Paramita, A.E..Greijer, J.M. Middeldorp
Dept. Of Pathology, VU University Medical Center and Faculty of Medicine, Gadjah Mada University, Yogyakarta,
Indonesia
KNAW-Nuffic, KWF-IN 2004-17
44. EBV non-coding RNAs hijack components of the miRNA machinery promoting viral oncogenesis
D. Koppers-Lalic, J.M. Middeldorp and D.M. Pegtel
Department of Pathology, VU University Medical Center
AICR 11-0157
45. EBV-LMP trafficking into exosomes controls oncogenic signaling
F.J. Verweij, C. Jimenez, D.M. Pegtel. J.M. Middeldorp
Dept. Of Pathology, VU University medical center, Amsterdam
151
Appendix 7: Ongoing projects
KWF-VU 2007-3775
46. EBV-RNA biomarkers in the serum of systemic lupus erythematosus
M. van Eijndhoven, A.E. Voskuyl, I.E.M. Bultink, B.M.E. van Blomberg, J.M. Middeldorp and D.M. Pegtel
Department of Pathology, VU University Medical Center
47. Epstein Barr Virus Activation and cytolytic antiviral therapy in nasopharyngeal carcinoma patients
AE.Greijer, SAMW.Verkuijlen, H.Juwana, M.Wildeman1, J.Kurnianda2, IB Tan1 and JM.Middeldorp
Dept. ENT, Netherlands Cancer Institute, Dept. Medical Oncology, Dr.Sardjito hospital, Gadjah Mada university,
Yogyakarta, Indonesia and Dept. Pathology, VU University medical center, Amsterdam
ZonMW2010, KWF VU 2010-4809
48. Epstein Barr virus elimination by small molecules as treatment for EBV-driven lymphomas and carcinomas
AE Greijer1, I de Esch2, R Leurs2, JM Middeldorp1
1Department of Pathology, VU University Medical Centre 2Division of Medical Chemistry FEW, Chemistry, VU,
Amsterdam, The Netherlands
STW submitted 2010-4557
49. Epstein-Barr virus (EBV) gene expression in African Burkitt Lymphoma
JM Middeldorp1, SA Verkuijlen1, H Juwana1, AE Greijer1, CJLM Meijer1, J Orem2, M.Allday3, E.Piriou4 and
E.Weiderpass5.
1Dept. Pathology, VU University medical center, 2Dept. Oncology, Makarere University Hospital, Kampala, Uganda, 3
Dept. Tumor virology, Imperial College of London, UK, 4Kenya Medical Research Institute, Kisumu, Kenya and 5Dept.
Epidemiology Karolinska Institute, Stockholm, Sweden
project EBV-Burkitt KI-Nordic Cancer Registry
50. Epstein-Barr virus and multiple sclerosis
S.Amor, R.Q.Hintzen, .I.Huitinga, P.van der Valk, J.M.Middeldorp
Dept. Pathology, VU University medical center, Amsterdam, Netherlands Institute for Neurosciences and Nederlandse
Hersenbank, Amsterdam and Dept. Neurology, Erasmus MC, Rotterdam
Erasmus MS Stichting
51. Epstein-Barr virus encoded miRNA in exosomes and their contribution to oncogenesis
D.M. Pegtel, D.A. Thorley-Lawson, J.M. Middeldorp
Department of Pathology, VU University Medical Center and Tufts University, Boston, USA
NWO-Veni, ZonMW2008
52. Epstein-Barr virus markers and epigenetic modulation in carcinogenesis
S.H. Hutajulu, E.K.Hoebe, E. Hopmans, T. Le Large, A.E. Greijer, J.M. Middeldorp
Department of Pathology, VU University medical center
KNAW-Nuffic, KWF travelfund
53. Human genes essential for the defence against oxygen toxicity
M. Corbin, D.A. Rockx, A.B. Oostra, A. Avan, K. Roohollahi, H. van Beek, H. Joenje, J.C. Dorsman
Department of Clinical Genetics, VU University Medical Center, Amsterdam
N.W.O.-Mozaïek; FARF
54. Identification and clinical validation of methylation markers for cervical adenocarcinomas and their precursor
lesions
S. Snellenberg, C.J.L.M. Meijer, P.J.F. Snijders, R.D.M. Steenbergen
Dept. of Pathology, VU University Medical Center, Amsterdam
KWF 2007-3771
55. Identification of novel oncogenes/oncomirs located at 13q involved in the progression of colorectal adenoma to
carcinoma
F.L.M. de Groen, B. Carvalho, R.D.M. Steenbergen, G.A. Meijer
Dept. Of Pathology, VU University Medical Center, Amsterdam
56. IFN-responses by EBV-RNAs in DCs of systemic lupus erythematosus
M. van Eijndhoven, T. de Gruijl, C.L.Verweij, J.M. Middeldorp and D.M. Pegtel
Department of Pathology, VU University Medical Center
57. IVF and retinoblastoma
C.J. Dommering1, A.H. van der Hout2, H. Meijers-Heijboer1, T. Marees3, A.C. Moll41
1Department of Clinical Genetics,VUmc; 2Department of Genetics, University Medical Center Groningen, University of
Groningen, Groningen; 3Department of Epidemiology, Biostatistics and HTA, Radboud University Medical Center,
Nijmegen; 4Department of Ophthalmology,Vumc
58. Mutations in the RB1 gene in Dutch retinoblastoma patients, a nation-wide cohort
C.J. Dommering1, H. Meijers-Heijboer1, A.C. Moll2, A.H. van der Hout3
Departments of 1Clinical Genetics, 2Ophthalmology, VUmc;3Department of Genetics, University Medical Center
Groningen, University of Groningen, Groningen
59. Pathway(s) compensating for FA gene defects: an in-vitro evolution approach
K. Roohollahi, M. Rooimans, A.B. Oostra, D.A. Rockx, J.P. de Winter, H. Joenje, J.C. Dorsman
Department of Clinical Genetics, section Oncogenetics, VU University Medical Center, Amsterdam
60. Proteins interacting with FANCI and FANCN/PALB2
A. Haitjema1, D.A. Rockx1, B. Brand2, J. de Winter1, H. Joenje1, J.C. Dorsman1
1Department of Clinical Genetics, section Oncogenetics, VU University Medical Center, 2IB-VU, Amsterdam
Internal funds; EU-ENFIN
61. Reproductive decisions of parents with an increased risk of having a child with retinoblastoma. A cross sectional
survey
C.J. Dommering1, M. Garvelink1, A.C. Moll,2, J. van Dijk3, S. M. Imhof4, Hanne Meijers-Heijboer1, L. Henneman1,5
1Department of Clinical Genetics, VUmc;2Department of Ophthalmology, VUmc;3Department of Medical Psychology,
VUmc;4Department of Ophthalmology, University Medical Center Utrecht, Utrecht;5Department of Public and
Occupational Health, EMGO Institute for Health and Care Research, VUmc
62. Risk of second primary malignancies after hereditary retinoblastoma according to type of RB1 mutation
C.J. Dommering1, T. Marees2,3, A.H. van der Hout4, S.M. Imhof2,5, H. Meijers-Heijboer1, Peter J. Ringens2, F.E. van
Leeuwen6,7, A.C. Moll2
152
Appendix 7: Ongoing projects
63.
64.
65.
66.
67.
1Department of Clinical Genetics, VUmc; 2Department of Ophthalmology, VUmc; 3Department of Epidemiology,
Biostatistics and HTA, Radboud University Medical Center, Nijmegen; 4Department of Genetics, University Medical
Center Groningen, University of Groningen, Groningen; 5Department of Ophthalmology, University Medical Center
Utrecht, Utrecht; 6Department of Epidemiology, the Netherlands Cancer Institute, Amsterdam, the Netherlands; 7EMGO
Institute, VUmc
Secondary prevention of gastrointestinal cancer
L. Bosch1, M. de Wit1, Q.J.M. Voorham1, Lisette Timmer1, Florence de Groen1, S.T. van Turenhout2, F. Oort2, J.S.
Terhaar2, S. Mongera1, J.S. Bolijn1, Marianne Tijssen1, R. Diaz-Lopez1,5, R. Lamerichs5, L.Knols4, Connie Jimenez3,
Fijneman R.J.A.1 , B. Diosdado1, B. Carvalho1, M. van Engeland4 and G.A. Meijer1
1Dept of Pathology, 2Dept of Gastroenterology, 3Dept of Oncology, VU University Medical Center, Amsterdam, 4Dept of
Pathology, Maastricht University and University Hospital, Maastricht, 5Philips Research, Eindhoven
The molecular carcinogenesis of retinoblastoma
B.M. Mol1, A.C. Moll2, D.A. Rockx1, W.A Kors3, M.I. Bosscha2, H. Joenje1, H. te Riele4, J. Cloos3, J.C. Dorsman1
Departments of 1Clinical Genetics, 2Ophthalmology, 3Pediatric Oncology, VU University Medical Center, Amsterdam and
4Molecular Biology, The Netherlands Cancer Institute, Amsterdam
CCA/V-ICI (round 2008)
The role of viral BARF1 oncogene in Epstein-Barr virus (EBV) driven carcinogenesis and its inhibition by antibodies
E.K. Hoebe, H. Juwana, AE. Greijer, J.M. Middeldorp
Department of Pathology, VU University Medical Center
KWF-VU 2007-3776
Towards improved melanoma treatment: gene identification, in vivo modeling and drug target discovery
W.J. Mooi
Dept. Of Pathology, VU University Medical Center, Amsterdam
Towards targeted treatment of (familial) breast cancer
J. Bakker1, H. Verheul2, H. Meijers1, J.P. de Winter1, Q. Waisfisz1
Department of Clinical Genetics, Division Oncogenetics, and 2Department of Medical Oncology, VUmc
Program 2
Expanded clinical pharmacological monitoring of thiopurine therapy in patients with inflammatory bowel disease
1. Influence of 5-aminosalicylic acid on 6-thioguanosine phosphate metabolite levels: a prospective study in patients
under steady thiopurine therapy
P. de Graaf (1), N.K.H. de Boer (2), D.R. Wong (3), S. Karner (4), B. Jharap (2), P.M. Hooymans (3), A.I. Veldkamp (1),
C.J.J. Mulder (2), A.A. van Bodegraven (2) and M. Schwab (4,5)
(1) Clinical Pharmacology & Pharmacy; VU University Medical Center, Amsterdam, (2) Gastroenterology and Hepatology;
VU University Medical Center, Amsterdam, (3) Clinical Pharmacy; Orbis Medical Center, Sittard-Geleen, (4) Dr Margarete
Fischer-Bosch Institute of Clinical Pharmacology (Stuttgart) and University of Tuebingen, Germany, (5) Department of
Clinical Pharmacology, Institute of Experimental and Clinical Pharmacology and Toxicology, University Hospital
Tuebingen, Tuebingen; Germany.
2. Limited stability of thiopurine metabolites in blood samples: relevant in research and clinical practice
P. de Graaf [1], R.M. Vos [1], N.H.K. de Boer [2], A. Sinjewel [1], B. Jharap [2], C.J.J. Mulder [2], A.I. Veldkamp [1] and
A.A. van Bodegraven [2]
[1] Clinical Pharmacology and Pharmacy, VU University Medical Centre, The Netherlands, [2] Gastroenterology and
Hepatology, VU University Medical Centre, The Netherlands
Immunopathogenesis of EBV-associated cancers
3. Immune responses to EBV tumour-associated proteins in nasopharyngeal carcinoma
D. Paramita, J.M. Middeldorp
Dept. of Pathology, VU University Medical Center, Amsterdam
KWF-IN 2004-17
In situ targeting and modulation of dendritic cells for tumor
4. In situ targeting and modulation of dendritic cells for immunotherapy: reversal of suppression
D. Oosterhoff1, J.J. Lindenberg1, R. van de Ven1, H. van Cruijsen1, S.M. Lougheed1, V.W. van Beusechem1, P. van den
Tol3, D.T. Curiel4, W.R. Gerritsen1, A.J.M. van den Eertwegh1, R.J. Scheper2, T.D. de Gruijl1
Depts. of 1Medical Oncology, 2Pathology, and 3Surgical Oncology,VU University Medical Center, Amsterdam and Division
of Human Gene Therapy, UAB, Birmingham, Alabama
NWO VIDI 917.56.321
Mycobacterial host-pathogen interaction
5. Immunomodulation by Mycobacteria
N.N. Driessen, B.J. Appelmelk, W. Bitter
Dept. of Medical Microbiology and Infection Control, VU University Medical Center, Amsterdam
V-ICI PV05/18 Prom
6. Unraveling a novel bacterial protein transport system: characterization of mycobacterial secretion system ESX-5
E.N.G. Houben, W. Bitter
Dept. of Medical Microbiology and Infection Control, VU University Medical Center, Amsterdam
VENI
Other projects
7. A human, in vitro, full-thickness tissue-engineered skin model to investigate hypertrophic scar
L. van den Broek1, T. Waaijman, M. Breetveld1, R.J. Scheper2, F. Niessen3, S.Gibbs1
Depts. 1Dermatology / 2Pathology / Plastic Surgery3, VU University Medical Centre
Nederlandse Brandwondenstichting WO/P08.103
8. A prediction model for the development of rheumatoid arthritis in anti-CCP and/or IgM rheumatoid factor positive
arthralgia patients
D. van Schaardenburg1,2, L. v.d. Stadt, W.H. Bos 1, C.L. Verweij1, D. Hamann4, M. Boers5, B.A.C. Dijkmans1, 2
153
Appendix 7: Ongoing projects
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
154
Depts. of rheumatology1, Jan van Breemen Institute, rheumatology2, VUMC, rheumatology3, AMC, Sanquin Research4
and clinical epidemiology5, VUMC
Reumafonds DAA 0801034
Antigen presentation in Leprosy skin tissues
A.M. Abdallah, Maaike van Zon, Wilbert Bitter, Nicole N. van der Wel, and Peter J. Peters
Department of Medical Microbiology and Infection Control, VU University medical centre, Amsterdam, The Netherlands
Cancer Institute, Antoni van Leeuwenhoek Hospital
Leprafoundation
Antigen presenting stromal cells within lymph nodes
R. Molenaar, R.E. Mebius
Dept. Mol. Cell Biology and Immunology, VU University Medical Center
NWO VICI 918.56.612
Application of cultured autologous keratinocytes in combination with a meshed split skin autograft for burn wound
healing
S. Gibbs, M. Ulrich
Dept. Of Dermatology, VU University Medical Center, Amsterdam, Burns Centre ADBC Beverwijk
Ned. Brandwonden Stichting WO/P07.116, 2010-1012
Biomarkers in systemic lupus erythematosus
J. Jacobs, L-A. Korswagen, I.E.M. Bultink, B.A.C. Dijkmans, A.E. Voskuyl
Department of Rheumatology, VU University Medical Center
Dendritic cell-targeted in vivo tumor vaccination: towards optimised prime-boost protocols
B.N. Hangalapura1, D. Oosterhoff1, R. van de Ven1, J. van Moorselaar2, E. Hooijberg3, V.W. van Beusechem1, W.R.
Gerritsen1, A.J.M. van den Eertwegh1, R.J. Scheper3, Y. van Kooyk4, T.D. de Gruijl1
B.N. Hangalapura1, D. Oosterhoff1, R. van de Ven1, J. van Moorselaar2, E. Hooijberg3, V.W. van Beusechem1, W.R.
Gerritsen1, A.J.M. van den Eertwegh1, R.J. Scheper3, Y. van Kooyk4, T.D. de Gruijl1
KWF-VU / Stichting Avanti/STR 2005-3284
Determination of the contribution of neuronal vs. mesenchymal expression of Raldh2 to lymph node development
S.A. van de Pavert, T. Konijn, R.E. Mebius
Dept. Mol. Cell Biology and Immunology, VU University Medical Center
ALW-TOP 854.10.005
Development of a 'chemokine/angiogenic cocktail' for facilitating closure of burns and improving scar quality
K. Kroeze1, S.C. Sampat1, M. Breetveld1, R.J. Scheper2, S.Gibbs1
Depts. 1Dermatology / 2Pathology, VU University Medical Centre
Nederlandse Brandwonden Stichting WO/P05.101
Development of a skin APC targeting glyco-vaccin for potentiation of anti-melanoma immunity
C.M. Fehres, T.D. de Gruijl, W.W.J. Unger, A.J. van Beelen, Y. van Kooyk
Dept. Cell Biology and Immunology, VU University Medical Center, Amsterdam
KWF
Development of tissue engineered, autologous human skin for studying sensitization and Immuno-Vaccination
Approaches
K. Ouwehand1, S.W. Spiekstra1, B.M.E. von Blomberg2, T. Rustemeyer1, R.J. Scheper2, T.J. De Gruijl2, S. Gibbs1
Departments of 1Dermatology and 2Pathology, VU University Medical Center
V-ICI
Development of tissue-engineered full-skin substitutes for use in wound healing and industrial screening
T. Waaijman1, M. Breetveld1, E. Middelkoop3, R.J. Scheper2, S. Gibbs1
Depts. 1Dermatology / 2Pathology, VU Medical Centre, 3Association of Dutch Burns centres
DPTE, ZON-MW grant no: 13657
Diagnosis and prognosis in early arthritis
D. van Schaardenburg1, 2, J. Ursum2, B.A.C. Dijkmans1, 2
Depts. of rheumatology1, Jan van Breemen Institute, rheumatology2, VUMC
Jan van Breemen Research Institute
Enteroviral infections in children
S. de Crom 1, Dr. Ch. Obihara 1, M. Peeters 2, S.A. Morré 3 , A. M. van Furth 4
1Dept. of Pediatrics, St. Elisabeth Ziekenhuis, Tilburg; 2 Dept. of Medical Microbiology , St. Elisabeth Ziekenhuis,
Tilburg; 3Dept. of Immunogenetica, VUmc, Amsterdam; 4Dept of Pediatric Infectious Diseases, Immunology, and
Rheumatology, VUmc, Amsterdam
Galactofuranose in cell wall integrity of Aspergillus spp
B. Tefsen1, A.F.J. Ram2, I. van Die1
1Depts. Of Molecular Cellular Biology and Immunology, VU University Medical Center, Amsterdam and 2Leiden
University, Institute of Biologie, Leiden
STW
Galectins in tumor progression and tumor immunology
A.I. da Silva Aresta Belo van Wijk, B. Tefsen, I. van Die
Department of Molecular Cell Biology & Immunology, VU University Medical Center, Amsterdam
eigen geld via FCT (Portugal)
Genetic profiling in bacterial meningitis
M. Sanders1, S. Ouburg1 , S.A. Morré1 , A.M. van Furth2
1Dept. of Immunogenetica, VUmc, Amsterdam; 2Dept of Pediatric Infectious Diseases, Immunology, and Rheumatology,
VUmc, Amsterdam
Helminth glycoproteins: a new therapeutic option to prevent or ameliorate MS?
L.M. Kuijk, H.E. de Vries, C.D. Dijkstra, I. van Die
Dept. Of Molecular Cellular Biology and Immunology, VU University Medical Center, Amsterdam
MS Stichting
How helminth glycans protect againt Inflammatory Bowel Disease
E.J. Klaver1, L.M. Kuijk1, G. Kraal1, G. Bouma2, I. van Die1
Appendix 7: Ongoing projects
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
1Depts. of Molecular Cellular Biology and Immunology, and 2 Gastroenterology, VU University Medical Center,
Amsterdam
V-ICI
Human post mortem immuno-histopathology of cerebral granuloma caused by M. tuberculosis
M. van der Kuip1, D. Zaharie2, R.H. Hewlett2, A.M. van Furth1
Depts. of 1Pediatric Infectiology, Immunology and Rheumatology, VU University Medical Center, Amsterdam, The
Netherlands and 2Anatomical pathology; neuropathology unit, Stellenbosch University, Tijgerberg hospital, Cape Town,
South Africa
European Society for Paediatric Infectious Diseases / Wyeth
Immune modulating properties of mycobacterial protein secretion system ESX-5
J. Bestebroer, W. Bitter
Dept. of Medical Microbiology and Infection Control, VU University Medical Center, Amsterdam
NovSecTB/EU Framework 7
Immune modulation by ESX-5 secreted proteins of mycobacteria
E.M. Weerdenburg, W. Bitter, B.J. Appelmelk
Dept. of Medical Microbiology and Infection Control, VU University Medical Center, Amsterdam
V-ICI
Immunogenetic, pharmacological and neurodevelopmental aspects of nosocomial sepsis and meningitis in preterm
AGA and SGA infants
F. van den Dungen1 , S.A. Morré2, P. Savelkoul3, M. M. van Weissenbruch1, A.M. van Furth4
1Dept of Neonatology, VUmc, Amsterdam 2Dept. of Immunogenetica, VUmc, Amsterdam; 3Dept of Medical
Microbiology, VUmc, Amsterdam, 4Dept of Pediatric Infectious Diseases, Immunology, and Rheumatology, VUmc,
Amsterdam
Immunoprofiling in chronic inflammatory disease: coeliac disease
M.W.J. Schreurs1, I.M.W. van Hoogstraten1, S.Gross1, S.A.G.M. Cillessen1, B.M.E. von Blomberg1
R.L.J. van Wanrooij , S.F. Bakker2, G. Bouma2, C.J.J. Mulder2
Depts. of 1Pathology, 2Gastroenterology, VU University Medical Center
Immunoprofiling in chronic inflammatory disease: contact allergy
I.M.W. van Hoogstraten1, D. Rachmawati1, M.W.J. Schreurs1, R.J. Scheper1, B.M.E. von Blomberg1, J. Muris2, C.J.
Cleverlaan2, A.J. Feilzer2, T. Rustemeyer3
Depts. of 1Pathology and 3Dermatology, VU University Medical Center , Dept. of 2Dental Materials Science, ACTA,
Amsterdam
Inflammatory host defense in children with Down syndrome
C.J.M. Broers1, M.E.Wijerman1,2 ; R.J.B.J. Gemke1 , A.M. van Furth3,4
1Dept. of Pediatrics, VU medical center, 2Dept. of Pediatrics, Diaconesseziekenhuis, Leiden; 3 Dept. of Pediatric
Infectious Diseases-Immunology and Rheumatology, VU University Medical Center, Amsterdam; 4Laboratory of
Experimental Internal Medicine, Academical Medical Center, Amsterdam
Inhibition of the apoptosis pathways in Enteropathy associated T-cell lymphomas
L.R. de Baaij1, J.M.W. van de Water1, N.J.Hijmering2, W. Vos2, O.J. Visser3, J.J. Oudejans2,4, B.M.E. von Blomberg2,
M.W.J. Schreurs2, C.J.L.M. Meijer2, C.J.J. Mulder1, S.A.G.M. Cillessen2
Depts. of 1Gastro-enterology and Hepatology,2Clinical Pathology, 3Hematology, VU University Medical Center,
Amsterdam. 4Dept of Pathology, Diakonessenhuis, Utrecht
V-ICI grant 2007
iNKT and Vγ9Vδ2-T cell based immunotherapies for solid tumors
F.L. Schneiders1, R.C. de Bruijn1, R.J. Scheper2, H.J. Bontkes2, B.M.E. von Blomberg-van der Flier2, A.J.M. van den
Eertwegh1, G.A.M.S. van Dongen3, R.C. Roovers4, H.M. Verheul1, T.D. de Gruijl,1 H.J. van der Vliet1
Departments of 1Medical Oncology, 2Pathology, and 3Otolaryngology/Head and Neck Surgery, VU University Medical
Center, Amsterdam and 4 Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht
University, Utrecht
ZonMw Clinical Fellowship, KWF Clinical Cancer Research Fellowship
Innate immunity in bacterial meningitis
G. Th.J. van Well1,2 ,D. Visser1, T. van der Poll3, J.J. Roord1, A.M. van Furth1,3
1 Dept. of Pediatric Infectious Diseases-Immunology and Rheumatology, VU University Medical Center, 2 Dept. of
Pediatrics, Maastricht University Medical Center; and 2Laboratory of Experimental Internal Medicine, Academical
Medical Center, Amsterdam
Interactions between siglec-1+ macrophages and dendritic cells: opportunities for anti-melanoma immunotherapy
H.. Veninga, E. Borg, G. Kraal, T.D. de Gruijl, Y. van Kooyk, J.M.M. den Haan
Depts of Molecular Cellular Biology and Immunology and Medical Oncology, VU University Medical Center, Amsterdam
KWF
Lymphoid stroma in control of immunity
A. Baptista and R.E. Mebius
Dept. of Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam
GABBA PhD Program (University of Porto, Portugal)
Mathematical modeling of tuberculous meningitis: granuloma formation in the brain. A murine model to study
cerebral granuloma formation using beads coated with purified protein derivate of M. tuberculosis
M. van der Kuip1, M. El-Kebir1, D. Kirschner2, A.M. van Furth1
Depts. of 1Pediatric Infectiology, Immunology and Rheumatology, VU University Medical Center, Amsterdam, The
Netherlands and 2Microbiology and Immunology, The University of Michigan Medical School, Ann Arbor, MI, USA
European Society for Paediatric Infectious Diseases / Wyeth (to MvdK) and the National Institutes of Health HL092853-01
(to DK)]
Mechanisms of mesenchymal cell differentiation towards stromal lymph node cells
J.J. Koning, G. Goverse, T. Konijn, R.E. Mebius
Dept. Mol. Cell Biology and Immunology, VU University Medical Center
NWO VICI grant 918.56.612
Mocosa: an alternative test method for risk assessment of potentially harmful substances in the oral cavity
155
Appendix 7: Ongoing projects
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
156
J. Reijnders1, S.W. Spiekstra,1 , B.P. Vriens2,3, S. Gibbs1
1Dermatology, VU University Medical Centre, 2 ACTA, 3 Mucosa BV, Amsterdam
ZON-MW Pre-Seed grant no: 40-41300-98-9044
Molecular targeting of intracellular proteins in cancer
KBJ Scholten1, TD de Gruijl2, GA Meijer1, GAMS van Dongen2 and E Hooijberg1
Departments of 1Pathology and 2Medical Oncology, VU University Medical Center
CCA 26V080
Mycobacterial factors involved in granuloma formation
Esther Stoop, Gunny van den Brink- van Stempvoort, Theo Verboom, Wilbert Bitter, Christina Vanderbroucke-Grauls,
Astrid van der Sar
Dept. of Medical Microbiology and Infection Control, VU University Medical Center, Amsterdam
Smart Mix
Mysteries beyond the mycomembrane:biogenesis of the mycobacterial capsule and its role in the host-pathogen
interaction
R. van de Weert, B. Appelmelk, C. Vandenbroucke-Grauls, J.J.G. Geurtsen
Dept. of Medical Microbiology and Infection Control, VU University Medical Center, Amsterdam
NWO/ALW VENI
Novel in vitro assays for detection of sensitizers: Sens-it-iv
J. Reinders1, G. dos Santos1, S.W. Spiekstra1, B.M.E. von Blomberg2, R.J. Scheper2, T. Rustemeyer1, S. Gibbs1.
Departments of 1Dermatology and 2Pathology, VU University Medical Centre
EU framework 6 project Sens-it-iv
Novel saliva-derived peptides for state-of-the-art clinical wound-healing applications
M. Boink1,3, S. Roffel1,3, T. Waaijman1, R.J. Scheper2, E. Veerman3, S. Gibbs1
Depts. 1Dermatology / 2Pathology, VU University Medical Centre, 3ACTA
STW 10695
PamGene kinase arrays to investigate kinase activities in blood from patients with rheumatoid arthritis
J.G. Wesseling1, S.A. Vosslamber1, T.D. de Jong1, M. Blits1, S. De Ridder1, M.Dankers2, R.Ruijtenbeek2, E.A. Voskuyl3,
W. Lems3, I. van der Horst3, L. Van der Stadt4, D. Van Schaardenbrug4, M.T. Nurmohamed4, B.A.C. Dijkmans3, C.L.
Verweij1,3
1Dept. Pathology, Immune Disease Profiling, VU University medical center, Amsterdam, 2PamGene International BV,
Den Bosch, 3Dept. of Rheumatology, VU University medical center, 4Reade/Jan van Breemen Institute, Amsterdam, the
Netherlands
CTMM TRACER
Preclinical rheumatoid arthritis
M.M.J. Nielen1, D. van Schaardenburg1, 2, R.J. van de Stadt1, I.E. van der Horst-Bruinsma2, J. W.R. Twisk3, H.W.
Reesink4, J.P. Vandenbroucke5, B.A.C. Dijkmans1, 2
Depts. of rheumatology1, Jan van Breemen Institute, rheumatology2, medical statistics3, VUMC, Sanquin Blood Bank4
and clinical epidemiology5, LUMC.
Predicting T-cell development in refractory coeliac disease patients
J.M.W. van de Water1, L.R. de Baaij1, N.J.Hijmering2, W. Vos2, O.J. Visser3, J.J. Oudejans2,4, B.M.E. von Blomberg2,
M.W.J. Schreurs2, C.J.L.M. Meijer2, C.J.J. Mulder1, S.A.G.M. Cillessen2
Depts. of 1Gastro-enterology and Hepatology,2Clinical Pathology, 3Hematology, VU University Medical Center,
Amsterdam. 4Dept of Pathology, Diakonessenhuis, Utrecht
CCA PV06/18MDL
Pre-validation of a two tiered approach to determine the skin sensitizing capacity and potential of chemicals
S. Gibbs, M Teunis, S. Casati, E Corsini
Dept. Of Dermatology, VU University Medical Center, ECVAM, Hogeschool Utrecht, University of Milan
ZonMw PAD 2010-2012
Prevalidation of a two-tiered approach to determine the skin sensitising capacity and potency of chemicals
J. Reijnders1, S.W. Spiekstra,1 , E. Corsini2 , R. Roggen3 , R. Pieters4, S. Casati5. C. Krul6, S. Gibbs1.
1Dermatology, VU University Medical Centre, 2 University of Milan, Milan, 3 Novozymes, Denmark, 4 Hoge School,
Utrecht, 5 ECVAM, Ispra, 6 TNO, Utrecht
ZON-MW PAD grant no: 40-40100-94-09015
Regulation of expression of retinaldehyde dehydrogenase enzymes in musocal dendritic cells
R. Molenaar, G. Goverse, R.E. Mebius
Dept. Mol. Cell Biology and Immunology, VU University Medical Center
NWO VICI 918.56.612
Retinoic acid mediates macrophage differentiation towards a separate lineage
G. Goverse, T. Konijn, R.E. Mebius
Dept. Mol. Cell Biology and Immunology, VU University Medical Center
ALW-TOP 854.10.005
Role of epithelial barrier disruption in Inflammatory Bowel Disease
I. Hiemstra, G. Bouma, J.M.M. den Haan, G. Kraal
Depts of Molecular Cellular Biology and Immunology and Gastroenterology, VU University Medical Center, Amsterdam
RSV and children with Down syndrome
B. Bloemers1, L. Bont1, M.E. Weijerman2,3 , C.J.M. Broers2, R.J.B.J. Gemke2, A.M. van Furth4.
1 Dept. of Pediatrics, WKZ, Utrecht, 2Dept. of Pediatrics, VU medical center, 3Dept. of Pediatrics,
Diaconesseziekenhuis, Leiden; 4 Dept. of Pediatric Infectious Diseases-Immunology and Rheumatology, VU University
Medical Center, Amsterdam
Signaling pathways in homeostasis and function of dendritic cells
M. Beijer, G. Kraal and J.M.M. den Haan
Dept of Molecular Cellular Biology and Immunology, VU University Medical Center, Amsterdam
NWO-meervoud
SkinCare
Appendix 7: Ongoing projects
57.
58.
59.
60.
61.
62.
63.
64.
L. Vink3, K. Kroeze1, G. Limandjaja1, E.M. de Boer1,3, C. van Montfrans1, CS. Blok1,3, T. Rutgers4, H. Fuchs5, R.J.
Scheper2,3, S.Gibbs1,3.
Departments of 1Dermatology and 2Pathology, VU University Medical Centre, 3A-SKIN Amsterdam, 4 Drug Discovery
factory Bussum, Cell Systems, Germany
International Innovation Programme by Agentschap NL SII082031
Targeting of proteins to the mycobacterial type VII secretion system ESX-5
M.H. Daleke, W. Bitter
Dept. of Medical Microbiology and Infection Control, VU University Medical Center, Amsterdam
NWO/ALW
The contribution of epigenetic processes in the pathology of vascular disease and of multiple sclerosis
P.J. van den Elsen
Department of Pathology, VU University medical center, Amsterdam, the Netherlands and Department of
Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands
MS Research Foundation and the SMART mix: Translational excellence in Regenerative Medicine
The development of a novel Wound Healing Formulation for advanced wound management
C. Reijnders1, R. Van der Pijl1 , T. Rutgers2, J. Bertram3, S. Scheper4,5, S. Gibbs1,5.
1Dermatology and 4Pathology, VU University Medical Centre, 2 Drug Discovery Factory, Bussum, 3IBA, Germany, 5 ASkin, Amsterdam
Agentschap NL - EuroTransBio grant no: ETB-2009-98
The development of immuno-competent human skin and oral mucosa equivalents and their use in determining
factors involved in T cell skewing and imprinting
I. Kosten1, S.W. Spiekstra1, B.M.E. von Blomberg2, T. Rustemeyer1, R.J. Scheper2, T.J. De Gruijl2, S. Gibbs1
Departments of 1Dermatology and 2Pathology, VU University Medical Center
The role of retinoic acid in regulation of gene expression during lymph node formation
D. Schooneman, R.E. Mebius, S.A. van de Pavert
Dept. Mol. Cell Biology and Immunology, VU University Medical Center
NWO ZonMW Horizon
TNF and IFN cross-regulation in rheumatoid arthritis
T.D. de Jong1, M. Blits1, J.G. Wesseling1, S. Vosslamber1, A. De Ridder1, T.C. Van der Pouw Kraan2, I. van der Horst3,
A.E. Voskuyl3, M.T. Nurmohamed4, M. Fero5, M. Schreurs1, M. Blomberg1, B. Crusius1, M. van der Wiel1,6,R.
Thurlings7, M. Bouwman7, P.-P. Tak7 , B.A.C. Dijkmans3 and C.L. Verweij1,3
1Dept. of Pathology, 2Dept. of Molecular Cell Biology, 3Dept. of Rheumatology and 6Dept. of Epidemiology, VU
University medical center, 4Reade/Jan van Breemen Institute, Amsterdam, 5Stanford University, Palo Alto, USA, and
7Academic Medical Center, Amsterdam, Netherlands
V-ICI, Dutch Arthritis Foundation 05-I-402, AUTOCURE (EU), CTMM “TRACER” and CMSB
Towards adjuvant immunotherapy for squamous cell carcinoma
AW Turksma, JJ Ruizendaal, H van den Heuvel, CJLM Meijer, CR Leemans and E Hooijberg
Dept. of Pathology, VU University Medical Center Amsterdam
KWF VU2007-3814
Towards preventive medicine in Rheumatoid Arthritis: Alterations in innate immunity in the preclinical phase of
rheumatoid arthritis
J.G. Wesseling1, S. Van der Tuin1, S. Vosslamber1, L. Van der Stadt2, A. Grutzkau3, A. Radbruch3,T.C.T.M. van der
Pouw Kraan4, G. Wolbink2,5, I. van der Horst6, M. Schreurs1, M. Blomberg1, B. Crusius1, M. van der Wiel1,7,B.A.C.
Dijkmans2,6, D. van Schaardenburg2,6, C.L. Verweij1,6
1Dept. of Pathology and 4Dept. of Molecular Cell Biology, 6Dept. of Rheumatology, and 7Dept. of Epidemiology, VU
University Medical Center, 3DFRZ, Charité, Berlin, Germany, 2Reade/Jan van Breemen Institute, 5Sanquin Research,
Amsterdam, The Netherlands
AUTOCURE (EU), CTMM “TRACER”, CMSB
Program 3
Alternative proteomics strategies for discovery of blood-based biomarkers
1. Label-free quantitative secretome proteomics for discovery of serum-based cancer biomarkers
S.R. Piersma1#, U. Fiedler2#, S. Span1, A. Lingnau2, T.V. Pham1, S. Hoffmann2, M.H.G. Kubbutat2, C.R. Jiménez1*
1Oncoproteomics Laboratory, Dept of Medical Oncology, VUmc-Cancer Center Amsterdam, VU University Medical
Center, Amsterdam, the Netherlands. 2ProQinase GmbH, Freiburg, Germany
CCA
2. Platelet proteomics for cancer biomarker discovery
M. Walraven1, S.R. Piersma2, H.J. Broxterman1, H.M.W. Verheul1*, C.R. Jiménez2*
1Angiogenesis Laboratory and 2OncoProteomics Laboratory, Dept. Medical Oncology, VU University Medical Center,
Amsterdam
VUmc CCA, Aegon
3. Proteomics of exosomes secreted by cancer cell lines
M. Lavaei1, R.J.A. Fijneman2, D.M. Fluitsma3, J.C. Knol1, S.R. Piersma1, T.V. Pham1, R. Steenbergen2, G.A. Meijer2,
M. Pegtel2, H.M.W. Verheul1, C.R. Jimenez1
1OncoProteomics Laboratory, Dept. Medical Oncology, 2Dept. Pathology, VU University Medical Center, Amsterdam, The
Netherlands
CCA
Antibody-based therapy with emphasis on head and neck cancer
4. Antibody derivatives as molecular agents for neoplastic targeting
D. Vugts1, A. Vervoort1, I de Roos, G.W.M. Visser2, G.A.M.S. van Dongen1,2
Dept. of 1Otolyryngology/Head-Neck Surgery, and 2Nuclear Medicine & PET research, VU University Medical Center,
Amsterdam
157
Appendix 7: Ongoing projects
Philips and other industries FP7LSHC-CT-2007-201342
Development of dual-specific nanobodies for cancer diagnosis and treatment
M. Vosjan1, M. Stigter–van Walsum1, G.W.M. Visser2, R. Roovers3, P.M P. van Bergen en Henegouwen3, C.R. Leemans1,
G.A.M.S. van Dongen1,2
Dept. of 1Otolaryngology/Head-Neck Surgery VU University Medical Center, 2Nuclear Medicine & PET Research VU
University Medical Center, 3Dept. Cellular Architecture & Dynamics, Utrecht University
the European Union FP6 and 7, STROMA and ADAMANT, STW, and Ablynx
6. The selective targeting of angiogenesis and of tumour stroma
R. Cohen1, R. de Bree1, M. Stigter-van Walsum1, G.W.M. Visser2, D. Neri3, C.R. Leemans1,G.A.M.S. van Dongen1,2
Dept. 1Otolaryngology/Head-Neck Surgery, 2Nuclear Medicine & PET Research VU University Medical Center, 3Swiss
Federal Institute of Technology,Zürich, Switzerland
European commision FP6-LSHC-CT-2003-503233
Brain proteomics
7. In-depth analysis of the cerebrospinal fluid proteome for biomarker discovery: abundant protein depletion sample
pretreatment method
S.A. Fratantoni, S.R. Piersma, C.R. Jimenez
OncoProteomics Laboratory, Dept. Medical Oncology, VUmc-Cancer Center Amsterdam, VU University Medical Center,
Amsterdam, The Netherlands
EU cNeuPRO project
8. Proteomics of meningiomas in correlation with growth rate
S. Peerdeman1, TMB. Schaaij-Visser2, R. Ariana1, JC. Knol2, S. Piersma2, CR. Jimenez2
1Dept. Neurosurgery, 2OncoProteomics Laboratory, Dept. Medical Oncology, VUmc-Cancer Center Amsterdam, VU
University Medical Center, Amsterdam, The Netherlands
CCA
9. Proteomics reveals minichromosome maintenance proteins as novel tumor markers for meningiomas
O. Saydam1, O. Senol1, T. Schaaij-Visser2, S.R. Piersma2, T.V. Pham2, S. Peerdeman3, C. Jimenez2
1Department of Neurology, Neurogenetic Unit, Massachusetts General Hospital, Harvard Medical School,
3OncoProteomics Laboratory, Dept. Medical Oncology, 3Department of Neurosurgery, VU University Medical Center
CCA
Breast cancer proteomics
10. Exploring differences in short-term response to cisplatin in sensitive and non-sensitive mouse mammary tumors
M. Warmoes1*, J. Jaspers2*, S. Rottenberg2, S. Piersma1, C.R. Jimenez1*, J. Jonkers2*
1OncoProteomics Laboratory, Dept. Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands,
2Molecular Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
CenE/Van Lanschot and the VUmc Cancer Center Amsterdam
11. Proteomics of murine BRCA1 deficient breast tumors identifies DNA repair proteins with prognostic value in human
breast cancer
Marc.O. Warmoes¹, Janneke Jaspers2, Thang V. Pham1, Sander Piersma1, Maarten P.G. Massink3, Hanne MeijersHeijboer3, Quinten Waisfisz3, S. Rottenberg2, Epie Boven1, Jos Jonkers2, Connie R. Jimenez1
1Oncoproteomics Laboratory, Dept. of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
2Division of Molecular Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 3Dept. Clinical
Genetics, VU University Medical Center, Amsterdam
CenE/Van Lanschot and the VUmc CCA
Colorectal cancer proteomics
12. Enrichment of tumorigenic stem-like cells in biopsy spheroids from colorectal cancer
U. Rajcevic1, J.C. Knol2, S. Piersma2, S. Bougnaud1, T.V. Pham2, E. Sundlisaeter3, P. Enger3, R. Bjerkvig1,3, S.P.
Niclou1, C.R. Jimenez2
1NorLux Neuro-Oncology, CRP-Santé, Luxembourg, 2OncoProteomics Laboratory, Dept. Medical Oncology, VU University
Medical Center, Amsterdam; 3Department of Biomedicine, University of Bergen, Bergen, Norway
CCA
13. Identification of new Biomarkers for Colon Cancer using integration of Genomics and Cell Surface Proteomics
M. de Wit1, C.R. Jimenez2, B. Carvalho1, J.A.M. Belien1, P.M. Delis-van Diemen1, S. Mongera1, S.R. Piersma2, G.A.
Meijer1, R.J.A. Fijneman1
1Dept. Pathology (Tumor Profiling Unit), 2Dept. Medical Oncology (OncoProteomics Laboratory), VU University Medical
Center
Phillips research and VUmc CCA
14. Label-free LC-MS/MS profiling of chromatin-associated proteins in colorectal adenoma and carcinoma tissues
J. Albrethsen1, J.C. Knol1, T.V. Pham1, S.R. Piersma1, S. Mongera?2, B. Carvalho2, M. de Wit2, R.J.A. Fijneman2, G.A.
Meijer2, C.R. Jimenez1*
1OncoProteomics Laboratory, Dept. Medical Oncology, 2Dept. Pathology, VU University Medical Center, Amsterdam. The
Netherlands
CCA
15. Protein biomarker discovery in stool for the early detection of colorectal cancer
Linda JW Bosch1, Meike de Wit1,2, Gideon Oudgenoeg2, Sandra Mongera1, Sander Piersma2, Thang Pham2, Jochim S
Terhaar Sive Droste3, Chris JJ Mulder3, Beatriz Carvalho1, Remond JA Fijneman1, Connie R Jimenez2, Gerrit A Meijer1
1Dept. Pathology (Tumor Profiling Unit), 2Dept. Medical Oncology (OncoProteomics Laboratory), 3Dept.
Gastroenterology, VU University Medical Center, Amsterdam, The Netherlands
VUmc CCA
16. Proteome profiling of mouse colon tumor proximal fluids reveals candidate biomarkers for colorectal cancer
screening
R.J.A. Fijneman1,2, M. de Wit1, M. Pourghiasian1,2, S. Piersma2, M. Warmoes2, P.M. van Diemen1, C. Piso1, E.C.
Robanus-Maandag3, R. Smits4, R. Fodde4, V.W.M. van Hinsbergh2,5, G.A. Meijer1, C.R. Jimenez2
1Dept. of Pathology, 2Dept. of Medical Oncology, 5Dept of Physiology, VU University Medical Center, 3Dept. of Human
Genetics, Leiden University Medical Center, Leiden, The Netherlands 4 Dept. of Pathology, Josephine Nefkens Institute,
Erasmus MC, Rotterdam, the Netherlands
5.
158
Appendix 7: Ongoing projects
Aegon International Scholarship in Oncology, and by the VUmc-Cancer Center Amsterdam.
17. Proteomics of cancer stem cell-enriched colon cancer spheroids - Secretome analysis of colon cancer stem cells
(CSC) and their isogenic differentiated progeny
B. Emmink1, W. van Houdt1, T.V. Pham2, S. Piersma2, I. Borel Rinkes1, C. Jimenez2^, O. Kranenburg1^
1Dept. Surgical Oncology, University Medical Center Utrecht and 2OncoProteomics Laboratory, Dept. Medical Oncology,
VU University Medical Center
18. Proximal Fluid Proteome Profiling of Human Colorectal Cancer Tissue Reveals Candidate Biomarkers for CRC
screening
R.J.A. Fijneman1, H. Kant2, M. de Wit1, S.R. Piersma2, T.V. Pham2, M. O. Warmoes2, S. Mongera1, H.M.W. Verheul2,
G.A. Meijer1, C.R. Jimenez2.
Dept. of 1Pathology, 2OncoProteomics Laboratory, Dept. Medical Oncology, VU University Medical Center, Amsterdam,
The Netherlands
Aegon International Scholarship in Oncology, and by the VUmc-Cancer Center Amsterdam.
19. Sub-nuclear proteomics in human colorectal cancer: Identification of proteins enriched in the nuclear matrix
fraction and regulation in adenoma to carcinoma progression
J. Albrethsen1, J.C. Knol1, S. Piersma1, T.V. Pham1, M. de Wit2, S. Mongera2, B. Carvalho2, H.M.W. Verheul1, R.J.A.
Fijneman2, G.A. Meijer2, C.R. Jimenez1*
1OncoProteomics Laboratory, Dept. Medical Oncology, 2Dept. Pathology (Tumor Profiling Unit), VU University Medical
Center, Amsterdam. The Netherlands
CCA
20. Targeted mass spectrometry-based candidate biomarker validation in biological matrices
G. Oudgenoeg1, L. Bosch2, M. de Wit1, R.J.A. Fijneman2, G.A. Meijer2 , C.R. Jimenez1
*OncoProteomics Laboratory, Dept. Medical Oncology, and **Tumor Profiling Unit , Dept. Pathology, VUmc Cancer
Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
CTMM DeCoDe
Diagnosis and treatment of EBV-associated cancers
21. Diagnosis and prognostic monitoring following radiochemotherapy treatment of nasopharyngeal carcinoma based on
EBV-markers
M. Adham, A.E. Greijer, S.A.Verkuijlen, H.Juwana, J.M.Middeldorp
Dept. ENT-Surgery, Fac. Medicine, Universitas Indonesia, Jakarta, Indonesia and Dept. pathology, VU University medical
center, Amsterdam
KWF-IN 2006-21
High-throughput body fluid peptide profiling by MALDI mass spectrometry for patient stratification by pattern diagnosis
22. Mass spectrometric serum peptide profiling for drug response prediction: signature validation
T.V. Pham1, J.C. Knol1, J.S.W. Lind2, H.M.W. Verheul1, E.F. Smit2, C.R. Jimenez1
1Department of Medical Oncology, VU University Medical Center, 2Department of Pulmonary Diseases, VU University
Medical Center
VUmc CCA
23. Serum peptide profiling in non-small cell lung cancer patients treated with sorafenib and erlotinib
T.V. Pham1, J.S.W. Lind2, J.C. Knol1, A.-M.C. Dingemans3, H.J.M. Groen4, P.E. Postmus1, C.R. Jimenez1*, E.F. Smit 2*
Departments of 1Medical Oncology and 2Pulmonary Diseases VU University Medical Center Amsterdam, 3Maastricht
University Medical Center and 4University Medical Center Groningen
VUmc CCA
Immuno-PET for diagnosis and therapy planning of head and neck cancer
24. PET tracers for (chemo)radiation of lung and head and neck cancer
A. Poot1, H. Hendriks, G.A.M.S. van Dongen1,2
Depts. of 1Otolaryngology/Head-Neck Surgery, and 2Nuclear Medicine & PET Research, VU University Medical Center,
NWO/STW: VBC6120 and 10074, CTMM Air Force, and Roche-Genentech
Improvement of the diagnosis of head and neck squamous cell carcinoma (HNSCC)
25. Evaluation and prediction of response
L. van der Putten1, O.S. Hoekstra3, C.R. Leemans1, R. de Bree1
Depts. of 1Otolaryngology/Head-Neck Surgery, 2Nuclear Medicine / PET Research, 3Oral and Maxillofacial Surgery,
4Radiology and 5Pathology, VU University Medical Center
ZonMw and CCA 945-04-311, 80-82305-98-08106
26. FDG-PET for avoidance of futile direct laryngoscopies under general anasthesia with taking op biopsies in patiens
with suspicion on recurrent laryngeal carcinoma after radiotherapy
L. van der Putten1, I. van der Waal2, O.S. Hoekstra3, E. Bloemena5, C.R. Leemans1, R. de Bree1
Depts. of 1Otolaryngology/Head-Neck Surgery, 2Nuclear Medicine / PET Research, 3Oral and Maxillofacial Surgery,
4Radiology and 5Pathology, VU University Medical Center
ZonMw and CCA 945-04-311, 80-82305-98-08106
27. Improvement of the sentinel node procedure in head and neck cancer by PET-CT lymfoscintigraphy, optical
techniques and minimal invasive surgery. Molecular targeting of intracellular proteins in cancer
Heuveling D, G.A.M.S. van Dongen, R. de Bree
Dept. Otolaryngology/Head and Neck Surgery, VU University Medical Center, Amsterdam
28. Screening for distant metastases and second primary tumors with FDG-PET (The school study)
A. Senft1, J.A. Castelijns2, R. de Bree1, O.S. Hoekstra3, C.R. Leemans1
Depts. of 1Otolaryngology/Head and Neck Surgery, 2Clinical PET Center, 3Nuclear Medicine, VU University Medical
Center, Amsterdam
ZonMw Doelmatigheidsonderzoek 945-11-014
29. Ultrasound guided fine needle aspiration cytology and sentinel node biopsy in the detection of occult lymph node
metastases of early oral and oropharyngeal cancer
G.B. Flach, J Castelijns, OS Hoekstra, E Bloemena, R. de Bree
Dept. Otolaryngology/Head and Neck Surgery, VU University Medical Center, Amsterdam
ZonMw 80-82305-98-08106
Lung cancer proteomics
159
Appendix 7: Ongoing projects
30. Exploration of sputum to develop protein-based assays for early detection, prognosis and drug response of lung
cancer
T.B.M. Schaaij-Visser1, B. Colak1, J. Hubers2, E.F. Smit3, (Erik) F.B.J.M. Thunnissen2, C.R. Jimenez1
1 OncoProteomics Laboratory, Department of Medical Oncology; 2 Department of Pathology, 3Dept. Pulmonology, VU
University Medical Center, Amsterdam, The Netherlands
VUmc CCA
31. Secretome proteomics to identify indicators for lung cancer treatment response prediction and monitoring
T.B.M. Schaaij-Visser1, N. Proost2, R. Nagel3, S.R. Piersma1, T.V. Pham1, R.H. Brakenhoff3, A. Berns2, C.R. Jimenez1
1OncoProteomics Laboratory, Department of Medical Oncology, 2Division of Molecular Genetics and Centre for
Biomedical Genetics, The Netherlands Cancer Institute, Amsterdam, The Netherlands; 3Department of
Otolaryngology/Head and Neck surgery, VU University Medical Center, Amsterdam
CTMM Airforce
Mining high dimensional proteomics data
32. Network-based data analysis for marker prioritization for targeted mass spectrometry validation
T.V. Pham1, L.G. Leon1, M.O. Warmoes1, S.R. Piersma1, C.R. Jimenez1
1OncoProteomics Laboratory, Department of Medical Oncology, VU University Medical Center, Amsterdam
VUmc CCA
33. Strategies for analyzing spectral count data in label-free tandem mass spectrometry-based proteomics
T.V. Pham, M. Warmoes, S.R. Piersma, C.R. Jimenez
OncoProteomics Laboratory, Department Medical Oncology, VUmc-Cancer Center Amsterdam, VU University Medical
Center
VUmc CCA
Signaling pathway proteomics for insight into cancer signaling, identification of drug targets and biomarkers for patient
stratification
34. Development of kinobeads for comprehensive capture of the kinome prior to analysis by proteomics
S.R. Piersma1, I. de Reus1, J. Weterings2, I. de Esch2, H. Verheul1, C.R. Jiménez1
1OncoProteomics Laboratory, Dept. Medical Oncology, VU University Medical Center; 2FEW-VU, Amsterdam
CCA
35. Global profiling of endogenous tyrosine phosphorylation events for identifying aberrant signaling in cancer
S.R. Piersma1, K.J. Gotink2, M. Labots2, R. de Haas2, H. Broxterman2, H. Verheul2, C.R. Jiménez1
1OncoProteomics Laboratory and 2Angiogenesis Laboratory, Dept. Medical Oncology, VU University Medical Center
VUmc CCA
Other projects
36. [11C]-(R)-PK11195 PET imaging of subclinical synovitis in rheumatoid arthritis patients in clinical remission
Y.Y.J. Gent, A.E. Voskuyl1, R.W. Kloet 2, E.F.I. Comans2, O.S. Hoekstra2, A.A. Lammertsma2, B.A.C. Dijkmans1, C.J.
van der Lakenl1
Depts of 1Rheumatology, 2Nuclear Medicine and PET Research, VU University Medical Center
37. [11C]-(R)-PK11195 PET imaging of subclinical synovitis in the pre-clinical phase of rheumatoid arthritis
Y.Y.J. Gent1, A.E. Voskuyl1, R.W. Kloet 2, E.F.I. Comans2, D. van Schaardenburg3, O.S. Hoekstra2, A.A. Lammertsma2,
B.A.C. Dijkmans1, C. J. Van der Laken1
Depts of 1Rheumatology, 2Nuclear Medicine and PET Research, VU University Medical Center,3Jan van Breemen
Institute, Amsterdam
38. Analysis of bacterial contamination of blood transfusion projects
I. Rood, A. Petterson, P.H.M. Savelkoul
Dept. of Medical Microbiology and Infection Control, VU University Medical Center, Amsterdam
Sanquin Bloodbank
39. Anca-PR-3 vasculitis studie; preventie van recidieven
A.E. Voskuyl
Dep Rheumatology, VU University Medical Center, Amsterdam
40. Assessment of blood-brain barrier function in pharmacoresistant patients with tumor-related epilepsy
F. Froklage1, R.A. Voskuyl6, J.J. Heimans1, N.H.M. Hendrikse3, J.C. Baayen2, R.M.C. Debets5, D. Velis4, A.A.
Lammertsma3, J.C. Reijneveld1,4
Departments of 1Neurology, 2Neurosurgery and 3Nuclear Medicine and PET-research, VU University Medical Center,
Department of 4Neurology, Academic Medical Center, Amsterdam, Departments of 4Neurology and 5Clinical
Neurophysiology, Stichting Epilepsie Instellingen Nederland (SEIN), Heemstede, and 6Department of Pharmacology,
Leiden/Amsterdam Center for Human Drug Research (L/A CHDR), Leiden.
Europese Unie Framework Program 7 (FP7 EURIPIDES project)
41. Bone disease in Multiple Myeloma
J.C. Regelink1, P. Sonneveld2, I.C. Pieters-van den Bos3, O.S. Hoekstra4, J.M. Zijlstra1, P.C. Huijgens1, S. Zweegman1
Department of hematology1, VU University Medical Center, department of Hematology2, Erasmus Medical Center
Rotterdam, Department of Radiology3 and Nuclear medicine and PET research4 VU University Medical Center
Stichting Vu Steunfonds Hematologie, Industry
42. Characterization of epileptogenic brain networks in primary brain tumor patients
L. Douw1, J.J. Heimans1, F. Bartolomei2,6, J.C. Baayen4, W.P. Vandertop 4, B.W. van Dijk2, D.N. Velis7, M. Klein3,
C.J. Stam2, J.C. Reijneveld1,5
Departments of 1Neurology, 2Clinical Neurophysiology, 3Medical Psychology, and 4Neurosurgery, VU University Medical
Center, 5Department of Neurology, Academic Medical Center, Amsterdam, 6Department of Clinical Neurophysiology,
Hospital de la Timone, Marseille, France, 7Department of Clinical Neurophysiology, Stichting Epilepsie Instellingen
Nederland (SEIN), Heemstede
Nationaal Epilepsie Fonds (NEF), Project NEF 08-08 08-08
43. Clinical and experimental high resolution ocular MR imaging: towards improved detection of retinoblastoma tumor
extent
P. de Graaf1, P. van der Valk2, A.C. Moll3, S.M. Imhof7, A.Y.N. Schouten-van Meeteren4, D.L. Knol5, P.W.J. Pouwels6,
J.A. Castelijns1
160
Appendix 7: Ongoing projects
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
Departments of Radiology1, Pathology2, Ophthalmology 3 and Epidemiology and Biostatistics5, Physics and Medical
Technology6, VU University Medical Center, Department of Pediatric Oncology4, Emma Children’s Hospital, Academic
Medical Center, Amsterdam, and Department of Ophthalmology, University Medical Center Utrecht
Grant ZonMw-AGIKO 2006, ODAS Foundation, National Foundation for the Blind and Visually Impaired, Blindenhulp
Foundation, Dutch Eye Fund (Grant 2004-23)
CTMM: ontwikkeling nieuwe tracers van lab tot kliniek
C. van der Laken, B.A.C. Dijkmans
Dep Rheumatology, VU University Medical Center, Amsterdam
Development of imaging markers, using PET(-CT), for early detection of RA and therapy monitoring
Y.Y.J. Gent1, K. weijers1, I. de Greeuw2, M. Verlaan2, B. Windhorst2, C. J. Van der Laken1, A.A. Lammertsma2, O.S.
Hoekstra2, B.A.C. Dijkmans1, C.F.M. Molthoff2, C.J. van der Laken1
Depts of 1Rheumatology, 2Nuclear Medicine and PET Research, VU University Medical Center, Amsterdam
Discontinuation of imatinib in CML patients in continuous complete molecular remission
J.J.W.M. Janssen, B. van Kuijk, G.J. Schuurhuis, J.J. Cornelissen, G.J. Ossenkoppele
Dept. of Hematology, VU University Medical Center
KWF
Early detection and photodynamic therapy in local recurrent nasopharyngeal carcinoma.
M. Wildeman, A.E. Greijer, S.A. Verkuijlen, H, Juwana, I.B. Tan, J.M. Middeldorp
Dept. of Pathology, VU University Medical Center, Amsterdam and Dept. ENT surgery, Netherlands Cancer Insitute,
Amsterdam
KWF-NKI 2008-4233
Experimental and clinical studies using positron emission tomography (PET) for monitoring response to
chemotherapy in (locally) advanced breast cancer
W.G.E. Direcks1, M. Lubberink1, S. Berndsen1, N. Proost1, M. van Gelder1, O.S. Hoekstra1, A.A. Lammertsma1, C.F.M.
Molthoff1
Dept. of 1Nuclear Medicine&PET Research, VU University Medical Center, Amsterdam
KWF 2003-2822
Explorative biomarker studies towards patient centric therapy in rheumatoid arthritis
S. Vosslamber1, T.D. de Jong1, M. Blits1, T.C. A. De Ridder1, J.G. Wesseling1, Van der Pouw Kraan2, I. van der Horst3,
A.E. Voskuyl3, M.T. Nurmohamed4, M. Fero5, M. Schreurs1, M. Blomberg1, B. Crusius1, M. van der Wiel1,6,R.
Thurlings7, M. Bouwman7, P.-P. Tak7 , G. Wolbink8, B.A.C. Dijkmans3 and C.L. Verweij1,3
1Dept. of Pathology, 2Dept. of Molecular cell Biology, 3Dept. of Rheumatology and 6Dept. of Epidemiology, VU
University medical center, 4Jan van Breemen Institute, Amsterdam, 5Stanford University, Palo Alto, USA, and
7Academic Medical Center, Amsterdam, 8Sanquin Research
Dutch Arthritis Foundation 05-I-402, AUTOCURE (EU), CTMM “TRACER” and CMSB
Identification of differentially expressed genes in CML stem cells
J.J.W.M. Janssen, W. Pouwels, B. van Kuijk, A. Zevenbergen, G.J. Schuurhuis, G.J. Ossenkoppele
Dept. of Hematology, VU University Medical Center
Stichting Vanderes
Imaging of ankylosing spondylitis by PET-CT
M.A.C. van der Weijden1, S.T. Bruijnen1, N.Hoetjes2, A.E. Voskuyl1, O.S. Hoekstra2, R. Boellaard2, J.P. Klein3, B.A.C.
Dijkmans1, I. E. van der Horst-Bruinsma1, C. J. Van der Laken1
Depts of 1Rheumatology, 2Nuclear Medicine and PET Research, 3Radiology, VU University Medical Center, Amsterdam
Incidence of retinoblastoma in the Netherlands 1950 - 2010: A shift in the proportion of hereditary retinoblastoma
M.I. Bosscha1, L. Razzaq2, C.J. Dommering3, F. E. van Leeuwen4, A.C. Moll1
1 Department of Ophthalmology, VU University Medical Center, Amsterdam, the Netherlands. 2 Department of
Ophthalmology Leiden University Medical Center, Leiden, the Netherlands. 3 Department of Clinical Genetics, VU
University Medical Center, Amsterdam, the Netherlands. 4 Department of Epidemiology, the Netherlands Cancer
Institute, Amsterdam, the Netherlands
Lesional epilepsy: the interplay between ictal onset and permissive networks
E. van Dellen1, L. Douw1, J.J. Heimans1, J.C. Baayen4, W.P. Vandertop 4, B.W. van Dijk2, D.N. Velis6, M. Klein3, C.J.
Stam2, J.C. Reijneveld1,5
Departments of 1Neurology, 2Clinical Neurophysiology, 3Medical Psychology, and 4Neurosurgery, VU University Medical
Center, 5Department of Neurology, Academic Medical Center, Amsterdam, 6Department of Clinical Neurophysiology,
Stichting Epilepsie Instellingen Nederland (SEIN), Heemstede
Nationaal Epilepsie Fonds (NEF), project NEF 09-09
Methylation status of glioma cell lines and Akt inhibition
C A Fedrigo1,2,3, P Sminia2, G. J. Peters3, B Garicochea1
1Pontifícia Universidade Católica do Rio Grande do Sul, Brazil; Departments of 2Radiotherapy and 3Medical Oncology,
VU University Medical Center, Amsterdam, the Netherlands
CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior)
Optimization of MR imaging studies in retinoblastoma patients
F. Rodjan 1, P. de Graaf 1, A.C. Moll 1, S.M. Imhof 2, P. van der Valk 1, J.A. Castelijns 1
1) VU University Medical Center, Amsterdam, 2) University Medical Center Utrecht, Utrecht
ODAS Stichting, LSBS, Stichting Blindenhulp
Peritoneal metastases from colorectal carcinoma; Diagnostic markers to identify patients that will benefit from
radical surgical resection
E. de Cuba, E.A. te Velde, G.A. Meijer, H.J. Bonjer
Dept. Of Surgery, VU University Medical Center, Amsterdam
PET imaging in giant cell vasculitis
KJ Lensen, I Smulders, E Coomans, C vd Laken, A Voskuyl
Dep Rheumatology, VU University Medical Center, Amsterdam
PET methodology: new methods and tools for advanced and optimized tumour response assessment
1FHP van Velden, 2H Verheul, 3EF Smit, 1R Boellaard,1OS Hoekstra, 1AA Lammertsma
1Depts of Nucl Med & PET research, 2Medical Oncology, 3Pulmonology
161
Appendix 7: Ongoing projects
CTMM
59. Pharmacogenomics of Interferon-ß therapy in multiple sclerosis
S.Vosslamber1, M. Schreurs1, M. Blomberg1, B. Crusius1, M. van der Wiel1,4, B. Uitdehaag4, L. van de Voort3, J.
Killestein3, T.C.T.M. van der Pouw Kraan2, M. Comabella5, X. Montalban5, C. Aubin6, D. Hafler7, Ph. De Jager6, C.H.
Polman3, C.L. Verweij1
1Dept. of Pathology, 2Dept. of Molecular Cell Biology & Immunology, 3Dept. of Neurology and 4Epidemiology, VUMC,
Amsterdam, The Netherlands, 5Unitat de Neuroimmunologia Clínica. Hospital Universitari Vall d´Hebron, Barcelona,
Spain, 6Dept. Of Neurology, Harvard University, Boston, 7Departments of Neurology and Immunobiology, Yale School of
Medicine, USA
MS Research #04-549 MS and MS Research #08-660 MS
60. Positron Emission Tomography (PET) for detection of histologic transformation of indolent non-Hodgkin’s
Lymphoma
M.J. Wondergem1, J.M. Zijlstra1, S.A.G.M. Cillessen2, J.J. Oudejans2, O.S. Hoekstra3, S. Zweegman1, P.C. Huijgens1
Department of Hematology1, Pathology2, Nuclear medicine and PET research3 VU University Medical Center
de Vilder Stichting
61. Prediction of progression in low-grade glioma using chromosomal copy number alterations
H.F. van Thuijl1,2, J.J. Heimans1, P. van der Valk2, S.J. Smeets2, B. Ylstra2, P. Wesseling2, J.C. Reijneveld1,3
Departments of 1Neurology and 2Pathology, VU University Medical Center, Amsterdam, Department of 3 Neurology,
Academic Medical Center, Amsterdam
KWF Kankerbestrijding VU 2009-4470
62. Predictive value of stem cell enumeration for the response to nilotinib in newly diagnosed CML patients
J.J.W.M. Janssen, A. Zevenbergen, B. van Kuijk, W. Pouwels, G.J. Schuurhuis, G.J. Ossenkoppele
Dept. of Hematology, VU University Medical Center
Novartis
63. Prognostic parameters in laryngeal cancer and lymphatic metastases
Drs. R. Ljumanovic1, Dr. O.S. Hoekstra4,5, Dr. J.A. Langendijk3, Prof. dr. C.R. Leemans2, Prof. dr. J.A. Castelijns1
1 Afdeling Radiologie, 2 Afdeling Keel-, Neus- en Oorheelkunde en Hoofd-hals chirurgie, 3 Afdeling Radiatie-Oncologie, 4
Afdeling Nucleaire Geneeskunde en PET research, 5 Afdeling Klinische Epidemiologie & Biostatistiek
64. Qualifying imaging biomarkers for response evaluation in cancer
SN Rizvi 1, J Zijlstra2, 3H v Tinteren, 3A Vincent, 1R Boellaard, 1OS Hoekstra
1Dept of Nuclear Medicine & PET research, 2Haematology and 3Netherlands Cancer Institute
65. Quantification and tumor delineation in PET
P. Cheebsumon, F.H.P. van Velden, R. Boellaard, A.A. Lammertsma
Dept. Of Nuclear Medicine & PET Research
CTMM, Thai Government
66. Quantitative PET-CT imaging with 11C-labeled docetaxel in lung cancer
A.A van der Veldt1, M. Lubberink1, E.F. Smit2, A.D. Windhorst1, A.A. Lammertsma1, N.H. Hendrikse1,3
Departments of Nuclear Medicine & PET Research1 and Pulmonology2, Clinical Pharmacology & Pharmacy3, VU
University Medical Center, Amsterdam, Netherlands
67. Tailoring of (immune-)therapy in R-CHOP refractory diffuse large B-cell lymphoma patients
S.A.G.M. Cillessen1, L.M.M. Moesbergen1, W. Vos1, G.J. Ossenkoppele2, J.J. Oudejans1,3, C.J.L.M. Meijer1
Depts. of 1Clinical Pathology, 2Hematology, VU University Medical Center, Amsterdam. 3Dept of Pathology,
Diakonessenhuis, Utrecht
Dutch Cancer Society 2007-3858
68. The inhibition of EGFR signalling network in NSCLC cells affects MRP-1 and P-GP expression
L. Porcelli (1,2), A. Asghar (2), E. Giovannetti (2), G. Jansen (3), Y. Assaraf (2,5), G.L. Scheffer (4), A. Azzariti (1), A.
Paradiso (1), G.J. Peters (2)
(1) Clinical Experimental Oncology Laboratory, National Cancer Institute, Bari, Italy, (2) Department of Medical
Oncology, (3) Rheumatology and (4) Pathology, VU University Medical Center, Amsterdam, The Netherlands (5) Technion
Institute, Haifa, Israel.
69. Tumor profiling of gastrointestinal (i.e. gastric & colorectal) cancer
C. Postma1, A.H. Hardebol1, J.C. Haan1, O. Krijgsman1, J.A.C.M. Goos1,4, A.A. Geldof4, O.S. Hoekstra4, R.P.A.
Brosens1,2, E. Belt1,2, M.A. Cuesta2, E.M.L.V. de Cuba1,2, E. te Velde2, M.Labots3, T. Buffart1,3, H. Verheul3, M.
Tijssen1, S. Mongera1, P.M. Delis-van Diemen1, A. Bolijn1, D. Israeli1, B. Ylstra1, R.J.A. Fijneman1, B. Diosdado1, B.
Carvalho1, N.C.T. van Grieken1, and G.A. Meijer1
1Dept of Pathology, 2Dept of Surgery, 3Dept of Oncology, 4Dept of Nuclear Medicine & PET Research, VU University
Medical Center, Amsterdam
KWF, CTMM DeCoDe WorkPackage 5 and 6 2002-2618 / 2004-3051 / 2007-3832 / 2007-3
Program 4
AML and CML
1. Characterization of relapsed acute myeloid leukemia
C. Bachas1,2, Z.J. Kwidama1,2, T.L. Nguyen1,2, G.J. Schuurhuis2, G.J.L. Kaspers1 J. Cloos1,2
Depts. of 1Pediatric Oncology/Hematology and 2Hematology, VU University Medical Center, Amsterdam
KWF KWF 2005-3666
2. Detection of residual leukemic stem cells during minimal residual disease in AML
M. Terwijn, G.J. Ossenkoppele, GJ. Schuurhuis
Dept. of Hematology, VU University Medical Center
KWF 2006-3695
3. Discovery by proteomics of factors that regulate therapy resistance in acute myeloid leukemia
S. Zweegman1, F.L. Kessler1, S.R. Piersma2, T.V. Pham2, P. Noordhuis1, C. Jimenez, G.J. Schuurhuis1
Dept of 1Hematology and 2OncoProteomics Laboratory, Dept. Medical Oncology
162
Appendix 7: Ongoing projects
CCA-V-ICI grant
Protein tyrosine phosphatases as new targets in childhood myeloid leukemia
M. Irandoust1, M. Akyuz1, E.M. van Beek2, A.J.F. Broekhuizen1,3, I. Hubeek1, K. Schornagel2, A.A. van de Loosdrecht3,
C.M. Zwaan4, G.J.L. Kaspers1, T.K. van den Berg2, J. Cloos1,3.
Depts. of 1Pediatric Hematology/Oncology, 2Sanquin Research and Landsteiner Laboratory, Academic Medical Center
and 3Hematology, VU University Medical Center, Amsterdam. 4Pediatric Oncology/Hematology, Erasmus MC/Sophia
Children’s Hospital, Rotterdam
Stichting KiKa 90.000,00
5. Targeting of CLEC12A positive AML stem cells with CR2357 and antibody-drug conjugates
P. Noordhuis, M. Terwijn, A.R. Rutten, G.J.Ossenkoppele, G.J.Schuurhuis
Dept. of Hematology, VU University Medical Center, Amsterdam
Crucell Nederland
6. The function of EVI-1 in Acute Myeloid Leukemia; Leukemic stem cells and chemotherapy resistance
B. Venniker-Punt, G. Brasser, D. de Leeuw, A. Rutte, P. Merle, G.J. Ossenkoppele, G.-J Schuurhuis, L. Smit.
Department of Hematology University Medical Center, Amsterdam, The Netherlands
Interna and St. Vu Steunfonds Hematologie
7. The identification of biomarkers/drugtargets specific for leukemic stem cells of Acute Myeloid Leukemia
L. Smit1, M. Terwijn1, A. Rutte1, S. Smeets2, B. Ylstra2, R. Menezes3, V. van Beusechem4, G. Ossenkoppele1, G.J.
Schuurhuis1
Department of Hematology1, Microarray Facility, department of Pathology2, Department of Biostatistics3, Department
of Medical Oncology4. VU University Medical Center, Amsterdam, The Netherlands
St VU steunfonds Hematologie
8. The identification of microRNA(s) (signatures) for leukemic stem cells of Acute Myeloid Leukemia and Chronic
Myeloid Leukemia
D. de Leeuw1, F. Cerisoli2, F. Denkers1, G.-J. Schuurhuis1, P. van Noort2, G.J. Ossenkoppele1 and L. Smit1
Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands.* InteRNA Technologies B.V.,
Bilthoven, The Netherlands
AICR and Interna
Brain
9. Targeted therapy in pediatric brain tumors
D.G. van Vuurden1,4, E. Hulleman2,4, P. van der Stoop2,4, T. Wurdinger2,4, 5, M. Irandoust1,3, G.J.L. Kaspers1, J.
Cloos1,3
Depts of 1Pediatric Oncology/ Hematology, 2Neurosurgery, 3Hematology and 4Neuro-Oncology Research Group, VU
University Medical Center, Amsterdam, 5Molecular Neurogenetics Unit, Massachusetts General Hospital and Harvard
Medical School, Boston, MA. VU University Medical Center, Amsterdam
VONK / CCA/STR 2005-2009
Combined radiotherapy with conventional chemotherapy and molecular targeted agents
10. Optimization of image-guided radiotherapy (IGRT) for lung cancer
S. Senan, F.J. Lagerwaard, F. Spoelstra, J.S.W. Lind, E.C.J. Phernambucq, E.F. Smit, V.L.J.L. Thijssen, B.J. Slotman
Departments of Radiation Oncolog, Pulmonology and Medical Oncology, VU University Medical Center, Amsterdam
Co-morbidity RA
11. Cardiovascular disease and Rheumatoid Arthritis
A. van Sijl1,2, M. Peters1,2, M.T. Nurmohamed1,2,4, A.E. Voskuyl2, C.D.A. Stehouwer4, M. Visser5, W.F. Lems3, R.J.
van de Stadt2, M.H.M.T. de Koning2, M. Boers6, B.A.C. Dijkmans1,2,3
Depts of 1Rheumatology, VUMC, 2Jan van Breemen Institute, 3Slotervaart Hospital, 4Dept of Internal Medicine VU
University Medical Center, 5Institute for Research in Extramural Medicine, 6Dept of Clinical Epidemiology, VUMC
Drug resistance
12. Drug resistance in childhood leukemia
N.E. Franke1, J. van Meerloo1, K. Votjekova1,3, S.E. Verbrugge2, A. Schimmer4, B.A.C. Dijkmans2, G.J.L. Kaspers1, G.
Jansen2, J. Cloos1,3
Depts. of 1Pediatric Oncology/Hematology, 2Rheumatology and 3Hematology, VU University Medical Center,
Amsterdam, 4Princess Margaret Hospital, Ontario Cancer Institute, Toronto, ON
Stichting Translation Research and the Netherlands Organization for Health Research and Development (ZonMw)
PV06/08 CCA
Early RA
13. BeSt strategies in Rheumatoid Arthritis (BeSt)
B.A.C. Dijkmans, F.C. Breedveld
Dept. of Reumatology, VU University Medical Center, Amsterdam
14. Het parelsnoer initiatief: Parel rheumatoide artritis/artrose
L van Tuyl1, MT Nurmohamed12, WF Lems12, BAC Dijkmans12
1 Dept Rheumatology, VU University Medical Center, 2 Reade, Amsterdam
Immuuntherapie
15. Optimizing strategies in dendritic cell vaccination in acute leukemia
W. van den Ancker1, T.M. Westers1, M.M.van Luijn1, M.E.D. Chamuleau 1, J.M. Ruben1, S. Santegoets2, A.G.M. Stam3,
H.J. Bontkes1, T.D. de Gruijl2, G.J. Ossenkoppele1, A.A. van de Loosdrecht1
Depts of 1Hematology, 2Medical Oncology and 3Pathology, VU University Medical Center
V-ICI
Improvement of treatment of head and neck cancer
16. Hypothyroidism after treatment for laryngeal cancer
A.M. Lo Galbo, R. de Bree, C.R. Leemans
Dept. Otolaryngology/Head and Neck Surgery, VU University Medical Center, Amsterdam
NDDO/Biolitec
17. Improvement of treatment of head and neck cancer. General aspects.
R. de Bree1, L. van der Putten1, P. Doornaert2, I. van der Waal3, J. Buter4 , O.S. Hoekstra5, C.R. Leemans1
4.
163
Appendix 7: Ongoing projects
Depts. of 1Otolaryngology/Head-Neck Surgery, 2Radiation Oncology, 3Oral and Maxillofacial Surgery, 4 Medical
Oncology, 5 Nuclear Medicine / PET research, VU University Medical Center, Amsterdam
Genetronics 80-82305-98-08106
Oncolytic adenovirus
18. Enhancement of the oncolytic potency of conditionally replicative adenoviruses
W. Dong1, H. van Wijngaarden1, M. Cascallo2, W.R. Gerritsen3, R. Alemany2, J.J.M. Meulenberg1, V.W. van
Beusechem1,3
1ORCA Therapeutics, Amsterdam, The Netherlands; 2Translational Research Laboratory, IDIBELL-Institut Català
d’Oncologia, Barcelona, Spain; and 3Department of Medical Oncology, VU University Medical Center, Amsterdam
SenterNovem SI2 EUREKA E! 4582
19. Exploiting miRNA to enhance oncolytic adenovirus potency
J.W.H. van Ginkel1, C. Vermeulen2, J. Hodzic2, A. Vermeulen3, J. Karpilow3, J.J.M. Meulenberg1, V.W. van
Beusechem1,2,4
1ORCA Therapeutics, Amsterdam, The Netherlands; 2Department of Medical Oncology and 4RNA Interference Functional
Oncogenomics Laboratory, VU University Medical Center, Amsterdam, The Netherlands; 3Thermo Fisher Scientific,
Dharmacon RNAi Technologies, Lafayette, CO, USA
20. Identification of virus inhibitors in cancer cells by RNA interference screening
C. Vermeulen1, N. Tol1, I.H. van der Meulen-Muileman1,2, W.R. Gerritsen1, V.W. van Beusechem1,2
Department of 1Medical Oncology and 2RNA Interference Functional Oncogenomics Laboratory, VU University Medical
Center, Amsterdam, The Netherlands
Technology foundation STW 7710
21. Virotherapy of glioblastoma multiforme using an infectivity-enhanced selectively replication-competent adenovirus
V.W. van Beusechem1, M.L.M. Lamfers2, J.M. Amado de Azevedo1, S. Idema3, C.M.F. Dirven2, W.R. Gerritsen1, W.P.
Vandertop3, D.P. Noske3
Depts. of 1Medical Oncology and 3Neurosurgery, VU University Medical Center, Amsterdam; 2Dept. Neurosurgery,
Erasmus MC, Rotterdam
ZonMw Translationeel Gentherapeutisch Onderzoek 43200003
Regulation of MHC class-II in acute myeloid leukemia and its impact on immunoserveillance
22. Low CLIP expression on leukemic blasts of AML patients is essential for generating an effective CD4+ T cell
response
M.M. van Luijn1,2, M.E.D. Chamuleau1, W. van den Ancker1, A. Zevenbergen1, T.M. Westers1, Y. Souwer2, G.J.
Ossenkoppele1, S.M. van Ham2, A.A. van de Loosdrecht1
1Department of Hematology, VU Institute for Cancer and Immunology, Cancer Center Amsterdam, VU University Medical
Center, Amsterdam, The Netherlands; 2Department of Immunopathology, Sanquin Research and Landsteiner Laboratory,
Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; 3Department of Biological Sciences,
University of Maryland, Baltimore County, Baltimore, USA
VanderEs / Stichting VU fonds Hematologie PV06/04 Prom
RNai
23. Identification of genes involved in resistance of lung cancer cells to cisplatin
E. Siebring-van Olst1, I. Kotov2, R.X. de Menezes3, T. Marti2, R. Stahel2, E.F. Smit1, V.W. van Beusechem4,5
Depts. of 1Pulmonary Diseases, 3Epidemiology and Biostatistics, and 4Medical Oncology, and 5RNA Interference
Functional Oncogenomics Laboratory, VU University Medical Center, Amsterdam; 2Laboratory of Molecular Oncology,
University Hospital Zurich, Switzerland
Foundation Avanti STR / Walter Bruckerhoff Stiftung
24. Identification of genes involved in resistance of prostate cancer cells to irradiation
J. Hodzic1, B. van Triest2, A. Geldof3, R.X. de Menezes4, I.H. van der Meulen-Muilemans1,5, W.R. Gerritsen1, M.
Verheij2, V.W. van Beusechem1,5
Departments of 1Medical Oncology, 3Urology, and 4Epidemiology and Biostatistics, and 5RNA Interference Functional
Oncogenomics Laboratory, VU University Medical Center, Amsterdam; 2Department of Radiotherapy, The Netherlands
Cancer Institute, Amsterdam
CCA, Avanti STR
25. Identifying new regulators of migration in human glioblastoma
P.M. van der Stoop1,2, L.E. Wedekind1,2, I.H van der Meulen3,4, V.W. van Beusechem3,4, W.P. Vandertop1,2, D.P.
Noske1,2 , T.Wurdinger1,2,5.
Depts. of 1Neurosurgery, 2Neuro-oncology Research Group, 3Medical Oncology, and 4RNA Interference Functional
Oncogenomics Laboratory, VU University Medical Center, Amsterdam.5Molecular Neurogenetics Unit, Massachusetts
General Hospital and Harvard Medical School, Boston, MA.
CCA/STR and www.stophersentumoren.nl
Symptoms and symptomatic treatment of cerebral glioma
26. Correlation between SV2A expression in tumour tissue and efficacy of levetiracetam in glioma patients with
epilepsy
M. de Groot1, J.J. Heimans1, E. Aronica5, C.J. Vecht6, M. Klein3, C.J. Stam2, J.C. Reijneveld1,4
Departments of 1Neurology, 2Clinical Neurophysiology, and 3Medical Psychology, VU University Medical Center,
Amsterdam, Departments of 4 Neurology and 5 Pathology, Academic Medical Center, Amsterdam, and 6Department of
Neurology, Medical Center ‘Haaglanden’, The Hague
UCB Pharma Nederland BV
Systemische sclerose
27. Capillair microscopie bij sclerodermie
H.M.A. Hofstee, E.H. Serne, I. Smulders, A.E. Voskuyl
Dep Rheumatology, VU University Medical Center, Amsterdam
28. Systemische sclerose
A. Voskuyl, C. Verweij, A. Boonstra
Department of Rheumatology, VU University Medical Centre, Amsterdam
2Department of Nuclear Medicine and PET Research, VU University Medical Centre, Amsterdam, The Netherlands
Treatment early RA
164
Appendix 7: Ongoing projects
29. Cohorts of biologicals in patients with rheumatoid arthritis (COBRA)
D den Uyl, AE Voskuyl, WF Lems, BAC Dijkmans
Dept. of Reumatology, VU University Medical Center, Amsterdam
TIPharma
Other projects
30. A multicenter, randomized phase II trial of paclitaxel plus bevacizumab versus paclitaxel, bevacizumab plus
capecitabine in HER2-negative locally recurrent or metastastic breast cancer
S.W. Lam, A.H. Honkoop, S. de Groot, S v.d. Wildt, H. van Tinteren, E. Boven
Depts. of Medical Oncology, VU University Medical Center and BOOG Study Center Amsterdam
Industry
31. A new definition for remission in rheumatoid arthritis
M. Boers (co-PI),1,2 D. Felson (co-PI),3 J. Smolen,4 G. Wells5, L. Van Tuyl.1,2
1. Dept of Clinical Epidemiology and Biostatistics; 2. Dept of Rheumatology; VUmc; 3 Boston University, USA; University
of Vienna, Austria; University of Ottawa, Canada
32. Adherence and patients’ experiences with the use of erlotinib in NSCLC and capecitabine in colon cancer
treatment; the influence on plasma concentration and the exploration of factors affecting the use in daily practice
L. Timmers1, E. Boven2, C. Boons1, EL. Swart1, D. Mangnus1, J. Moes1, J.G. Hugtenburg 1,3
1Department of Clinical Pharmacology and Pharmacy, VU University Medical Center; 2Department of Medical Oncology;
3EMGO+ Institute for Health and Care Research, VU University Medical Center
33. Alternative antigen processing and loading is involved in HLA class I and II antigen presentation on leukemic blasts
M.M. van Luijn1,2, M.E.D. Chamuleau1, M.E. Ressing3, E.J. Wiertz3, A. Zevenbergen1, Y. Souwer2, S. OstrandRosenberg4, G.J. Ossenkoppele1, A.A. van de Loosdrecht1, S.M. van Ham2
1Department of Hematology, VU Institute for Cancer and Immunology, Cancer Center Amsterdam, VU University Medical
Center, Amsterdam, The Netherlands; 2Department of Immunopathology, Sanquin Research and Landsteiner Laboratory,
Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands; 3Department of Medical
Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands. 4Department of Biological Sciences,
University of Maryland, Baltimore County, Baltimore, USA
Stichting Vanderes
34. Antiproliferative effects of novel aliphatic acetogenin analogs against aggressive solid tumor cell lines
Leticia G Leon 1,2, Elisa Giovannetti,2,3 Claudia Alecci,2 Fiorella Giancola,2 Niccola Funel,3 Paolo Zucali,4 Godefridus
J. Peters,2 José M. Padrón1
Universidad de La Laguna, La Laguna, Spain; 2 Department of Medical Oncology, VU University Medical Center,
Amsterdam, The Netherlands; 3 University of Pisa, Pisa, Italy; 4 Istituto Clinico Humanitas, Milan, Italy
35. Application of bortezomib in pediatric acute lymphoblastic leukemia
D. Niewerth1, J. van Meerloo1, N.E. Franke, G. Jansen2, G.J.L. Kaspers1, J. Cloos1,3
Depts. of 1Pediatric Oncology/Hematology, 2Rheumatology and 3Hematology, VU University Medical Center, Amsterdam
Stichting KIKA
36. Bacteriele Artritis Corticosteroid Interventie (BACI)
R. van Vugt, B.A.C. Dijkmans
Dep Rheumatology, VU University Medical Center, Amsterdam
37. Biological cohorten bij Spondylartopathieen - infliximab, adalimumab, etanercept
IE van der Horst-Bruinsma, BAC Dijkmans
Dep Rheumatology, VU University Medical Center, Amsterdam
38. Brain tumor miRNA in the development of 'genetic' chemotherapeutics
R. J. A Nilsson1,2, M. Smits1,2, S. van Rijn1,2 , W.P. Vandertop1,2, D.P. Noske1,2, T Wurdinger1,2,3
Depts. of 1Neurosurgery, 2Neuro-oncology Research Group, VU University Medical Center, Amsterdam. 3Molecular
Neurogenetics Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA
Van Reekum/van Moorselaar stichting, CCA/STR, Swedish Research Council
39. Brainstem tumors: development of anti-tumor drugs for convection enhanced delivery
V. Caretti1,2,3,P.van der Stoop1,3 , J. Cloos2,3, WP. Vandertop1,3, G.J.L. Kaspers2,3, D.P. Noske1,3, T.
Wurdinger1,3,4
Depts. of 1Neurosurgery, 2Pediatric Oncology/ Hematology, 3Neuro-oncology Research Group ,VU University Medical
Center, Amsterdam. 4Molecular Neurogenetics Unit, Massachusetts General Hospital and Harvard Medical School,
Boston, MA
VONK/Semmy/Stichting Egbers
40. Carboplatin study: assessment and optimization of carboplatin exposure in pediatric oncology using different
markers of kidney function
H.N. Blufpand1, F.C.H. Abbink1, G.J. Peters3, G.J.L. Kaspers1, B. Stoffel-Wagner4, A. Bökenkamp2
Department of Pediatrics, subdivisions 1Pediatric Oncology/Hematology, and 2Pediatric Nephrology, 3Medical Oncology,
VU University Medical Center, 4Clinical Chemistry and Clinical Pharmacology, Bonn University Medical Center
VUMC Childhood Cancer Research Foundation VONK
41. Chronological or random reading of radiographs in long term follow-up studies of Rheumatoid Arthritis?
L. Van Tuyl,1,2 D.M.F.M van der Heijde, 3 M. Boers (PI)1,2
1.Dept of Clinical Epidemiology and Biostatistics; 2. Dept of Rheumatology; VUmc; 3. Dept of Rheumatology, Leiden
UMC
Reumafonds
42. Circulating endothelial cells as markers for anti-angiogenic therapy
L.Vroling, K.Hoekman, Y.Yuana, R. de Haas, V.W.M. van Hinsbergh1, E. Boven, G.J. Schuurhuis2, H.J.Broxterman
Depts. of Medical Oncology, 1Physiology and 2Hematology, VU University Medical Center
EU (FP6): Integrated Project: Angiotargeting 504743
43. Comparative effectiveness research on stereotactic radiotherapy for stage I non-small cell lung cancer
S. Senan1, W.F.A.R. Verbakel1, J.P. Cuijpers1, F.J. Lagerwaard1, C.J. Haasbeek1, B.J. Slotman1, D.A. Palma2, A.V.
Louie2, G. Rodrigues2 , O. Visser3
165
Appendix 7: Ongoing projects
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
166
Departments of Radiation Oncology, 1VU University Medical Center, Amsterdam and 2Department of Radiation
Oncology, London Regional Cancer Program, Canada, 3 Comprehensive Cancer Center Amsterdam
Development of anti-angiogenic miRNA-based therapeutics
J. van Beijnum1, M. van Berkel1, S. van der Velden1, V.L. Thijssen, A.W. Griffioen1,
Depts. of 1Medical Oncology
TI Pharma
Development of DCOne/MUTZ-3 and novel AML-derived cell lines for DC-based allogeneic tumor vaccination
S.J.A.M. Santegoets1, D. Oosterhoff2, R. van de Ven1, W. van den Ancker3, P.J.G.T.B. Wijnands2, A. Reurs2, M.
Meerendonk2, J. Kaspers2, S. van Wetering2, A.J.M. van den Eertwegh1, Rik J. Scheper1,4, H.J. Bontkes3,4, A.A. van de
Loosdrecht3, A.M. Kruisbeek2, T.D. de Gruijl1
Department of 1Medical Oncology, 2DC Prime BV, and the Departments of 3Hematology and 4Pathology, VU University
Medical Center, Amsterdam
DC Prime, Biopartner FSG & Senter Grant, ZonMW Translationeel Research Grant 40-41200-98-9106
Development of preclinical pediatric brain tumor imaging models
L. Hiddingh1,2,3, V. Caretti1,2,3, T. Lagerweij1,2,3, E. Hulleman1,2,3, G.J. Kaspers1, W.P. Vandertop2, C. Molthoff4,
B.A. Tannous4, D. Noske2,3, T. Wurdinger2,3,5
Depts of 1Pediatric Oncology/ Hematology, 2Neurosurgery, 3Neurooncology Research Group, VU University Medical
Center, 4VU University RNC, 5Massachusetts General Hospital and Harvard Medical School, Boston, MA
Stichting Kika
Differential metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126
A.D. Adema1, N. Losekoot1, K. Smid1, H.M. Verheul1, F. Myhren2, M.L. Sandvold2, G.J. Peters1*
1Dept Medical Oncology, VU University Medical Center, Amsterdam, the Netherlands. 2Clavis Pharma, Oslo, Norway
Clavis Pharmaceutical, Oslo, Norway
Discrepancies between plasma, serum, whole blood and cellular concentrations of various tyrosine kinase
inhibitors
R. Honeywell 1, E. Giovannetti1, I. Kathman1, C. Tibaldi2, F. Cappuzzo2, J.S. Lind4, E.F. Smit4, H.M. Verheul1, G.J.
Peters1
R. Honeywell 1, E. Giovannetti1, I. Kathman1, C. Tibaldi2, F. Cappuzzo2, J.S. Lind4, E.F. Smit4, H.M. Verheul1, G.J.
Peters1
1Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands; 2Division of Oncology,
Department of Oncology, Azienda USL-6 of Livorno, Italy; 3Division of Oncology, Department of Oncology, Azienda
Ospedaliero-Universitaria of Parma, Italy, 4
Department of Pulmonology, VU University Medical Center, Amsterdam the Netherlands
Elucidating TMZ resistance in glioma
L. Hiddingh1,2,3, G.J. Kaspers1, W.P. Vandertop2, P. Wesseling4, B.A. Tannous5, D. Noske2,3, J. Jeuken4, T.
Wurdinger2,3,5
Depts of 1Pediatric Oncology/ Hematology, 2Neurosurgery, 3Neurooncology Research Group, VU University Medical
Center, 4Pathology, RUNMC, 5Massachusetts General Hospital and Harvard Medical School, Boston, MA
Stichting www.stophersentumoren.nl
Evaluation of (neuro)toxicity of systemic anti-cancer therapy and neuroprotection
T.J. Postma1, A.A. Geldof2, P.C. Huijgens3, N.K. Aaronson6, G.J. Peters4, B.J. Slotman5, J.J. Heimans1
Departments of 1Neurology, 2Endocrinology, 3Hematology, 4Medical Oncology, 5Radiotherapy, VU University Medical
Center, Amsterdam, Department of 6Psychosocial Research and Epidemiology, The Netherlands Cancer Institute,
Amsterdam
Experimental therapy rationale for prostatic cancer
A.A. Geldof1,2, JJL Jacobs1, I.V. Bijnsdorp1, P. J. Frantzen1 , A. Vis1 and R.J.A. van Moorselaar1
Depts. of 1Urology and 2Nuclear Medicine & PET Research, ¬VU University Medical Center, Amsterdam
Exploring the role of endothelial galectins in tumor angiogenesis
I. Schulkens1, R. Heusschen1, A.M. Dingemans2, V. Van den Boogaart2, H.M. Verheul1, A.W. Griffioen, V.L.J.L.
Thijssen1,3
Depts. of 1Medical Oncology, VU University Medical Center, 2Pulmonology, Maastricht University Medical Cencer,
Maastricht, and 3Radiotherapy, VU University Medical Center
KWF 2009-4358
High Aldehyde Dehydrogenase Activity (ALDH) Is a Marker for Normal Hematopoietic Stem Cells but Not Leukemic
Stem Cells in Acute Myeloid Leukemia
G.J. Schuurhuis, L.A. Min, H. Meel, R. Wouters, M. Terwijn, A. Kelder, A.N. Snel, G.J. Ossenkoppele, L. Smit
Department of Hematology, VU University Medical Center, Amsterdam
St. VU steunfonds Hematologie
Hypoxia measured with PET: 18FAZA technical validation
1I Bahce, 2P Raijmakers, 2R Boellaard, 1EF Smit, 2J Eriksson, 2RC Schuit, 2OS Hoekstra, 2AA Lammertsma
1Depts of Pulmonology, 2Nucl Med & PET research
CTMM
Image-guided and adaptive radiotherapy
S. Senan, W.F.A.R. Verbakel, M. Dahele, J.R. van Sörnsen de Koste, J.P. Cuijpers, F.J. Lagerwaard, M. Dahele, CL Ong,
C.J. Haasbeek, P. Doornaert, F.O.B. Spoelstra, B.J. Slotman
Departments of Radiation Oncology, VU University Medical Center, Amsterdam
Image-guided and adaptive radiotherapy for oligometastases
S. Senan, W. Verbakel, M. Dahele, B.J. Slotman
Departments of Radiation Oncology, VU University Medical Center, Amsterdam
Imaging and targeting of macrophage folate receptor-beta in rheumatoid arthritis
K. Weijers1, G. Jansen1, C.F.M. Molthoff2, B. Windhorst2, J.W. van der Heijden1, A. Voskuyl1, P.S. Low3, M. Ratnam4,
Y.G. Assaraf 5, A.A. Lammertsma2, B.A.C. Dijkmans1, and C.J van der Laken1
Depts. of 1Rheumatology and 2PET-Center/Nuclear Medicine, VU University Medical Center, Amsterdam, The
Netherlands, 3Endocyte, West Lafayette, IN, USA, 4Dept of Biochemistry and Molecular Biology, Medical University of
Toledo, Toledo, OH. U.S.A., 5Dept. of Biology, The Technion, Israel Institute of Technology, Haifa, Israel
Appendix 7: Ongoing projects
Nationaal Reumafonds NRF-09-404
58. Immune correlates of clinical response and survival in castration resistant prostate cancer patients treated with
Prostate GVAX and anti-CTLA4 immunotherapy
S.J.A.M. Santegoets2, A.J.M. van den Eertwegh1, A.G.M. Stam2, S.M. Lougheed1, H. Gall1, P.E.T. Scholten2, B.M.E. von
Blomberg2, E. Hooijberg2, K. Jooss4, N. Sacks4, K. Hege4, I. Lowy5, R.J. Scheper2, W.R. Gerritsen1, T.D. de Gruijl1
Departments of 1Medical Oncology and 2Pathology of the VU University medical center, Amsterdam, The Netherlands;
3Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA; 4Cell Genesys Inc.,South San
Francisco, CA; 5Medarex, Bloomsbury, NJ
Prostate Cancer Foundation Research Award, Dutch Cancer Society KWF-VU 2006-3697
59. Immunemodulation in myelodysplastic syndromes
H.J. Bontkes, C. Alhan, J.M. Ruben, C. Eeltink, T.M. Westers, G.J. Ossenkoppele, A.A van de Loosdrecht
Dept. of Hematology, VU University Medical Center, Amsterdam
St. VU Steunfonds
Hematologie, CCA/V-ICI
60. Immunological studies supporting phase 1-3 active specific vaccination and chemo-immunotherapy trials in clinical
cancer
S.J.A.M. Santegoets1, A.G. Stam2, H. van Cruijsen1, S.M. Lougheed1, P.E.T. Scholten2, B.M.E. von Blomberg2,
P.Pohlmann1, J. Buter1, H.M. Pinedo1, M. Suhoski3, C.H. June3, W.R. Gerritsen1, R.J. Scheper2, H. Verheul1, J.J. van
der Vliet1, A.J.M. van den Eertwegh1, T.D. de Gruijl1
Depts. of 1Medical Oncology and 2Pathology, VU University Medical Center, Amsterdam; 3Abramson Family Cancer
Research Institute, University of Pennsylvania, Philadelphia, PA.
KWF-VU 2006-3697
61. Immunomodulation in melanoma sentinel lymph node
M.F.C.M. van den Hout1, B.J.R. Sluijter1, S.J.A.M. Santegoets, P.A.M. van Leeuwen1, S. Meijer1, P. van den Tol3,
A.J.M. van den Eertwegh2, R.J. Scheper3, T.D. de Gruijl2
Departments of 1Surgical Oncology, 2Medical Oncology, and 3Pathology, VU University Medical Center, Amsterdam
Heelkundefonds
62. Immuno-PET in non-Hodgkin’s lymphoma
J.M. Zijlstra1, S.N.F. Rizvi2, J.M. Lubberink2, O.S. Hoekstra2, G.A.M.S. van Dongen2,3, H. v. Tinteren4, P.C. Huijgens1
Depts. of 1Hematology, 2Nuclear Medicine & PET Research, 3Otolaryngology, VU University Medical Center
4e geldstroom
63. Innovative techniques for intracranial stereotactic radiotherapy
Lagerwaard FJ, Meijer OWM, Haasbeek CJA, Vandertop WP, Baaijen JC, van den Berg R, Postma TJ, Leemans CR,
Slotman BJ
Depts. of Radiation Oncology, Neurosurgery, Radiology, Otolaryngology/Head and Neck Surgery and Neurology, VU
University Medical Center, Amsterdam
Varian - RapidArc
64. Is c-Abl a potentail target for therapy in Enteropathy Associated T-cell Lymphomas?
M. Radersma1, C.J.L.M. Meijer2, O.J. Visser3, B.M.E. von Blomberg2, G. Bouma1, C.J.J. Mulder1, S.A.G.M. Cillessen2
Depts. of 1Gastro-enterology and Hepatology,2Clinical Pathology, 3Hematology, VU University Medical Center,
Amsterdam
MLDS grant WO-9-28
65. Leukemia associated antigen loading of dendritic cells for vaccination of acute myeloid leukemia patients
J.M. Ruben1, W.A. van den Ancker1, T,D de Gruijl2, T.M. Westers1, G.J. Ossenkoppele1, H.J. Bontkes1, A.A. van de
Loosdrecht1
Departments of Hematology1 and medical oncology2, Cancer Center Amsterdam, VU University Medical Center
66. MAMMOTH; Molecular breast cancer imaging for diagnosis and therapeutics decision making
T. J. Wong1, Y. Paulis1, R.R. de Haas1, R. Heusschen1, H.M. Verheul1, V.L.J.L. Thijssen1,3, A.W. Griffioen1
Dept. of 1Medical Oncology, VU University Medical Center
67. Measuring intraprostatic androgen concentrations using LC-MS/MS: from bench to bedside
T. van der Sluis, JJL Jacobs, AA Geldof, RJA van Moorselaar and A Vis
Dept. of Urology, VU University Medical Center, Amsterdam
68. Metabolic volume measures as indicators of response to therapy in cancer
1V Frings,1R Boellaard, 1P Cheebsumon, 3H van Tinteren, 1FHP van Velden, 2EF Smit, 1OS Hoekstra
1Dept of Nuclear Medicine & PET research, 2Pulmonology, 3Netherlands Cancer Institute
69. Methodological aspects of perfusion measurements with CT and PET
1G Kramer, 1R Boellaard, 2MR Meijerink, 3EF Smit, 1OS Hoekstra
1Dept of Nuclear Medicine & PET research, 2Radiology, 3Pulmonology
70. MicroRNA-21 from bench to bedside and back: a potential marker of clinical outcome and a target to overcome
resistance to gemcitabine in pancreatic cancer
Giovannetti E,1,2 Funel N,3 Erozenci LA,1 Del Chiaro M,3 Leon GL,1 Vasile E,4 Pollina LE,3 Groen A,2 Falcone A,4 Boggi
U,3 Campani D,3 Verheul HM,1 Danesi R2, Peters GJ1
1VU University Medical Center, Amsterdam, The Netherlands; 2Dept. Internal Medicine University of Pisa, 3Divisione di
Chirurgia Generale e dei Trapianti dell'Uremico e del Diabetico, Hospital of Pisa, 4Unit of Medical Oncology-2, Azienda
Ospedaliero-Universitaria Pisana, Pisa, Italy
71. Modulation of miRNAs in glioma stem-like cells
S. van Rijn1,2, M. Smits1,2, J. Nilsson1,2, D.P. Noske1,2, T. Würdinger1,2,3
1Neuro-oncology Research Group, 2Department of Neurosurgery, VU University Medical Center, 3Molecular
Neurogenetics Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA
CCA/STR funding
72. Molecular basis of intrinsic and acquired bortezomib resistance in non-small cell lung cancer
L.H.A.M. de Wilt 1, G. Jansen2, Y.G. Assaraf 3, J. van Meerloo4, J. Cloos4, A.D. Schimmer5, C.J. Kirk6, G.J. Peters1¬¬,
F.A.E. Kruyt7
1Dept Med Oncol, 2Dept Rheumatol, VU University Medical Center, Amsterdam, 3 The Fred Wyszkowski Cancer Research
Lab, Dept Biol, Technion-Israel Institute of Technology, Haifa, Israel, 4Dept Pediatr Oncol/Hematol, VU University
167
Appendix 7: Ongoing projects
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
168
Medical Center, Amsterdam, 5Princess Margeret Hospital, Ontario Cancer Institute, Toronto, Canada, 6Onyx
Pharmaceuticals, San Franscisco, U.S.A., 7Dept Med Oncol, Univ Medical Center Groningen
KWF 2006-3567
Molecular basis of sensitivity/resistance for folate antagonist and other targeted drugs
G. Jansen1, J.W. van der Heijden1, R. Oerlemans1, W.F. Lems1, R.J. Scheper2, J. Cloos3, N.E. Franke3, S.E.
Verbrugge1, C.L. Verweij1,2, R. de Jonge5, G.J. Peters4, Y.G. Assaraf 6 and B.A.C. Dijkmans1
Depts. of 1Rheumatology, 2Pathology, 3Pediatric Oncology and 4Medical Oncology, VU University Medical Center,
Amsterdam, The Netherlands, 5 Dept. of Clinical Chemistry, Erasmus Medical Center, Rotterdam, The Netherlands,
6Dept. of Biology, The Technion, Israel Institute of Technology, Haifa, Israel
Near Infrared Fluorescent imaging of the Sentinel Node
MHGM van der Pas1, M. Ankersmit1, DA van Dam1, GAMS van Dongen2, O. Hoekstra2, WJHJ Meijerink1
Depts of 1Gastro-intestinal Surgery, 2Nucleaire Geneeskunde en PET research, VU University Medical Center
Optimalisation of ciclosporine exposure in HSCT
A.J. Wilhelm1, J.J.W.M. Janssen2, P.C. Huijgens2, E.L. Swart1
Depts. of 1Clinical Pfarmacology and Pharmacy and 2Hematology, VU University Medical Center
Peri-implantitis, implant loss and radio-osteomyelitis in head and necktumor patients
H. Dekker, Chr. ten Bruggencate, B. Schulten, N. Braveboer, E. Bloemena
Dept. Of Pathology, VU University Medical Center Amsterdam
IOT/ACTA
PET methodology: quantification of long-lived PET tracers in oncology and immunology
1N Makris, 2GAMS van Dongen, 3J Zijlstra, 4EF Smit, 2R de Bree, 5H Verheul, 5CW Menke-van der Houven van Oordt, 6J
van der Laken, 1OS Hoekstra, 1R Boellaard
1Depts of Nucl Med & PET research, 2 Otolaryngology/Head-Neck Surgery 3 Haematology, 4Pulmonology, 5Medical
Oncology, 6Rheumatology
CTMM
PET methodology: the impact of partial volume corrections in oncology
1N Hoetjes, 1P Cheebsumon, 1FHP van Velden, 2EF Smit, 2AJ de Langen, 1AA Lammertsma, 1OS Hoekstra, 1R Boellaard
1Dept of Nucl Med & PET research, 2Pulmonology
Photoimmunodetection of colorectal cancer
M. Ankersmit1, DA van Dam1, MHGM van der Pas1, EA te Velde, E. De Cuba, GAMS van Dongen2, WJHJ Meijerink1
Depts of 1Gastro-intestinal Surgery, 2Nucleaire Geneeskunde en PET research, VU University Medical Center
Proteasome inhibitor targeting of the (immuno)proteasome: effects on immune effector cells and therapeutic
consequences for cancer and chronic inflammatory diseases
S.E. Verbrugge1, T.D. de Gruijl2, R.J. Scheper3, M. Aujay4, C.J. Kirk4, J. Cloos5, Y.G. Assaraf 6, B.A.C. Dijkmans1, and
G. Jansen1
Depts. of 1Rheumatology, 2Medical Oncology, 3Pathology, 5 Pediatric Oncology, VU University Medical Center,
Amsterdam, The Netherlands, 4Onyx Pharmaceuticals, South San Francisco, USA. 6Dept. of Biology, The Technion, Israel
Institute of Technology, Haifa, Israel.
V-ICI Pro07/36
Radiation and targeted therapy of brain tumours
Sminia P, van Nifterik KA, van den Berg J, Ameziane N, Stalpers LJH, Hulsebos TJM, Leenstra S, Peters GJ, van der Valk
P, Lafleur MVM, Baumert BG, Steenbergen RDM, Slotman BJ
Depts. Radiation Oncology, Oncogenetics, Molecular Pathology, Pathology, Dept Medical Oncology, VU University
Medical Center, Depts. Radiation Oncology, Neurogenetics, Academic Medical Center, Amsterdam; Dept. Neurosurgery,
St. Elisabeth Ziekenhuis, Tilburg; Dept. Radiation Oncology Maastricht Universitair Medisch Centrum
KWF VU2000-2149
Resistance to Disease Modifying Anti-Rheumatic Drugs and other experimental anti-rheumatic drugs
R. Oerlemans1, J.W. van der Heijden1, W.F. Lems1, J. Cloos2, R.J. Scheper3, G.L. Scheffer3, Y.G. Assaraf 4, B.A.C.
Dijkmans1 and G. Jansen1
Depts. of 1Rheumatology, 2Pediatric Oncology, 3Pathology, VU University Medical Center, Amsterdam, The Netherlands,
4Dept. of Biology, The Technion, Israel Institute of Technology, Haifa, Israel
Nationaal Reumafonds/V-ICI grant NRF-03-40I
Review of ovarian cancer, bladder cancer, mesothelioma, Kaposi sarcoma; focus on paclitaxel, gemcitabine,
pegylated doxorubicin
J.G. Hugtenburg1,2, C. Boons1, E. Boven3
1Department of Clinical Pharmacology and Pharmacy, VU University Medical Center; 2EMGO+ Institute for Health and
Care Research, VU University Medical Center; 3Department of Medical Oncology
ZonMW
Role of flow cytometry in the diagnosis and prognostication of myelodysplastic syndromes
C. Alhan, T.M. Westers, C. Cali, G.J. Ossenkoppele, A.A. van de Loosdrecht
Dept. of Hematology, VU University Medical Center, Amsterdam
Stichting Hematologie Fonds, Cellgene/Roche as part of HOVON89
Sensitivity and resistance of tumor cells to the antiangiogenic tyrosine kinase inhibitor sunitinib
K.J. Gotink1, H.J. Broxterman1, R.R. de Haas1, H. Dekker1, R.J. Honeywell1, M. Labots1, Y.G. Assaraf1, R. Pili2, G.J.
Peters1, H.M.W. Verheul1
1 Dept. of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands, 2 Roswell Park Cancer
Institute, Buffalo, New York, USA
Single Port Surgery
DA van Dam1, MHGM van der Pas1, M. Ankersmit1, WJHJ Meijerink1
Depts of 1Gastro-intestinal Surgery, VU University Medical Center
Small molecule bioluminescent screening for novel therapeutics for pediatric brain tumors
E. Hulleman1,2,4, J. Cloos1,3, G.J.L. Kaspers1, W.P. Vandertop2,4, B.A. Tannous5, D.P. Noske2,4, T.Wurdinger2,4,5
Depts of 1Pediatric Oncology/ Hematology, 2Neurosurgery and 3Hematology and 4Neuro-oncology Research Group,
5Molecular Neurogenetics Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA. VU University
Medical Center, Amsterdam
Appendix 7: Ongoing projects
Stichting KIKA en NIH-R21
88. Study on the interaction between angiogenesis inhibition and radiotherapy
Thijssen VLJL, Castricum K, Senan S, Griffioen AW, Verheul HM, Slotman B
Depts. of 1Radiotherapy, VU University Medical Center, and 2Radiotherapy, VU University Medical Center
89. Sunitinib for advanced renal cell cancer: pharmacodynamic aspects
A.A.M. van der Veldt1, A.J.M. van den Eertwegh1, J.B.A.G. Haanen2, E. Boven1
Depts. of 1Medical Oncology, VU University Medical Center, and 2Medical Oncology, The Netherlands Cancer Institute –
Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
Industry
90. Targeted therapy in hematological malignancies: Antibody-targeting, erythropoietin and granulocyte-colony
stimulating factor, farnesyl protein transferase and tyrosine kinase inhibitors
G.J. Ossenkoppele1, P.C. Huijgens1, J.J.W.M. Janssen1, J.M. Zijlstra1, O. Visser1, M.J. Wondergem 1, A.A. van de
Loosdrecht1
Department of 1Hematology, VU University Medical Center, Amsterdam, The Netherlands
91. Targeted therapy of osteosarcoma, with a focus on lung metastases
drs. J. Posthuma de Boer1, dr. M. N. Helder1, dr. V.W. van Beusechem2, prof. dr. G.J.L. Kaspers3. prof. dr. B.J. van
Royen1
1Department of Orthopaedic Surgery, VU University Medical Center, 2department of Medical Oncology, VU University
Medical Center and 3department of Pediatric Oncology/Haematology, VU University Medical Center. Supported by
Aarhus University Hospital, Denmark, Stichting VUmc fonds VONK and the department of Orthopaedic Surgery, VU
University Medical Centre, Amsterdam
Danish grant and VONK
92. Targeting galectin-1 for the diagnosis and treatment of cancer
R. Heusschen1, I. Schulkens1, A.W. Griffioen1, H.M. Verheul1, V.L.J.L. Thijssen1,2
Depts. of 1Medical Oncology, VU University Medical Center, and 2Radiotherapy, VU University Medical Center
KWF UM 2008-4101
93. The role of CD34 in the nature of leukemia stem cells in acute myeloid leukemia
P. Noordhuis, L. Smit, G.J. Ossenkoppele, GJ. Schuurhuis
Dept. of Hematology, VU University Medical Center
St. VU-fonds Hematologie
94. The role of epigenetics in the treatment of pediatric brain tumors
S.E. Mir1,5, E. Hulleman1,2,5, T. Wurdinger2,5, D. Noske2,5, G.J.L. Kaspers1, B. Drukarch3, J. Cloos1,4
Depts of 1Pediatric Oncology/ Hematology, 2Neurosurgery, 3Anatomy and Neusosciences and 4Hematology, 5Neurooncology Research Group, VU University Medical Center, Amsterdam
Mozaiek, KWF fellowship
95. The role of impaired FPGS splicing in methotrexate response in childhood acute lymphoblastic leukemia
Wojtuszkiewicz1,2, G.J.L. Kaspers1, Y.G. Assaraf3 J. Cloos1,2, M. Stark3, G.J. Peters4, G. Jansen5
1Dept. of Pediatric Oncology / Hematology, 3Dept. of haematology, 4Medical Oncology and 5Rheumatology, VU
University Medical Center; 2Dept. of Dept. of Biology, The Technion-Israel Institute of Technology, Haifa, Israel
Stichting KIKA “kinderen kankervrij”
96. Thymidine protection of rapamycin cytotoxicity is mediated by increased p70/S6k phosphorylation and autophagy
I.V. Bijnsdorp, F.A.E. Kruyt, M. Fukushima, G.J. Peters
Department of Medical Oncology, VUmc, Amsterdam, Taiho Pharmaceuticals, Tokushima, Japan, Department of Medical
Oncology, UMCG, Groningen
Taiho Pharmaceuticals, Japan
97. Towards comprehensive therapy for diffuse intrinsic pontine gliomas in children
M.H.A. Jansen, D.G. van Vuurden, D.P. Noske, M.W.J. Brok, F.C.H. Abbink, P.H. Spruijt, A.H.M. Piet, E. Sanchez Aliaga,
R.J. Vermeulen, P. van de Ven, F. Barkhof, O.S. Hoekstra, P. van der Valk, P. Wesseling, W.P. Vandertop, G.J.L.
Kaspers
Depts of Pediatric Oncology, Neurosurgery, Radiotherapy, radiology, Nuclear Medicineand Pathology, VU University
Medical Center, Amsterdam
Stichting Semmy, SKF
98. Towards personalized therapy using PET-labelled drugs: the case of 11C-erlotinib
1I Bahce, 2AA Lammertsma, 1EF Smit, 2AD Windhorst, 2RC Schuit, 2,3NH Hendrikse
1depts of Pulmonology, 2Nucl Med & PET research, 3Pharmacology
99. TRAIL activates kinases involved in cell migration and invasion in resistant NSCLC cells
K Azijli1, S Yuvaraaj4, MP Peppelenbosch3, H Dekker1, J Joore2, GJ Peters1, S de Jong3 and FAE Kruyt4
1Dept. Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands; 2Pepscan Systems B.V., Lelystad,
The Netherlands; 3Dept. of Gastroenterology and Hepatology, Erasmus MC-University Medical Center Rotterdam; 4Dept.
Medical Oncology, University Medical Center Groningen, University of Groningen, The Netherlands
Top Institute Pharma T3-112
100. Treatment and survival of indolent and aggressive NHL patients; population based studies in the Netherlands
D.E. Issa, O. Visser, J.M. Zijlstra, S. Zweegman, P.C. Huijgens
Department of Hematology, VU University Medical Center
101. Ultrasound-guided breast-sparing surgery to improve cosmetic outcomes and quality of life A prospective
multicentre randomised controlled clinical trial comparing ultrasound-guided surgery to traditional palpationguided surgery (COBALT trial)
N.M.A. Krekel, B.M. Zonderhuis, S. Muller, A.M.F. Lopes Cardozo, H. van der Veen, P Poortman, L. de Widt, W.K. de
Roos, A.M. Bosch, A.H.M. Taets van Amerongen, E. Bergers, H.W.H. Schreurs, E.S.M. de Lange de Klerk, M.H.M. van der
Linden, H.A.H. Winters, M.P. van den Tol, S. Meijer
Dept. Of Surgery, VU University Medical Center, Amsterdam
Borstkanker stichting Pink Ribbon; Osing Kluis Foundation
102. Validation of the one-step nucleic acid amplification assay as Intra-operative diagnostic method for the detection
of lymph node metastases in colon cancer
169
Appendix 7: Ongoing projects
Validation of the one-step nucleic acid amplification assay as Intra-operative diagnostic method for the detection of
lymph node metastases in colon cancer
Depts of 1Gastro-intestinal Surgery, 2Dept. of pathology , VU University Medical Center
Program 5
Late effects of brain tumor therapy
1.
Efficacy and toxicity of cerebral glioma treatment
I. Bosma1, M.J. Vos1, E. Sizoo1, M. de Groot1, T.J. Postma1, J.C. Reijneveld1,11, M.J.B. Taphoorn1,13, W.P.
Vandertop2,12, J.C. Baayen2, B.J. Slotman¬3, F. Lagerwaard3, J.Buter4 , M. Klein5, O.S. Hoekstra6, F. Barkhof7, E.
Sanchez7, P. van der Valk8, A.A.T.P. Brink8, M.A. Blankenstein9, J. Berkhof10, J.J. Heimans1
Department of 1Neurology, 2Neurosurgery, 3Radiotherapy, 4Medical Oncology, 5Medical Psychology, 6 Nuclear
medicine, 7Radiology, 8Pathology, 9Clinical Chemistry, and 10Clinical Epidemiology and Biostatistics, VU University
Medical Center, Department of 11Neurology and 12Neurosurgery, Academic Medical Center, Amsterdam, 12Department
of Neurology, MC ‘Haaglanden’, Den Haag
Late effects of tumor treatment
2. ALL treatment in acute lymphoblastic leukemia in children: a study into adjustment, quality of life, and costs
R.R.L. van Litsenburg¹, E.M.M. Meijer-van den Bergh², J. Huisman³, P.M. Hoogerbrugge4, C. Verhaak², G.J.L. Kaspers¹,
R.J.B.J. Gemke¹
Department of ¹Pediatrics VU University Medical Center, ²medical psychology UMC Nijmegen, ³Medical Psychology, VU
University Medical Center and 4Pediatrics UMC Nijmegen.
AGIKO
Patient reported outcome in head and neck cancer
3. Health related quality of life in head and neck cancer patients: survival, response shift, and care
I.M. Oskam1, I.M. Verdonck-de Leeuw1, R. de Bree1, D.H.F. Rietveld2, J.A. Langendijk3, N.K. Aaronson4, C.R.
Leemans1
1Departments of Otolaryngology/Head-Neck Surgery, VU University Medical Center, 2Radiotherapy, VU University
Medical Center, 3Radiotherapy, University Medical Center Groningen, 4Division of Psychosocial Research &
Epidemiology, The Netherlands Cancer Institute Amsterdam
4. OncoCompass Development and pilot testing of a e-health monogement platform to optimise disease management
in cancer patients
C.R. van Uden-Kraan, C.R. Leemans, R. de Bree, W.R. Gerritsen, C. van Kalken, R.A. Kraaijenhagen, P. Cuijpers, I.M.
Verdonck-de Leeuw
Dept Otolaryngology/Head-Neck Surgery, VU University Medical Center, VU University Medical Center, Amsterdam
NDDO Foundation
5. OncoQuest: touch screen computer based screening of health related quality of life and distress
I.M. Verdonck-de Leeuw, A. Houffelaar, R. de Bree1, C.R. Leemans
Departments of Otolaryngology/Head-Neck Surgery, VU University Medical Center
6. Patient and proxy reported outcome in HNSCC
I.M. Verdonck-de Leeuw1, C.F. van Uden-Kraan1, I.M. Oskam1, R.N.P.M. Rinkel1, R. de Bree1, P. Doornaert2, J.A.
Langendijk3, N.K. Aaronson4, C.R. Leemans1
1Departments of Otolaryngology/Head-Neck Surgery, VU University Medical Center, 2Radiotherapy, VU University
Medical Center, 3Radiotherapy, University Medical Center Groningen, 4Division of Psychosocial Research &
Epidemiology, The Netherlands Cancer Institute Amsterdam
Fonds NutsOhra 0702-118, 0901-072, KWF/Alpe d'Huzes 2504467
Psycho-Oncology / Palliative Care
7. Psychosocial aspects in head and neck cancer patients
I.M. Verdonck-de Leeuw1, A.M.H. Krebber1, P. Cuijpers2, I.C. Riepma2, B. Steunenberg2, A. van Straten2, R. de Bree1,
C.R. Leemans1
1,Depts. Otolaryngology/Head-Neck Surgery, VU University Medical Center and 12Clinical Psychology, VU University
ZonMw DO 80-82305-98-09001, ZonMw DM (600-82600-98-8043/300020012); ZonMw PZ 1151.0003, Fonds NutsOhra 080T045
Psychosocial aspects in head and neck cancer
8. Internet-based treatment of low-grade glioma patients with depression and fatigue; randomized controlled trial
M.Klein1, J.C. Reijneveld2,3, I. Verdonck4,5, J.J. Heimans2, P. Cuijpers5
Departments of 1Medical Psychology, 2Neurology, VU University Medical Center, 3Neurology, Academic Medical Center,
4Head-Neck Surgery, VU University Medical Center, 5Clinical Psychology, VU University, Amsterdam
KWF (Alpe d'Huzes) 4615-4804
Psychosocial aspects in head and neck cancer patients
9. Costeffectiveness of psychological intervention via the internet in head and neck cancer patients
Krebber AMH, Cuijpers P, Steunenberg B, van Straten A, de Bree R, Leemans CR, Verdonck-de Leeuw IM
Dept. Otolaryngology/Head and Neck Surgery, VU University Medical Center, Amsterdam
ZonMw DC
10. Stepped care to improve symptoms of anxiety and depression in cancer patients
Krebber AMH, Cuijpers P, Steunenberg B, van Straten A, de Bree R, Leemans CR, Verdonck-de Leeuw IM
Dept. Otolaryngology/Head and Neck Surgery, VU University Medical Center, Amsterdam
ZonMW
11. Structured life review using autobiographical retrieval practice in depressed palliative head and neck cancer
patients
Riepma I, Krebber AMH, Cuijpers P, Steunenberg B, van Straten A, de Bree R, Verdonck-de Leeuw IM
Dept. Otolaryngology/Head and Neck Surgery, VU University Medical Center, Amsterdam
ZonMw
Voice, speech and swallowing in head and neck cancer
12. Prediction of radiation-induced swallowing dysfunction after curative (chemo) radiation for head and neck cancer
170
Appendix 7: Ongoing projects
M.C.E.M. Christianen, I.M. Verdonck-de Leeuw, M. de Bruijn, R.N. Rinkel, C.R. Leemans, P. Doornaert, J.A. Langendijk
Dept. Otolarynogology'/Head-Neck Surgery, VU University Medical Center Amsterdam
KWF RUG 2008-3938
13. Objective speech assessment in head and neck cancer: acoustic-phonetic and feature analyses by a neural network
M. de Bruijn1, L. ten Bosch 2, J.A. Langendijk3, C.R. Leemans1, I.M. Verdonck-de Leeuw1
1Dept Otolaryngology/Head-Neck Surgery, VU University Medical Center, 2 Language and Speech, Radboud University,
Nijmegen, 3Dept Radiotherapy, University Medical Center Groningen
KWF Dutch Cancer Society RUG2008-3983, Fonds NutsOhra 080T-043, Eureka 2614 GGN371, VAZ/CVZ Doelmatigheid
00143 2008-3983
14. Prevention of speech, swallowing, and shoulder impairment after treatment for head and neck cancer
I.C. Cnossen1, R.N. Rinkel, Y Aalders1, C de Goede2, R. de Bree1, D.H.F. Rietveld3, C.R. Leemans1, I.M. Verdonck-de
Leeuw1
1Dept Otolaryngology/Head-Neck Surgery, 2Dept of Physiotherapy, , 3Dept Radiotherapy, VU University Medical Center,
Amsterdam
KWF Dutch Cancer Society RUG2008-3983, Fonds NutsOhra 080T-043, Eureka 2614 GGN371, VAZ/CVZ Doelmatigheid
00143 080T-043
15. Efficacy of voice therapy in patients with voice problems after treatment for early glottic cancer
C.D.L. van Gogh1, H.F. Mahieu1, R.N. Rinkel1, R. de Bree1, J.A. Langendijk2, P. Doornaert3, C.R. Leemans1, I.M.
Verdonck-de Leeuw1
1Dept Otolaryngology/Head-Neck Surgery, VU University Medical Center, 2Dept Radiotherapy, University Medical Center
Groningen, 3Dept Radiotherapy, VU University Medical Center, Amsterdam
KWF Dutch Cancer Society RUG2008-3983, Fonds NutsOhra 080T-043, Eureka 2614 GGN371, VAZ/CVZ Doelmatigheid
00143 00143
Other projects
16. A combined physical exercise and psychosocial training program to improve physical fitness in children with cancer
K.I. Braam1, E.M. van Dijk2, E. van Dulmen-den Broeder1, M.A. Veening1, M. Bierings3, J. van der Net3, P.J.M.
Helders3, G. Sinnema3, M. Chinapaw4, T. Takken3, J. Huisman2, G.J.L. Kaspers1
1Pediatric Oncology/ Hematology, VU University Medical Center, and 2Dept of medical Psychology VU university
medical center; 3Wilhelmina Children’s Hospital, University Medical Center Utrecht; 4EMGO institute, VU University
Medical Center
Alpe d’HuZes/KWF 2009-4305
17. Distress and quality of life of patients treated with autologous stem cell transplantation following high-dose
chemotherapy: Outcome of stepped care
A. Braamse1, B. van Meijel2, O. Visser3, P.C. Huijgens3, A. Boenink1, P. Cuijpers4, P. van Oppen1 , A.T.F. Beekman1, J.
Dekker1
1 Dept. of Psychiatry VU Univ Medical Center, 2 Research Group Mental Health Nursing, Inholland Univ3 Dept. of
Hematology VU Univ Medical Center, 4 Dept. of Clinical Psychology, FPP, VU Univ
VU University Medical Center and Inholland University
18. Early-detection of quality of life problems in children with Retinoblastoma and their parents
A.G. La Rivière1, J. van Dijk2, J. Huisman2, A. Frankfoorder1, G. Buurmans-Kool1, M. Bosscha1, P. Ringens1, M.A.
Grootenhuis4, I.M. Verdonck-de Leeuw3 and A.C. Moll1
Depts. of 1Ophthalmology, 2Pedriatic Psychology, 3ENT/Head and Neck, VU University Medical Center, and 3Clinical
Psychology, Free University, and Psychosocial Department, Pediatrics, University Hospital of Amsterdam
NutsOhra, grant 0901-072
19. Enhancing quality of life in low-grade glioma patients by attacking fatigue through modafinil: a randomized
magnetoencephalography study
K. Hilverda1, L. Douw2, M. de Groot2, M.J.B. Taphoorn2,4, J.J. Heimans2, J.C. Reijneveld2,3, M. Klein1
Departments of 1Medical Psychology and 2Neurology, VU University Medical Center, Amsterdam, 3Department of
Neurology, Academic Medical Center, Amsterdam, 4Department of Neurology, MC ‘Haaglanden’, Den Haag
Fonds NutsOhra Zorgsubsidies
20. Glucocorticoid induced HPA axis suppression in childhood acute lymphoblastic leukaemia and lymphoma
M.S. Gordijn, R.J.B.J. Gemke, J. Rotteveel, M.B. Bierings, G.J.L. Kaspers
Dept. Of Peadiatric Oncology/Hematology, VU University Medical Center, Amsterdam and Pediatric
Hematology/Oncology, Wilhelmina Children’s Hospital, University Medical Center Utrecht
Dutch Cancer Society, grant VU 2010-4859
21. Health-related quality of life in high-grade glioma patients and their partners in the end-of-life phase
E. Sizoo1, J.J. Heimans1, M. Klein2, T.J. Postma1, R. Grant6, W. Grisold7, C. Marosi 8,G. Stockhammer9, H.R.W.
Pasman3, L. Deliens3 J.C. Reijneveld1,4, M.J.B. Taphoorn1,5
Departments of 1Neurology, 2Medical Psychology, and 3EMGO+, VU University Medical Center, Amsterdam, 4Department
of Neurology, Academic Medical Centre, Amsterdam, 5Department of Neurology, Medical Centre ‘Haaglanden’, Den
Haag, 6Department of Neurology, Western General Hospital, University of Edinburgh, United Kingdom, 7Ludwig Bolzman
Institute for Neuro-Oncology, Kaiser Franz Josef Hospital, Vienna, 8Department of Internal Medicine, Medical Univeristy,
Vienna, and 9Department of Neurology, Neuro-Oncology Group, Medical University of Innsbruck, Austria.
Jacobus Stichting
22. Maintaining health-related quality of life of caregivers of glioblastoma patients: a randomized, two-group,
controlled trial
J. Lenting1, J.J. Heimans2, T.J. Postma2, M.J.B. Taphoorn2,3 J.C. Reijneveld2,4, M. Klein1
Departments of 1Medical Psychology and 2Neurology, VU University Medical Center, 4Department of Neurology,
Academic Medical Center, Amsterdam, 3Department of Neurology, Medical Center ‘Haaglanden’, Den Haag
Tug McGraw Foundation / National Brain Tumor Foundation
23. Quality of life and neurocognitive functioning in meningioma patients
D. van Nieuwenhuizen1, S.M. Peerdeman2, L.J.A. Stalpers5, W.P. Vandertop2,6, , M. Waagemans1,3, J.J. Heimans1, M.
Klein3, J.C. Reijneveld1,4
171
Appendix 7: Ongoing projects
D. van Nieuwenhuizen1, S.M. Peerdeman2, L.J.A. Stalpers5, W.P. Vandertop2,6, , M. Waagemans1,3, J.J. Heimans1, M.
Klein3, J.C. Reijneveld1,4
24. Quality of life in patients treated with radiotherapy for head and neck cancers
P. Doornaert, M.R. Vergeer, C.R. Leemans, B.J. Slotman
Dept of Radiation Oncology, Otolaryngology/Head and Neck Surgery, VU University Medical Center, Amsterdam
25. Reproductive function, ovarian reserve, and risk of premature menopause in female childhood cancer survivors: a
nationwide study
A. Overbeek1, M.H. van den Berg1, C.B. Lambalk2, G.J.L. Kaspers1, F.E. van Leeuwen3, E. van Dulmen-den Broeder1
Depts. of 1Pediatric Oncology/Hematology and 2Obstetrics & Gynaecology, VU University Medical Center,
3Epidemiology, Netherlands Cancer Institute, Amsterdam
KWF / Kika Foundation 2006-3622
26. Risk factors for impairments of quality of life after colorectal cancer: a feasibility study
A.M.J. Braamse1, C.J.J. Mulder 2, B Penninx1, J.H. Smit1, S.T. van Turenhout2 , J. Dekker1,3
Depts. Of 1Psychiatry, 2 Gastroenterology and Hepatology, 3 Rehabilitation Medicine, VU University Medical Center
VU University Medical Center
172

Similar documents

PDF bestand Page 1. VUmc Cancer Center Amsterdam VUmc CCA

PDF bestand Page 1. VUmc Cancer Center Amsterdam VUmc CCA VUmc Cancer Center Amsterdam (VUmc CCA) VU University Medical Center PK 7 Z 182 De Boelelaan 1117 1081 HV Amsterdam The Netherlands phone: (31)20 4443113 e-mail: [email protected] website : www.vumc...

More information

PDF bestand VUmc Cancer Center Amsterdam (VUmc CCA)

PDF bestand VUmc Cancer Center Amsterdam (VUmc CCA) Address VUmc Cancer Center Amsterdam (VUmc CCA) VU University Medical Center PK 7 Z 182 De Boelelaan 1117 1081 HV Amsterdam The Netherlands phone: (31)20 4443113 e-mail: [email protected] website :...

More information